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Abstract 
A systems approach in the study of blood-biomaterial interactions (BBI) is likely to provide 
better insight into the transient behaviors of complex biological systems. Although some attempts 
have been made to apply a systems approach in blood-biomaterial studies, a good framework for 
applying a systems approach has not yet been achieved. In this thesis, the case for a systems approach 
is presented and a framework is proposed. As a demonstration, the systems approach is applied to the 
development of an in vitro model for BBI. 
In vitro models play an important role in the initial investigation of BBI. Therefore, careful 
consideration of their parameters to mimic physiological parameters is crucial for results that can be 
translated to physiological conditions. The parameters of the in vitro model used in this thesis were 
determined using a systems approach method. The fluid dynamics of the model were characterized, to 
account for the model blood sample always including air, and an improved time-averaged wall shear 
stress was proposed. Since wall shear stress is an important parameter that determines cell activation 
and adhesion, in vitro studies were performed to investigate and validate the model with experiments. 
In line with a systems approach and clinical relevance, whole blood samples were used in the in vitro 
experiments. 
Platelet activation was investigated, as characterized by platelet microparticle (PMP) 
formation and expression of both P-selectin and the integrin glycoprotein receptor GPIIb/IIIa. For 
whole blood, in the absence of model stents, there was no significant sample volume or shear effect 
on PMP formation for wall shear stress up to 56 dyn/cm2.  However, in the presence of model stents, 
combined volume and shear-dependent PMP formation was observed. While GPIIb/IIIa expression 
was reduced, P-selectin, on the other hand, did not generally show significant change after 2 hours of 
incubation. 
Leukocyte activation was also investigated, as characterized by the expression of tissue factor 
(TF), Mac-1, C3aR and toll-like receptor 4 (TLR-4). In the absence of model stents, sample volume 
had minimal effect on leukocyte activation but in the presence of model stents, a sample volume 
effect was observed at high shear rates, especially on Mac-1 expression. The other markers, TF, C3aR 
and TLR-4 did not show sensitivity to the volume effect. However, under combined volume-stent-
shear, all markers were down-regulated at high shear. Correspondingly, platelet-leukocyte 
aggregation was also generally reduced. Leukocytes, as well as platelets, were sensitive to surface-
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area-to-volume ratio. The use of low surface area-to-volume ratio, below the ISO Standard 
recommended limit, resulted in reduced platelet and leukocyte sensitivity to shear and/or material. 
However, sensitivity to shear was still high on platelet-leukocyte aggregation. Also cell surface 
adhesion was shear-dependent but could not be linked to a sample volume effect. 
Complement inhibitor FUT-175 reduced PMP formation but had less effect on GPIIb/IIIa 
expression. Complement inhibition also reduced leukocyte activation, especially under shear 
conditions. Considerable reduction in leukocyte activation was observed under shear in the presence 
of model stents. These conditions would normally be expected to produce high complement 
activation. Furthermore, the conditions with the most reduction in platelet and leukocyte activation 
corresponded with the most reduction in platelet-leukocyte aggregation in the fluid phase. On the 
stent surface, FUT-175 inhibited leukocyte adhesion but allowed some platelet adhesion. Thus, 
complement inhibition with FUT-175 has the potential to reduce thrombosis while possibly retaining 
platelet function in hemostasis. 
The effect of surface roughness was investigated with inhomogeneous multiscale roughness 
surfaces. Although the unetched and acid-etched stent surfaces had similar average surface roughness 
values, the acid-etched surface resulted in increased platelet activation and platelet-leukocyte 
aggregation. In addition, platelet-leukocyte aggregates seemed to be more resistant to shear-induced 
disaggregation. However, when complement inhibitor FUT-175 was introduced, platelet and 
leukocyte activation and aggregation were reduced to similar levels as for unetched stents. This 
suggests that complement inhibition with FUT-175 has the potential to reduce material-induced 
thrombosis in the presence of nano/micro-structured stent surfaces such as those used for drug-eluting 
stents.  
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A set of plasma proteins that act together to attack extracellular forms of 
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Chapter 1 
Thesis scope and hypotheses 
1.1 Introduction 
Coronary stents are common cardiovascular intervention devices for arterial stenosis. 
However, one of the adverse outcomes of coronary stent implantation is material-induced thrombosis 
(MIT), which is normally prevented by anti-platelet, anti-coagulant and thrombolytic therapies. 
Despite years of research in biomaterials sciences and blood-biomaterial interactions, the holy grail of 
material-induced thrombosis (the formation of a blood clot) has not been found. Although 
considerable progress has been made, “the perfect material is yet to be identified” [5] and some 
researchers have suggested that “the perfect stent … will probably never exist” [6]. The sentiments 
expressed in these statements in no way suggest that it is fruitless to continue research in these areas. 
To the contrary, they highlight the current dilemma and perhaps the need to rethink research 
methodologies. There are a variety of reasons for the continued search for the illusive holy grail of 
biocompatibility, none more important than the dynamic complexity and adaptability of the immune 
system. This results in complex blood-biomaterial interactions, which are not completely understood 
[7, 8]. For that reason, it has been suggested that the “true effect of a biomaterial surface on blood can 
only be identified when whole blood is used” [9]. Indeed a holistic approach has been previously 
undertaken to study blood interaction with polymeric materials [10]. Furthermore, a systems approach 
to blood-biomaterial studies has been suggested [11]. 
A systems approach is a problem solving method which “addresses the total problem-
solving cycle’’ [3]. To that end, a systems approach can be defined as a holistic and integrated 
problem solving method that entails both quantitative and qualitative decision-making processes to 
achieve a comprehensive solution. Although a systems approach has increasingly been used to study 
biological systems such as coagulation [12, 13], an important system in thrombosis, there is generally 
limited application of systems methods in blood-biomaterial interaction studies. This could be due to 
a variety of reasons, such as lack of standardized tests and guiding principles for biocompatibility 
analysis [14]. Ideas for a framework for blood-biomaterial interaction assessment have been recently 
provided [4]. However, there is no framework for a systems approach in blood-biomaterial studies. 
Therefore, it is necessary to develop a systems approach framework for blood-biomaterial studies that 
also incorporates in vitro model design. 
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Various in vitro flow models [15-17] have been used to study blood-biomaterial interactions. 
Although there is rationale for each model, one of the key parameters that define each model is the 
ability to generate a wide range of shear rates. Shear rate is indeed one of the mechano-stimulators 
that has long been known to influence various aspects of cell interaction, activation and aggregation 
kinetics involved in hemostasis and thrombosis [18]. It also influences cell/protein-biomaterial 
interaction/adhesion [19]. Although these transient cell and protein behaviors have been observed 
from a variety of systems that can produce both constant or time-varying shear stress, there are other 
fundamental properties of flow that play equally important roles in influencing cell/protein behavior. 
These include the geometry of the model and the flow type and profile. Even though the response 
elicited by shear stress is generally known, the role of changes to the in vitro model design 
parameters, such as sample volume and flow type, and their influence on the rate, level and ultimate 
thrombotic behavior under flow conditions, are not well understood. As a result, there is no consistent 
and standardized set of in vitro model parameters, even for studying the same physiological location 
of interest such as coronary arteries. Hence, it is necessary to elucidate the role of other 
physiologically-based in vitro model design parameters and their possible impact on the interpretation 
of experimental results. 
To understand material-induced thrombosis, much work has been done on polymeric 
materials. This is not surprising as they are used in a variety of medical applications, both short term 
and long term, such as catheters, dialysis tubing, blood warmers, stent coatings, etc. However, 
metallic biomaterials have continued to play an equally significant role in medical devices because of 
their unique properties and have found various applications in orthopedic, dental and cardiovascular 
implants [20]. Various metallic biomaterials have different levels of biocompatibility. The ones that 
are reasonably biocompatible and are used in cardiovascular devices include nitinol and Ti-6Al-4V 
[21]. These biomaterials still cause some level of blood activation, mostly because they are inorganic 
materials and will trigger an immune response [22, 23]. This results in the activation of leukocytes, 
which subsequently express cell surface markers such as Mac-1 and tissue factor (TF). The TF 
protein, which is expressed on monocytes and macrophages only after activation [24], is recognized 
as one of the key coagulation initiators. To understand the regulation of TF by biomaterials, it is 
necessary to understand the mechanism of leukocyte activation by biomaterials. Consequently, it 
would be informative to concurrently investigate other leukocyte receptors, which are related to 
recognition of foreign material, such as complement receptors. Complement proteins, which are one 
of the immune system surface recognition proteins, play an important role in biomaterial response 
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[22]. Since they also activate and recruit leukocytes, it is necessary to understand the regulation of 
their receptors on leukocytes. Understanding their regulation by biomaterial surface characteristics 
such as surface roughness and the impact of complement inhibition is also important in elucidating 
the pathways involved in material-induced TF expression and thrombosis since surface characteristics 
may influence the activation pathway [25]. In addition, platelets activation, which together with 
complement have been found to play an important role in material associated thrombosis [10], needs 
to be concurrently investigated in line with the need for a systems approach in blood-biomaterial 
interactions. 
The adhesion of activated leukocytes to material surface depends on the material as well as 
the shear stress [26, 27]. Platelets similarly adhere in a shear and material-dependent manner. Since 
leukocyte surface adhesion is facilitated by complement fragments, as well as fibrinogen, and 
activated platelets and leukocytes form platelets-leukocyte aggregates which may localize on the 
surface, the effect of complement inhibition on leukocyte and platelet adhesion has been previously 
investigated [10]. While leukocyte adhesion was reduced, platelet adhesion was unaffected. This 
means the inhibition still left the problem of thrombogenicity. Because complement inhibition 
represents one of the important pathways to reduce material-induced thrombogenicity, it is necessary 
to investigate other methods of complement inhibition on platelet and leukocyte activation and 
surface adhesion. Since platelets mediate leukocyte TF expression [28], the link between TF 
expression and surface attachment or detachment has not been clearly studied. Therefore, there is 
need to elucidate the link between leukocyte and/or platelet adhesion and TF expression. 
This thesis builds on the work started towards a systems approach in whole blood studies. 
The premise is that since a systems approach follows a methodology to establish the relationship 
between the emergent system behavior and the interactions of its elements, it facilitates tracing 
process pathway linkages and interactions that are important in blood-biomaterial studies. This will 
not only assist in interpreting experimental results, but will assist in activation measurements that are 
related to the physiological environment. A systems approach will also facilitate numerical 
simulations. Therefore, the objectives of this thesis are to: 
 
1) Establish a systems approach framework and concepts in blood-biomaterial studies; 
2) Select/design an appropriate in vitro model for coronary studies applying a systems approach 
method: 
a. Develop a set of in vitro model parameters for coronary studies 
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b. Establish an appropriate sample volume selection method 
c. Characterize fluid flow and friction parameters 
d. Establish the interaction relationships between volume, shear and a model stent; 
3) Design, fabricate and characterize model stents for blood-biomaterial interaction studies; 
4) Investigate the effect of volume and combined volume-shear-stent interactions on platelet and 
leukocyte activation and aggregation under flow conditions; 
5) Investigate the effect of complement inhibition on platelet and leukocyte activation and 
surface adhesion with a selected volume-shear-stent combination; 
6) Investigate the effect of model stent surface roughness on platelet and leukocyte activation 
and surface adhesion with a selected volume-shear-stent combination. 
 
1.2 Thesis scope and format 
Using a systems approach, in vitro model design requirements and constraints were 
developed based on the physiological location of interest. Three in vitro flow models were evaluated 
on the basis of their operation principles and one model with geometric and hemodynamic parameters 
that closely matched the design parameters was selected for modification, flow characterization and 
for use in this research. Since metallic biomaterials are extensively used as implants, metallic model 
stents were fabricated and used to investigate blood-biomaterial interactions under conditions 
mimicking coronary flow. The parameters of interest were expression of TF, Mac-1, complement 
fragment C3a receptor (C3aR) and toll-like receptor 4 (TLR-4) on leukocytes. Platelet microparticle 
formation was investigated to elucidate platelet activation. The interaction of platelets with leukocytes 
was investigated by platelet-leukocyte aggregation formation in the fluid phase as well as on a 
material surface. Since complement plays an important role in inflammation, particularly C3, which is 
a possible therapeutic target, the role of its fragment was investigated by expression of its receptor. 
Toll-like receptor 4 is an important recognition molecule in leukocyte inflammatory response and 
therefore was included in the investigation. More importantly, it is informative to profile other 
receptors in addition to the standard markers as receptors are often engaged in a specific combination 
for a specific immune response. Flow cytometry was used to study all blood activation/aggregation in 
the fluid phase and scanning electron microscopy was used to investigate material surface adhesion. 
All the investigations in this study were done with whole blood. 
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The thesis is comprised of independent but linked chapters. Chapter 2 presents an overview 
of the relationships and interactions of biological systems that play a role in blood-biomaterial 
interactions. An introduction of a systems approach framework and the use of a systems approach in 
these interactions and their role in thrombosis is also presented. Chapter 3 presents the selection of the 
in vitro flow model, analysis of model fluid mechanics characteristics and their significance in the 
interpretation of experimental results. In Chapter 4, model stents with specific characteristics are 
designed, fabricated and characterized. Chapter 5 examines the implications of model parameters, 
such as blood sample volume, on leukocyte and platelet activation and aggregation, with and without 
model stents. Some of the work in this chapter has been previously published [29]. Chapter 6 presents 
the effect of complement classical and alternative pathway inhibition on platelet and leukocyte 
activation, aggregation and adhesion. Chapter 7 presents the effect of model stent roughness on blood 
activation. Chapter 8 summarizes the contributions of this work and lessons learnt. Chapter 9 
provides a summary of the conclusions. 
1.3 Hypotheses and thesis objectives 
The overall goal of this thesis was to demonstrate that a systems approach provides an 
invaluable tool in the critical analysis of linkages and translation of a biological system to an in vitro 
model. 
Hypotheses were formulated to assess mechanisms involved in material-induced platelet and 
leukocyte activation using a systems approach. These hypotheses are given below and associated with 
specific chapters of the thesis. 
Chapter 3 – Two hypotheses were formulated in this chapter; (i) in vitro flow model parameters 
mimicking physiological location of interest are better designed following a systems approach and (ii) 
blood sample volume influences flow dynamics and hence wall shear stress. 
Chapter 4 – The objectives of this chapter were to design and fabricate model stents with specific 
geometric and surface characteristics. An additional objective was to characterize the model stents 
and acquire essential information that would facilitate interpretation of investigation results of their 
influence on hemodynamics and blood activation. 
Chapter 5 – The hypothesis was that under shear and stent conditions, blood sample volume has 
different effects on blood cell activation and surface adhesion. 
Chapter 6 – The hypothesis was that under flow shear conditions, complement inhibition reduces 
leukocyte and platelet activation and surface adhesion. 
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Chapter 7 – Two hypotheses were formulated in this chapter; (i) under flow shear conditions, multi-
scale surface roughness influences leukocyte activation and (ii) surface roughness influences the 
effectiveness of complement inhibition. 
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Chapter 2 
Blood-Biomaterial Interactions in Thrombogenicity and the Case 
for a Systems Approach 
2.1 Introduction 
Cardiovascular diseases are the major cause of morbidity and mortality globally [30, 31]. 
While mortality is trending down, prevalence remains high. In the United States it is estimated that 
the prevalence of cardiovascular diseases (CVD) is greater than 1 in 3 adults (83.6 million) and 
coronary heart disease exists in 15.3 million (1 in 14 adults) [32]. The United States has seen a 28% 
increase in cardiovascular operations and procedures from 2000 to 2010. In 2009, the total inpatient 
hospitalizations from CVD was approximately 1 out of every 6 hospital stays, accounting for $71.2 
billion (approximately one fourth of the total inpatient care). The overall economic impact, i.e. direct 
and indirect cost, in 2010 was estimated at $315.4 billion [32]. In Canada, it is estimated that heart 
diseases and stroke contribute 2.5 million hospitalizations per year [33] with an overall economic 
impact in 2009 estimated at $22.2 billion CAD; direct costs (e.g. hospitalization) accounting for $7.6 
billion CAD and indirect cost (e.g. lost economic productivity) accounting for $14.6 billion CAD 
[33]. These statistics illustrate not only the burden of disease, but the broader social, health and 
economic implications, both at personal and national levels. While there are great prevention methods 
at population, community and personal levels, there is great need for cost effective intervention 
methods. 
The most common intervention method for the most prevalent cardiovascular disease, 
ischemic heart disease, which is caused by narrowing of coronary arteries (stenosis), is angioplasty 
followed by implantation of coronary stents. Angioplasty is a method of opening an occluded blood 
vessel with an inflatable balloon and the stent, which is a scaffold, keeps the blood vessel lumen 
patent. Although these devices have greatly improved patient outcomes, there has been a constant 
problem of in-stent thrombosis (formation of blood clots within a stent), for both first generation bare 
metal stents and drug-eluting stents [34-37]. First generation drug-eluting stents (DES) have reduced 
in-stent thrombosis to about 3% [38], but the risk of a late occurrence of material-induced in-stent 
thrombosis remains unabated. However, current studies show improvement with the use of second 
generation DES [39-41], although interestingly in terms of mortality, some studies suggest no 
significant difference between the first and second generation DES [39, 40]. Material-induced in-stent 
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thrombosis has been associated with a number of factors [42], more importantly delayed 
reendothelialization [43], which leaves stent struts exposed to blood for extended periods of time. 
Although this has also been improved by second generation DES [44], it has not been eliminated. The 
development of in-stent thrombosis can have several consequences. The blood clot (thrombus) may 
grow in situ and block blood flow, which would result in myocardial infarction and heart attack. The 
thrombus can also break off, flow with the blood and block blood supply to major organs such as the 
brain or lungs. Blockage of blood supply to the brain would result in a stroke, which is also a major 
cause of morbidity and mortality. Thus, in-stent thrombosis can cause serious complications, possibly 
resulting in debilitating permanent disability or death. 
Several therapeutic interventions are available for preventing in-stent thrombosis [45]; 
anticoagulants, which block proteins that participate in coagulation pathways, antiplatelets [46], 
which block platelet receptors responsible for aggregation, and thrombolytic agents, which dissolve 
the thrombus. One common feature with these interventions is that they are curative and not 
preventive. In addition, they are usually prescribed for more than a year and thus do not only have 
systemic side effects, such as risk of developing bleeding complications [45], but also have economic 
implications for the patient. For that reason, there is need for better preventive solutions that stop or 
control the development of in-stent thrombosis in the first place. However, development of preventive 
interventions, whether device and/or pharmaceutical, requires better understanding of mechanisms 
involved in biomaterial-induced initiation and propagation of in-stent thrombosis. 
Consequently, there has been extensive research in all areas of biomedical and biotechnology 
related to this problem; biomaterial sciences, blood-biomaterial interactions, devices and therapeutic 
interventions. Biomaterial sciences and blood-biomaterial interactions research areas particularly play 
a key role in this initiative, with the common objective of meeting the new functional 
biocompatibility requirements [47]. To that end, research and development in stent and other 
cardiovascular device materials has seen a great evolution in the last couple of years [47-49]. Despite 
the development of new materials, material-induced in-stent thrombosis remains a major concern. 
This is partly because in spite of years of research in blood-biomaterial interactions, “the fundamental 
principles of the causation of specific cellular responses as a result of the influence of materials are 
still not well known” [50].  Hence, there has been a call for a holistic approach to address not only the 
complexity of biocompatibility but also to include other aspects such as regulations [8]. Such an 
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approach requires systems thinking, which in turn requires clearly defining and understanding the 
various systems at play and their relationships. 
There are three main systems involved in the development and propagation of in-stent 
thrombosis. These are (i) the blood (biochemical/cell-plasma) system, (ii) the fluidics system and (iii) 
the biomaterial system. The first two systems are intrinsic while the biomaterial system is extrinsic. 
Each of the systems has characteristic properties that define its role in the mechanism and level 
(spatial and time scales) of interaction. The blood system is really a system of systems, i.e. the system 
components are systems in their own right. These components or (sub)systems include  the contact, 
the hemostatic and the immune systems. There is constant cross-talk between these systems in both 
health and disease states. The fluidics (transport) system is composed of the coronary arteries with 
their geometry and hemodynamics characteristics. The biomaterial system is characterized by the 
implant design structure, geometry and surface characteristics. The interactions between the systems 
elicit activation of complex pathways and biochemical networks that are involved in the initiation and 
propagation of in-stent thrombosis. The mechanisms involved in the interaction of these systems and 
the signal propagation pathways are not well understood. The key to understanding these mechanisms 
lies in understanding material-induced blood activation pathways and how these interactions 
propagate to produce thrombosis. Applying systems thinking to blood-biomaterial interactions would 
be invaluable in unraveling some of these complex interactions. 
Therefore, this research presents the case for a systems approach for the study of blood-
biomaterial interactions. In this chapter, a detailed literature review of each of the three systems and 
their interaction from a systems perspective will be discussed. The case for a systems approach is then 
presented and a framework for further development of this initiative is provided. In the subsequent 
chapters, the systems approach is applied in developing the in vitro model and in holistic laboratory 
experiments. The motivation for continued research in blood-biomaterial interaction is not only to 
address the continued risk of development of in-stent thrombosis in patients with coronary stents but 
also to contribute knowledge in biomaterial-induced thrombosis, especially with respect to the 
development of a systems approach framework. 
2.2 The blood system 
The blood system is really a system of (biochemical) systems. Blood is an inhomogeneous 
colloidal fluid composed of relatively homogeneous plasma fluid (viscosity of 0.0012 Pa.s [51]) with 
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a suspension of particles (cells and proteins) of varying sizes, shapes and complexity (Table 2-1). The 
colloidal nature of blood gives it complex rheological properties. Its viscosity (0.003-0.004 Pa.s[52]) 
is influenced by a number of factors, including flow rate and hematocrit. Hematocrit, defined as 
volume ratio of red blood cells to the total blood sample volume, varies by individual but normal 
hematocrit level is about 45% [51]. Under isothermal conditions, blood has a relatively constant 
density, estimated at ρ≈1060 kg/m3 [51], independent of pressure. Hence, it exhibits the properties of 
an incompressible fluid.  
 
Table 2-1. Blood constituents. Data adapted from [1, 53].  
Constituent Size 
(µm)  
Density 
(% by weight) 
% of 
constituent 
% of cell 
volume 
% of blood 
volume 
Plasma 
o Water 
o Proteins 
Ø Albumin 
Ø Immunoglobulins 
Ø Fibrinogen 
o Other solutes (salts, 
gases, nutrients, etc.) 
_  
91g/ml (91%) 
7g/ml (7%) 
 
 
 
2g/ml (2%) 
 
 
 
58% 
38% 
4% 
_ 55 
Red blood cells (erythrocytes) 8-9 4.2-5.8x106 /µL  95% 45 
White blood cells (leukocytes) 
o Neutrophils 
o Lymphocytes 
o Monocytes 
o Eosinophils 
o Basophils 
 
10-15 
7-18 
12-20 
10-15 
10-15 
5-9x103 /µL 
 
 
 
60-70% 
20-25% 
3-8% 
2-4% 
0.5-1% 
0.1% 
Platelets 2-4 250-400x103/µL  4.9% 
 
The volume of blood in the human body is about 5L [54]. About 50% of the blood volume is 
composed of blood cells. Red blood cells, which have a lifespan of 120 days, form the most 
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constituent cell volume. They play an important role in metabolism while the other cells play a key 
role in defense. As discussed above, red blood cells also determine hematocrit, which has great 
influence on blood rheology and hemodynamics [55]. Thus, their influence on blood flow has 
mechanical implications on blood-biomaterial interaction as they influence flow segregation and 
particle dispersion [56, 57]. However, they can also have biochemical effects, such as in the event of 
hemolysis. Therefore, they cannot be ignored when performing in vitro flow studies. 
Blood plasma, which constitutes a little over half of the blood volume, is mostly composed of 
water, about 90% by volume. The other 10% of the plasma volume is mostly occupied by proteins, 
which play a variety of roles including immune response. The fact that water constitutes close to 50% 
of the blood volume makes it an important constituent. It has both transport and regulatory roles. It is 
a solvent for a number of substances, such as proteins, gases and electrolytes. It also regulates 
osmotic pressure and tightly controlled blood acid-base balance; blood pH is maintained at a tight 
range of 7.35-7.45 [58]. More importantly, at material surfaces, water influences interfacial 
interactions and hence adsorption of molecules [59]. Consequently, it needs to be considered in 
blood-biomaterial interactions. 
All the various components (sub-systems) of the blood are interlinked but have specialized 
broad functions, such as metabolism, regulation, transport and defense. While all the systems are 
important in vivo and in blood-biomaterial interactions, often they are not all investigated in in vitro 
studies based on their relative importance in influencing the results. Metabolism and regulation 
functions are often not investigated since their broader impact, such as change in blood pH and cell 
exhaustion, are minimized in the in vitro model by limiting the blood incubation time. Although in a 
comprehensive systems approach, it would be necessary to include all the systems, a systems 
approach can also be applied within defined system boundaries. Unlike standard modeling approach, 
which is not necessarily holistic, the systems approach is holistic by design, regardless of the extent 
of the defined system boundaries. For the purpose of this research, only the key systems generally 
related to blood-biomaterial interaction, i.e. systems responsible for transport and defense functions, 
are included. 
The cardiovascular system defines the geometry and fluid dynamics parameters that 
characterize the coronary transport phenomenon. In vivo, these parameters modulate cellular and 
vascular functions, under both normal and disease conditions. They influence vessel wall intimal 
remodeling [60] and, development and localization of atherosclerotic lesions [61, 62]. Hemodynamics 
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can cause cell trauma in circulatory devices as well as cell activation. Similarly, the systems 
responsible for the defense (immune system) define parameters that characterize blood activation, 
coagulation and thrombosis. In both in vivo and in vitro, these parameters are influenced by 
hemodynamics as well as the “intruder system” (biomaterial) properties. There is a complex tripartite 
interaction between immune system, biomaterial and hemodynamics that often results in devices 
related complications. Therefore, it is important for the transport phenomenon of in vitro model 
design to mimic physiological conditions. Similarly, for in vitro investigations to mimic physiological 
interactions with biomaterials in vivo, it is necessary to mimic the biochemical environment by using 
whole blood. Hence, the important parameters for each of these systems need to be clearly defined. 
2.2.1 The immune system 
The immune system is a defense system protecting the host against microbial invasion or 
infection. It is composed of various elements at several levels of organizational complexity; from 
molecules to organs. The immune system is generally divided into three response mechanisms; the 
anatomical, innate and the adaptive response mechanisms or systems [63]. All the immune response 
mechanisms have their level of complexity and sophistication. The anatomical mechanism, which 
forms the body’s first line of defense, has some of the basic response mechanisms, which is simply to 
form a barrier. In medical device implant procedures, there are established methods to overcome or 
bypass this first line of defense. Therefore, this mechanism is not discussed in this work because this 
research deals with system responses after the medical device is implanted. In any case, 
complications that occur at this level of defense would trigger the subsequent levels of defense. 
The innate and adaptive systems can in reality be regarded as a system of systems, but for 
simplicity, the word system will generally be used with understanding based on the context. Only 
where it is necessary to make a distinction will subsystem be used. There are similarities between the 
two systems in terms of functional purpose, i.e. recognition and elimination of infecting agents. 
However, there are distinct differences that are pertinent to their functional roles: the innate system 
has broad specificity in that it can immediately recognize self from non-self (‘what’) but has no 
memory of ‘who’ it encountered, and for that reason is sometimes thought to lack specificity [63, 64]. 
On the other hand, the adaptive system has fine antigen specificity for not only the ‘what’ but has 
memory of ‘who’ it encountered. It should be clarified here that as will be discussed in subsequent 
sections, the innate system does have some level of sophisticated specificity as well, albeit without 
memory, because of its receptor-ligand specificity. Hence the innate system responds rapidly during 
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the acute phase of injury or implanting of any foreign material and the adaptive is only activated in 
the chronic phase. Although the two mechanisms overlap through antigen-presenting cells such as 
dendritic cells and macrophages during the transition from acute to chronic phase, they can be 
compartmentalized and investigated independently. Therefore, only the innate system is relevant in 
the acute phase of blood-biomaterial studies. 
At the core of the innate immune system is the ability to recognize foreign material, such as 
microbial agents. This is achieved through two recognition strategies; pattern recognition of 
conserved molecules on the microbial surface and the recognition of ‘missing’ molecules. Thus, 
molecules come in two forms; the conserved molecules are called pathogen-associated molecular 
patterns (PAMPs) and the missing molecules that are released from damaged or stressed cells, which 
are called danger/damage-associated molecular patterns (DAMPs). The recognition of pathogens, 
with or without conserved molecular patterns, is achieved through a variety of distinct host proteins 
called pattern recognition receptors (PRRs) [65, 66]. PRRs are distributed on the cell membrane 
surface as well as inside the cell, which enables targeting both extracellular (e.g. bacterial 
recognition) and intracellular pathogens (e.g. viral nucleic acids recognition) [2]. The main PRRs in 
innate immunity are the toll-like receptors (TLRs) [67]. TLRs occur on the cell surface as well as 
intracellular endosomes/lysosomes [66]. In general, microbial PRRs can be divided into three types; 
cytosolic/intracellular type, which include the retinoic acid-inducible gene I-like receptors (RLRs) 
and the nucleotide-binding oligomerization domain (NOD) and leucine-rich repeat-containing 
receptors (NLRs), soluble/secreted type, which include collectins and pentraxins, and transmembrane 
type (cell surface and endosomal/lysosomal), which include TLRs and C-type lectins [2, 68]. Figure 
2-1 is a schematic depicting the PRRs and their effects.  
Pattern recognition receptors that are of particular interest to this research are the pentraxins, 
collectins mannose binding lectins (MBL) and the TLRs because they form part of the innate immune 
system mechanisms. The MBL forms one of the plasma complement protein activation pathways, 
which are a component of the innate immune response called humoral response mechanism. TLRs 
occur on leukocytes, which form the second innate immune response called the cellular response 
mechanism. The humoral and cellular response mechanisms/system work in tandem with the 
hemostatic system in inflammation, coagulation and thrombosis, as described in subsequent sections. 
The interaction and crosstalk between these systems is well recognized. While inflammatory response 
prepares the stage for coagulation, they are intertwined processes as some of the inflammatory 
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response continues during coagulation, especially where there is infection. Hence, the two processes 
are discussed together, although the emphasis in this research is on coagulation and thrombogenicity, 
and any distinction should be understood from the text or specific sections. 
 
 
Figure 2-1. Schematic of pattern recognition receptor types 
 
This section examines and further investigates some of the pertinent issues that arise from the 
crosstalk and interaction between elements of the immune system in the presence of metallic 
biomaterials, under flow conditions. Although it is known that the innate immune system response is 
based on the intensity of the intruder signal as well as the identity in some cases, where there is 
ligand-receptor specificity, the response is generally nonspecific, in the form of inflammatory 
mediators. There is an interesting question of whether the stimulus sensing mechanism has the ability 
to decompose the signal into other dimensions to facilitate response and determine the level of each 
inflammatory mediator. In this research, each system is examined and important questions that arise 
from a systems view are highlighted and where possible postulations are made.  
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2.2.1.1 Complement system 
The complement system, which is made up of 32 proteins (plasma and membrane-bound) [2], 
is the backbone of the humoral innate system response mechanism, which plays an important role in 
health and disease states [69, 70]. It is always in an active surveillance state for any microorganism or 
foreign bodies. Consequently, complement proteins are immediately activated by the presence of 
microorganisms and/or implants through pattern recognition receptors, such as the mannose binding 
lectins or implant surface-bound proteins, such as immunoglobulin IgG. The complement system is 
composed of plasma proteins C1 up to C9 and regulatory proteins that mediate the various functions 
of activated complement fragments [2]. Complement system proteins occur at various physiological 
concentrations. The serum concentrations of the main proteins are presented in Table 2-2. The active 
enzymes are as described below in the system activation. 
 
Table 2-2. Physiological concentrations of the main complement proteins, adapted from [58]. Protein	   Serum	  concentration	  (mg/ml)	   Estimated	  molecular	  weight	  (kDa)	  
Active	  enzyme	  
C1	   (C1q,	   C1r,	  C1s)	   (0.05-­‐0.1,	  0.035-­‐0.04,	  0.032-­‐0.04)	   (459,	  83,	  83)	   C1r,	  C1s	  C2	   20-­‐35	   108	   C2a	  C3	   1.5-­‐1.7	   185	   C3bBb,	  C3b2Bb,	  C4b2a3b	  C4	   0.3-­‐0.6	   200	   C4b2a	  C5	   0.12-­‐0.18	   185	   	  
 
The complement system is activated through three main pathways: classical pathway (CP), 
lectin pathway (LP) and alternative pathway (AP), which all converge at a common point by 
formation of C3 convertase, which amplifies complement activation. The activation of fluid phase or 
surface-bound complement proteins occurs through a cascade of proteolytic cleavage of complement 
components and results in the generation of biochemically active complement fragments which 
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perform three main functions; inflammation (C3a, C4a and C5a anaphylatoxins), opsonization 
tagging (C4b and C3b opsonins) and membrane attack (terminal complement complex, MAC C5b-9), 
Figure 2-2.  
 
 
Figure 2-2. Schematic of the conventional complement activation cascade, adapted from [2]. 
 
The detailed conventional complement cascade is depicted in Figure 2-3. In the classical 
pathway (CP), complement C1 is activated by its component C1q directly binding to pathogen 
surface, e.g. CRP, apoptotic cells or indirectly binding to surface-bound antibodies, predominantly the 
immunoglobulins IgM and IgG [2]. This results in the activation of C1r, which activates C1s. 
Activated C1s then cleaves C4 to release anaphylatoxin C4a and surface bound C4b. C4b binds C2, 
which in turn is cleaved by C1s to release C2b and form the CP C3 convertase, C4b2a. In the lectin 
pathway, MBL is structurally similar to C1q and the mannose-binding-lectin-associated serine 
protease (MASP-2) enzyme plays the same activation pathway as the C1s in the classical pathway. 
Hence, the end result is the LP C3 convertase, C4b2a. 
For the alterative pathway, which accounts for about 80-90% of complement activation [69], 
the key complement protein is C3. C3 is the most abundant as well as structurally and functionally 
diverse protein [2], which as described above, also plays a central role in all the three complement 
activation pathways. The spontaneously hydrolyzed complement component C3, C3(H2O), binds 
factor B, which is cleaved by the always active state factor D to form soluble C3 convertase, C3bBb. 
This then activates C3 into the soluble C3a and surface-bound C3b fragments. While C3a (9 kDa) is 
an anaphylatoxin that plays a role in leukocyte chemotaxis, C3b (176 kDa) is a short lived fragment 
with half-life ≈90-100 µs [71, 72] that has multiple binding sites [2, 71] and covalently binds to 
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surfaces [73]. Its half-life is increased 10-fold by binding to properdin [70]. It is then either 
inactivated by factor I to form the immobilized opsonin iC3b and other fragments (e.g. C3c, C3dg) or 
binds to factor B, subsequently cleaved by factor D, to form the potent surface bound C3 convertase. 
 
 
Figure 2-3. Detailed schematic of the conventional complement cascade. Rectangles indicate 
enzymes, red circles indicate anaphylatoxins, green ellipses indicate some of the main complement 
proteins, a red ellipse represents opsonin and a dashed red ellipse represents a membrane attach 
complex. The open arrows represent proteolytic activity. 
 
The C3 convertase further cleaves C3 in a feedback loop, thus amplifying C3 activation. 
Additionally, C3 convertase also binds C3b to form C3b2Bb, C5 convertase. C5 convertase binds C5, 
which is then cleaved by the active site, Bb, to form the anaphylatoxin C5a and surface bound 
fragment C5b. C5b then binds C6 and other complement proteins C7, C8 and C9 bind to the C5b6 
complex and go through conformational change that enables their hydrophobic sites to be inserted 
into the cell membrane, ending with the formation of a terminal complement complex (TCC), C5b-9, 
also called membrane attack complex (MAC). The end result of MAC is a 10 nm pore on the cell 
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surface [2], which compromises the cell membrane integrity. The MAC can also exist in a soluble 
form by binding of an S-protein through C5b-7 to form sC5b-9, which prevents surface binding. 
While the above description forms the backbone of complement activation pathways, it only 
represents the classical or conventional view. Current knowledge suggests that the complement 
system is also activated through extrinsic pathways from the hemostatic as a well the coagulation 
system. Platelets can activate the classical and alternative pathways [74] and thrombin and other 
factors of the coagulation cascaded can cleave C3 and C5 [70, 75]. There is also evidence of other 
extrinsic pathways even in soft tissue [76]. Based on current knowledge, an updated representation of 
the complement cascade is presented on Figure 2-4. 
 
 
Figure 2-4. Schematic of the updated complement activation cascade. For simplicity no 
regulatory pathways are included; only the main activation feedback pathways (dashed lines) are 
shown. On the coagulation cascade there are many other factors involved, which include plasma 
kallikrein and factor Xa. 
 
However, regardless of the activation pathway, there are three main functions that emanate 
from complement activation; inflammation, opsonization and cell lysis. In addition to these common 
functions, there has been evidence of a variety of other functions, including bridging the innate and 
adaptive immune systems [2], tissue remodeling and non-lytic complement C5b-9-mediated effects, 
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such as hemostasis (endothelial cell secretion of von Willebrand factor) [77] and platelet 
microparticle formation [78, 79]. Hence, complement proteins are an important component of the 
blood-biomaterial interaction system, in vivo and in vitro, and a complete investigation of MIT 
requires inclusion of complement activation. The broad variety of functions resulting from 
complement activation, as well as cell functions facilitated by complement fragments are depicted in 
a schematic in Figure 2-5. 
 
 
Figure 2-5. Schematic of the functions of complement and complement-mediated cell functions 
 
2.2.1.1.1 Complement-biomaterial interaction 
In the presence of a biomaterial implant, the presence of water and other proteins in the 
plasma means complement competes with other proteins for specific interactions with cell receptors 
and non-specific interactions with a material surface. The arrival of proteins at the surface in a 
diffusion-limited case would depend on their diffusion coefficients and molecular weights. Some of 
the major proteins and their diffusion coefficients are listed on Table 2-3. Thus, based on simple 
diffusion-limited phenomenon, the arrival of the proteins at the implant surface will be in the order of 
first arrival; albumin>IgG>IgA>C3>fibrinogen [80]. In comparison, water has the highest diffusion 
coefficient at about 4840x10-7 cm2/s. Therefore, in reality water would appear ahead of albumin, 
giving the arrival sequence of water>albumin>IgG>IgA>C3>fibrinogen. However, under flow 
conditions, convective transport effects and lateral diffusion, influenced by the geometry of the 
conduit result in a much more complex phenomenon and these factors would have to be taken into 
account to develop a realistic interaction model. Due to water’s volume effect, dynamic conditions 
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may have little influence on its arrival at the surface. More importantly, water molecules can easily 
dissociate into hydrogen and hydroxyl ions, which react with biomaterial surface molecules, raising 
important issues on surface hydration [81]. This makes water an important role player in blood-
biomaterial interactions and therefore worthy of detailed investigation. 
 
Table 2-3. Diffusion coefficients of some major blood proteins. Data adapted from [58, 80]. 
Protein Concentration 
(mg/ml) 
Molecular 
weight 
(kDa) 
Diffusion 
coefficient 
(10-7 cm2/s) 
Isoelectric point 
in neutral 
solution 
Half-life 
(days) 
Albumin 40-55 66-66.5 6.1 4.7-4.9 17-23 
IgG 6.5-16.5 150 4.0 6.3-7.3 20-21 
Fibrinogen 2.0-4.0 340 2 5.5-5.8 3.1-3.4 
C3 1.5-1.7 180-185 4.5 6.1-6.8, 5.7 [71]  - 
IgA 1.0-4.0 150-162 4  - 5.0-6.5 
 
The arrival of proteins at the surface is not necessarily related to the participation of the 
protein in the formation of the biomaterial surface protein layer. The protein layer is determined 
predominantly by the protein and material characteristics, such as surface chemistry and surface 
charge. Hence, the isoelectric point has great significance because it is an indicator of the charge 
carried by the molecule in the blood. An isoelectric point is the pH at which the molecule carries no 
charge. At lower pH than its isoelectric point, the molecule becomes electropositive because of 
protonation (gain hydrogen atom) and at higher pH it becomes electronegative, because of 
deprotonation. Thus, at blood level pH (≈7.4), the proteins will carry negative charge. This has great 
relevance to biochemical interactions of blood molecules with a biomaterial surface and hence will 
influence the protein function and participation in the formation of a protein layer on the biomaterial 
surface. Of particular interest are complement proteins, which although are influenced by a variety of 
material properties, have shown pH sensitive surface binding efficiency; increasing with decreasing 
pH [73] and C1 has affinity for negative surfaces [25].  
At the biomaterial surface, complement is mostly activated through the alternative pathway 
although the other pathways also play an important role [7, 82, 83], such as the reported delay in the 
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alternative pathway related to lack of the classical pathway C4 [83]. When complement fragment C3b 
is bound to a foreign surface, it is stabilized by factor P (properdin) to ensure stability of C3 
convertase [2, 71, 84]. The extent and pattern of complement activation is determined by biomaterial 
surface characteristics, such as size, chemistry and topography [25, 85]). The preference of C3 and 
C3b for hydroxylated surfaces [71], raise very interesting questions about complement interaction 
with TiO2 since the presence of water forms hydroxyl groups on the titanium surface. Besides 
covalent bonding to hydroxyl groups, C3b can also form stable amide bonds with amino groups. 
Interestingly, C3b, which forms the basis for the alternative pathway C3 and C5 convertases, can 
adsorb on other surface bound proteins, except fibrinogen [83]. Although this suggests a competitive 
advantage in surface adsorption, some of the adsorbed proteins reduce complement activation [86]. 
Therefore, surface characteristics play an important role in influencing complement activation and 
adsorption. 
The presence of surface-bound convertase facilitates localized amplification of complement 
activation, resulting in increased release of soluble leukocyte activating and recruiting anaphylatoxins 
C5a, C3a andC4a, in order of potency. Hence, C5a and C3a, which act through their specific G 
protein-couples receptors, C5aR and C3aR, respectively, are the most important and the most 
investigated receptors [87]. They are of particular interest because of the linkage between 
inflammation and thrombosis. In addition, fragment iC3b acts as an opsonization agent, with the aid 
of antibody IgG binding to the FcγR (immunoglobulin receptor) on leukocytes. More importantly, in 
addition to leukocyte recruitment, biomaterial bound fragment iC3b is a ligand for leukocyte Mac-1 
receptors, which facilitates leukocyte adhesion and possible localized oxidative stress, which can be 
detrimental to cell and tissue function. Indeed, fragments C3a and C5a have been associated with late 
lumen loss in drug-eluting stents [88]. Hence, complement inhibition has been investigated to reduce 
these effects and leukocyte activation.  
It is important to note that the detrimental effects of activated complement are controlled by 
specific regulatory proteins that inhibit complement activation or formation of convertase. 
Complement C1 activation is inhibited by C1 inhibitor (C1INH), which binds C1r, C1s and activated 
MASP-2. Proteins that inhibit formation of C3 convertase include the decay-accelerating proteins 
(DAF) (displaces Bb or 2a from C3 convertase), factor H (displaces Bb) and complement receptor 1, 
CR1, (displaces 2a or C3b) [2]. There is also autologous cell protection from formation of MAP by 
   22 
CD59 (protectin). Although these proteins are not discussed in this research, their role need to be 
recognized as they are equally important in regulating the cascade as well as the effector functions. 
2.2.1.2 Leukocytes and the coagulation system 
The leukocyte system is made up of a number of cell subpopulations; neutrophils, 
lymphocytes, monocytes, eosinophils and basophils. Leukocytes constitute only 0.1% of the blood 
cell volume, but they play various key roles in health and disease states. Leukocytes originate from 
the pluripotent hematopoietic stem cells of the bone marrow, with the common myeloid progenitor 
cell lineage [2]. They are already terminally differentiated when they are released into the peripheral 
blood circulation. Leukocytes have structural and biochemical similarities and differences. As a result 
they have some overlapping as well as specialized roles. Most of the leukocytes participate in the 
inflammatory response in vivo [54]. However, in subsequent coagulation and immune response to the 
presence of a biomaterial implant, monocytes and neutrophils are the main leukocytes known to play 
a significant role. Although eosinophils perform similar functions to neutrophils, they are small in 
number and so are not usually considered in blood-biomaterial studies. Hence, in this thesis, only 
neutrophils and monocytes are discussed. Some of the typical neutrophil and monocyte characteristics 
are depicted on Table 2-4. Although neutrophils and monocytes have some structural and biological 
similarities, they also have distinct differences, such as lifespan, both in circulation and in tissue, that 
are also reflected in their functions [67].  
 
Table 2-4. Neutrophil and monocyte characteristics. Data adapted from [89]. 	   Geometry	   Percentage	  of	  cell	  volume	  	   Volume	  (µm3)	   Surface	  area	  (µm2)	   Granules	   Mitochondria	  
Neutrophils	   190	   300	   15.4%	   0.6%	  
Monocytes	   230	   430	   2.6%	   3.5%	  
 
2.2.1.2.1 Neutrophil structure and function 
Neutrophils, also known as polymorphonuclear leukocytes (PMNs) because of their 
multilobe-shaped nuclei, are the most abundant cells of the leukocyte family, making up 60-70% of 
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the leukocyte population. They are formed in the bone marrow and released already terminally 
differentiated into peripheral blood circulation at a rate of about 1011 cells per day [90], with a 
turnover of 6.6 days. Most of the produced neutrophils are held in the bone marrow and released into 
circulation on demand, such as during inflammation, but their homeostasis level is predominantly 
regulated by the granulocyte colony-stimulating factor (G-CSF) [91]. In mice only about 1% of 
PMNs are in circulation at any point in time [91]. Their lifespan in vivo is dependent on their location 
as well as the state of health and disease. In blood their lifespan is 4-8 hours and in tissue it is 4-5 
days, but shorter in disease conditions [54]. However, it has been suggested that their lifespan may be 
extended by TLR4 stimulation and the presence of monocytes [92]. 
Under physiological conditions, quiescent circulating neutrophils are spherical with randomly 
shaped and distributed surface membrane folds and microvilli [93]. The height of the membrane folds 
is estimated at about 0.2 µm [94]. The pleated membrane surface can unfold when the cell is 
stimulated to allow shape change and increase the surface area [93]. Leukocyte cell membranes 
constitutively express a variety of cell receptors that assist with the initial sensing of the environment 
and initial cell adhesion. P-selectin glycoprotein ligand 1 (PSGL-1) receptor, which is important for 
leukocyte arrest under shear [95-98], is expressed on the leukocyte microvilli at a density of 104 
molecules/cell [99]. Also co-expressed on microvilli is L-selectin, which mediates surface scanning 
and secondary leukocyte arrest [97, 98, 100]. PMNs also express an integrin family of receptors, 
which stabilize adhesion interactions, such as the multifunctional Mac-1 [101]. Mac-1 is 
predominantly stored in the intracellular granules in quiescent PMNs and is translocated to the 
surface upon activation [102]. Other constitutively expressed receptors that assist with the initial cell 
response and function are called pattern recognition receptors. There are several pattern recognition 
receptors [65], but the most important receptors for this research are the toll-like-receptors (TLRs) 
and the complement receptors. TLRs, which are expressed predominantly on monocytes compared to 
neutrophils, are the main pattern recognition receptors in innate immunity [67]. There are nine human 
TLRs, but only TLR4 is of particular interest because in association with the co-receptor CD14, it is a 
receptor for the conserved bacterial gram-negative lipopolysaccharide (LPS), which is commonly 
encountered on biomaterial surfaces [103-105]. TLR-4 signals through the two independent TLR 
adaptor proteins, MyD88 (myeloid differentiation primary-response gene 88) and TRIF (Toll/IL-1R 
domain containing adapter protein-inducing interferon-β), with downstream activation of 
transcription factors NF-κB or the interferon response factors (IRFs) [2]. Activation of NF-κB 
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pathway results in an inflammatory response (production of pro-inflammatory cytokines) and can also 
activate adaptive immune responses [66]. On the other hand, activation of IRFs results in an antiviral 
response (production of interferon IFN α/β). Therefore, the NF-κB pathway is of particular interest in 
biomaterial studies because it is also the pathway for leukocyte tissue factor expression [106]. 
Besides pattern recognition, TLRs fall into a class of receptors called chemotactic receptors 
[92], together with receptors for platelet activating factor (PAF) and N-formyl peptide. The formyl 
peptide receptor (FPR), which has the tripeptide formyl-methionyl-leucinyl-phenyalanine (fMLP) as 
its ligand, is one of the important leukocyte receptors because its intracellular signal is transduced 
through cytoskeletal actin microfilaments. fMLP is an effective chemotactic and greatly influences 
leukocyte function. There are also constitutively expressed complement receptors, C3aR, C4aR and 
C5aR, which are expressed on most leukocytes [107, 108]. Neutrophils express approximately 3100 
C3aR and 63500 C5aR molecules/cell [108]. These receptors are signaling receptors, which induce a 
variety of functions other than inflammation, such as chemotaxis; an important leukocyte function 
that enables the cells to emigrate from circulation through the vascular wall into tissue (leukocyte 
extravasation) as a response to inflammation. Leukocyte extravasation predominantly occurs in 
venules [97], where shear stress is very low, although mechanisms that facilitate rolling and arrest at 
high shear have been recently highlighted [98]. After fulfilling their function in tissue, neutrophils are 
eliminated by apoptosis. 
Neutrophil functional capabilities are also dictated by their intracellular biology. Inside the 
neutrophil cytoplasm, like all eukaryotic cells, is a cytoskeleton formed from abundant actin 
microfilaments, microtubules and intermediate elements [109, 110]. The cytoskeleton provides a 
signal transduction pathway for the chemical and shear sensitive G-protein-coupled receptor, FPR. 
Actin filaments and other cytoskeletal elements form an intracellular calcium dependent contractile 
mechanism that can be dynamically rearranged (expand and retract) in response to environmental 
chemical or mechanical (shear) conditions. The cytoskeletal rearrangement results in the rapid 
formation of pseudopods and lamellipods that induce change in morphology and confer leukocyte 
function to neutrophil [111]. Consequently, neutrophils have the capacity to rapidly respond and 
migrate to inflammatory sites where they can release inflammatory mediators, release oxygen radicals 
or engulf microorganisms (phagocytosis). Some of the important inflammatory mediators are the 
neutrophil extracellular trap (NETs) because of their possible role in mediating thrombosis [112, 
113]. Phagocytosis is one of neutrophils main functions stimulated by chemotactic agents, such as 
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complement iC3b fragment. During chemotaxis, PMNs exhibit an asymmetric and directional cellular 
motility [114, 115], facilitated by intracellular calcium-dependent rearrangement of their abundant 
contractile proteins in the cytoskeleton [115]. Neutrophils also contain abundant granules in their 
cytoplasm, which contain lysozymes. During phagocytosis, neutrophils degranulate and release the 
enzymes to digest foreign materials, simultaneously releasing oxygen radicals through respiratory 
burst. This two-pronged process neutralizes any foreign material that cannot be digested by the 
lysozymes. 
There are possible side effects that may occur while neutrophils perform their functions. Side 
effects include tissue damage from respiratory burst, which could trigger a further inflammatory 
response [116-118]. One mechanism of inflammation regulation by neutrophils is through production 
of anti-inflammatory cytokine, interleukin-10 (IL-10) [119, 120]. Another mechanism that controls 
inflammation is the PMN programmed cell death (apoptosis), which is followed by phagocytosis 
from macrophages, as cell membrane fragments could trigger coagulation [121]. The respiratory burst 
is also to some extent self-regulating because of the limited capacity of oxygen-dependent energy 
production. Neutrophils produce their energy primarily through anaerobic glycolysis [122] because 
they have few mitochondria compared to monocytes [93, 123] and hence the limited amount of 
oxygen used for respiratory burst. Their mitochondria seem to play a bigger role in apoptosis [123] 
and regulation of glycolysis. Thus, neutrophils have a broad range of functions, both at the 
biochemical as well as the cellular level. The broad range of functions are depicted on Figure 2-6.  
 
 
Figure 2-6. Illustration of neutrophil functions 
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2.2.1.2.2 Monocyte structure and function 
Monocytes are formed in the bone marrow, from the same myeloid progenitor lineage as 
neutrophils. Monocytes are larger than the other leukocytes. They constitute 3-8% of the leukocyte 
population and have a lifespan of 10-20 hours in blood [54]. Some of the monocytes in circulation 
extravasate through the vascular walls into tissue and become macrophages, which have a longer 
lifespan of several months. Macrophages may subsequently merge to form large and more aggressive 
foreign body giant cells, which have a lifespan of days [54]. 
Similar to PMNs, under quiescent physiological conditions, circulating monocytes are 
spherical with randomly shaped and distributed surface membrane folds and microvilli. Monocytes 
express the same family of selectins and integrin receptors. In monocytes, Mac-1 is translocated from 
intracellular vesicles to the surface upon activation [124]. Similarly, monocytes constitutively express 
the same pattern recognition receptors as PMNs although the surface expression density may vary. 
Monocytes express more TLR2 and TLR4 than PMNs [125]. Monocytes also express on average 2-
fold more C3aR and 2-fold less C5aR than PMNs; 6000 C3aR and 34100 C5aR molecules/monocyte 
[108]. In the cytosol, monocytes have abundant intracellular cytoskeleton similar to PMNs, which 
facilitates similar functions as described for PMNs. However, unlike PMNs, they do not possess the 
same number of granules and hence do not possess the same phagocytotic capacity as PMNs. Their 
phagocytotic capacity is enhanced after they differentiate into macrophages. 
Although some monocytes functions are generally similar to PMNs, such as production of 
pro/anti-inflammatory agents and physical participation in thrombus formation, one function where 
they play a distinct role is the tissue factor-dependent coagulation, especially LPS-induced tissue 
factor. Monocytes are recognized as the main leukocyte source of tissue factor (TF). It should 
however be noted that there is evidence that neutrophils are also indirectly involved in facilitating TF-
dependent coagulation/thrombosis by cleaving tissue factor pathway inhibitor [126]. TF can be 
induced by a variety of stimulants under both in vitro and in vivo conditions [127-134]. One of the 
known TF regulating agonists is LPS, which has been shown to regulate TF expression at both the 
transcription and posttranscription levels on monocytes [135]. TF is induced through a number of 
pathways. LPS induces TF expression on monocytes through three MAPK pathways [24, 136], which 
can be inhibited by the PI3K/Akt signaling pathway [24, 136]. LPS is a ligand for TLR4 (and co-
recognition of CD14), which signals through the NF-κB pathway [63]. This provides another TF 
expression mechanism as the NF-κB pathway has been implicated in TF expression. There has also 
been evidence of intracellular localization of TF in whole blood monocytes [137]. The significance of 
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this in biomaterial-induced thrombosis is not clear. The broad functions of monocytes are depicted on 
Figure 2-7. Since TF-dependent coagulation cascade is important in thrombosis, it is appropriate to 
discuss coagulation in more detail. 
 
 
Figure 2-7. Illustration of monocyte functions 
 
Coagulation is a complex biochemical process that involves cellular and plasma protein 
components to form a blood clot. It is characterized by a cascade of proteolytic activation of clotting 
factors, with amplifying pathways, which result in the formation of fibrin and activation of platelets. 
It is activated following an inflammatory response to vascular endothelial wall injury or response to a 
foreign body, such as an implant. In vascular wall injury, coagulation prevents blood loss by forming 
a hemostatic plug. In response to an implant, coagulation results in encapsulating the implant. 
However, if the implant is in a blood vessel lumen, such as a stent, blood coagulation may 
subsequently result in thrombosis, with undesirable consequences as discussed above. Regardless of 
the trigger mechanism, the coagulation cascade involves two pathways, the intrinsic and extrinsic 
pathways, Figure 2-8. As depicted in Figure 2-8, these pathways function in collaboration with other 
systems as previously described. The extent of involvement of each pathway in triggering coagulation 
may depend on the stimulus. 
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Figure 2-8. Block schematic of the coagulation cascade. The intrinsic and extrinsic pathways form 
the core of the classical coagulation system. Interaction with other systems is depicted but for 
simplicity the regulatory pathways are not included. 
 
In the case of biomaterial implant, coagulation involves the two pathways. The intrinsic 
pathway, also called the contact activation pathway, forms the backbone of the contact system, 
section 2.2.2. The extrinsic pathway is composed of the tissue factor-dependent pathway. Tissue 
factor is a 45 kDa glycoprotein member of the class-2 cytokine family of receptors, well recognized 
as the blood coagulation initiator in vivo [24]. It is a transmembrane receptor, constitutively expressed 
in some cells, such as vascular smooth muscle cells and adventitial fibroblasts [24]. The constitutive 
expression of TF in the vascular adventitia facilitates its ability to initiate blood coagulation in vivo 
since it can be immediately exposed to blood proteins. In addition, in lung derived fibroblasts 75% of 
the synthesized TF is stored in Golgi and transported to the surface after surface TF complexes with 
FVIIa [138], suggesting that additional TF may be immediately sequestered in these cells. 
Tissue factor is only expressed on endothelial cells, monocytes and macrophages [24], 
platelets [139] and PMNs [140, 141], when the cells are activated. It is also found in circulation on 
microparticles or as a soluble variant [142]. The issue of TF expression on platelets continues to be 
unresolved as some studies have shown platelet expression while others have shown surface 
expression after surface attachment of microparticles from other cells [143]. There has also been 
controversy on PMN TF expression [113]. The issue of TF expression on blood cells has been 
previously reviewed [144]. Thus, only monocytes and microparticle derived TF are undisputedly 
recognized as the main sources of TF in material-induced thrombosis. The TF-dependent cascade, 
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involves a number of proteins, Table 2-5. Most of the proteins form pathways common to the contact 
system, which is discussed in section 2.2.2.  
 
Table 2-5. Some coagulation cascade proteins. Data adapted from [58, 145]. Protein	   Plasma	  concentration	  	   Estimated	  molecular	  weight	  (kDa)	  
Protein	  half-­‐life	  (hours)	  
Active	  enzyme	  complex	   	  Fold	  activity	  increase	  
Tissue	  factor	   	  -­‐	   43-­‐53	   	  -­‐	   	  -­‐	   	  -­‐	  Prothrombin	   1.1	  µM	   72	   48-­‐72	   	  -­‐	   	  -­‐	  Factor	  V	   7	  µg/ml	   >300	   12-­‐15	   	  -­‐	   	  -­‐	  Factor	  VII	   0.5	  µg/ml	   50	   2-­‐5	   TF.FVIIa.Ca2+.PL	   57,000	  [146]	  Factor	  VIII	   0.5	  nM	   >250	   8-­‐17	   	  -­‐	   	  -­‐	  Factor	  IX	   3-­‐5	  µg/ml	   55-­‐57	   24	   FIXa.FVIIIa.Ca2+.PL	   200,000	  [147]	  Factor	  X	   10	  µg/ml	   59	  dimer	   24-­‐40	   FXa.FVa.Ca2+.PL	   500,000	  [148]	  Factor	  XIII	   70	  nM	   320	   216-­‐240	   FXIIIa.Ca2+	   -­‐	  Fibrinogen	   6-­‐13	  µM	   340	   72-­‐120	   	  -­‐	   	  -­‐	  
 
The detailed tissue factor dependent cascade is depicted on Figure 2-9. The intrinsic pathway 
is included for completeness as it is covered in section 2.2.2. Tissue factor has high Ca2+-dependent 
binding affinity to its cofactor, the vitamin K-dependent factor VII or its activated form (FVIIa), with 
dissociation constant Kd<10 pM [149]. Factor VII cleavage by FXa produces FVIIa, an enzyme with 
Ca2+-dependent affinity to phospholipids (PL). Upon binding to phospholipids, FVIIa goes through 
conformational change, which exposes epitopes that enable binding with TF [150]. The enzymatic 
function of FVIIa, a stable protein with half-life of 2.5 hours [151], has little dependence on 
phospholipid binding, but is activated by forming a complex with TF [152]. In the presence of 
calcium ions, the complex {TF.FVIIa.Ca2+.PL} has affinity for FIX, which when bound is cleaved to 
form FIXa. Cleavage of FIX to FIXa is also produced by FXIa from the contact system (section 
2.2.2), from where the two systems have a common pathway. Factor IXa then forms a complex with 
FVIIIa (described below). In addition, the {TF.FVIIa.Ca2+.PL} complex also cleaves fluid FX to FXa. 
In this reaction, the phospholipid has an important role because it decreases the Michaelis constant 
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Km for FXa and thus increases the catalytic constant Kcal (Kcal=Vmax/Km) [145]. FXa forms a 
prothrombinase complex with FVa, which rapidly activates prothrombin to thrombin. 
Thrombin then cleaves fibrinogen to form fibrin, which forms the base membrane for 
thrombus formation. The developing thrombus is stabilized by the cross-linking of fibrin by FXIIIa. 
Therefore, FXIIIa may play a big role in thrombus growth [153], which may need closer examination.  
Thrombin is also a potent agonist for platelets. Hence it activates platelets and in a cyclic feedback 
amplifies some of the clotting factors. Activated platelets adhere to fibrin and conformational 
changed fibrinogen. Fibrinogen conformation change or structural unfolding occurs upon surface 
contact and adsorption [154-158], which results in the dissociation or opening of the αC regions of its 
molecule [157], and subsequently exposes binding epitopes that are normally hidden [155, 156, 159]. 
Conformationally changed fibrinogen also offers similar binding epitopes to fibrin, which also bind 
leukocytes [160]. Hence, the TF expression initiates a TF-dependent blood clot formation, which 
without platelets will just be a fibrin mesh, with leukocytes and trapped RBC. Leukocytes have been 
found to form 16% of a blood clot [161]. Thus, they play an important role in initiation of TF-
dependent thrombosis. In addition, monocyte-derived microparticles expressing TF seem to 
predominantly trigger thrombin formation in a TF-dependent pathway while platelet microparticles 
seem to trigger thrombin generation in a FXII-dependent pathway [162]. This may also provide a 
mechanism for propagation. 
Besides extracellular effects of coagulation, the TF/FVIIa complex also possesses 
intracellular effects (signal transduction) through the G-protein coupled protease-activated receptor, 
PAR2 receptor [131]. This provides diverse roles, including inflammation, cancer progression and 
angiogenesis, which have been a subject of several reviews [163-165]. 
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Figure 2-9. Schematic of the coagulation cascade. The pathways boxed with dashed lines represent 
the coagulation initiating process and the unboxed pathways are common pathways, which represent 
the propagation and amplification processes. For simplicity inhibitory pathways are not included. 
HMWK: high molecular weight kininogen, Prekal: pre-kallikrein, Kal: kallikrein, PL: phospholipid, 
PT: prothrombin. 
 
While there are known inhibitory pathways, both at the cellular and molecular levels, to stop 
pathologic propagation of the clot, pathologic thrombotic conditions do occur in the presence of 
biomaterials. Mechanisms that regulate these pathways in the presence of biomaterials under flow 
conditions are not well understood. To develop intervention methods or novel biomaterials, it is 
necessary to understand the influence of biomaterial-blood-flow interactions on coagulation 
pathways. 
2.2.1.2.3 Effect of flow on leukocytes 
Mechanical fluid shear stress/rate generally activates leukocytes resulting in the upregulation 
of surface receptors, such as Mac-1 and TF. However, there is evidence that at high shear rates 
leukocyte sensitivity to shear is reduced by internalization of the leukocyte mechanosensor, formyl 
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peptide receptor (FPR), and retraction of pseudopod [94, 166], which has also been shown in a rat 
model [167]. Shear stress has also been shown to inactivate the integrin αMβ2 [166]. Recent studies 
have also shown Mac-1 down-regulation under high shear [168]. It is not clear what other factors 
influence the point at which leukocytes sensitivity to shear is reduced. Also the general implications 
of these observations are not clear on other receptors, such as TF, or on leukocyte material interaction 
under shear. As for leukocyte adhesion, generally high shear seems to reduce adhesion. However, 
there have also been conflicting reports, which may be partly attributed to experimental conditions, as 
highlighted by Gorbet, et al [169]. Further investigations are necessary to clarify the effect of shear 
rate on leukocyte activation. 
2.2.1.2.4 Leukocyte-biomaterial interaction 
Biomaterial surface properties can activate leukocytes to express both TF [170] and Mac-1 
[171], which are important receptors for coagulation and adhesion/aggregation [172], respectively. 
For that reason, they play an important role in material-induced thrombosis, as previously highlighted 
[7]. Material-dependent leukocyte activation is mediated by recognition molecules, such as 
complement proteins. The level of complement activation and hence, leukocyte recruitment and 
activation, depends on biomaterial surface characteristics. Complement anaphylatoxin C5a plays a 
double role in enhancing inflammatory response in a material-dependent manner. C5a induces both 
Mac-1 and TF expression on neutrophils [173], even though the two proteins are expressed through 
different mechanisms. While Mac-1 is translocated from cell vesicles, TF expression follows gene 
transcription and translation [135]. It is interesting to note that surface properties, such as chemistry, 
have been found to not only influence the overall cell receptor expression, but also influenced specific 
coagulation pathways such as the preference of the intrinsic (FXIIa-dependent contact system) over 
the extrinsic (TF/FVIIa-dependent) pathway [170]. Thus, in investigating leukocyte activation, it is 
important to note that the coagulation initiating pathway may not be reflected merely from the cell 
receptor expression. 
Activated leukocytes physically interact with a biomaterial surface through surface adsorbed 
proteins, predominantly complement fragment iC3b and fibrinogen. As previously described, 
complement fragment iC3b is a surface-bound ligand for Mac-1 receptors and therefore facilitates 
leukocyte adhesion. Similarly, surface adsorbed fibrinogen conformational change exposes its 
hydrophobic D domain binding peptide sequences P1 (γ190-202) and P2 (γ377-395) [160], which 
have affinity for integrins, such as Mac-1 receptors. The P1 and P2 peptide sequences also exist on 
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fibrin, facilitating leukocyte adhesion to fibrin. The ability of proteins to adsorb varies, not only with 
the biomaterial, but with each protein’s intrinsic and extrinsic properties, bulk concentration [174], 
molecular weight, structure and conformational stability [174, 175].  
The primary material characteristics that influence protein conformational change and 
adsorption are surface chemistry [174], surface energy and surface electrostatics/charge [176]. The 
secondary material properties are roughness and topography, and geometry. Thus, material 
characteristics influence the pattern or selective expression of absorbed protein epitopes, e.g. RGDS 
sequence on fibrinogen [155], the rate of structural transition, e.g. different polymeric materials 
induce different structural transition rates [177] and the extent of binding sequence exposure [160]. 
Both the rate of protein structural transition and the extent of binding sequence exposure have 
implications for the accumulation of leukocytes, which have an equally important role as platelets in 
material-induced thrombosis [178]. While the extent of sequence exposure will influence the extent of 
aggregation and thrombus formation, the rate of leukocyte accumulation may be particularly 
important in determining the fate of the thrombus. It remains unclear whether the accumulation rate 
has any effect on the stability of the thrombus or on the localized detrimental effects of oxidative 
stress. 
Therefore, the effect of material characteristics on the rate of protein structural transition – 
leukocyte accumulation rate – may need closer scrutiny. This is important not only for in vivo, but 
also for in vitro conditions. Besides the need to understand its effect on thrombus, the effect on in 
vitro investigation results are crucial. If the investigation is terminated before transition is complete, 
the rate will influence the interpretation and extrapolation of experiment results. Hence, this is a 
critical issue that needs to be determined for in vitro models. 
2.2.2 Contact system 
The contact system is a component of the coagulation system and is composed of four main 
proteins; factor XI (FXI), factor XII (FXII), plasma pre-kallikrein and high molecular weight 
kininogen (HMW kininogen or HMWK), Table 2-6. While the rest of the proteins are zymogens 
(inactive form of enzymes) for active enzymes, only HMWK is a non-zymogen. HMWK is a co-
factor for pre-kallikrein and FXI zymogens and their respective enzymes, with dissociation constants 
of Kd=15nM [179] and Kd=32nM [180], respectively. Besides existing as a co-factor, HMWK 
facilitates binding of the complex to negatively charged surfaces, such as phospholipids. Factor 
XII/XIIa on the other hand can bind directly to negatively charged surfaces. The binding of the 
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proteins to the surface facilitates the surface-initiated and propagated coagulation process. Thus, 
limiting coagulation in the fluid phase. 
 
Table 2-6. Contact system proteins, adapted from [58, 145]. Protein	   Plasma	  concentration	   Estimated	  molecular	  weight	  (kDa)	  
Active	  enzyme	   Protein	   half-­‐life	  (hours)	  
Factor	  XI	   6µg/ml	  (≈35	  nM)	   150	  dimer	   FXIa	  (SP)	   48-­‐84	  Factor	  XII	   40µg/ml	  (≈500	  nM)	   80	   FXIIa	  (SP)	   50-­‐60	  Pre-­‐kallikrein	   40µg/ml	  (≈500	  nM)	   85-­‐88	   Kallikrein	  (SP)	   	  -­‐	  HMW-­‐kininogen	   70-­‐90µg/ml	  (≈1	  µM)	   110	   Co-­‐factor	   	  -­‐	  
SP: serine protease 
 
The contact system interaction and activation pathways are depicted on Figure 2-10. 
Generally it is accepted that FXII plays a central role in the contact system. When FXII is activated, 
either auto-catalytically or through conformational changes after surface binding, it forms the αFXIIa 
(80 kDa) and βFXIIa (28 kDa) isoforms. The αFXIIa, which consists of disulfide-linked light and 
heavy chains, remains surface bound because of the heavy chain affinity to negatively charged 
surfaces. αFXIIa then acts through two main pathways; the pre-kallikrein and the FXI pathways. In 
the former pathway, αFXIIa cleaves plasma pre-kallikrein to plasma kallikrein, which in turn 
amplifies FXIIa by cleaving FXII or converts αFXIIa to βFXIIa. Kallikrein also cleaves HMWK to 
release bradykinin (an inflammatory mediator) and reorganizes HMWK, which has higher affinity for 
negatively charged surfaces. In the FXI pathway, αFXIIa cleaves FXI to FXIa, the main effecting 
enzyme in coagulation, which activates factor IX of the common pathway with TF-FVIIa, resulting in 
the production of prothrombinase and subsequently thrombin. The contact system is regulated in part 
by C1-inhibitor, which inhibits FXIIa. 
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Figure 2-10. Schematic of the contact system pathway. Open arrows represent catalytic activity. 
 
2.2.2.1 The common pathway 
Although the released FXIa is an enzyme, in the presence of Ca2+, its catalytic activity 
increases 2000-fold [145]. The {FXI.Ca2+} enzyme cleaves FIX (the same bonds as TF-dependent 
enzyme) to FIXa. FIX and FIXa have Ca2+-dependent affinity to negatively charged phospholipid 
(PL). The surface-bound FIXa, binds to FVIIIa, which is also surface bound and in the presence of 
calcium ions, the {FIXa.FVIIIa.Ca2+.PL} complex cleaves vitamin K-dependent fluid phase FX 
zymogen to FXa. The FVIIIa comes from cleaving of FVIII which circulates bound to co-factor vWF. 
Thrombin separates FVIII into fragments; one fragment which remains bound to vWF and another 
procoagulant heterodimer which has surface affinity, independent of calcium. The produced FXa 
heterodimer has Ca2+-dependent affinity for acidic phospholipids. FXa activity is increased by non-
enzymatic FVa, which is also surface-bound. FVa comes from cleavage of fluid phase FV by 
thrombin. In the presence of calcium, the surface bound prothrombinase complex {FXa.FVa.Ca2+.PL} 
binds circulating vitamin K-dependent prothrombin, through FVa, and cleaves it to release thrombin 
into circulation. The prothrombinase complex plays a crucial role in rapid thrombin production 
because of its very high catalytic activity, which is 500,000-fold compared to FXa alone [148]. As 
noted above, thrombin amplifies the reactions by cyclically activating some of the co-factors. It is 
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worth mentioning that a recent study has found that some of the coagulation factors are expressed by 
cells such as monocytes, suggesting the possibility of much more involvement of these cells in 
coagulation than merely providing surface or expressing receptors [181]. 
2.2.2.2 Flow effect on the contact system 
Blood flow influences the contact system reaction kinetics by transporting liquid phase 
zymogens and enzyme molecules to wall/surface bound activated or activating sites. More 
importantly, flow is known to induce formation of monocyte and platelet microparticles as discussed 
in sections 2.2.1.2.3 and 2.2.3.1.1, respectively. While all cell derived microparticles expose abundant 
phospholipids, specifically phosphatidylserine, which are binding sites for FXII activation, platelet 
microparticles seem to be dominant in generating thrombin in a FXII-dependent pathway [162]. Thus, 
the effect of flow on the contact system seems to be through kinetics and indirect activation through 
other systems. 
2.2.2.3 Contact system-biomaterial interaction 
The contact system proteins interact with a material surface [182] in a matter of seconds after 
implantation. In the presence of a negatively charged material, the proteins may activate each other 
but the most likely initiator of contact system activation could be FXII since its sensitivity to 
kallikrein increases 500-fold after surface adsorption [183]. The presence of a biomaterial is also 
known to induce formation of platelet microparticles, which as discussed above activate the contact 
system. Figure 2-11 is a representation of the surface-mediated activation of the contact system. In the 
presence of a biomaterial, it is possible that conformationally changed fibrinogen could directly 
activate FXII and contribute to polymerization since there is evidence of direct FXIIa interaction with 
fibrin to influence the clot structure [184]. Adherent and activated platelets also expose 
phospholipids, which provide a localized activation surface for contact system proteins. In addition, 
activated platelets may enhance contact system activation by releasing polyphosphates from their 
dense granules, which have been shown to activate FXII in vivo [185]. Certainly, a variety of 
mechanisms may contribute to the activation of the contact system in the presence of biomaterials. 
While some kinetics of the process have been described [186, 187], there is limited detailed in vitro 
kinetic parameters for biomaterial studies simulating a stented coronary artery. 
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Figure 2-11. Contact system-biomaterial interaction schematic. Prekall: plasma prekallikrein, 
Kall: plasma kallikrein. Curved arrow: proteolytic cleavage, open arrow: consequences. Adapted 
from [145]. 
 
Under flow conditions, the reaction kinetics will increase due to the transport dispersion 
effect. The strength of protein adsorption would depend on the surface characteristics of the material. 
Since surface adsorption is a critical factor in initiating and facilitating activation of the contact 
system, it is not clear if the system proteins have higher adhesion force than other proteins. It is also 
not clear if there is a shear stress at which the contact system is inhibited, such as by dislodging the 
proteins or reducing enzyme-substrate contact time. 
2.2.3 Hemostatic system 
The hemostatic system is responsible for the formation of a hemostatic plug in the event of 
vascular wall injury and plays a role in wound healing in vivo. It is composed of the vascular 
endothelium and platelets, which are the key components. The hemostatic system collaborates with 
other systems; coagulation and fibrinolytic systems. The coagulation system collaborates in several 
processes, including the polymerization of fibrinogen to form fibrin, while platelets are the ones 
responsible for the hemostatic plug. The fibrinolytic system plays a regulatory role. 
In blood-biomaterial studies, platelets are still the key component of the hemostatic system. 
However, there are also important plasma proteins that play a vital role in the hemostatic system. 
These include von Willebrand factor (vWF), fibrinogen and fibronectin. vWF is an effective protein 
in mediating adhesion of activated platelets at high shear stress. Fibrinogen, which is polymerized 
into fibrin by thrombin, also mediates platelet adhesion and platelet aggregation. Since platelets play 
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a central role in hemostasis and thrombosis, they have developed structural and biological capabilities 
that enable them to play divergent roles. 
2.2.3.1 Platelet structure and function 
Platelets are minute anuclear plate-shaped blood cells produced by fragmentation of large 
bone marrow cells called megakaryocytes, which are a sub-lineage of myeloid progenitor cells. About 
30x103 platelets are produced per day per microliter, with a turnover of 10 days [54]. They are about 
2-4 µm in size and number 250-400x103 per microliter of blood. Despite the lack of a nucleus, 
platelets possess very complex biological mechanisms. In the cytosol, platelets contain messenger-
RNA and abundant translation regulators, micro-RNAs, enabling platelets to synthesize a variety of 
proteins [188]. Splicing of mRNAs has been implicated in the existence of TF mRNA in platelets and 
hence expression of functional TF on platelets [139]. Although TF expression on platelets is still a 
topical issue of debate, the splicing of mRNAs in platelets sheds some light on their complexity. In 
addition, platelet cytosol uniquely contains α and dense granules which release adhesive proteins and 
activation mediators upon platelet activation [189]. 
The platelet membrane structure, like other cell membranes, is composed of phospholipids 
whose proportion distribution between the extracellular and intracellular space depend on the state of 
the cell. On the surface of quiescent platelet the proportional distribution of the phospholipids results 
in a neutral charge on the surface because the negatively charged phospholipids, phosphatydilserine 
(PS) and phosphatylinositol (PI) are in the cytosol. Upon activation, the phospholipids flip inside out 
and hence the majority of the PS and PI are on the surface, effectively dictating the surface charge, 
which becomes negative. This facilitates binding of proteins and enzymes with affinity for negatively 
charged phospholipids. 
Platelets express a variety of receptor molecules for adhesion and/or transmembrane 
signaling; some constitutively and some upon activation. These include the glycoprotein GPIIb/IIIa 
for fibrinogen, GPIb/V/IX for VWF, protease activated receptor (PAR1/4) for thrombin and 
P2Y1/P2Y12 for adenosine 5’-diphosphate (ADP) [189]. Some selected key receptors and their 
densities are presented on Table 2-7. Constitutive receptors include TLR4 and integrin αIIbβ3 
(GPIIb/IIIa). Although platelets express TLR4, in general it is believed that they do not express the 
associated CD14 for LPS recognition and hence LPS does not effectively stimulate some of the 
platelet functions, such as formation of microparticles. However, there has also been evidence to 
suggest that platelets express CD14 and hence LPS can stimulate platelet secretion and potentiates 
   39 
aggregation through TLR4 [190]. One wonders also whether platelet TLR4 may play an important 
part in biomaterial-platelet-leukocyte interaction and TF expression. 
 
Table 2-7. Selected platelet receptors, adapted from [191]. 
Receptor	   Density	  
(No.	  receptors/platelet)	  
Ligand	  
GPIIb/IIIa	   60,000-­‐100,000	   Fibrinogen,	  vWF,	  	  GPIb/V/IX	   25,000	   vWF	  GPVI	   15,000-­‐25,000	   Collagen	  P-­‐selectin	   12,000	   PSGL-­‐1	  
 
Platelets can be activated by a variety of biochemical agonists as well as mechanical stimulus. 
The biochemical agonists include thrombin, thromboxane A2, adenosine 5’-diphosphate (ADP) and 
platelet activating factor (PAF). Activated platelets express receptors, such as glycoprotein GPIIb/IIIa 
and P-selectin, and release a number of byproducts, some of which promote further activation and 
aggregation, and some inhibit platelet aggregation [192]. Byproducts such as ADP, Ca2+, serotonin 
and thromboxane A2 activate more platelets through positive feedback loops. The result of ADP 
feedback through P2Y receptors on platelets is rapid mobilization of platelet cytosolic Ca2+, in the 
order of 20 ms, which is estimated to be 10 times faster than thrombin and thromboxane A2 [193]. 
ADP also induces integrin αIIbβ3 (GPIIb/IIIa) expression, which has affinity for fibrinogen. Therefore, 
the consequence of the ADP effect on both platelets (GPIIb/IIIa expression) and monocytes 
(increased Mac-1 affinity to fibrinogen and FX [194]) is promotion of platelet-leukocyte aggregation. 
Platelet-leukocyte aggregation is also initiated by the P-seletin-PSGL-1 interaction.  
In addition, the effect of increased Mac-1 affinity to FX results in promotion of coagulation 
within and/or on the aggregate as Mac-1 can also coordinate FX activation [195]. It is interesting to 
note that besides enhancing Mac-1 expression and affinity, activated platelets also release soluble 
CD40 ligand (sCD40L), which binds to Mac-1 and induces TF expression, thus amplifying the 
coagulation cascade. Blood flow may help promote coagulation because there is constant transport of 
reactants to the immobilized substrate. These mechanisms have the potential to promote thrombus 
propagation. 
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Besides receptor expression and protein release, activated platelets are characterized by shape 
change. Activated platelets become round and form long filaments that allow them to increase their 
surface area and adhere to fibrin mesh, thereby blocking larger cells and stopping bleeding. In 
addition, they degranulate and form microparticles, about 0.1 µm in size [196], carry surface binding 
proteins [196, 197] and hence amplify the hemostatic interaction with other clotting systems, such as 
the intrinsic coagulation system. Therefore, activated platelets facilitate their functions by expressing 
surface receptors, releasing proteins, forming microparticles and changing their shape. The properties 
of each of these transformations allow them to contribute in various biological processes. Thus, 
platelets play a variety of roles in inflammation [198], coagulation, thrombosis and hemostasis [199]. 
A recent review suggests that they may be playing much more diverse roles than the classical ones 
(e.g. hemostasis and coagulation) [192]. The main platelet functions are summarized on Figure 2-12. 
 
 
Figure 2-12. Illustration of platelet functions 
 
2.2.3.1.1 Flow effect on platelets 
Mechanical stress, such as shear stress is known to mediate platelet activation and 
aggregation both in vivo and in vitro. The molecular basis of flow effects have been reviewed 
elsewhere [200, 201]. Blood flow influences platelet activation and aggregation through two main 
mechanisms – fluid forces and transport phenomenon [202]. In whole blood, these mechanisms are 
always augmented by biochemical agonists. Fluid shear stress type (e.g. pulsatile vs continuous) 
[203], level [204] and exposure time [204] predominantly influence platelet activation. The 
relationship between shear type, level and time is not clear. However, to predict the effect of shear 
and exposure time, various platelet activation models have been previously proposed [199, 202, 204, 
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205]. There are also more elaborate models that have taken into account some biochemical aspects 
[206]. 
The other important flow parameter that influences platelet activation and aggregation is 
transport phenomena, which influences particle distribution, hence affects cell-cell or cell-wall 
interaction and subsequent aggregation. A parameter that is a function of the transport phenomenon is 
the cell collision efficiency, previously described [199]. Thus, platelet activation and aggregation may 
be defined as a much more complex function besides shear magnitude or time-averaged shear stress. 
The existence of biochemical kinetics inherently complicates the relationship between platelet 
activation/aggregation and the various parameters. At what point one parameter overrides the others, 
e.g. shear over collision efficiency, is not clear, granted that these are intertwined. 
Generally high shear stress increases platelet receptor expression as well as protein release 
from dense granules. High shear stress also correlates with one other key property of activated 
platelets; the formation of microparticles [207, 208]. Microparticles, which are a common feature of 
cardiovascular diseases, from both activated leukocytes and platelets [209], are formed through cell 
degranulation. MPs express their parent cell proteins and bioactive molecules, which can have both 
pro-inflammatory and anti-inflammatory effect [210]. MPs carry TF, which plays an important role in 
thrombosis [163, 211]. Platelet microparticles (PMPs) express abundant factor V (FVa) receptor 
[197], which is a catalyst in the coagulation cascade, and PMPs from high shear activated platelets 
have been shown to enhance time-dependent cytokine production and Mac-1 expression on 
monocytic THP-1 cells [212]. In addition, activated platelets and PMPs have been shown to express 
procoagulant TF [139]. More importantly, PMPs and TF expression have been implicated in 
thrombosis. Thus, microparticles are an important feature in in vitro investigations.  
Besides, influencing platelet activation, shear stress also influences platelet adhesion and 
shape change [213]. Platelets have developed adhesion mechanisms under different shear rates [214]. 
In vivo, low physiological shear rates do not significantly activate platelets, but can sensitize platelets 
for high shear activation. On the other hand, high shear rates activate platelets and increases affinity 
of immobilized vWF, which enables platelets to still adhere at high shear rates, above 1000 s-1. 
However, under in vitro conditions, high shear stress may produce contrary results, such as decreased 
platelet adhesion, depending on the type of flow, even though platelet activation is still high [215]. 
This is an important difference to note in in vitro investigations. The threshold of activation may vary 
according to the type of flow as well as on whether PRP or whole blood is used. 
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2.2.3.1.2 Biomaterial-platelet interaction 
In addition to shear and biochemical agonists, platelets can be activated by biomaterial 
surfaces [7, 216-218], mediated by adsorbed proteins, which form a surface layer of about 0.1-0.5 
µg/cm2 [174], depending on material surface properties as well as the size and orientation of the 
adsorbed proteins. Fibrinogen is particularly an important protein in platelet adhesion [219]. 
Fibrinogen interaction with biomaterial surface results in material-dependent conformation change 
and surface absorption [220, 221], which results in selective expression of absorbed protein epitopes, 
such as the RGDS sequence [155]. The exposure of epitopes that have affinity for platelet integrin 
GPIIb/IIIa greatly influences platelet adhesion and activation. As previously discussed, material 
properties do not only influence the extent of binding sequence exposure, but more importantly can 
influence structural transition rates [177]. The issue of structural transition rates is important because 
that may relate to thrombin production rate, which as highlighted by Gorbet et. al [169] may be one of 
the better indicators of thrombogenicity. This begs the question what epitopes are expressed, and at 
what rate, in the case of specific biomaterial surfaces such as TiO2, which is found on some of the 
common metallic biomaterials such as titanium and its alloys? Which material property plays what 
role in the rate, pattern and extent of structural change? Fundamental understanding of these 
mechanisms is necessary in order to derive relationships between these interfacial phenomenon and 
platelet activation and adhesion and hence thrombin generation and thrombogenicity. 
2.2.4 Fibrinolytic system 
There are three main subsystem levels of control in this system. The main function of the 
fibrinolytic system is to degrade fibrin and thus dissolve unwanted blood clots, such as to control the 
growth of a clot after successful wound healing. A fine balancing interplay between fibrinolytic and 
coagulation systems is necessary because any imbalance can be detrimental. Imbalance towards 
fibrinolysis would result in bleeding and towards coagulation would result in excessive thrombus, 
which in blood vessels would occlude blood flow. Fibrinolytic system proteins cross-talk with 
proteins and inhibitors from other systems involved in coagulation [75]. Therefore, it has a role in 
material-induced thrombosis. While this is recognized, fibrinolytic system proteins are not 
investigated in this thesis and therefore, the relevance of the system is only mentioned for 
completeness and is not discussed any further. 
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2.2.5 Summary 
The immune system response to the presence of a biomaterial is a very complex process, 
which is influenced by material characteristics as well as blood flow. It involves various biochemical 
cascades and feedback loops that amplify as well as regulate the response. A simplified schematic of 
the system interactions is presented on Figure 2-13. While there is a lot of knowledge on the various 
pathways and material-induced thrombosis, the mechanisms involved in the regulation of some of the 
key pathways, such as the tissue factor pathways, in the presence of biomaterials are not completely 
understood. Hence, further investigations into the roles of the various pathways in material-induced 
thrombosis are necessary. 
 
 
Figure 2-13. Schematic of interactions in material-induced thrombosis. Adapted from [169]. 
 
Material characteristics are often investigated for adsorption of major proteins like fibrinogen 
and cell activation and adhesion. However, since phospholipids influence coagulation factor 
adsorption and reaction kinetics such as {FXa.FVa.Ca2+.PL} complex, the question that remains is 
what are the effects of material characteristics, e.g. TiO2 on coagulation proteins and reaction kinetics. 
This question is valid even for the {TF.FVIIa.Ca2+.PL} complex, which seems to have less 
dependence on phospholipids [222]. Although TF is not an active enzyme, discussions on its 
function/activity seem to treat it as if it is an active enzyme. To that end, there is need to pay more 
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attention to the link between TF and the co-factor FVIIa, especially because there is evidence that 
recombinant FVIIa can activate FX by itself [223], tissue factor accumulates in thrombus and not 
hemostatic plugs [224] and tissue factor has been shown to disappear from wound sites [225]. This 
raises the question whether this also occurs with physiological FVIIa and if there are specific 
circumstances under which FVIIa may preferentially act on its own. 
With regards to the contact system, its role in thrombosis is predominantly linked to the 
generation of thrombin. However, there is evidence that FXIIa also interacts directly with fibrin, to 
influence the clot structure, in a dose dependent manner [184]. This raises the question of whether, in 
the presence of biomaterials, which could localize FXIIa activity, FXII does not also interact directly 
with fibrinogen after conformational change and polymerized fibrin to influence material-induced 
thrombogenicity. This may suggests that the contact system may be playing a wider role in 
thrombosis development and propagation than initially thought. Further investigations are necessary 
to elucidate this fact. 
Clearly a holistic approach, at various complexity levels, is necessary to investigate the 
interaction between the various systems. Various high level representations of the system interactions 
have been previously presented. Since cells play an important role in expressing receptors, providing 
a surface for enzymes or substrate and physical aggregation, it is possible to represent them as the 
pillars of the interactions. Others have also noted the importance of including cells in relation to 
coagulation [226]. Therefore, from a cellular response point of view, the interaction of blood with 
other systems can be represented by a cellular-based triad, Figure 2-14. This representation 
emphasizes the already known fact that water and plasma proteins play a central role in the initial 
interaction with a biomaterial surface. Hence, after interrogation, the pattern of response and the 
‘decision’ to involve cellular components lies with this milieu. Proteins provide the initial and 
subsequent hidden reaction permutations. How these permutations are controlled by material 
characteristic remains largely unclear. Cells predominantly respond according to information from 
proteins. They complement the proteins by recruiting more and controlling the termination of the 
response. Therefore, closer attention needs to be paid to the material and shear-dependent protein 
dynamics as well.  
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Figure 2-14. Cellular-based interaction and crosstalk triad between blood and other system. The 
arrows depict communication in both directions. The big circle represents the milieu of interactions 
around the biomaterial, driven by several systems/cascades. Interactions within the triad occur 
regardless of flow, but with different dynamics. Adapted from [7]. 
 
Figure 2-14 can be examined at the system level in terms of the systems involved. These are; 
(i) the fluidics (dynamics) system, (ii) the blood/biochemical system and (ii) the biomaterial system. 
All these systems have essential characteristic parameters that allow them to interact with each other 
at different spatial and time scales. Similar to the blood system discussed above, the other two 
systems and their characteristics are discussed in the next sections.  
2.3 The fluidics system 
The fluidics system is defined by the cardiovascular system geometry and hemodynamics. 
The vascular system is composed of blood vessels of various geometric and structural differences, 
Figure 2-15. The blood vessels are also characterized by numerous curvatures and bifurcations, which 
facilitate blood distribution throughout the body. These physical characteristics of the vascular tree 
influence hemodynamic parameters, such as flow velocity, blood pressure, type of flow and vessel 
wall shear stress (WSS). 
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Perhaps the prominent influence of vascular geometry and hemodynamics is in development 
and localization of atherosclerotic plaques, which preferentially develop in the distal aorta, carotid 
artery, lower extremity arteries and coronary arteries [61]. Atherosclerotic plaque is a major risk 
factor for arterial lesions, such as thrombosis or stenosis, which are the major causes of 
cardiovascular diseases and some of the leading causes of mortality and morbidity. Due to the 
significance of the geometric and hemodynamic characteristics in atherosclerosis, and in this 
research, a review of these parameters in the coronary systems is appropriate. This section examines 
the geometric parameters of the cardiovascular system and their relevance to the design of in vitro 
flow models and to the function and distribution of immune system components. 
2.3.1 Geometric parameters of the coronary system 
The coronary system supplies blood to the myocardium (heart muscle), with two main 
coronary arteries emanating from the aorta. These are the left main coronary artery (LMA) and the 
right coronary artery (RCA).  The LMA, with typically internal diameter of 4.5±0.5 mm [227], 
supplies blood to the left ventricle. It branches into the circumflex (LCx) and the left anterior 
descending (LAD). The significance of the LAD is that it supplies blood to the left ventricle; the main 
Figure 2-15. Geometric and structural properties of the vascular system. Not drawn to scale. 
Used with permission from Elsevier. Source: Berne, R.M. and M.N. Levy, Cardiovascular 
physiology. 7th ed. 1997, St. Louis: Mosby, xi, 324 p.  
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heart chamber for pumping blood into circulation. Hence occlusion of the LAD has immediate impact 
on cardiac function. The RCA is also susceptible to stenosis but its occlusion is often survivable 
because it supplies blood to the right ventricle. Thus, any consideration for geometric and 
hemodynamic parameters in this research will be with particular reference to the LAD. However, the 
LAD and RCA are relatively similar in size, Table 2-8. They also have similar curvature [228], 
although there can be some differences in tortuousity [228]. Therefore, any discussion on LAD is in 
many cases applicable to the RCA. 
 
Table 2-8. Typical dimensions of coronary arteries. Values are mean±SD. Adapted from [229]. 
Vessel	   Internal	  diameter	  (mm)	   Area	  (mm2)	   Area	  taper	  (%	  per	  cm)	  
LAD	   3.7±0.5	   11.1±2.8	   9.8±3.3	  
RCA	   3.6±0.5	   10.2±2.8	   6.8±2.3	  
 
The basic physical parameters that define the arterial blood vessels are diameter, wall 
thickness, surface topography, modulus of elasticity, cross-sectional profile, length, branching angle 
and tortuousity. Only parameters pertinent to this research are discussed. 
2.3.1.1 Diameter 
The blood vessel diameter is controlled by smooth muscle cells (vasoconstriction and 
vasodilation), which form the major constituent of the arterial wall, Figure 2-15. Coronary arteries do 
not have constant diameter, but taper off with each bifurcation [230]. As a result, the diameters of the 
coronary arteries are often measured at midpoints of defined segments: proximal segment, mid-
segment and distal segment. Some typical diameters are 4.5±0.5 mm for LMA, and 3.7±0.4 mm and 
1.9±0.4 mm for LAD proximal and distal segments, respectively [227]. Taking average diameter and 
applying Poiseuille and Navier-Stokes equations to flow in arteries, the flow resistance is inversely 
proportional to the fourth power of vessel diameter and the shear stress is inversely proportional to 
the third power of the diameter [231]. In addition, the diameter also affects viscosity due to the 
colloidal nature of blood – Newtonian in arteries and non-Newtonian in capillaries [52]. Therefore, 
the vessel internal diameter is an important physiological parameter to mimic in developing in vitro 
models because of its implications on fundamental hemodynamic parameters. 
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2.3.1.2 Elasticity 
Blood vessels show viscoelastic properties, which gives them compliance. As a result, the 
diameter of coronary arteries varies intermittently with the pulsatile cardiac cycle. At a nominal 
physiological heart rate of 60-70 beats per minute, the main frequency of pulsatility is F=1.0-1.2 Hz 
(cycle period T=0.8-1.0 s). This frequency relates more to the curvature variation than the diameter 
variation as there has been evidence of harmonics in arterial flow. Although it has been suggested that 
collision of a particle with an elastic wall may reduce shear stress by about 25% [232], in general 
when performing blood flow analysis, elastic effects can be ignored because they have been found to 
introduce very little error [60]. Hence, flow equations for rigid tube analysis, with mean pressure and 
volume, can be applied without loss of generality. Thus, unless the study is investigating the physics 
of pulsatile flow, a rigid vessel is reasonably appropriate for most in vitro flow models. 
2.3.1.3 Surface topography 
One common feature of the cardiovascular system is the existence of endothelial cell lining in 
all blood vessels Figure 2-15, which forms a barrier between the blood and the sub-endothelial milieu. 
The endothelial cell lining provides a smooth and non-thrombogenic surface. The smooth surface 
ensures efficient flow with little friction resistance. This topography may change with the 
introduction of a vascular device such as a stent. If the stent strut size is too large, the struts may 
introduce turbulence in regions that originally had laminar flow. The strut size and shape lower the 
critical Reynold’s number at which flow transitions from laminar to turbulent flow [233]. The 
relevance of topography in in vitro models incorporating stents is that it introduces roughness and 
therefore additional friction in the model vessel. This factor needs to be considered in fluid mechanics 
analysis of the model. While it is recognized that fluid dynamic changes in vivo will affect endothelial 
cells lining the vasculature, e.g. remodeling and expression of adhesion molecules, the focus of this 
thesis is on the interaction of blood with biomaterials and thus endothelial cells are not investigated. 
2.3.1.4 Cross-sectional area 
The cross-sectional profile of normal vascular arteries is generally circular, Figure 2-15. The 
circular approximation has been significantly used in developing engineering analysis of the arterial 
wall dynamics as well as developing blood flow equations. In diseased vessels, e.g. due to 
atherosclerotic plaque lesions, the cross-sectional profile can be quite different. The existence of a 
lesion will also affect flow parameters and any analysis would need to take this into account. This 
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type of analysis is beyond the scope of this research and therefore a circular geometry is assumed for 
the purpose of this research. 
2.3.1.5 Curvature and tortuousity 
Coronary arterial curvature emanates from a number of geometric factors. These include 
heart curvature, arterial tortuosity and bifurcation. Curvature introduces several velocity components 
and dispersion of colloid suspensions which can result in wall adaptations, correlating with 
atherosclerotic lesions in arteries [234] and arterioles [235]. More importantly, curvature and 
tortuosity, as well as torsion, have been shown to have considerable individual variability, which may 
account for variation in parameters that mediate development of atherosclerosis among individuals 
[228]. In vivo, curvature varies with cardiac pulsatility, both spatially and in time.  
Tortuousity, the degree of winding and meandering along the length of a vessel, exists to 
varying degrees throughout the circulatory network. The LMA is generally straight, but the other 
main coronary vessels (RCA, LAD and LCx) have varying degrees of tortuousity. Blood vessel 
tortuousity affects flow dynamics; WSS on the outer wall is higher than on the inner wall of the 
curvature. Representative in vitro models have shown its effect on flow parameters [236]. It is also an 
important factor to consider in device design and implantation. A tortuous vessel can increase the 
possibility of perforation. In addition, the location of an implant relative to the sharp curvature also 
affects flow, as demonstrated by the effect of stent position in studies with 90° bends. Thus, curvature 
and tortuousity are important to take into account in understanding flow-mediated phenomenon. 
2.3.1.6 Bifurcation  
Bifurcation is a flow divider and as a result it introduces change in flow dynamics, which can 
result in complex fluid velocity distribution and shear stress patterns. Wall shear stress on the inner 
wall of the bifurcating branch is higher than WSS on the outer wall of the branch [61, 234], which 
mimics flow at a curvature of a tortuous vessel. Bifurcation influences WSS distribution both in 
steady and pulsatile flow [237]. Simulation studies of the coronary artery have also shown that the 
velocity profile is skewed toward the inner wall of the bifurcating branch during diastole [238]. The 
region of low shear stress and complex flow has been found to be a preferential location for 
atherosclerotic lesions [61, 234]. Thus, bifurcation is one of the important geometric parameters that 
have great influence on blood flow patterns. 
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The role of red blood cells (RBC) cannot be ignored in flow geometries. In a straight tube at 
low shear rate <100 s-1, they behave like ordinary particles. At high shear rates, they are deformed 
into elliptic shape aligned with the direction of flow [239]. In curved flow, these ellipses cannot be 
expected to remain in the center of the flow because of the secondary flow vortices. This is important 
because in different simulation studies, RBC collisions have been shown to influence leukocyte [240] 
and platelet [241] wall interactions. The relevance of curvature and its influence on hemodynamics is 
discussed in section 2.3.2.4. Some positive aspects of the influence of this geometry on fluid flow are 
exploited for various industrial and biomedical engineering applications [242-244]. 
2.3.2 Hemodynamic parameters of the coronary system 
The geometric characteristics of the vascular system and the blood fluid properties influence 
the blood flow (hemodynamic) parameters. The important hemodynamic properties that influence the 
fluid dynamics as applied to blood are blood rheology, velocity and wall shear stress/rate. The 
specific fluid mechanics parameters that define these hemodynamic properties may vary according to 
the physiological location of interest (PLOI). 
Fluid dynamics equations to describe blood flow are derived on the basis of continuum 
mechanics, i.e. fluid motion can be described in terms of the laws of classical continuum physics 
(conservation of mass, conservation of momentum and conservation of energy). It should be noted 
that while blood flow is pulsatile, generally steady state solutions for a rigid tube are used in flow 
analysis. Pulsatile flow and wall compliance add considerable complexity and exclusion of the 
pulsatile component has been shown to have little effect on the accuracy of the analysis. Thus, unless 
otherwise stated, the flow is assumed to be steady, laminar and fully developed. 
2.3.2.1 Blood rheology 
As discussed in section 2.2, blood is an incompressible and colloidal non-homogeneous fluid, 
with complex rheological properties. Due to the complex rheological properties of blood, its viscosity 
is influenced by a number of factors, including hematocrit and strain rate. At high shear rates, such as 
in the microcirculation, blood displays non-Newtonian fluid behavior, with non-constant viscosity – 
decreasing non-linearly with decreasing flow rate or increasing shear rate. This is because particle 
interactions increase at low flow rates. Thus, blood rheology in capillaries is often modeled as a non-
Newtonian power law fluid, with the shear stress, τ, given by the equation, 
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nKγτ =           (1) 
 
where, K is the consistency coefficient (Pa.s), n (<1 for pseudoplastic or shear-thinning fluids) is a 
dimensionless power law index and γ is shear rate. However, in larger blood vessels with high shear 
rates, such as arteries, blood behaves like a Newtonian fluid with relatively constant dynamic 
viscosity, estimated at 0.003-0.004 Pa.s [52]. 
2.3.2.2 Blood velocity 
Blood flow velocity is important for transportation of metabolic products, immune system 
agents and other biochemical agents to regulate physiological processes. It also plays a significant 
role in enzyme-substrate interaction kinetics [149]. Hence, the velocity distribution in vascular 
systems is related to function. Fluid dynamic equations to describe blood flow are derived from basic 
fluid mechanics principles. 
Assuming a rigid horizontal cylindrical tube of constant cross-sectional area, the blood flow 
velocity can be derived based on the following fluid assumption; Newtonian incompressible fluid 
(constant density), steady state (flow independent of time), fully developed flow and laminar. The 
derived velocity is described by a parabolic profile (based on the Poiseuille equation) with the axial 
component, expressed as, 
 
ν r( ) =
ΔP( )R2
4µL 1−
r
R
#
$
%
&
'
(
2)
*
+
+
,
-
.
.
       (2) 
 
where ΔP is the pressure gradient across a fluid element, L is the length of the element, r is the radial 
coordinate, R is the radius of the tube and µ is the fluid viscosity. Since this is a pressure driven flow, 
the axial pressure gradient drives the flow velocity while the radial pressure gradient results in the 
circumferential wall stress. In blood flow in arteries, the tensile stress, which can be approximated by 
Laplace’s Law [61], will change with arterial geometry as well as cardiac cycle. In this research, the 
geometry is considered constant.  
The general velocity profile, equation (2), predicts that the velocity is zero at the wall, 
assuming no slippage. This means transport of molecules near the wall is aided by diffusion forces, 
whereas the axial transport of the bulk of the blood components is predominantly driven by 
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convective forces. However, it has been shown that the presence of red blood cells enhances platelets 
dispersion and interaction with the vessel wall so that diffusion alone is not sufficient for particle 
interaction with the wall [149]. Equation (2) can also be written in terms of volumetric flow rate (Q) 
as, 
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Hence the average velocity is expressed as, 
 
ν =
vmax
2 =
Q
πR2          (4) 
 
These equations are used in arterial blood flow analysis since arterial elastic effects can be ignored 
[60] and because blood behaves like a Newtonian fluid in the arteries. Using the physiological stroke 
volume Vs and heart rate frequency F, the cardiac output is defined as Q=FVs. With a nominal heart 
rate of 60 to 70 beats per minute, giving a frequency F=1.0-1.2 Hz, and a stroke volume of 
approximately 80 ml per contraction cycle, the cardiac output is about 4.8 L/min [51]. 
The assumption of laminar flow in deriving the velocity equation is characterized as a 
dimensionless ratio of inertial forces to the viscous forces, called the Reynolds number. It is defined 
by the equation  
 
Re =
ρνD
µ
          (5) 
 
where ρ is fluid density, ν is mean velocity, D is vessel diameter and µ is dynamic viscosity (Pa.s). 
For Poiseuille flow, laminar flow in a tube occurs for Re<2100 [245]. When fluid is flowing in a tube, 
the tube wall resistance to flow results in wall shear stress, an important parameter that influences cell 
activation and adhesion. 
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2.3.2.3 Shear stress/rate  
Wall shear stress is a measure of wall viscous frictional force per unit area. Related to shear 
stress is the rate of shear, which is used to characterize local flow conditions in relation to local shear 
forces. The rate of shear or shear rate, for pipe flow with only axial velocity component, is defined as 
the rate of axial velocity increase with distance away from the vessel wall to the vessel centre. The 
WSS for a rigid circular straight tube with fully developed Newtonian fluid flow is defined as the 
derivative of equation (3) with respect to the radius. At the wall where r=R, the wall shear rate is 
expressed as, 
 
γw =
4Q
πR3           (6) 
 
where Q and R are as previously defined. 
Shear rate influences phase separation in multi-phase flows [244]. The significance of this 
effect on blood is that blood experiences shear thinning at high shear rates [57], meaning the red 
blood cells migrate to the center of the flow, and plasma, which contains more platelets than the 
center [149], forms the boundary layer between the thick center and the vessel wall. Shear rate does 
not only affect particle dispersion in flowing blood, but also activates immune system cells. Shear rate 
has been shown to influence platelet adhesion [60, 246, 247], platelet interaction with immobilized 
tissue factor [248] and tissue factor initiated coagulation [249]. Thus, shear rate influences a variety 
of cell functions. 
Shear rate is related to shear stress by equation (1). For a Newtonian fluid, as it applies to 
blood in large arteries, the constants are n=1 and K=µ, the dynamic viscosity. Therefore, the wall 
shear stress is expressed as, 
 
τ w =
4µQ
πR3           (7) 
 
This equation has been used to estimate the physiological vascular WSS magnitude [250] and mean-
average WSS [251]. Vascular shear stress is particularly important because it has been found to 
modulate a number of vascular physiological responses and adaptation mechanisms [252]. 
Physiological shear stress in the arteries is estimated at 10 to 70 dyn/cm2 [250], with the nominal 
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value taken as 15 dyn/cm2. Deviation from this range has pathologic consequences. Endothelial cells 
have been reported to lose structural integrity at wall shear stresses above 420 dyn/cm2 [253]. At 
molecular level, low shear stress (<4 dyn/cm2), which may occur at bifurcations, is associated with 
expression of the transcription factor nuclear factor-κB (NF-κB) in endothelial cells [149], with 
consequential vascular remodeling and expression of inflammatory proteins, such as monocyte 
chemoattractant protein (MCP-1) and intercellular adhesion molecule (ICAM-1). MCP-1 and ICAM-
1 are responsible for leukocyte recruitment and adhesion to the endothelial cells. At functional level, 
low shear stress has been shown to induce intimal thickening [60]. 
Besides modulating endothelial cell function, shear stress also modulates function in plasma 
proteins and blood cells. Blood from hypertensive individuals with intimal thickening has elevated 
levels of C-creative protein (CRP), an inflammatory response protein [254]. High shear stress also 
modulates platelet activation and adhesion through activation of calcium channels – up-regulating 
cytosolic Ca2+ concentration [255]. Wall shear stress greater than 50 dyn/cm2 has been shown to 
activate plate rich plasma (PRP) [149]. It is also suggested that periodic high shear stress, as may 
occur due to stenosis or heart valves, sensitizes platelets to activation at low shear stress [256]. More 
importantly, shear stress has been shown to have some correlation with in-stent thrombosis [257]. 
Thus, hemodynamic parameters are important in examining blood-biomaterial interactions as 
they modulate cellular and vascular functions, both under normal and disease conditions. While the 
role of endothelial cells in vascular function is important to consider in the development of stenosis, 
their role in thrombosis is not investigated in this research because the emphasis is on blood-
biomaterial interactions. 
2.3.2.4 Flow in a curved tube 
Physiological curvature, due to heart curvature, tortuousity or bifurcation, defines geometric 
parameters that influence curved tube flow dynamics. One of the important parameters that is used to 
characterize curved tube geometry, and hence curved tube flow, is the non-dimensional curvature 
ratio, which can be defined as the ratio of the internal tube radius to curvature radius or vice versa, 
equation (8), 
 
κ =
R
R0
          (8) 
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where R is mean internal vessel radius and R0 is mean radius of curvature. Curvature ratio influences 
some of the key fluid mechanics parameters that characterize curved tube flow [242, 258-260]. The 
physiological curvature ratio for the left coronary arterial tree varies from 0.02 to 0.5 [261]. It is 
influenced by the spatial location of the observation point as well as the cardiac cycle. 
An additional parameter that characterizes flow in a curved tube, besides curvature ratio (κ), 
is the Dean number (Dn) and its related Reynolds number (Re). Although the Dean number is related 
to the Reynolds number, which is used to characterize both straight and curved flows, it is important 
to recognize their differences. In a straight tube flow the Dean number is zero even though the 
Reynolds number can still be defined. The Dean number is defined as, 
 
Dn = Re κ           (9) 
 
One of the interesting influences of curvature on Re is that it increases the transition point to turbulent 
flow slightly above the 2100 for the straight tube flow. For curved flow, the critical Reynolds number 
for transition to turbulent flow is expressed as [262], 
 
Re = 2100 1+12 κ( )          (10) 
 
The significance of the Dean number is its influence on the development of secondary flow 
vortices, which were first described by Dean as early as 1927 and 1928 [263]. The overall effect of 
additional velocity vector components in curved tube flow is increasing radial mixing and mass 
transfer [264]. This has been demonstrated numerically [264] as well as experimentally in whole 
blood [56]. The increased radial and reduced axial dispersion results in reduced residence time 
distribution, which can make the flow approach plug flow and the velocity showing an ‘M’ profile 
[262]. Particle dispersion has direct impact on cell-wall interactions in vivo [61], and hence is very 
relevant for in vitro blood-biomaterial interaction studies under flow conditions and interpretation of 
results. For that reason, all the flow parameters such as velocity and shear rate/stress need to be 
appropriately defined in terms of curvature parameters. 
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2.3.3 Summary 
The coronary geometry and hemodynamics define the fluidics system. The geometry defines 
some of the boundary parameters of the fluid flow. These parameters are important in vivo as they 
relate to some of the pathologic conditions in the coronary system. Flow is equally important in vitro 
as it influences cell-cell or cell-material interaction and adhesion. Hence, close attention to the design 
of the in vitro model is necessary. In this research, the governing conditions for the transport 
phenomena, such as the geometry and hemodynamics of the location of interest, are closely examined 
in order to relate them to the in vitro model design. One of the key parameters that characterizes flow 
in coronary arteries is curvature ratio. However, it is important to note that the dimensional 
parameters of the ratio are equally important. This is because similar curvature ratios can be obtained 
with vastly different curvature and tube radii, yielding fluid dynamics results that may not be 
comparable. Therefore, if an in vitro model is designed with a similar dimensionless ratio to the 
physiological location of interest (PLOI), the results may not be relevant if the curvature radius and 
vessel radius are not comparable. For that reason, this is an important aspect of the in vitro model 
design. 
A systems approach is adopted because there are several systems that are involved in vivo in 
the physiological system response to biomaterials. The effect of the in vitro model parameters can 
then be investigated in the attempt to unravel the pathways involved in blood-biomaterial interactions 
under the in vivo conditions, for the selected location of interest. Thus, the motivation for this 
research is the application of a systems approach for investigating mechanisms involved in in vitro 
conditions mimicking coronary in-stent thrombosis. Hence the coronary system is of particular 
interest in understanding transport phenomenon and translating parameters to in vitro model design. 
2.4 The biomaterial system 
The selection of biomaterials for various biomedical applications is based on a variety of 
mechanical and chemical properties, such as material tensile strength, corrosion resistance and 
biocompatibility [20]. Biocompatibility determines the suitability of a biomaterial for biomedical 
applications. It has been defined as the ability of a biomaterial to positively interact with the 
biological system in a specific application [1]. It is of particular significance because it is a function 
of material surface characteristics, which are the main determinants of the initial implant interactions 
with the biological system.  
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There are a variety of reasonably biocompatible polymeric, ceramic and metallic biomaterials 
available for biomedical applications [265]. Some of the relatively biocompatible and commonly used 
metallic biomaterials in orthopedic, dental and cardiovascular implants are made from titanium and 
its alloys, e.g. Nitinol® and Ti-6Al-4V [20]. These are used because of their chemical and mechanical 
characteristics. Both are reasonably biocompatible, corrosion resistant and have high tensile strength. 
Nitinol is an alloy made from approximately equal amounts of nickel and titanium. Ti-6Al-4V is 
made by replacing some of the Ti atoms with aluminum (Al) and vanadium (V) to increase its 
strength, see Appendix A for detailed material composition and characteristics. Thus, Ti-6Al-4V has 
both alpha (Al) and beta (V) phases. The alpha phase has hexagonal structure, is soft and ductile 
whereas the beta phase has cubic structure and is harder and stronger. Because Ti-6Al-4V has both 
alpha and beta phases, it can be heat treated to stabilize at desired phase proportions. For example, at 
high temperatures, it exists predominately in the beta phase. The rate of heating and cooling cycles 
determines the transformation dynamics. This property is exploited in making model stents for this 
research. 
While material bulk properties are important, the surface characteristics are of particular 
significance in blood-biomaterial interactions because they influence protein adsorption and cell 
adhesion and proliferation, just as much as mechanical cues imposed by hemodynamics. Numerous 
studies have been done to investigate the effect of material properties on protein and cell adhesion 
[266, 267]. Both nitinol and Ti-6Al-4V can be subjected to various surface treatment methods, such 
as mechanical polishing, chemical etching and heat treatment, during or after the manufacturing 
processes, in order to produce desirable surface characteristics. The effects of some of these methods 
on nitinol have been reported [268]. Of particular interest is the heat treatment method, which can be 
used during manufacturing and device shape setting. Studies have shown that heat treatment alters 
surface oxide layer nanostructure by increasing its thickness and roughness, on both nitinol [269] and 
Ti-6Al-4V [267]. Increased roughness may be desirable where there is need for adhesion as it 
increases surface energy, such as orthopedic or dental implants. Biomaterial surface properties that 
are of interest are surface topography/roughness, surface chemical composition, surface energy and 
wettability. 
2.4.1 Surface roughness and topography 
Topography and roughness are sometimes used interchangeably. While they both describe 
texture, they are two different concepts. Topography is usually qualitative while roughness is 
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quantitative. While topography can be defined in terms of form, waviness and roughness [270], which 
is equivalent to texture, in this research it is generally used to describe the qualitative surface 
morphology or form and roughness is generally used for quantitative description. Two surfaces can 
have comparable roughness values but vastly different topography, e.g. one with spiky ridges and the 
other with square ridges [271]. 
Biomaterial surface topography and roughness influence cell adhesion and proliferation, 
depending on the range and scale of roughness as well as on the cell type [266, 272]. For example, 
fibroblasts and osteoblasts have been shown to respond differently to the same roughness, for both 
nitinol [273] and Ti-6Al-4V [274]. Surface topography and roughness parameters are both equally 
important as materials of the same roughness but different topographies can produce very different 
cell responses [272]. However, roughness may have limited effect on adsorption of proteins, such as 
albumin [275] and fibrinogen [220]. When considering protein adsorption, it may be necessary to 
consider the scale of roughness (micro or nano) as nanopores have been shown to affect complement 
activation and adsorption [85]. Furthermore, molecular level surface roughness is important because 
it has implications on surface energy, due to the fact that when atoms are closer together, there is 
stronger interactions, which reduces surface energy [276]. Increase in surface roughness can have the 
effect of increasing surface energy. Thus, it is important to determine the surface topography and 
roughness in blood-biomaterial interaction studies in order to relate them to observed biological 
effects. 
2.4.2 Surface chemistry 
Although the bulk chemical composition of the biomaterial is important for the overall 
chemical and mechanical characteristics of the material, the surface elemental composition is even 
more important in cardiovascular devices because it determines initial release or non-release of ions 
and subsequent electrostatic material-blood interaction, regardless of the roughness and topography 
length scales. Surface chemistry is probably the most fundamental characteristic of the material. It 
determines both surface charge and energy. Consequently surface chemistry influences interfacial 
water properties [277], protein-biomaterial interaction dynamics and subsequent adsorption [170, 220, 
275, 278]. Conformational change and adsorption of fibrinogen, one of the important proteins that 
mediate material-blood interaction, is dependent on surface chemistry [160]. Platelet microparticle 
formation has also been shown to exhibit surface chemistry sensitivity compared to leukocytes in a 
polymeric bead model [178].  
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One of the most important surface chemistries in metallic biomaterials is the oxide layer, 
particularly the titanium oxide surface layer, which forms spontaneously on titanium alloys because 
of titanium’s thermodynamically driven affinity to oxygen. Titanium oxide surfaces react with a 
number of substances, including metals and inorganic and organic substances, which has made them 
suitable for a variety of applications [279]. 
2.4.2.1 Fundamentals of titanium oxide 
Atomic elements are composed of electrons spinning around the nucleus of an atom in 
different configuration states and energy levels. The electron spin configuration states are described 
by probability functions; orbitals. Orbitals describe the spin state and specific energy levels of 
electrons and thus describe the basic chemistry of each atomic element. They are labeled as 1s2, 2s2, 
2p6, 3s2, 3p6, 3d10, 4s2, 4p6, 4d10, etc., where the numbers indicate the energy level and superscripts 
indicate the maximum number of possible electrons. Electrons fill the lower energy states first, but 4s 
is slightly lower than 3d and thus will be filled first before 3d in most atoms. 
Titanium is a transition metal with 22 electrons arranged in orbitals as follows: 1s2, 2s2, 2p6, 
3s2, 3p6, 4s2, 3d2. Thus, it has four incomplete 3d orbitals. On the other hand, oxygen has 8 electrons 
arranged in orbitals as follows: 1s2, 2s2, 2p4, resulting in one incomplete 2p orbital. When titanium 
oxide (TiO2) is formed, the compound has 3d0 because the electrons fill the 2p orbitals first as they 
are at a lower energy level than the 3d orbitals, which explains the titanium affinity to oxygen. The d 
orbitals, unlike the s and p orbitals can have complicated shapes. As a result TiO2 can have several 
phases and exhibit complex interaction mechanisms. There are three forms of TiO2 layers; rutile, 
anatase and brookite [279]. The rutile TiO2 layer is the strongest and most stable layer, and hence the 
predominant layer on titanium alloy biomaterials. The rutile layer has three forms, designated as 
(110), (100) and (001) [279, 280]; determined by their atomic surface termination structure. The basic 
structural element of TiO2 (110) is composed of one titanium atom surrounded by six oxygen atoms 
in an octahedral coordination [281]. TiO2 (110) surface is composed of alternating rows of oxygen 
atoms and 5-fold coordinated titanium atoms. The oxygen atoms protrude above the surface because 
the surface termination is similar to the bulk structure. Because of the similarity between termination 
and bulk geometry, TiO2 (110) has been found to have the lowest surface energy, and thus better 
thermodynamic stability compared to TiO2 (100) and TiO2 (001). Therefore, any discussion on TiO2 
will be based on the strongest rutile TiO2 (110) form unless stated otherwise.  
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The spontaneously formed titanium oxide layer on Ti-6Al-4V has a thickness of 3-10 nm 
[274]. Surface TiO2 layer forms on both nitinol and Ti-6Al-4V [282]. Despite formation of TiO2 layer 
on nitinol, nickel ion (Ni) can still be released from the surface, depending on nitinol treatment 
method [283]. However, the Ni release rate diminishes over time in vitro [282]. Several nitinol 
treatment methods, have been used to reduce surface Ni [268]. Nitinol heat treatment in air and 
annealing in argon at 500 °C for 20 minutes can reduce surface Ni content [284], and higher 
temperature increases surface Ti, which would promote formation of TiO2 layer. The formation of a 
surface hydrophilic TiO2 layer has significance in biomaterials because it facilitates biological 
integration of the biomaterial. In orthopedic implants, the integration is through formation of a 
calcium-phosphate layer. In blood, the TiO2 layer promotes blood plasma protein adsorption, mostly 
through the RGD sequence. The charge on the oxide surface is a function of the surface treatment 
method. 
2.4.3 Surface charge 
The predominant TiO2 layer on titanium alloy biomaterials has an isoelectric point at pH ≈ 5 
[285]. As previously described, the isoelectric point is the pH at which a molecule carries no net 
charge. At higher pH it becomes electronegative, which means at the blood pH level (≈7.4), the TiO2 
layer is negatively charged. The strength of charge on the oxide layer may be influenced by the 
material treatment method [286]. This is important to note because the surface interaction with blood 
proteins depends on its charge and chemistry. Surface charge has been shown to have a differential 
effect on contact pathway and platelet activation [176]. Current data suggests that even though steady 
state adsorption is influenced by other factors such as competitive adsorption, surface chemistry 
seems to play a key role in initiating contact system adsorption and activation. For example, 
complement proteins have been shown to be activated by negatively charged surfaces. With regards 
to protein adsorption, it has been reported that in the presence of low molecular weight ions that can 
be co-adsorbed, electrostatic repulsion between a biomaterial surface and proteins is not sufficient to 
prevent absorption [175]. 
When TiO2 is in an electrolyte solution, complex interactions, which are pH dependent, occur 
at the titanium oxide-fluid interface. There is initial preferential adsorption of water through the 
hydroxylation of the Ti ion (TiOH), followed by some cations replacing some of the water molecules 
by interacting with surface oxygen [287]. Experimental studies have suggested that peptide binding to 
the TiO2 layer is facilitated by pH dependent electrostatic bonding through the carboxyl group [288], 
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although conformational change may also involve an amide group. A study on fibrinogen adsorption 
on TiO2 at pH 7.4 suggests involvement of hydrogen bonding (TiO2 - H2O) and electrostatic 
interactions through the amide groups [289]. Different surfaces may involve different binding groups, 
which would influence protein adsorption and subsequent cell adhesion. The hydroxyl binding group 
which favors complement activation and adsorption, has also been shown to favor leukocyte adhesion 
[278]. 
Molecular dynamics simulation of the interaction between the TiO2 atoms and RGD sequence 
groups, using fibronectin, has confirmed the involvement of the carboxyl group, both under different 
surface topographies [290] and different water solutions [291]. The bonding happens through 
replacement of water molecules from the TiO2 layer [290]. Interestingly, once the peptide is adsorbed, 
the spatial orientation is influenced by the topography of the TiO2 surface [290] and the solvent [291]. 
The peptide-TiO2 bonds were found to be stronger on grooved surfaces [290], possibly due to the 
increase in surface energy and surface  area with increased roughness of the TiO2 layer [276]. This 
particular RGD binding with the TiO2 layer is important because it suggests that the amide groups are 
the ones available to interact with the cell membrane. 
2.4.4 Surface energy 
Besides electrostatic material-blood interactions, there are also hydrophilic/hydrophobic 
interactions that are determined by thermodynamic factors; material surface energy. A hydrophilic 
surface possesses relatively high surface free energy while a hydrophobic surface possesses low 
surface free energy and the limits are generally 72.8 mJ/m2 and ≈36 mJ/m2, respectively [292]. Thus, 
the material surface energy determines the ability of water to wet the surface. Titanium surface 
hydrophilicity and hydrophobicity have been shown to influence the expression and recognition of 
cell activation markers [293]. Material hydrophilicity/hydrophobicity is used to indicate general 
material-solution interaction tendencies and thus provides a general measure of surface wettability, 
which depends on material chemistry and surface roughness.  
The fundamental basis of wettability is that a water droplet will tend to spread on a 
hydrophilic surface more than on a hydrophobic surface. Hence, one of the common methods used to 
determine wettability is the contact angle method, which assesses the ability of a liquid to spread on a 
surface. A small droplet of a selected fluid, such as water, with size in the capillary length range 
(<=1mm radius), is placed on the material surface and the internal droplet contact angle at the 
liquid/vapor/material interface is measured. When a liquid droplet is placed on a surface, it will 
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spread according to interfacial surface tension. The sum of the interfacial tensions for a perfectly 
smooth surface is given by Young’s equation [294],  
 
€ 
γ sv −γ sl −γ lv cosθ = 0          (11) 
 
where γsv, γsl and γlv represent surface free energy at solid-vapor, solid-liquid and liquid-vapor 
interfaces, respectively. Another method that is used to determine surface energy is the Wilhelmy 
method, discussed in Chapter 4. Equation (11) can also be written in terms of the dispersive and polar 
intermolecular components of the surface free energy [295],  
 
€ 
γ l 1+ cosθ( ) = 2 γ ldγ sd + γ lpγ sp( )        (12) 
 
where γl and γs represent liquid and solid surface free energy. The effect of the dispersive (van der 
Waals) and polar (acid-base) interactions depend on the wettability of the surface, with hydrophobic 
predominately dispersive and hydrophilic predominantly polar [292]. Ultrapure water with free 
surface energy of 72.8 mJ/m2 has a dispersive component of 21.8 mJ/m2 and a polar component of 
51.0 mJ/m2 [295, 296]. Experiments have suggested that molecular interactions are dictated by the 
dispersive component of the surface energy [295] and the polar component plays a role in cell 
adhesion [50]. For liquids, this energy takes the form of surface tension. Typical surface tension 
values for water and blood are presented on Table 2-9. It is interesting to note the low sensitivity of 
water surface tension to temperature. Even at 60°C it only drops to 66.2 dyn/cm [51]. Since water 
makes approximately 50% of blood, it can be expected that the surface tension for the plasma and 
whole blood at 37°C will not be significantly different from that at 20°C. 
 
Table 2-9. Typical surface tension values. Adapted from [51, 58, 297]. 
Liquid	   Surface tension, γ  (dyn/cm)	  
Water 72.8 (20°C), 70 (37°C)	  
Blood plasma 50.0-56.2 (20°C)	  
Whole blood 55.5-61.2 (20°C)	  
1 dyn/cm = 1 mN/m = 1 mJ/m2 
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Materials with low surface energy or that result in a negative Gibbs free energy at the solid-
fluid interface, thermodynamically favor protein adsorption [175]. Thus, it has long been established 
that in general increasing hydrophobicity on polymeric surfaces increases protein adsorption but 
minimizes blood activation, while increasing hydrophilicity has the opposite effect [292]. Some of the 
most common polymers such as poly-tetra-fluoro-ethylene [298] and coatings such as diamond-like 
coatings [299] are based on this principle. Although it is generally true that materials with the lowest 
critical surface energy reduce adhesion and platelet shape change [300], the interactions are much 
more complex and hence results can be contradictory. Equilibrium between hydrophobic and 
hydrophilic properties is usually desirable. However, the right combination is still illusive. Simulation 
studies have suggested that even hydrophilic surfaces can show properties generally associated with 
hydrophobic surfaces [301]. 
When the surface is rough, a roughness factor can be incorporated into the above equations as 
roughness influences contact angle [302]. Taking the roughness factor into account suggests that 
roughness enhances hydrophobicity [303, 304]. However, it has also been suggested that based on the 
equation, roughness enhances hydrophobicity only if the initial contact angle of the material is above 
90° (θ>90°) but otherwise it enhances hydrophilicity [305]. This may depend on the material as it has 
also been found that commercially pure titanium contact angles increased with roughness for θ>45° 
and decreased with roughness for θ<45° [306]. While Ti-6Al-4V followed similar contact angle 
increases with roughness for θ>45°, it did not show sensitivity to roughness change for θ<45° [306]. 
An increase in hydrophobicity and decreased cell adhesion was previously observed with patterned 
titanium surfaces [50]. It should be noted that although wettability is generally accepted as an 
indicator of surface adhesion tendencies, it lacks details on the microscale solid-liquid interfacial 
interactions [307] and hence some of the difficulty remains in using it to accurately predict surface 
adhesion.	  
2.4.5 Electrochemistry 
Biomaterial electrochemical properties are important parameters that influence material 
biocompatibility. The electrochemical nature of the biomaterial determines the chemical stability of 
the material surface and hence its susceptibility to react with an electrolytic fluid, such as blood.  The 
susceptibility to reaction is related to susceptibility to corrosion. Previous studies, using cyclic 
voltammetry [308] and anodic polarization of nitinol and Ti-6Al-4V [282], have shown that Ti-6Al-
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4V has better corrosion resistance than nitinol. Electrochemical properties have been shown to 
influence cytokine production in soft tissue [309], platelet and thrombus formation on stent surfaces 
of other types of biomaterials [310]. For investigation of acute blood-biomaterial interactions, this test 
can be used to determine the stability of the TiO2 surface layer on the material samples. 
2.4.6 Summary 
The interaction of biomaterial surfaces with proteins results in conformational change, 
adsorption and binding sequence exposure on proteins such as complement and fibrinogen. While this 
fact is known, it remains unclear whether specific biomaterial characteristics induce specific spatial 
orientation on binding sequences that in turn influence cell adhesion patterns. It is also not clear if 
flow conditions induce different conformational change or enhance binding sequence exposure. The 
dynamics of protein conformational change and cell activation and adhesion need further 
investigation. Material characteristics and their broad implications in blood-biomaterial interaction 
can be summarized as in Table 2-10. Their subtle synergistic influence on thrombogenicity is not well 
understood. 
Clearly biomaterial characteristics augmented by flow influence blood activation and 
function at macro as well as molecular and cellular levels. The multiscale interactions between these 
complex systems compound the problem of discerning the mechanism of influence between the 
countless variables. Therefore, the fundamentals of blood-biomaterial interaction under flow 
conditions needs further scrutiny. Perhaps a different approach may be necessary at this point. 
 
Table 2-10. Surface characteristics and their broad implications 
Surface	  property	   Implications	  Surface	  chemistry	   Influences	  surface	  water	  structure	  and	  protein	  conformational	  change	  Surface	  charge	   Attraction	  or	  repulsion.	  Facilitates	  enzyme	  activity	  Surface	  energy	   Influences	  surface	  water	  structure,	  protein	  adsorption,	  cell	  adhesion	  Surface	  morphology	   Influences	  surface	  energy,	  adsorption/adhesion	  strength	  Can	  influence	  fluid	  retention	  and	  flow	  at	  surface	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2.5 The case for a systems approach in blood-biomaterial studies 
A variety of organizational and physical constructs, whether natural or engineered, form 
systems and in some cases a system of systems. These include social systems, engineering systems, as 
well as biological systems. Examples of these systems include healthcare systems, defense systems 
and the human body. One common feature between these systems is that they are complex. They 
embody characteristics that define complex systems; i.e. nonlinear, adaptive, dynamic, compensatory 
and where small perturbations can have large consequences. For the systems to achieve their goal, 
there are underlying functional characteristics/properties, such as collaboration, cooperation, etc. that 
determine the interaction between the system elements. To understand the driving force behind a 
particular system’s behavior requires a systems approach. The fundamental thinking behind a systems 
approach is to understand how the behavior or properties of a complex system emanates from the 
interactions of the fundamental components of the system or system of systems. While engineering 
systems have often applied a systems approach in analyzing system input, control and output 
parameters, biological systems operate under similar principles and hence a systems thinking is 
equally applicable. The human body, which can be viewed as a system of systems, is composed of 
some of the systems that are of particular interest in this research, specifically the coronary systems, 
as previously discussed. 
The purpose of this section is to examine the relevance of systems approach in blood-
biomaterial interaction studies, with particular emphasis on the coronary system and the use of a 
systems approach in designing an in vitro model. General representations of the system interactions 
are proposed and form the basis of a systems approach framework proposal.  
2.5.1 The biological tripartite 
The tripartite interaction between blood components, flow and blood vessel endothelial cell 
walls has long been represented by the Virchow’s triad [311]. In view of the role played by medical 
devices, the triad has also been adapted to reflect this fact by including biomaterials [4]. The broad 
description of a systems perspective in sections 2.2 through 2.4 highlights the key roles played by the 
major system of systems pillars – blood system, fluidics system and biomaterials system. This two-
dimensional tripartite interaction can be referred to as the blood-biomaterial interaction triad (BBIT). 
However, with the introduction of biomaterials, the BBIT may not sufficiently represent the 
interactions in vivo. A more general representation of the interactions between all the systems would 
be a blood-biomaterial interaction pyramid (BBIP) or more appropriately the blood-biomaterial 
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interaction triad of triads (BBITT or BBIT2), Figure 2-16. The acronym for this interaction could also 
be based on the four vertices of the blood-biomaterial-flow-geometry (BBFG) pyramid. 
 
 
Figure 2-16. Schematic representation of the blood-biomaterial interaction triads (BBITs) 
 
The BBITs or BBFG representation emphasizes the fact that even in the case of in vitro 
investigations where the interest is in the blood-biomaterial-flow triad, geometry still plays an 
important role. In vascular geometry, there are some differences in arterial, venous and 
microcirculation, which influence subsequent mechanisms involved in the development of 
thrombosis. Hence, there is a need to distinctly identify the role of geometry. Moreover, even for a 
biomaterial, the geometry of the device plays a distinct role compared to the surface characteristics. 
For that reason, the BBITs representation remains valid for in vitro investigations. It is inherently 
understood that all the interactions will vary with time and therefore the time dimension has not been 
included in the BBITs representation. Thus, the proposed BBITs should provide an improved high-
level representation of the interactions between the various systems, without including the embodied 
complexities. 
2.5.2 Blood-biomaterial interaction cube 
The interaction of blood with biomaterials occurs at various multiscale levels, both 
organizational/dimensional as well as time scales. The purpose of the proposed blood-biomaterial 
interaction triads (BBITs) is to provide a high level understanding of the interactions between various 
systems. However, it is also necessary to understand the system interaction mechanisms at various 
length-scale or organizational complexity levels of the system. The length-scale levels can usually be 
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broken down from the organism down to the basic atom. For the purpose of this research, the basic 
level of the atom is understood and the levels are grouped into molecular, cellular, tissue, organ and 
organism level. The organ and organism levels are listed for completeness, but are assumed to exist 
for the other levels to exist and therefore are not specifically discussed. Therefore, only the molecular, 
cellular and tissue levels are relevant for blood-biomaterial interactions. In addition, the interaction 
time-scales between parameters are not specifically discussed but need to be considered and 
understood as they depend on the organizational level as well as the specific system. 
A representation that includes the first level complexities of the system, i.e. depicting primary 
level characteristics of each system that facilitate the various interactions is necessary. To do that, the 
BBITs is represented in a different form applicable to in vitro models. First the flow and geometry are 
combined to form the fluidics system. The BBITs representation is then extended to a 3-dimesional 
cube, similar to the Rubik’s cube, to conjure the complex interactions between system 
components/elements, Figure 2-17. It is important to highlight the fact that using a systems approach, 
some of the fundamental components, such as the role of water, can be included. Water plays a vital 
role in blood-biomaterial interaction and without this understanding a big piece of the 
biocompatibility puzzle is missing [292]. 
 
 
Figure 2-17. 3-dimensional representation of the blood-biomaterial interaction framework 
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Clearly the cube representation brings to the fore the complexity embodied in blood-
biomaterial interactions and the fact that the solution for the key to the holy grail is buried in the vast 
number of combinations. It also gives a much better visual representation that immediately shows the 
possible system permutations. In a fully developed framework, the interaction permutations would 
have weighting functions that can be used to indicate the relevance of each element in a particular 
investigation. For the purpose of this work, it is sufficient to show only the permutations. Since 
currently there is no consistent framework to apply a systems approach, the proposed blood-
biomaterial interaction cube (BBIC) provides the initial work towards developing such a framework. 
Furthermore, the modes of interactions need to be understood. 
2.5.3 The SAXSA sequence 
Since the broad relationship between the various systems as represented by the BBITs and the 
framework parameters that facilitate interactions as represented by the BBIC are understood, it is now 
important to understand the mode of interaction. Thus, it is necessary to develop another framework 
representation level that deals with the interactions between the various systems. For the interactions 
to occur, one or more of the interactions has to initiate the process, i.e. act as the stimulus. The 
purpose of the stimulus is to activate the system, i.e. to initiate a system response, regardless of 
whether it is intentional. The activated system subsequently expresses specific proteins for specific 
activity or function. For the proteins to carry out the intended activity, there has to be an element of 
stability built in or facilitated by co-factors. The above description can be presented in a simplified 
framework in the form of a sequence, Figure 2-18. It should be understood that the sequence is 
merely a representation as the interactions are not linear. The sequence can be applied to one system 
or to a system of systems, where the expression or the activity could be inputs to other systems or 
feedback to the system itself. From the Stimulus, Activation, eXpression, Stability and Activity 
sequence, the acronym SAXSA is proposed. 
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Figure 2-18. Schematic of the mode of interaction, the SAXSA sequence 
 
While the broad idea of initiation, propagation and amplification is well known, e.g. in 
coagulation [148, 226], the SAXSA sequence incorporates important mechanistic information. Hence 
a closer look at the cube framework and the SAXSA sequence reveals that in order to understand the 
implications of the interactions, it is necessary to clearly characterize the system, particularly the 
stimulus, whether it is mechanical shear or biological agonist. This is because the cause and effect 
relationship is stimulus-dependent. Some stimuli may only effect specific aspects, such as expression, 
activity or stability. Examples include activation of platelets, leukocytes and complement. As 
previously described, material bound C3b, which has a short half-life, is stabilized by factor P in 
order to maintain activity. On leukocytes, the chemoattractant fMLP increases Mac-1 expression 
without increasing affinity [312] while on the other hand ADP increases Mac-1 affinity without 
increasing expression [194]. Interestingly, expression with or without function is also observed with 
platelet microparticle formation. In some cases, there are clear biological reasons for these 
interactions but in some cases the rationale is unclear or has not been investigated because there is no 
overall view on the mode of interactions. Therefore, the SAXSA framework is proposed to facilitate 
characterization of different aspects of the system in order to develop a mechanism for investigating 
cause and effect in blood-biomaterial interactions. 
Further to the SAXSA sequence, system characteristics can be defined in terms of functions 
at various levels – main and sub functions. Due to the complex interactions, there can be both specific 
and non-specific effects from each on the overall system behavior. Each function level can then be 
broken down further into tasks and sub-tasks. The same should be done with interconnections. This 
way a protein can be mapped out as to what role and pattern it plays in achieving a goal, e.g. 
coagulation. As an illustration, very rudimentary system properties and the basic effect of their 
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interactions based on organizational levels are presented on Table 2-11. Thus, each level of the 
system interactions can be represented by an appropriate framework to facilitate investigations. 
 
Table 2-11. Basic representation of systems and effect of interaction based on organizational 
level 
 Property and effect 
Level Blood system Biomaterial Hemodynamics Geometry 
Molecule/ 
protein 
Recognition 
molecules (e.g. 
complement, TLR4) 
(signal transduction, 
defense, activation, 
chemotaxis) 
Surface chemistry, 
energy, charge 
(surface water 
structure, protein 
epitope exposure, 
adsorption) 
Microdynamics 
(interaction, bond 
mechanics, epitope 
exposure, 
act/deactivation) 
Adhesion 
surface 
Cell 
 
Leukocytes, platelets 
(mechano- 
transduction, 
adhesion, 
aggregation, 
defense) 
Surface morphology, 
surface area 
(activation, 
adsorption) 
Shear 
(shear-induced 
dispersion, activation, 
lysis) 
Cell-surface 
interaction 
(flow 
profile, wall 
interaction) 
Tissue  Rheology 
(transport medium) 
Surface area, device 
design geometry 
(aggregation pattern) 
Shear (Newtonian vs 
non-Newtonian) 
(mass transport, phase 
separation, wall shear 
stress)  
Flow type 
(flow 
profile) 
 
2.5.4 Blood-biomaterial interactions and the broader picture 
The motivation for the previous discussions was to understand systems relationships, 
parameters and the modes of interaction that occur in various health and disease states. In disease 
states, the subsequent motivation is to develop appropriate intervention methods. Therefore, 
understanding of the system interactions at various complexity levels forms the basis for the 
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development of mechanism-based clinical intervention methods. They form part of a much bigger 
picture beyond investigations, which warrants a systems view. 
Based on the previous discussions, it is possible to build a typical model of interactions in 
line with a systems approach, Figure 2-19. The system and its functions are first identified, from 
which the interactions, can be represented in a schematic; in this case the example is the complement 
and leukocyte collaboration in identifying and responding to the presence of a foreign body. From 
this schematic, a typical flow chart type representation can be drawn to show the flow of information 
or influence. Once this is completed, with additional existing information on kinetics, experimental or 
mathematical models can be built for further investigation of the interactions. The end result should 
be understanding of the interactions from an input, control and output point of view as well as the 
development of intervention methods, such as device or drug delivery. The intervention methods are 
meant to influence the identified pathway(s) and therefore, they also provide additional input to the 
system. Hence, analysis of the effect of the intervention methods would also be necessary. 
In the simplified representation of the foreign body response to a biomaterial in Figure 2-19, 
a collaborative and cooperative system approach is assumed. For the most part, this is valid in blood. 
It is important to establish the type of system because this influences the emergent behavior and the 
way the system is analyzed. In a collaborative system, one may ignore (without excluding it in the 
analysis) the conflict parameters, for the most part. In homogenous systems, such as the case of bees, 
the collaboration/cooperation system behavior can easily be deduced. However, in the case of 
bacterial quorum-sensing to influence group behavior, complex communication issues can arise [313, 
314]. The situation is even much more complex in an inhomogeneous environment of cells and 
proteins, such as in blood. Sequential decision making to enhance value is no longer straight forward. 
Although generally collaboration and cooperation are the norm, conflict may arise from self-
preservation or opposing goals. How the conflict is resolved remains unclear. What is known is that 
the desire to preserve the tissue and hence the organism does not always win. This is a systems 
approach problem since its fundamental premise is that interactions between components determine 
the system behavior or properties. 
While a representation such as this is possible to develop, there still remains the actual work 
required to understand the fundamental interactions and the kinetics to build a systems approach 
model. Individual attempts have been made to use a systems approach, but there is no defined 
framework that provides guidance and building block for all researchers. 
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Figure 2-19. Schematic of systems approach based on immune system 
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2.5.5 A systems approach framework 
As previously discussed and illustrated, the interaction of biological systems with implants 
involves a combination of complex interconnected and overlapping pathways. To understand such 
complex systems, it is often necessary to apply a holistic or systems approach. While systems 
approach methods have been previously applied to the blood coagulation system, there has been 
limited discussion in the context of biomaterial interactions. A systems approach compels researchers 
to appropriately characterize the system or subsystem of interest, their mode of control and input and 
output parameters. This provides a structured framework, which facilitates application of simulation 
methods used in complex systems. It also facilitates design of in vitro experiments in the context of 
their relevance for evaluating specific system functions or tasks. Therefore, building on previous 
work, a high-level breakdown of the blood-biomaterial interaction system into subsystems that are 
relevant for in vitro studies is examined. It should be noted that this approach is also applicable for 
numerical models. The use of systems methods in blood-biomaterial studies is proposed not only to 
facilitate understanding of subsystem interactions but to also assist in examining subtle system factors 
that may not be obvious when looking at bulk measurements. 
In cell biology, intracellular pathways have been extensively studied in various 
specializations such as pharmacology, molecular cell biology and biochemistry. In recent years, there 
have been numerous initiatives to apply systems thinking to understand and characterize these 
biochemical networks and their interactions [315, 316]. Due to the complexity of the systems 
(multiscale organization, network interconnections, spatial and time dimensions), qualitative 
descriptions are not sufficient to explain the interaction kinetics. Therefore, quantitative analysis and 
description of these interaction kinetics have applied engineering and mathematical principles, such 
as network analysis and differential equations. These in turn are amenable to the application of 
computer simulations, which are excellent research tools to validate experiments but can also be used 
for deciding specific interventional tools, such as drug delivery and kinetics of control. From these 
initiatives has emerged the field of systems biology, which deals with how molecular interactions 
form building blocks for cellular operation that form physiological function. Blood-biomaterial 
interactions involve the same biochemical networks, except with an added level of complexity due to 
the presence of biomaterials. Therefore, this provides the impetus for a case for a systems approach in 
blood-biomaterial interaction studies. 
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The need for systems approach in blood-biomaterial studies due to the complex nature of the 
interactions has previously been identified [11] and the complexity of blood-biomaterial interactions 
has been previously highlighted by other researchers [7, 14]. A schematic representation of 
extracellular signals and interactions between cell-cell, cell-shear and between cells-milieu of 
cascades around the biomaterial was presented on Figure 2-14. Numerous experiments have 
investigated the co-relation between biomaterial characteristics and blood activation parameters. 
While these are invaluable in establishing the network pathways, they cannot provide sufficient 
information that describes the true interactions in whole blood. To that end, there has been use of a 
holistic approach by using whole blood and investigating several parameters simultaneously [317] 
and cytokine profiling in vivo [309, 318]. The number of dynamic variables in such holistic approach 
studies makes it difficult to analyze and understand without systems analysis, especially if they are 
coupled with intracellular interactions. 
There have already been studies that employed a systems approach to understand the 
coagulation system [12, 13, 319]. Since the coagulation system plays a central role in thrombosis, 
these studies provide an invaluable stepping stone for the adoption and application of a systems 
approach in blood-biomaterial studies. What is required is a methodology framework that through 
consensus can be adopted and refined with time, as guidance for blood biomaterial studies. The 
fundamental principles of a systems approach as it applies to blood-biomaterial studies needs to be 
defined. To start the work towards this initiative, a systems approach illustration is proposed. An 
example with the design of an in vitro model is provided. 
Based on the above discussions and previous subsections, the overall systems approach 
framework is presented as a flowchart representation where all the data is integrated to design an 
appropriate model. This is because one of the features of this framework is the requirement to mimic 
the physiological location of interest. The framework is depicted in Figure 2-20. For the framework to 
be useful, there is need for reference simulation models and data that has been validated so that other 
researchers do not have to reinvent the wheel. The development of reference data requires concerted 
efforts in standardization of protocols [320]. For simulation models, the Cardiac Physiome Project, 
whose progress and challenges are reviewed elsewhere [321], provides an excellent example. The 
development of a data repository provides a mechanism for data improvement through constant 
update. It also provides an invaluable tool for data mining research. There are also several online 
databases and some of the well known examples of the reference data that are useful to other 
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researches are the genome and proteomics databases. The development of a database on material 
treatment methods and characteristics is crucial for the framework. 
The other important aspect of the framework is the need for comprehensive indicators for 
specific investigations under specific conditions. Generally known indicators are used for most 
investigations but there has been evidence that some markers vary with physiological conditions. For 
example, although C-reactive protein (CRP) levels after stent implantation have been reported to be 
higher for bare-metal stents compared to drug-eluting stents [322], CRP has also been found to be a 
predictor of in-stent thrombosis for drug-eluting stents [323]. Also the case of only C5a correlating 
with implantation of drug-eluting stents, and C3a correlated with development of in-stent thrombosis, 
while both correlated with late lumen loss [88]. In addition, to facilitate translation of results, it is 
important to include clinical biomarkers such as cell count and hematocrit. Review of current 
evidence suggests they are risk factors for coronary heart diseases [324]. Leukocyte cell count in 
particular has been shown to be independently associated with mortality [325, 326]. Therefore, how 
they correlate with biomaterial response would be informative. In particular, profiling cell sub-
populations as opposed to bulk investigation would be beneficial. These issues point to the need to 
develop methods-based biomarkers. Thus, the use of a systems approach framework will go a long 
way in not only unraveling the much sought after causation relationship between material properties 
and biochemical pathways, but in standardizing investigations and comparison of results.  
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Figure 2-20. Schematic of the systems approach framework 
 
2.5.5.1 Applying the framework principles to in vitro model design parameters 
In vitro models form the cornerstone of investigations for research and development. 
Therefore, in designing an in vitro model, the aim is to mimic the physiological location of interest 
and the intended implant application. Hence, the design of an in vitro model, by its very nature 
requires a reductionism approach since the in vivo system cannot be duplicated. The problem then 
becomes how does one identify the key systems or components to preserve for experimental or 
mathematical modeling. Based on the previous discussion and the framework, the following general 
design methodology can be applied, Figure 2-21. 
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Figure 2-21. In vitro model design flowchart 
 
The general methodology can be applied for model stent design as well. Ideally the minimum 
physiological parameters and key end-use implant characteristics, in the case of model stents, would 
be standardized on a reference database. Based on the above procedure, the initial rationalization of 
parameters is developed, as presented on Table 2-12. It should be noted that the multiscale interaction 
levels as discussed before are understood and taken into account in detailed design. Where there are 
no weighting functions to provide a quantitative mechanism to validate the rationalization decision, 
the overriding factor to mimic the PLOI is used. This rationalization of parameters forms the basis for 
subsequent development of detailed design parameters. One of the essential applications of a systems 
approach as discussed under the SAXSA sequence is appropriate characterization of the stimulus as 
this forms the input to the system. The system input is one of the key determinants of the system 
output. Hence, understanding its characteristics is vital. In the case of an in vitro model, the stimulus 
is the flow shear and the biomaterial under study. This is applied in the detailed design of the model 
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as discussed in Chapter 3. Even though the information below indicates all material and flow 
parameters are included, the cellular transport dynamics at the material surface is not addressed 
thoroughly by the bulk flow model. Only multiscale modeling would address that level of interaction. 
 
Table 2-12. Rationalization of in vitro model parameters 
Property	   Parameters	   In	  vitro	  parameters	   Rationale	  
Geometry	   Curved	  -­‐curvature	  ratio,	  Dean	  number	  Diameter	  
Curved	  tube	  and	  diameter	  mimic	  physiology	  
Curvature	  and	  diameter	  influence	  flow	  characteristics	  
Flow	   Shear	  stress	  -­‐duration,	  level,	  frequency,	  pulse	  width,	  time-­‐averaged	  
All	  included	  under	  steady	  flow	   All	  important	  in	  vivo,	  not	  only	  duration	  and	  level.	  Mimic	  in	  vivo	  as	  close	  as	  possible	  
Material	  
surface	  
Surface	  morphology	  -­‐indent	  vs	  protrusion	  -­‐multiscale	  vs	  homogeneous	  Surface	  chemistry,	  energy,	  electrostatics	  
All	  considered	   Important	  in	  blood	  activation	  
Stent	   Length	  Diameter	  Surface	  area	  Structural	  design	  
All	  included	  +	  surface	  area-­‐to-­‐volume	  ratio	   All	  influence	  flow,	  e.g.	  friction,	  and	  blood	  activation	  
Rheology	   Whole	  blood	  vs	  plasma	  Newtonian	  vs	  non-­‐Newtonian	  
Whole	  blood,	  Newtonian	   Holistic	  approach,	  Newtonian	  acceptable	  in	  arteries	  
 
2.5.6 Summary 
In this section, the case for applying a systems approach in blood-biomaterial interaction 
studies was presented. Some of the important aspect of a systems approach such as methods-based 
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indicators, standardized tests and rationalization of parameters [14], multi-parameter profiling [327] 
and a repository database for blood-biomaterial interaction studies were highlighted. More 
importantly, representative models of system interactions and the systems approach framework were 
proposed. However, there is still work to be done.  
To develop a comprehensive systems approach framework, it is also necessary to incorporate 
a number of disciplines such as chaos theory. Although chaos theory stems from mathematics, its 
concept of the “butterfly effect” is relevant to biological systems. A small perturbation can result in 
large system changes over time as it propagates through the system. There is already some evidence 
of this in the feedback loops in some of the biochemical pathways, which are triggered by low levels 
of substrate-enzyme but amplified through cyclic positive feedback loops. Also the issues raised in 
bacterial quorum-sensing studies and reviews [313, 314], such as system noise and the integration of 
signals, raise some interesting questions that are relevant to blood-biomaterial interactions. Is there 
any prioritization to signal response and does it have effect on outcome? Are certain stimuli more 
likely to cause noise? Similar studies may be necessary in blood-biomaterial studies to elucidate cell 
communication strategies. 
Clearly a concerted effort is necessary [320], such as the one that has seen the development of 
systems biology. At the organizational level, there is need to develop a collaboration model for the 
various disciplines involved in this problem. The current model of learning from each other without a 
defined collaboration model is not feasible to produce a holistic approach to this problem. 
2.6 Conclusion 
In this chapter, the relationships between the various systems involved in blood-biomaterial 
interactions were presented. Some literature review was presented and pertinent issues related to a 
continued search to resolve the issue of material-induced thrombogenicity were highlighted. The case 
for a systems approach was presented and a systems approach framework was proposed. 
Subsequently, an illustration to apply the systems methodology to determine design parameters for an 
in vitro model was presented. A comprehensive systems approach will require concerted effort and 
therefore a collaboration model is also necessary. This chapter has presented information to support 
and demonstrate the significance of a systems approach in blood-biomaterial studies. A thorough 
development of this concept is necessary. 
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Chapter 3 
A Systems Approach to In Vitro Model Design 
3.1 Introduction 
In vitro models are mockup devices used to study complex biological systems. They play an 
important role in the investigation of complex biological systems because they are cheaper, easily 
controllable and provide more reproducible results compared to clinical and animal studies. Over the 
years, numerous static and flow models have been developed and used to investigate a variety of 
biological system interactions such as cell-cell/molecule interactions, blood-biomaterial interactions 
or the effect of flow shear stress on blood activation [15-17, 272, 328-330]. While static models are 
used to investigate material-induced biochemical processes, flow models, which are more 
physiologically relevant, incorporate the effect of flow in addition to biomaterials. Hence, their design 
is more elaborate since the incorporation of flow requires consideration of geometry and other factors. 
Geometry is particularly important because it affects flow parameters. A typical illustrative example 
of the effect of geometry on flow is the comparison of the average velocity between a cylindrical tube 
and a rectangular tube, which is half of the maximum velocity and two-thirds of the maximum 
velocity, respectively [331]. A relevant physiological example is the evidence of complex flow and 
low shear stress at curvatures and bifurcations [61, 234]. Nonetheless, in vitro models simulating flow 
in blood vessels have come in various configurations, such as straight circular tube flow [332], curved 
circular tube [15, 333], idealized stenotic coronary artery [334], rotating disc [17], cone and disc 
[329] and rectangular channel [335]. While some of the configurations may be useful in investigating 
specific fluid dynamics aspects, translation of the results to physiological relevance encounters some 
difficulties. 
However, there are also models that have taken into consideration some of the geometrical 
parameters of the physiological location of interest they are designed to mimic. These include the 
orifice plate and chamber which mimics the heart valve flow [336] and the Chandler loop which 
mimics blood flow in curved arteries [15]. While in vitro models, regardless of the design geometry, 
have known limitations [337], they have contributed and continue to contribute tremendous 
knowledge to the understanding of blood rheology, blood interaction with biomaterials or 
immobilized molecules and biomaterial interaction with tissue. They also provide an invaluable tool 
for validating computer simulation models. The existence of limitations means that closer attention 
   81 
needs to be paid to the models design, starting with the fundamental properties and not merely the 
gross requirement for flow. Hence, it is necessary to apply a systems approach when designing in 
vitro flow models. 
From a systems perspective, the in vitro model is equivalent to the fluidics system discussed 
in Chapter 2 and therefore should ideally mimic this complex physiological system. For that reason, it 
is important that the model geometric and hemodynamic design parameters closely mimic the 
physiological location of interest (PLOI). Geometric characteristics, in particular, have a major 
impact on hemodynamics and localization of atherosclerotic lesions in vivo [61, 62, 250, 338], 
regardless of whether the influencing mechanism is from other cardiac pathologies or within the 
coronary arteries [237]. One of the key geometric features that influence a variety of flow parameters 
is curvature and/or curvature ratio. Curvature influences the skewing of the axial velocity profile 
[258], induction of centrifugal force-driven secondary flow vortices [258], the pressure gradient 
across the tube diameter and hence fluid friction [258] and axial pressure loss [260]. While other flow 
parameters are equally important, the dimensionless Dean number is often used to characterize the 
effect of curvature on hemodynamics [259]. Therefore, one cannot describe the fluid mechanics of 
coronary studies without including or recognizing the effect of the Dean number. 
The key hemodynamic parameter that is linked to the in vivo localization of lesions as well as 
in vitro cell-wall interactions is wall shear stress (WSS). Fluid shear stress influences near wall 
transport phenomenon [56, 57] and consequently influences platelet dispersion [149, 339] and 
adhesion [247], platelet interaction with tissue factor [249], as well as monocytic cell [332] and 
neutrophil [334] adhesion. More importantly, shear stress has been shown to have some correlation 
with in-stent thrombosis [257]. Hence, it is an important parameter in blood-biomaterial interaction 
studies. While shear stress/rate can be produced with various geometries, other hemodynamic 
parameters such as the flow pattern or velocity profile depend on the geometry. Hence, the geometric 
and hemodynamic factors need to be taken into account in determining the appropriate in vitro model 
for this research. 
Therefore, the objective of this work was to design or select an appropriate in vitro blood 
flow model that mimicked the physiological location of interest for this research using a system 
approach. It was hypothesized that in vitro flow model parameters mimicking physiological location 
of interest are better designed following a system approach and that blood sample volume influences 
flow dynamics and hence wall shear stress. Hence, specifically, this chapter describes the process that 
   82 
was followed to, (a) evaluate existing in vitro flow models and select the appropriate model, (b) 
determine model design parameters, (c) analyze the model fluid mechanics and (d) implement the 
model.  
3.2 In vitro flow model selection 
As highlighted above, the design or selection of a model needs closer attention as it already 
provides a limited representation of a biological system. Hence, it is necessary to follow a systematic 
procedure as highlighted on Figure 2-21, Chapter 2. 
3.2.1 Materials and methods 
3.2.1.1 Physiological location of interest (PLOI) and parameters 
The main question was how to establishing the design requirements for in vitro model that 
mimics the PLOI for systems approach experimental investigations. The PLOI for this research was 
the coronary arteries, more precisely the left anterior descending (LAD). Some details of coronary 
arterial system were discussed in Chapter 2. In this section, the main physiological parameters are 
summarized, Table 3-1. The relative importance of each parameter in in vitro model design varies 
with the objective of the design or the specific study. For this work, the objective was to design or 
select an in vitro flow model appropriate for coronary flow studies. The functional parameters were 
considered in terms of the need for flow. Here they are stated in terms of the systolic pressure, which 
drives flow in the coronary arteries, and the heart rate. While flow requires pressure, the specific 
driving pressure was considered less important as different mechanisms could be used to generate 
flow. Regarding the structural parameters, it has been previously suggested that the error in using 
fixed geometry is reasonably small, comparable to the assumption of rigid vessel wall and Newtonian 
rheology [261]. This suggests fixed geometry could be used within reasonable error. Hence, the 
structural parameters were not considered important for this research. On the other hand, both the 
geometric and hemodynamics parameters are considered very important as previously discussed in 
Chapter 2, and therefore critical in determining model parameters. 
Some of the important geometric parameters for the coronary system are the heart curvature 
and vessel tortuosity [228, 237], and vessel bifurcation and diameter [229, 340]. Hence, curvature, 
vessel radius and lumen cross-sectional shape are key physiological geometric parameters. Since 
curvature is a critical property of the coronary arteries, the corresponding curved flow is equally 
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important. The effect of curvature on hemodynamics is predominantly characterizes by the Dean 
number [259]. The other important hemodynamic parameters of interest included the velocity profile, 
Reynolds number and shear stress. Shear stress is particularly a critical parameter because of its role 
in atherosclerosis and thrombosis [250, 338, 341], blood coagulation [149] and material induced 
thrombosis [257]. In vitro models used to study coronary flow should ideally take into account the 
parameters listed on Table 3-1. Although both the geometric and hemodynamic parameters vary 
dynamically (spatial and time) due to the pulsatile nature of myocardial contraction, nominal values 
can be adopted as previously discussed.  
 
Table 3-1. Physiological parameters. NB: ranges of physiological parameters may vary slightly, 
depending on the quoted study. 
Parameter	  type	   PLOI	   Parameter	  
Functional	   Coronary	  arteries	   Maintain	  flow	  at	  80	  mmHg,	  1	  Hz	  
Structural	   Coronary	  arteries	  
• Elastin	  
• Collagen	  
• Smooth	  muscle	  
E	  =	  0.1	  MPa,	  viscoelastic,	  anisotropic	  [51]	  	  E	  =	  0.3	  MPa	  [51]	  E	  =	  100	  MPa	  [51]	  E	  =	  0.1-­‐0.2	  MPa	  [51]	  
Geometric	   Heart	  LAD	  	  
Radius	  of	  curvature	  =	  42.8	  mm	  [238],	  56.3	  mm	  [237]	  Diameter	  =	  3.7±0.5	  mm	  [229]	  Curvature	  ratio	  =	  0.02-­‐0.5	  [261]	  Lumen	  X-­‐section:	  circular	  [342]	  
Hemodynamic	   LAD	  	  	  	  
Velocity	  =	  10.6-­‐43.0	  cm/s	  [229]	  Dean	  number	  =	  22.9	  [331]	  Reynolds	  No.	  =100-­‐217	  [229]	  Shear	  rate	  =	  100-­‐1000	  s-­‐1	  [52]	  
E: Young’s modulus 
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3.2.1.2 Model requirements and constraints 
Based on the above discussion, the in vitro model requirements and constraints are as listed in 
Table 3-2. The flow and geometric parameters are important in the design of in vitro models design 
[320]. The functional need for whole blood is in line with the systems approach. The free variable 
was the operating temperature. 
 
Table 3-2. Model requirements and constraints 
Requirement/constraint	   Parameter/property	  Functional	   Must	  have	  curved	  flow	  and	  use	  whole	  blood	  Technical	   Shear	  rate	  =	  100-­‐1200	  s-­‐1	  Velocity	  =	  10-­‐43	  cm/s	  Flow	  tube	  diameter	  <	  5	  mm	  Curvature	  radius	  40-­‐60	  mm	  Circular	  x-­‐section	  flow	  tube	  Blood	  sample	  <	  10	  ml	  Quality	   Flow	  tube	  must	  be	  medical	  grade	  Economic	   Low	  operating	  cost	  
  
3.2.1.3 Model analysis/evaluation Although	  a	  number	  of	   flow	  models	  have	  been	  used	   for	  coronary	   flow	  studies,	   some	  of	  them	   are	   variations	   of	   the	   three	   commonly	   used	  models;	   cone	   and	   plate,	   parallel	   plate	   flow	  chamber	  and	  Chandler	  loop	  model.	  Hence,	  the	  evaluation	  to	  select	  an	  appropriate	  model	  for	  this	  research	  was	  based	  on	  these	  three	  models. The evaluation was based on information from section 
3.2.1.2 and the models’ theoretical operating principles. The selection was based on meeting the 
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stated design requirements/constraints and the ability to mimic PLOI parameters. Because of the 
manageable number of parameters, it was not necessary to develop extensive ranking criteria. 
3.2.1.3.1 Cone-and-plate model 
This model is used to apply shear by a circulating cone on a flat plate [329]. A schematic of 
the cone-and-plate model is depicted on Figure 3-1. This model and modified versions [343, 344] are 
often used to investigate the effect of shear on platelets or immobilized proteins/molecules or cells 
[343, 344]. While this model is useful for isolating the effect of shear and can generate a wide range 
of shear rates, it does not mimic physiological geometry and hemodynamic flow conditions. The 
parameters that influence shear rate are the cone angle and its rotational speed [329]. One interesting 
feature of this model is its standardized geometry. 
 
 
Figure 3-1. Schematic of the cone-and-plate model 
 
3.2.1.3.2 Parallel plate flow chamber model 
This model is composed of a perfusion pump, flow tube and sample chamber [16]. A 
schematic of the parallel plate flow chamber model is depicted on Figure 3-2. It has been mostly used 
to study blood interactions with immobilized proteins or cells [16, 248]. This model uses a tube flow 
but the sample under study is subjected to plate flow. The model parameters that influence shear rate 
are the plate separation distance, plate width and flow rate [16]. 
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Figure 3-2. Schematic of the parallel plate chamber model 
 
3.2.1.3.3 Chandler loop model 
The Chandler loop model is based on a circular loop configuration. It is composed of a tubing 
loop on a rotating turntable [15]. A schematic of the Chandler loop model is depicted on Figure 3-3. 
The circular loop provides curved flow, with a skewed velocity profile and secondary flow pattern 
[345], similar to that observed at physiological curvatures and bifurcations [331, 346]. This model has 
been used to study whole blood thrombus formation and blood interaction with immobilized 
molecules [15, 347-349] as well as stents [26, 27, 350]. Model parameters that influence shear are the 
loop curvature and tube radius. 
 
 
Figure 3-3. Schematic of the Chandler loop model 
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3.2.2 Results and discussion 
Comparison of the three in vitro flow models on the basis of their operating principle shows 
that they can be used to generate a wide range of shear rates within physiological range, Table 3-3. 
However, their appropriateness for coronary flow studies is quite diverse. The cone-and-plate model 
can easily isolate the effect of shear stress and can be used to generate pathologic shear conditions. 
However, when the model geometry and other hemodynamic factors such as the flow pattern are 
considered, the model turns out to be inappropriate for this research because it does not meet some of 
the model requirements/constraints and does not mimic physiological geometry and hemodynamic 
flow conditions.  
For the parallel plate chamber flow model, the use of a plate chamber makes it unsuitable for 
this research because there is a difference between plate flow and tube flow dynamics, which would 
influence material deposition kinetics on the surface. Although the plate chamber is commonly used, 
this model can be adapted by replacing the chamber plate with a rectangular or circular tube. Since it 
uses a pump, the tube could also be configured to form a loop or curve. Other chamber modifications 
such as introducing vertical-steps have been used to study the effect of disturbed flow on monocyte 
dispersion and adhesion [335], neutrophils [351] and whole blood leukocytes [352]. A modified 
version of the perfusion system can also be used to perform parallel studies and provide pulsatility 
[353]. The limitation with parallel investigations is that the investigations have to be identical as there 
is one common pump. This model may offer versatility where the geometry of the chamber or tube 
needs to be adapted for specific studies. However, it was not selected because of the possibility of 
platelet activation or sensitization from the perfusion pump, which could affect experimental results. 
The effect of pumping on platelet activation and hemolysis has also been demonstrated with a roller 
pump loop model when compared to the Chandler loop [333]. For that reason, it was not considered 
appropriate for this research. 
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Table 3-3. Comparison of three in vitro flow models.  
Flow model Wall shear 
rate (s-1) 
Ref Relevance to physiological conditions 
Cone and plate 
γ =
πω
30ψ  
[329] • Good for isolating effect of shear on sample 
• Generates wide range of shear rates, including pathologic  
• Does not mimic physiological geometry and hemodynamic 
flow conditions. 
Parallel plate 
flow chamber  
γ =1.03 6Qab2  
[16] • Active sample pumping makes it possible to study the effect of 
channel geometry changes, such as stenosis 
• Generates wide range of shear rates 
• Plate flow does not mimic physiological geometry and 
hemodynamic flow conditions 
Chandler loop 
€ 
γ =
2πR0ω
15R  
[354] • Passive flow makes it difficult to simulate effect of channel 
geometric changes, such as stenosis 
• Generates wide range of shear rates within physiological ranges 
• Curved tube flow mimics physiological coronary flow. 
γ=wall	   shear	   rate	   (sec-­‐1),	  ω=angular	   velocity	   in	   revolutions	   per	  minute	   (RPM),	  ψ=cone	   angle	  (radians),	   Q=volumetric	   flow	   rate	   (ml/sec),	   a=slit	   width	   (cm),	   b=slit	   height	   (cm),	   R0=loop	  radius,	  R=tube	  radius. 
 
The circular	   loop	  configuration	  of	   the	  Chandler loop configuration mimics	  physiological	  curvature	   and	   meets	   the	   requirements/constraints.	   It	   produces curved flow, with a skewed 
velocity profile and secondary flow pattern similar to that observed at physiological curvatures, such 
as coronary vessel curvature resulting from heart curvature, and bifurcations [61,	  331]. Hence,	  it	   is	  fitting	  for	  in	  vitro	  coronary	  blood	  flow	  studies.	  An additional benefit of this model is the ability to 
study several biomaterials simultaneously [350]. This model has the advantages of simplicity, clinical 
relevance and ease of modification to mimic desired physiological conditions. It is also referenced in 
ISO 10993-4 Standard [355]. It may have limitations where pathologically high shear rates are 
necessary. However, it is suitable for physiological hemodynamic conditions and modified versions 
have been used to mimic pulsatile flow [333] and coronary pulsatility [356]. For this research, vessel 
pulsatility is not included as it has been shown to have limited error implications on the wall shear 
stress [261]. Therefore, the Chandler loop model was considered appropriate for this research. The 
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determination of specific model parameters and issues regarding their implications on fluid dynamics 
are discussed in the subsequent sections. 
3.3 Determining model design parameters 
To determine the specific model parameters, previous experiments using the Chandler loop 
model were reviewed. A great diversity was observed in the range of parameters selected by the 
investigators [15, 26, 27, 347, 349, 354], but with little guidance on the method used to select the 
parameters. Therefore, the model requirements and constraints together with parameters of the PLOI 
were used as a guide to generate the specific model parameters. Thus, in this section, the key 
physiological parameters considered relevant for any investigation mimicking coronary flow and 
hence relevant to this research, are determined. 
Figure 3-4 a schematic representation of the circulating loop model with model stent. The 
parameter R0 is the mean loop radius or radius of curvature, 2R is the tube internal diameter (radius 
R) and ω is the loop rotational speed (RPM). Since the error in using a fixed geometry is considered 
reasonably small [261], the tube and loop radii were held constant in this research. To mimic 
coronary arteries, a commercially available Silastic silicone circular tube #62999-874 (VWR, PA, 
USA) with internal diameter of 0.188“ (4.775 mm) and external diameter of 0.313” (7.950 mm) was 
selected. The length of the sample tubes (371 mm) was selected to give a radius of curvature of about 
59 mm. One of the consequences of the presence of curvature on flow is the development of 
centripetal force due to the change in momentum of the flowing liquid. As a result, there exists a 
centripetal pressure on the outer wall given by equation [51], 
 
P = 2ρν 2 RR0
          (13) 
 
where ρ is fluid density and ν is average flow velocity. Thus, there exists a pressure gradient across 
the tube. To assess the effect of curvature on the pressure gradient, it has previously been proposed 
that the design Reynolds number should meet the condition Re < 40 R0 R  [357]. This condition 
may or may not be desired, depending on the experiment. Thus, loop curvature has major 
implications on the fluid mechanics of the model. In this research, curvature radius is held constant 
both in space and time while flow is varied. 
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Figure 3-4. Representation of circulation loop with blood sample and model stent 
 
Fluid mechanics of the Chandler loop model with fixed curvature have been previously 
described by Gardner [354]. The model wall shear rate from Gardner’s analysis is given by the 
equation, 
 
γw =
2πR0ω
15R           (14)
 
 
Besides shear rate, some of the key parameters characterizing steady state flow in a curved circular 
tube are the curvature ratio, Dean number (Dn) and/or Reynolds number [259]. They influence 
skewing of axial velocity profile, pressure loss and fluid friction [258, 259]. Therefore, these 
parameters were included to characterize the circulation loop fluid mechanics. Defining the average 
axial velocity in terms of the angular velocity gives the expression, 
 
v = 2πωR0           (15) 
 
Using previous definitions from Chapter 2, a summary of the important fluid mechanics parameters of 
the Chandler loop model is presented on Table 3-4. 
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Table 3-4. Fluid mechanics equations for the Chandler loop model 
Average velocity	   Curvature ratio	   Reynolds 
number	  
Dean number	   Wall shear rate	  
ν =
πR0ω
30  κ =
R
R0
 Re =
πρωR0R
15µ 	   Dn = Re κ 	   γw = 2πR0ω15R  
ρ is fluid density, R0 is loop radius (curvature radius), R is tube internal radius, µ is fluid dynamic 
viscosity and time is defined in seconds. 
 
Based on the shear rate equation and the selected model geometry, the range of rotational 
speeds necessary to give the shear rate corresponding to a physiological range is approximately 10-
100 RPM. As an example, two rotational speeds (24 and 45 RPM) were selected for comparison 
purposes, Table 3-5. Unless quoted directly from a reference, some of the data are calculated based on 
equations in Table 3-4. Considering the rheological properties of blood at the selected shear rates and 
the model tube size, the blood sample can be assumed to behave as a Newtonian fluid [52]. While this 
assumption simplifies fluid mechanics and holds the viscosity constant, it does not take away the 
particle dynamics that occur under shear and hence the need for consideration in analyzing 
experimental results. Comparison of the model parameters with some of the physiological parameters 
shows that the choice of experimental parameters was close to the physiological parameters, 
suggesting that the selected model is reasonably appropriate for LAD flow studies. 
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Table 3-5. Comparison of selected model parameters to average physiological LAD parameters 
Parameters Physiological  Model  
Geometry Diameter 3.2-4.2 mm [229] 4.78 mm 
Surface topography Smooth Smooth 
X-sectional profile Circular Circular 
Heart radius of curvature 42.8 mm [238] 59 mm 
Curvature ratio 0.04-0.05 0.04 
Flow 
dynamics 
Bifurcation/Curvature Curved tube flow Curved tube flow 
Rheology ρ=1060 kgm-3,  
µ=0.003-0.004 Pa.s [52] 
ρ=1060 kgm-3,  
µ=0.0035 Pa.s 
Velocity: Inlet 
Downstream 
10.6-16.6 cms-1 [229] 
13.0-43.0 cms-1 [229] 
24 RPM 
15.5 cms-1 
45 RPM 
29 cms-1 
Reynolds number (Re) 100-217 [229] 215  402 
Dean number (Dn) 19-48 * 43 81 
Wall shear rate 100-1000 s-1 [52] 
(350-1200 s-1) [229] 
250 s-1  470 s-1 
Biochemical  Physiological thrombi Similar thrombi [347] 
*Calculated based on other physiological parameters in the table. 
 
3.3.1 Discussion In	   this	   section,	   relevant	   in	   vitro	   model	   parameters	   were	   determined	   based	   on	   the	  physiological	   location	   of	   interest.	   However,	   one	   physiological	   parameter	   that	   is	   not	   included	  above	  is	  the	  dynamic	  cardiac	  cycle	  and	  pressure	  pulsatility.	  As	  discussed	  in	  Chapter	  2,	  cardiac	  cycle	  does	  not	  only	  influence	  the	  dynamic	  variation	  of	  curvature,	  but	  also	  determines	  the	  flow	  frequency	   and	   the	   vessel	   diameter.	   Although	   the	   importance	   of	   geometric	   variation	   with	  pulsatility	  on	  flow	  has	  been	  demonstrated	  [261,	  358],	  it	  is	  important	  to	  note	  that	  the	  difference	  in	  wall	  shear	  stress	  (WSS)	  between	  dynamic	  and	  static	  conditions	  is	  heavily	  dependent	  on	  the	  selected	  curvature	  ratio	  as	  well	  as	  the	  assumed	  amplitude	  of	  the	  change	  of	  radius	  of	  curvature	  [261].	  The	  difference	  is	  small	  for	  low	  curvature	  ratio	  and	  small	  deformation	  amplitude	  change.	  Hence,	   it	  has	  been	  suggested	  that	  the	  error	   in	  using	  fixed	  geometry	   is	  reasonably	  small	   [261].	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Therefore,	   besides	   the	   fact	   that	   it	   is	   also	   important	   to	   understand	   flow	   dynamics	   at	   specific	  geometries,	   such	   as	   at	   mean	   geometric	   values,	   based	   on	   Table	   3-­‐5,	   the	   effect	   of	   curvature	  variation	  can	  be	  considered	  small.	  Hence,	   fixed	  geometry	  was	  adopted	  in	  this	  research.	  Model	  parameters,	  such	  as	  the	  curvature	  ratio,	  were	  based	  on	  mean	  physiological	  values.	  Comparison	  of	  the	  selected	  model	  parameters	  and	  LAD	  suggest	  that	  model	  parameters	  reasonably	  mimic	  the	  physiological	  location	  of	  interest.	  	  Flow	   pulsatility	   or	   frequency	   on	   the	   other	   hand	   remains	   relevant	   for	   in	   vitro	   models	  because	  it	  influences	  flow	  parameters	  even	  in	  the	  absence	  of	  vessel	  geometric	  variations	  [359].	  For	   the	   selected	  model,	   the	   fact	   that	   flow	   is	   induced	  by	   rotation	   at	   various	   angular	   velocities	  means	  some	  aspect	  of	   flow	   frequency	  can	  be	  mimicked,	  which	  raises	   the	  question	  of	   relevant	  frequency	   and	   volumetric	   flow	   rate.	   Furthermore,	   the	   fact	   that	   sample	   volume	   occupies	   a	  portion	  of	  the	  circulation	  loop	  raises	  the	  question	  of	  the	  appropriateness	  of	  the	  sample	  volume	  and	   its	   implications	  on	   fluid	  dynamics.	  Therefore,	  while	   the	  main	  parameters	  are	  as	   listed	  on	  Table	   3-­‐5,	   the	   issues	   of	   frequency	   and	   sample	   volume	   are	   important	   aspects	   of	   the	   model’s	  relevance	  to	  physiological	  flow	  parameters.	  The	  issues	  concerning	  fluid	  dynamics	  are	  analyzed	  further	  in	  section	  3.4.	   
3.4 Fluid dynamics analysis of the model 
Fluid dynamics influences both vascular response and blood activation kinetics under 
different in vitro and in vivo conditions [149, 360, 361]. Understanding flow characteristics is also 
important in coagulation diagnostic instruments [362]. For that reason, it is essential to appropriately 
characterize flow for the evaluation of blood-biomaterial interaction in order to enhance interpretation 
of results. Since the sample volume for the selected model occupies a portion of the circulation loop, 
it was hypothesized that sample volume has an effect on fluid dynamics and hence blood activation. If 
that is the case, then the question of what is the appropriate sample volume arises. In addition, how is 
this volume determined? Review and comparison of previous studies [15, 26, 27, 333, 347, 349, 354] 
revealed variability in sample volume selection with no guidance on how the sample volumes were 
selected. Therefore, there was a need to develop a method to determine the appropriate blood sample 
volume for this model and determine its influence, if any, on the model fluid dynamics. 
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3.4.1 Determination of sample volume 
In determining the model hemodynamic parameters, Gardner [354] used a 50% volume 
fraction and an implicit assumption of sufficient sample volume and fully developed flow was used. 
Since then, the shear rate equation has been used with different volume fractions under the 
assumption of fully developed flow but with little validation as to whether this is met. Hence, there 
has been no guidance on the minimum volume required for this model. Furthermore, the use of this 
model in the presence of stents has not been accompanied by justification of the selected volume and 
stent size to meet the ISO 1993 standard for the ratio of material surface area to blood sample volume. 
This means, such studies may inadvertently violate the standard and hence produce erroneous results. 
Therefore, there is need to develop a method for determining the minimum sample volume required 
for in vitro experiments, taking into account the entrance length and the surface area-to-volume ratio. 
In order to assume fully developed flow, the sample volume must be generally greater than 
the entrance length, the flow adjustment region where the velocity profile is dependent on both the 
radial and axial directions and is characterized by high friction [331, 346]. Hence, to perform fluid 
mechanics analysis of the in vitro model under the assumption of fully developed flow conditions, the 
sample volume must greatly exceed the minimum entrance length requirement. A number of 
equations have been developed to describe entrance length for laminar and turbulent flow, Table 3-6. 
Since entrance length is related to the characteristics of the flow, all entrance length correlations 
depend on the Reynolds number. The extent of the Reynolds number dependence is influenced by the 
geometry and the type of flow. For example, in a smooth straight tube, the entrance length for steady 
laminar flow is longer and has high dependence on Re compared to turbulent flow. Similarly, in 
curved tubes steady flow has longer entrance length than pulsatile flow [363]. The entrance length 
equation relevant to the in vitro model selected for this study is the one for curved flow [364]. 
 
Table 3-6. Entrance length correlations. χ eϑ  is in degrees of axial curvature. 
Flow type Tube type Entrance length Ref 
Steady laminar Straight χe = 0.057ReD  [331] 
Curved 
χeθ = 49Re1 3
R
R0
 
[364] 
Steady turbulent Straight χe = 0.693Re1 4D  [365] 
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As stated above, in experiments where biomaterial samples such as model stents are included, 
the flow model should also satisfy biochemical requirements, in additional to geometric and 
hemodynamic requirements. To determine the appropriate sample volume for an in vitro flow model 
with a biomaterial sample, a theoretical analysis was performed based on minimum volume 
requirements. It is necessary for the sample volume to meet two conditions: 
 
(i) To greatly exceed the fluid flow entrance length 
(ii) To meet the ISO 10993 Standard on the ratio of material surface area-to-volume ratio (0.5-
6.0 cm2/ml) 
 
To perform analysis for the entrance length condition, assuming Newtonian fluid and a rigid 
tube wall, the entrance length volume element can be defined in terms of tube diameter as, 
 
Ve = π
D
2
!
"
#
$
%
&
2
χD          (16) 
 
where χ, which has been estimated as 3 from previous studies [364], is a multiple of tube diameter, D. 
This approximation is valid for nominal Re in coronary arteries. As observed from Table 3-6, the 
entrance length for curved tube flow is less dependent on Re compared to straight tube flow.  It is 
interesting to note that based on a straight tube approximation, the entrance length for the LAD has 
been estimated as 3.8±0.8 diameters [229]. 
If the tube volume fraction occupied by the sample is defined by a parameter λ (0<λ<1) as 
λ=V/V0, where V is blood sample volume and V0 is tube volume, then the entrance length volume 
fraction condition becomes λ>>Ve/V0. To avoid solid body rotation, the tube cannot be full and thus 
the volume fraction constraint can be expressed as, 
 
δ Ve V0( ) ≤ λ ≤C          (17) 
 
where δ>1 is a selected weight factor and C is less than one and is a function of the angular velocity. 
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To meet the ISO limits, which require the surface area-to-volume ratio of 0.5-6.0 cm2/ml, the 
volume constraint becomes A/6≤V≤2A, where A is a known model stent surface area in cm2 and 6 and 
2 have units of cm2/ml and ml/cm2, respectively. Using	  the	  λ	  definition,	  the	  ISO	  constraint	  can	  be	  written	   as	   A/(6V0)≤λ≤2A/V0.	   Based	   upon	   the	   above	   requirements	   and	   volume	   fraction	  constraints	  a	  Chandler	  loop	  sample	  volume	  fraction	  (CLSVF)	  criterion	  was	  developed,	  equation	  (18),	  	  
max δ VeV0
, A6V0
!
"
#
$
%
& ≤ λ ≤min 2AV0
,C!
"
#
$
%
&        (18)	  
 
If high angular velocities are used, the limiting value of C can be evaluated from the 
meniscus relationship from Gardner [354]. For this research, the limiting value was not evaluated 
because of the selected angular velocities. To calculate the volume fraction using the CLSVF 
equation (18), it is necessary to determine δ. The other variables can be determined from the model 
specifications. From Table	   3-­‐5, V0=6.64 ml, Ve=0.26 ml and A is determined from Table	   4-­‐2, 
depending on the stent size. If δ is defined in terms of the stent length normalized by its diameter or 
radius, this gives a range of λ values. Hence, for the 20 mm and 35 mm stents λ=0.3 and 0.6 were 
selected, respectively. This gives 2 ml and 4 ml as two sample volumes for the blood activation 
experiments. 
Because of the sample surface area and volume relationship, a given surface area will impose 
a limit on the minimum loop size. Similarly, a given loop tubing size will impose a limit on the 
maximum sample surface area under study. With regards to the maximum sample volume, there is 
another factor that needs to be considered – the rotational speed. Once the maximum sample volume 
is selected accordingly, it will impose limits on the maximum rotational speed to avoid the leading 
end of the sample spilling over at high rotation. If the maximum rotational speed has been selected as 
a fixed variable then the volume would be restricted accordingly by the speed. 
Thus, the CLSV equation provides a reasonable method for determining blood sample 
volume for the Chandler loop model, which was not previously addressed in the literature. The other 
aspect of sample volume that required further investigation was to determine if it had any 
implications on model flow characteristics. 
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3.4.2 Analysis of the significance of volume 
Besides blood sample volume size, the effect of the sample volume on fluid mechanics and 
blood activation has not been discussed in previous studies. Since the effect is not intuitively clear, 
further analysis was necessary to elucidate the effect of sample volume in this model. 
In the previous section, the appropriateness of the sample volume was addressed by 
developing the CLSV equation. However, even when the conditions for the appropriate sample 
volume are met, it still raised the question of whether varying the sample volume within the 
appropriately defined limits has any significance on the experimental results. Sample volume in 
previous studies showed variations, but very little discussion on its possible effects on some of the 
key hemodynamic factors, such as the continuum effect and shear stress, and consequently on blood 
activation. It is possible that this may have been due to the fact that according to the simplified 
approximation equation developed by Gardner [354], shear rate does not depend on sample volume. 
The level of accuracy of this equation has not been evaluated, but the fact that second-order effects 
have been ignored may introduce some error. More importantly, the shear equation has no 
dependence on the Dean number, one of the key parameters that characterize curved tube flow. This 
is particularly important because although the analysis is for a rotating curved tube, only curvature 
conditions related to centripetal force are included and not rotation conditions related to the Coriolis 
force. For consistency, analysis and derivation of shear stress approximation in this research are based 
only on curvature conditions. 
To address the question of sample volume effect, a stationary observer, equivalent to an 
adherent particle or thrombus, in the tube wall will be assumed. For this observer, strictly speaking 
flow in this model is intermittent since the blood sample occupies only a fraction of the loop. If the 
characteristic circulation period is T = 30 πω  seconds, then the fraction of time that the fluid flows 
over the observer can be represented approximately by a square wave with pulse width λT, where λ is 
as previous defined. Since the internal diameter of the tubes falls within the definition of large 
arteries, Newtonian rheology can be assumed for this model [52]. Hence, the wall shear rate equation 
(14) can be converted to WSS by using the Newtonian relation τ = µγ , where τ is the fluid shear 
stress, γ is the shear rate of the fluid, and µ is blood dynamic viscosity, which gives the shear stress 
equation, 
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τ w =
2πR0ωµ
15R           (19) 
 
This WSS is predominantly on the outer walls of the curved tube. Thus, the square wave is 
represented on Figure 3-5. 
 
 
Figure 3-5. Pulse wave representation of circulating blood sample flow for stationary observer 
 
From this point of view, it can be seen that the flow can be characterized as unidirectional 
and cyclical. For simplicity, the pulses are represented with instantaneous rise and fall. In reality, 
there would be a trailing edge transition. Although periodic shear change as represented on Figure 3-5 
is appropriate for flow in coronary arteries, the change in vivo is not instantaneous. However, the 
model remains a useful representation as it incorporates the main feature of periodicity. It is important 
to note that depending on the investigation, the model may not always have to be completely realistic 
to be useful; given the objectives of this thesis the step change approximation used in this model is 
acceptable. 
Since the experienced shear stress would be time variant, it is appropriate to express it as 
time-averaged wall shear stress. Shear stress in vivo is also expressed as time-averaged because of the 
pulsatile nature of the cardiac cycle. Time-averaged shear stress is expressed as, 
 
τ =
1
T τ
!
0
λT
∫ dt           (20) 
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where T is the period, τ
!
 is the magnitude of the axial wall shear stress vector. Hence, the time-
averaged shear experienced by the adherent particle would be, 
 
τ = τ wλ           (21) 
 
Thus, the effect of sample volume is scaling the shear magnitude by the volume fraction λ. 
If the observer now is in a small volume element, it experiences shear rate almost for the 
whole period T. However, there are intermittent disruptions each time the element reaches the 
proximal or distal end of the flowing sample due to the fluid-air interface. Rigorous analysis can 
estimate the fraction of time that the volume element takes at the interface and the radial velocity 
component due to secondary flow, but for the purpose of this study, it can be assumed that the 
fraction of time at the air interface and the radial velocity gradient are negligible. Since the volume 
element also follows a helical path due to the secondary flow vortex, it has the axial component of the 
secondary vortex. It is possible to calculate the vortex axial component numerically [259], but for the 
purpose of this work, simplifying assumption can be made. 
If the internal diameter of the tube is taken as the maximum characteristic distance that the 
cell travels before it experiences shear again (after fluid-air interface), then the average characteristic 
distance can be taken as the tube radius. For simplicity a straight travel is assumed since the distance 
is a short arc, especially if the flow approaches plug flow. Since the intensity of the secondary flow 
vortex cannot be determined, for simplicity it can be assumed to be approximately 50% of the axial 
velocity as previously reported [366]. Hence, the time to travel the fluid-air interface can be expressed 
as, 
 
tσ =
60R
πωR0
          (22) 
 
As a function of T for this model, tσ =ζT , where ζ=80.9x10-3. This small time difference can be 
visualized on Figure 3-5 (above) as the difference between λT and T. As λT approaches T, the pulse 
is almost continuous for the whole period. It is difficult to determine the shear stress during the fluid-
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air interface transition. If it is assumed its magnitude is a fraction of the wall shear stress, given by 
τ w
' =στ w , then the time-averaged shear stress can be expressed as, 
 
τ =
1
λT + tσ
τ w
0
λT
∫ dt + τ w' dt
λT
λT+tσ
∫
"
#
$
%
&
'        (23) 
 
which becomes, 
 
τ = τ w
λ +σζ
λ +ζ
!
"
#
$
%
&          (24) 
 
where, based on the previous velocity estimation, σ can be estimated as 50%. Hence, the time-
averaged wall shear stress is a fraction of the original wall shear magnitude. The difference is reduced 
by small tube diameter or increasing volume fraction, λ. When λ is doubled, i.e. increased from 0.3 to 
0.6, the bracket term increases from 0.89 to 0.94. This means that in the absence of stents, the volume 
effect on wall shear stress is minimal. 
While the analysis assumed small parabolic flow, the presence of red blood cells and the 
existence of secondary flow vortices would make the flow approach plug flow, as previously 
highlighted. That means the velocity gradient along the radial direction is almost zero dv dr ≈ 0( ) . 
For this condition, tσ ≈ 0 , which supports the above analysis. Thus, this work has shown through 
mathematical analysis that the time-averaged fluid shear in the absence of a stent is very close to the 
shear magnitude, regardless of the volume. However, this does not preclude a small volume effect on 
blood activation as biochemical activity is not dependent on shear alone. 
3.4.3 Frequency and volumetric flow rate analysis 
Besides curvature ratio and Dean number, volumetric flow rate is one of the parameters that 
characterizes pulsatile flow in curved tubes [363]. The frequency and volumetric flow rate from the 
left ventricle or cardiac output have been previously discussed in Chapter 2. At a nominal 
physiological heart rate of 60 beats/minutes (fundamental frequency F≈1.0 Hz), the cardiac output is 
approximately 4.8 L/min [51]. However, this is not the volumetric flow rate for the coronary arteries 
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because the cardiac output occurs during systole while flow in the coronary arterial tree peaks during 
diastole, which has lower pressure than systole, but occupies two-thirds of the cardiac cycle. 
The total volumetric flow rate for the coronary arteries is approximately 0.25 L/min and for 
the left coronary arteries has been estimated at 0.15 L/min [229]. The volumetric flow rate can also be 
calculated from Q = Axν , where Ax is the vessel cross-sectional area and ν is the average blood 
velocity. Using the physiological average LAD radius R=1.9 mm and velocity range ν=10.6-43.0 
cm/s from Table 3-5, gives estimated LAD volumetric flow rates Q=0.07 L/min to 0.29 L/min. Just as 
the cardiac output is necessary for physiological functions, the volumetric flow rate for the coronary 
arteries is critical for proper metabolic exchange in the myocardium and cardiac function. Thus, the 
volumetric flow rate is relevant for an in vitro model because of its importance in the rate of exchange 
of biochemical agents. 
In vivo pulsatile flow is induced by variation of the heart geometry, which also deforms the 
coronary arteries. As a result, there are complex spatial, phase and time interactions between 
geometric and hemodynamic parameters in the coronary arteries, especially at bifurcations [237]. For 
in vitro modeling, if the mean coronary arterial geometry is adopted, pulsatile frequency can be 
simulated by intermittently varying the fluid flow. This method of fixing the geometry and varying 
the flow is adopted in this research. The flow frequency for the model is given by the expression 
F = πω 30 . Therefore, for any sample volume V and loop volume V0, the volumetric flow rate can 
be defined as Q = FV0λ , where λ is the volume fraction as previously defined. Using the selected 
experimental volumes and angular velocities, the model frequencies and volumetric flow rates can be 
determined, Table 3-7. The volumetric flow rate for 2 ml at 2.5 Hz was similar to the calculated LAD 
flow rate. Although the frequency is up to 4.7 Hz and volumetric flow rates are high, thus producing 
high shear stress, it is interesting to note that cardiac cycle harmonics of up to 5 Hz have been 
reported and therefore used in investigating the effect of dynamic curvature on wall shear stress in 
coronary arteries [358]. Therefore, the use of frequencies other than 1 Hz is reasonable with this 
consideration.  
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Table 3-7. Model frequency and volumetric flow rate Angular	  velocity	  
ω	  (RPM)	   Frequency	  F	  (Hz)	   Period	  T	  (s)	   Volumetric	  flow	  rate	  2	  ml	  sample	   4	  ml	  sample	  Q	  (L/min)	   Q	  (L/min)	  24	   2.5	   0.4	   0.3	   0.6	  45	   4.7	   0.2	   0.6	   1.1	  
 
3.4.4 Fluid friction factor analysis Fluid	   flow	   is	   characterized	  by	   a	  number	  of	   parameters,	   such	   as	   flow	   type	   (laminar	   or	  turbulent),	  fluid	  type	  (viscous	  and	  non-­‐viscous),	  entrance	  length	  and	  friction.	  Friction drag, as an 
inherent feature of any flowing fluid, has implications for a variety of engineering applications, such 
as long distance transport of piped oil. Researches have investigated several drag reduction methods, 
some of them with biomedical applications [243]. Because friction is an important flow parameter, a 
number of friction factor correlation equations for engineering applications at high Reynolds numbers 
have been developed [367]. These formulas are used to calculate the friction factor in pipe flow under 
laminar and turbulent flow.  
The effect of curvature on flow, such as reduced flow rate and skewing of velocity profile, 
have been highlighted since early in the 19th century in some of the work by Dean [263]. Since then, 
fluid flow characteristics in curved tubes of various configurations have been extensively studied, as 
demonstrated in the review by Naphon and Wongwises [242]. Curved tube flow has numerous 
applications that take advantage of its effective mixing and mass transport characteristics. These 
include industrial heating and cooling [368], biochemical or biomedical microreactors and 
micromixers for oxygenation [369, 370]. Although the curvature increases the Reynolds number point 
of transition to turbulent flow, the curvature-induced pressure loss and friction can be a concern due 
to its effect on wall shear stress. A number of friction factor correlations have been developed for 
both smooth and rough tubes of specific roughness. Table 3-8 presents some of the equations that 
may be applicable to a curved loop model, such as the Chandler loop. Therefore, the purpose of this 
work was to determine the friction factor for the Chandler loop model and analyze the relevance of 
friction in an in vitro model since it is an important feature of fluid flow, especially in curved 
geometry. 
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Table 3-8. Typical friction factor equations for laminar flow 
Tube type Friction factor Ref 
Straight smooth 
Fanning: f0 =
16
Re
 
Darcy: f0 =
64
Re
 
[346] 
Curved smooth 
f = 0.5 Dn16
!
"
#
$
%
&
0.2
+1.5  
[262] 
Curved smooth 
non-rotating pipe 
f
fD
= 0.0899Dn0.5 1+12.4Dn−0.701( )  
[371] 
Straight rough 
(helical-finned) 
f = 0.108Re−0.283N 0.221
ε
D
"
#
$
%
&
'
0.785
ϕ 0.78  
[372] 
Dn is Dean number, ε is internal rib height, D is internal tube diameter, N is number of rib starts and ϕ 
is helix angle 
 
3.4.4.1 Loop friction factor 
There is little discussion on the issue of friction in the Chandler loop model, with or without 
stents. It is therefore necessary to determine its significance in this model. Most applications where a 
friction factor is determined, the tube is filled with fluid or a sufficiently large volume is assumed. 
However, in some applications, such as the Chandler loop in vitro model, the existence of a liquid-air 
interface mimics open channel flow. This requires special attention since the blood cells do not 
experience the same magnitude of shear all the time. 
The friction equation for curved smooth pipes has been previously described by Soeberg 
[262] and Ishigaki [371]. Comparison of these friction factors based on the parameters of the model 
as described in Table 3-5 shows that they provide very similar friction approximations up to low 
Dean numbers, Figure 3-6. However, examination of the equations reveals that the Ishigaki equation 
does not reduce well to a straight tube. Thus, for brevity we adopt the curved flow friction factor 
equation by Soeberg [262], as the friction factor for the Chandler loop model. This is expressed as, 
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fcs =
32
Re
0.5 Dn16
!
"
#
$
%
&
0.6
+1.5
'
(
)
)
*
+
,
,
        (25) 
 
where Dn = Re R R0 is the Dean number and the subscript cs denotes a curved smooth tube. 
 
 
Figure 3-6. Comparison of friction factor equations for curved smooth tubes 
 
3.4.4.2 Loop friction factor with model stent 
To perform fluid dynamics analysis of the flow model in the presence of model stents, it was 
necessary to incorporate a stent with specific geometric and structural measurements. To this end, 
helical shaped model stents were designed and fabricated, as described in Chapter 4. The parameter 
specifications for the model stents are as presented Table 4-2. 
In the presence of stents, the stent struts introduce wall roughness, which causes friction and 
flow disturbance. Studies have demonstrated the effect of stent strut design height and shape on 
hemodynamics; in straight tubes [373, 374] as well as inter-connections in curved tubes [375, 376]. 
The hemodynamic effect of stent design may translate to development of in-stent thrombosis. 
Therefore, it is necessary to develop analytical equations that describe the effect of each stent design 
(such as the one used in this research) on flow friction in a curved tube that mimics the curvature of 
the coronary arteries. 
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To derive a suitable friction factor equation for the Chandler loop with a helical model stent, 
the stent struts can be represented as fins within a tube and it is necessary to know the stent design 
struts dimensions and shape. For brevity, the Fanning friction factor equation for a straight helical-
finned tube previously developed by Li and Webb [372], was adopted. Assuming fully developed 
flow, this is expressed as, 
 
fsr = 0.108Re−0.283
ε
D
"
#
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%
&
'
0.785
N 0.221ϕ 0.78        (26) 
 
where ε is the internal rib height, D is the internal tube diameter, N is number of rib starts, ϕ is the 
helix angle of the ribs and the subscript sr denotes a straight rough tube. For the purpose of this 
research, model helical stents with parameters presented in Table 4-2 are used.  
Since equation (26) is for a rough straight tube, it is necessary to introduce a correction factor 
in order to derive an appropriate equation suitable for the curved loop with a helical roughness. The 
correction factor can be expressed as [377], 
 
fr =
fsr
fss
          (27) 
 
where fss =16 Re  is the Fanning friction factor for a smooth straight tube [378]. Hence the corrected 
friction factor for a rough curved tube is then expressed as, 
 
fcr = fcs
4 fsr
f0
          (28) 
 
where f0 = 64 Re  is the Darcy friction factor for a straight smooth pipe with laminar flow. The 
factor of 4 was introduced since equation (24) was based on the Fanning friction factor. Therefore, 
the friction factor equation for a circular curved loop model with helical roughness, is given by 
equation (29), 
 
   106 
fcr = 0.054 0.5
Dn
16
!
"
#
$
%
&
0.6
+1.5
'
(
)
)
*
+
,
,
Re−0.283
ε
D
!
"
#
$
%
&
0.785
N 0.221ϕ 0.78     (29) 
 
This is the in-stent friction factor equation for the Chandler loop with a helical stent. In order to 
appreciate the impact of the friction factor on flow, it is necessary to relate it to wall shear stress. 
3.4.4.3 Loop shear stress with model stent 
To relate equations (25) and (29) to shear stress, the Blasius equation correlating wall shear 
stress with friction factor is applied. This is expressed as [378], 
 
τ = f ρ v
2
2           (30) 
 
where τ is wall shear stress and ν is average velocity. After rearranging the terms as described in 
Appendix B, the wall shear stress is given by equation (31), 
 
τ = f Re16
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where τ w  is wall shear stress as defined by equation (19). Therefore, the wall shear stress for the 
smooth loop without the stent becomes, 
 
τ s = fcs
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The wall shear stress for the loop with roughness becomes, 
 
τ r = fcr
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In establishing the above equations for the circulation loop, an implicit assumption was that 
the whole lumen of the loop has helical roughness. However, in the case of the Chandler loop model, 
only a small portion of the lumen has roughness due to the stent; there is a defined length of 
roughness. In addition, the sample volume does not occupy the whole tube. Therefore, further 
analysis is necessary to take the stent length and sample volume into account. This would make the 
friction factor appropriate for the in vitro model used. 
Due to the cyclical nature of the flow, the time period that the stent experiences shear stress 
in one cycle is only λT, where the period T is as previously defined. If the ratio of stent length to tube 
length is defined as α, then the periodic time fraction for the stent can be defined as βT=αλT. The 
period circulation of the stent in and out of the fluid sample can be represented by a square wave 
superimposed on Figure 3-5. The resulting pulse train wave event is depicted on Figure 3-7. 
 
 
Figure 3-7. Pulse wave representation of circulating blood sample with model stent 
 
Since shear stress is time-dependent, it is appropriate to introduce the concept of time-
averaged wall shear stress for this model. Then using the time-averaged wall shear stress as defined 
by equation (19), the integral for the pulse train in Figure 3-7 becomes, 
 
τ =
1
T τ r dt0
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Substituting equations (32) and (33), it can be shown that the loop fluid time-averaged wall shear 
stress for the Chandler loop model with a model stent can be expressed by equation (35). 
 
τ =
τ wRe
16 β fcr + λ −β( ) fcs
"# $%         (35) 
 
This can also be written as, 
 
τ =
τ wRe
16 λ α fcr + 1−α( ) fcs
"# $%         (36) 
 
In the absence of a stent, equation (36) reduces to the time-averaged wall shear stress for the Chandler 
loop with the friction factor term, which is, 
 
τ =
τ wRe
16 fcsλ           (37) 
 
Equation (37) represents the time-averaged wall shear stress for a stationary point in the loop outer 
wall, in the place of a stent. For the fluid element, the flow is assumed relatively continuous for the 
reasons previously discussed. In detail, the time-averaged wall shear stress for the Chandler loop 
model with and without a helical stent can be expressed as equations (38) and (39), respectively. 
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To predict the effect of the selected sample volume and stent lengths on time-averaged wall 
shear stress, the weighting factors for the stent and loop friction factor terms, equation (36), were 
determined based on the volume of the circulation tube (6.644 ml), Table 3-5. When the sample 
volume is doubled without changing the stent length, both weighting factors for the stent and loop 
friction factor terms (α and 1-α, respectively) are unchanged, Table 3-9. The counter effect of the 
volume increase on the surface area-to-volume ratio is a decrease by a factor of two. For this case, the 
sample volume fraction seems to be the dominant parameter, in terms of influencing both the surface-
area-to-volume ratio and the friction factor. However, when doubling the sample volume is 
accompanied by an increase in stent length to maintain similar surface area-to-volume ratios, the stent 
friction factor weighing term (α) increases 1.8-fold and the loop friction term (1-α) barely changes. In 
this case, the combined effect of volume and stent has a higher effect on friction factor. Similarly, if 
both samples have increased sample volume (4 ml) and the stent length is almost doubled, the stent 
friction factor increases 1.8-fold and there is almost no change with loop friction factor term. Thus, 
for these parameters, the combined effect of sample volume and stent length has greater influence on 
friction factor weighting, and hence time-averaged wall shear stress, especially at larger sample 
volumes. 
 
Table 3-9. Volume and stent ratio effect on friction factor weighting 
 2 ml + 20 mm 4 ml + 20 mm 4 ml + 35 mm 
   Fold-increase 
relative to 
2ml+20mm 
 Fold-increase 
relative to 
2ml+20mm 
Fold-increase 
relative to 
4ml+20mm 
λ  0.3012 0.6024 2.00 0.6024 2.00 1.00 
α  0.0539 0.0539 1.00 0.0943 1.75 1.75 
1-α  0.9461 0.9461 1.00 0.9057 0.96 0.96 
 
The effect of the weighting factors on shear stress are explored further by plotting equations 
(19), (38) and (39) in Figure 3-8. There are three interesting points to note: (i) compared to Eqn 19, 
wall shear stress in the Chandler loop is nonlinear and is much higher than estimated by the original 
equation (19), (ii) there is an interesting grouping of the data plots around 2 ml and 4 ml samples and 
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(iii) the time-averaged wall shear stress for samples with stents is slightly lower than for samples 
without stents. The data plot grouping by volume indicated the dominating effect of sample volume. 
 The results indicate that in the presence of a stent, time-averaged wall shear stress depends 
on both stent length and sample volume. Comparison of the 2 ml curve with the 4 ml curves shows 
that for the selected parameters, time-averaged wall shear stress is much more sensitive to sample 
volume than stent length, especially at higher rotational velocities. The low sensitivity of shear stress 
to stent length suggests that at the same angular velocity, stent surface area may play a bigger role 
compared to friction, for samples with the same volume but different stent lengths. On the other hand, 
for samples with comparable surface area-to-volume ratios, activation may be more shear-dependent, 
which is influenced by sample volume fraction. Taken together, these results indicate that time-
averaged wall shear stress for the Chandler loop model is nonlinear and much higher that previously 
thought. In addition, sample volume, as well as stent length, have an effect on wall shear stress.  
Typical wall shear stress/rate values for 25 RPM and 45 RPM, read from Figure 3-8 are 
presented on Table 3-10. As observed above, the original equation (19) did not take into account the 
sample volume fraction or the presence of a stent, and hence the time-averaged wall shear stress is the 
same as the wall shear stress magnitude for this case. On the other hand, the new time-averaged wall 
shear stress reflects the effect of changes in sample volume and stent length on fluid dynamics. 
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Figure 3-8. Time-averaged wall shear stress as a function of angular velocity. For this study, 
λ=0.3012 and 0.6024, α=0.0539 and 0.0943 (β=0.0162, 0.0325 and 0.0568) 
 
Table 3-10. Time-averaged wall shear stress for selected sample volumes and stent samples 
	   Wall	  shear	  stress	  (rate)	  at	  
24	  RPM	  
Wall	  shear	  stress	  (rate)	  at	  
45	  RPM	  
Experimental	  groups	   Eqn	  19,	  
dyn/cm2	  (s-­‐1)	  
Eqn	  36,	  
dyn/cm2	  (s-­‐1)	  
Eqn	  19,	  
dyn/cm2	  (s-­‐1)	  
Eqn	  36,	  
dyn/cm2	  (s-­‐1)	  
2	  ml	   9.1	  (260.0)	   13.3	  (380.0)	   16.4	  (468.6)	   27.8	  (794.3)	  
4	  ml	   9.1	  (260.0)	   33.3	  (951.4)	   16.4	  (468.6)	   55.7	  (1591.4)	  
2	  ml+20	  mm	   9.1	  (260.0)	   12.6	  (360.0)	   16.4	  (468.6)	   26.3	  (751.4)	  
4	  ml+20	  mm	   9.1	  (260.0)	   25.2	  (720.0)	   16.4	  (468.6)	   52.7	  (1505.7)	  
4	  ml+35	  mm	   9.1	  (260.0)	   24.1	  (688.6)	   16.4	  (468.6)	   50.4	  (1440.0)	  
NB. 2 ml + 35 mm stent samples were not used because it results in very low surface area-to-volume 
ratio. Eqn (36) is equivalent to equation (38). 
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In the above analysis of the model fluid dynamics, it was inherently assumed that the effect of 
air in the loop was minimal. However, the possible implications and limitations on controlling the 
blood-to-air ratio have been previously raised [29]. If it is now assumed that the loop is occupied by 
two incompressible and immiscible fluids, which remain separate during flow, then a new analysis is 
necessary. In this case the pulse wave representation of Figure 3-7 can be represented as Figure 3-9, 
where the period 0 to λT is occupied by one fluid and λT to T is the other fluid. 
 
 
Figure 3-9. Pulse wave representation of circulating blood sample with model stent, including 
effect of air. xT=(λ+β)T, which accounts for the stent sample in the air portion of the loop. 
 
Suppose that the two fluids are defined by characteristic parameters ρ1, µ1, ν1  and 
ρ2, µ2, ν2 , where ρ, µ, ν are their density, viscosity and average velocity, respectively. Then 
equation (34) with two fluids becomes, 
 
τ =
1
T τ r1 dt + τ s1 dt + τ r2 dt + τ s2 dtλT+βT
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Using Blasius correlation equation (30) to substitute for the shear stress terms, the above equation 
becomes,  
 
τ =
ρ1ν
2
2 β fcr1 + λ −β( ) fcs1
"# $%+
ρ2ν
2
2 β fcr2 + 1−λ −β( ) fcs2
"# $%     (41) 
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where the subscript on the velocity was dropped because the two fluids have the same velocity and it 
is assumed that the friction factors as discussed previously are applicable for both fluids. Suppose the 
first fluid is blood and the second fluid is air. Then it can be noted that the first fluid terms can be 
replaced by equation (35). However, the equation for wall shear stress as defined by Gardner [354], is 
not applicable for the air sample. Therefore, equation (41) becomes, 
 
τ =
τ wRe
16 β fcr + λ −β( ) fcs
"# $%+
ρaν
2
2 β fcra + 1−λ −β( ) fcsa
"# $%     (42) 
 
In the absence of a stent, equation (42) can be expressed as, 
 
τ =
τ wRe
16 λ fcs +
ρaν
2
2 1−λ( ) fcsa        (43) 
 
 Since blood is composed of almost 50% water, the water vapor saturation pressure was used 
to calculate the density of moist air in the loop, see Appendix C for details on vapor pressure 
determination. From the calculation, the density of humid air in the loop at 37°C is ρa=1.1166 kg/m3 
and the air viscosity µa=19.03x10-6 Pa.s. Using these values, the second terms of equations (42) and 
(43), representing shear stress contribution from the air sample, are plotted in Appendix C. From the 
data, the highest time-averaged wall shear stress due to air is less than 0.04 dyn/cm2. The combined 
effect of blood and air samples on wall shear stress, as expressed by equations (42) and (43), are 
plotted on Figure 3-10. 
Based on comparison of Figure 3-8 and Figure 3-10, it is clear that the effect of air shear 
stress is minimal. Therefore, ignoring the effect in the previous analysis is acceptable. It was 
however, informative to perform the analysis and prove that the air effect can be ignored, which has 
not been done previously. Therefore, from a hemodynamic stand point, the air sample volume can be 
neglected and equations (38) and (39) can be used as time-averaged wall shear stress equations for the 
Chandler loop model with and without a helical model stent. 
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Figure 3-10. Combined time-averaged wall shear stress due to blood and air in the loop 
 
3.4.5 Discussion 
The design parameters of an in vitro model greatly influence its relevance and accuracy. 
Although previous studies have made important contributions to the understanding of the fluid 
dynamics of the Chandler loop model [354], the importance of sample volume in this model has not 
been addressed. In this section, the importance of blood sample volume in the Chandler loop model 
was highlighted and demonstrated through analysis and characterization of the model fluid dynamics. 
A method for determining the appropriate blood sample volume for the Chandler loop model was also 
developed through the CLSVF criterion. In addition, time-averaged wall shear stress analysis was 
provided. 
The importance of blood sample volume in in vitro blood-biomaterial interaction studies has 
been emphasized by the development of a guidance standard, the ISO 10993 Standard, which 
stipulates a material surface area-to-blood volume ratio of 0.5 to 6.0 cm2/ml. This parameter (surface 
area-to-volume ratio) can easily be met under static conditions, but under flow conditions the selected 
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sample volume may violate some of the fluid dynamics assumptions. Therefore, under flow 
conditions, it is necessary to consider the hemodynamics of the selected sample volume since 
inappropriate sample volume can result in wrong assumptions and incorrect hemodynamic 
parameters, which has implications on interpretation of experimental results. In the Chandler loop 
model with a stent, the significance of blood sample volume is three-fold; (i) it affects the ISO 10993 
Standard compliance, (ii) it influences the fully developed flow condition and (iii) it influences the 
length of time shear stress is applied to a model stent. Putting all these together, the CLSVF criterion 
was developed as guidance for determining the appropriate sample volume fraction and the concept 
of time-averaged wall shear stress was introduced as an important aspect of this model. 
Another important parameter of the Chandler loop model that has not been considered is the 
friction factor. In coronary arteries, friction may be introduced by curvature or the presence of a stent 
implant. Similarly, in the circulation loop model, the curved flow and introduction of model stent 
introduce friction drag. In this work, flow and friction factor for the Chandler loop model were 
appropriately characterized, an element that had been absent in the literature. An analytical friction 
factor equation was derived for the Chandler loop, which can be used with any stent with a defined 
friction factor. For this research, the particular equation was for a helical stent model. Consequently, a 
time-averaged wall shear stress equation, dependent on friction, was also derived. It was 
demonstrated that in the presence of a model stent, wall shear stress is not only influenced by friction, 
but is influenced by blood sample volume and stent length. 
Analysis of the wall shear stress equation plots revealed that the loop shear stress is nonlinear 
and much higher than the prediction from the original equation. The difference in linearity and 
magnitude between the original equation and the new developed equation is partly due to the fact that 
the new equation includes some of the important parameters in curved tube flow not included in the 
original equation. It was also interesting to note the grouping of the data around sample sizes, which 
suggests the critical role played by the sample volume in time-averaged wall shear stress, with or 
without stents. The effect of sample volume in this model was not previously discussed in the 
literature. The other interesting point is that the time-averaged wall shear stress for samples with 
stents is slightly lower than that for samples without stents. A decrease in the in-stent wall shear 
stress, dependent on stent design, has been previous shown in in vitro [379] and computational fluid 
dynamics simulations [380], which can be exacerbated  by overlapping stents [380, 381]. The shear 
recovery at the distal end, which may be higher than inlet shear at the proximal end, is partly due to 
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the sudden flow disturbance vortex as the fluid enters the stent. There are also recirculation zones 
within the stent that would reduce the flow. In our case, the shear at specific locations within the stent 
cannot be determined without numerical simulation, but the overall observed results may be partly 
explained by what has been reported in the literature.  
There was also a difference in the effect of stent length on time-averaged shear stress when 
samples with similar volume size but different stent lengths were compared. The longer stent shows a 
slightly lower time-averaged wall shear stress compared to the shorter stent samples. The difference 
in spatial distribution of in-stent wall shear stress between long and short stents has previously been 
shown in a different model; straight tube model with no volume effect [381]. The difference between 
the previously reported measurement results and our analytical results is that time-averaged wall 
shear stress is lower for the longer stent. This may be partly due to the curvature in our case versus a 
straight tube in their model and the sample volume-stent length interaction. The impact of a longer 
stent on blood activation is increased residence time from reduced shear and increased recirculation 
zones, which would have implications for blood activation. Indeed, longer stents have been associated 
with adverse clinical outcomes, more so first generation DES than second generation DES [382]. The 
information on the impact of stent length is important for interpreting the effect of hemodynamics on 
blood activation using the Chandler loop model. 
Like any other model, the Chandler loop model has some limitations. These include the fact 
that, (i) it cannot exactly reproduce the physiological conditions, (ii) it is closed-loop and (iii) there is 
air in the circulation loop. The first limitation is a limitation of all in vitro models. The effect of this 
limitation has been addressed in the design and analysis of model parameters as described in the 
previous sections of this chapter. The second limitation is inherent due the design of the model, but 
limiting the experimental time can reduce its effects. The third limitation, although recognized and 
acknowledged in previous studies, has not been analyzed. Therefore, analysis was performed and it 
was demonstrated that the air-blood interface has an intermittent shear stress effect, which depends on 
the sample volume. However, analysis of the wall shear stress effect of the air sample demonstrated 
that the air sample had minimal effect on the overall wall shear stress of the model. Thus, from the 
analysis the air sample can be considered to have little additional hemodynamic effect. While the 
effect of the air sample on shear stress was analyzed, the biochemical effect, which may be caused by 
such factors as the difference in oxygen partial pressure between the air and the blood samples, 
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remains to be investigated. Nonetheless, the proposed time-averaged wall shear stress equations for 
the Chandler loop models can be used without loss of generality. 
3.5 Implementing the model 
The main components of the in vitro flow model are the rotor, the rotating disk turntable 
connected to the rotor by a shaft and the tubing loop for containing the blood. Therefore, to 
implement the model, a rotor (Roto-Torque™, model RT50, Cole-Palmer Instrument Co., IL, USA) 
was used to drive a single plane turntable where the sample loops were mounted, Figure 3-11. The 
rotor speed could vary from 0 to 60 revolutions per minute (RPM), which was calibrated with a 
model 461831 Digital Stroboscope Tachometer (Extech Instruments, Melrose, MA, USA). The 
calibration procedure is summarized in Appendix D. The turntable had brackets located at 
approximately 60 mm and 100 mm from its center, which were used for holding blood sample tube 
loops. With modification, additional loops of similar or larger radii may be mounted, if necessary. 
When the sample loops were mounted, the turntable was positioned in a vertical orientation. The 
blood sample loop tubes were non-permeable medical grade Silastic silicone tubes (VWR, PA, USA). 
The tubes were spliced with similar silicone tube approximately 25 mm long, 7.95 mm internal 
diameter and 12.70 mm external diameter, to complete the loop. The splicing piece was kept short to 
reduce its impact on the smoothness of the loop curvature. Incorporation of the stents also did not 
alter the loop geometry, i.e. did not alter both the tube diameter and the smoothness of the loop. 
While the silastic tubing is a biomaterial, the use of the term biomaterial in this study only refers to 
the materials under test (model stent), unless otherwise stated.  
 
 
 
 
 
 
 
 
 
 
Rotating disk Silicone tubing 
Rotor 
Figure 3-11. Rotor with rotation disk and loops used as the in vitro flow model 
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Before performing in vitro experiments, the model was tested to ensure that the leading edged 
of the blood sample would not spill over when either volume or rotational speed was increased. For 
this, the circulation loop was filled with either a 2 ml or 4 ml blood sample. For each blood sample 
volume, the loop was rotated at 24 and 45 RPM, at separate times, making a total of four 
experimental runs. For each experiment, it was confirmed, through visual observation of the meniscus 
level, that the fluid did not spill over during rotation. After 2 hours of testing, no obvious clots were 
observed in the tube.  
3.6 Summary 
This work has demonstrated that although wall shear stress is an important parameter that 
characterizes flow both in vivo and in vitro, it does not entirely define the flow characteristics as it is 
only one of the many parameters that characterize flow. Some of the important flow characteristics 
are the geometry of the flow (e.g. tube vs plate flow or straight vs curved tube flow) and the type of 
flow (e.g. continuous vs pulsatile flow). Hence in the selection or design of a flow model, other 
parameters that characterize flow in the physiological location of interest need to be considered. This 
guiding principle, which was based on the systems approach framework proposed in Chapter 2, was 
applied in determining and designing/selecting the appropriate model for this research. Hence, the 
Chandler loop model was found to be a reasonably appropriate model for this research because of its 
geometry and flow characteristics. For this research, the model geometric parameters were based on 
the coronary system. 
The model flow characteristics were analyzed and a time-averaged wall shear stress 
(TAWSS) equation was developed. Although the TAWSS equation was based on previously 
validated work, further numerical validation of the developed equation may be necessary. The 
TAWSS, which depends on blood sample volume, loop friction factor (with or without stent) and the 
model stent length, greatly contributes to the understanding of flow in the Chandler loop model. 
Appropriate flow characterization is important for understanding blood activation as well as drug 
delivery kinetics [383]. Since a method for determining the appropriate blood sample volume did not 
exist, a method was developed for the same. Overall the method and critical analysis presented in this 
work are significant for understanding the Chandler loop model and further investigations of its fluid 
dynamics. 
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3.7 Conclusion 
In this chapter a systems approach was used for the design of the in vitro flow model and its 
parameters. A systems approach by its very nature ensures consideration of all the necessary factors 
and their linkages. Therefore, it facilitates the implementation of a comprehensive model. Hence, 
using a systems approach as a guiding method, this work developed a method for determining the 
sample volume, characterized flow and introduced the concept of time-averaged wall shear stress for 
the Chandler loop model. More importantly, an improved time-averaged wall shear equation for this 
model has been proposed. An analysis to show the hemodynamic effect of air in the loop was also 
presented. Further investigation into the biochemical effect is necessary. Overall the results support 
the hypothesis that a systems approach is better suited for designing in vitro flow model that mimics 
the physiological location of interest. In general, this work also supports the hypothesis that sample 
volume consideration is important in this model, especially in biomaterial studies. The improved 
time-averaged wall shear stress will go a long way in providing appropriate model design parameters, 
which will not only facilitate interpretation of in vitro results, but also provide a reasonable 
approximation of physiological parameters. The next step in this work is to characterize blood 
activation in the Chandler loop model in relation to the new model fluid dynamics characterization. 
Simulation studies would also be useful. 
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Chapter 4 
Model Stent Design, Fabrication and Characterization 
4.1 Introduction 
Coronary stents come in various strut shapes, sizes and structural design patterns, regardless 
of whether they are bare-metal or drug-eluting stents. The strut design [374] and pattern of connectors 
[376, 379] have implications on hemodynamics and subsequent in-stent thrombosis. The design of 
such stents requires expensive and time-consuming laser patterning. As a result, stents are too 
expensive to use in in vitro experiments unless the numbers are limited. The cost of bare metal stents 
varies but can be estimated in the range of $500 to $1000 per unit, based on a 2009 review [384]. 
Therefore, in order to study blood biomaterial interactions that mimic physiological conditions with 
an implanted stent it was necessary to design model stents for cost considerations. Furthermore, the 
use of in kind donation of commercial stents may also come with restrictions on publication of the 
data. 
As discussed in Chapter 2, some of the commercially available metallic biomaterials are 
made from Nitinol and Ti-6Al-4V. These materials are already commonly used in a variety of 
applications, such as dental fixtures, orthopedic devices and coronary stents.  As discussed in Chapter 
2, Ti-6Al-4V has both an alpha phase, which is soft and ductile, and a beta phase, which is harder and 
stronger. The presence of the two phases in Ti-6Al-4V, alpha and beta, allows it to be heat treated to 
stabilize it at desired phase proportions [385, 386]. For example, at high temperatures, above 1010°C 
(β transus) it exists predominately in the beta phase. The rate of heating and cooling cycles 
determines the transformation dynamics [386]. This property is exploited in making model stents for 
this research. In addition, the spontaneous formation of a surface oxide layer makes these materials 
reasonably biocompatible. Hence, these materials were selected for use in model stents. 
The role of material surface characteristics in determining interfacial phenomena, and thus 
blood-biomaterial interactions, was described in Chapter 2. Since material surface characteristics play 
an important role in influencing protein adsorption and subsequent cell activation and adhesion, there 
are several standards addressing material properties, such as qualitative and quantitative parameter 
description of surface morphology, ASTM F2791-09 standard [271]. For that reason, material surface 
characterization is an integral part of both in vitro and in vivo investigation of material interaction 
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with biological systems. Hence, there was a need to undertake surface characterization of the 
fabricated stents to ascertain their suitability for in vitro studies. 
Although studies have been done with materials in different shapes and configurations, the 
use of a model stent in this study was considered more appropriate for stented coronary flow studies. 
The design of model stents with specific structural patterns provides motivation for detailed analysis 
of the effect of stent design on hemodynamic parameters, such as fluid friction. Thus, the purpose of 
this part of the thesis was to design, fabricate and characterize model stents. 
4.2 Model stent design and fabrication 
4.2.1 Materials and methods 
Nitinol and Ti-6Al-4V ELI wires, specified at 0.005” (0.127 mm) diameter, were purchased 
from Fort Wayne Metals, Fort Wayne, USA. The surface was specified as smooth. These titanium 
alloys were selected for my experiments because they are both commonly used in implants. Ti-6Al-
4V ELI (extra low interstitial) is a higher purity alloy with lower iron and carbon elements compared 
to the standard Ti-6Al-4V. Threaded A4 stainless steel rod (the metric equivalent of 316 stainless 
steel) and nuts were purchased from Spaenaur, Waterloo, ON, Canada.  
The choice of the diameter of the threaded rod was based on the internal diameter of the 
selected silicone tube. The threaded rod was selected with the aid of the machinery handbook [387], 
to find a minor diameter that would produce the appropriate stent diameter, Table 4-1. The choice of 
the rod was made with allowance for sharp pitch, which means the wire leaves a gap in the groove 
when wound along the threads. One of the challenges encountered was the difficulty in matching the 
threaded rod with the tube internal diameter to a precise fit. This is because when the two are 
manufactured under different measurement systems, i.e. one metric and the other imperial, the 
conversion of one measurement unit to the other introduces errors and small differences. 
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Table 4-1. Matching the tube to the rod. WD is the wire diameter, 0.005”. 
Tube 
IDxOD inch. 
(mm) 
Screw thread minor 
diameter = ID-2(WD) inch. 
(mm) 
Closest screw 
type 
Coupler 
IDxOD inch. 
0.188x0.313 
(4.775x7.950) 
0.178 
(4.521) 
(#12-28) 
0.1711/0.1722 
(#62999-884) 
0.313x0.500 
 
A typical cross-section of the threaded rod, with 0.005” wire, is depicted on Figure 4-1, not 
drawn to scale. 
 
 
Figure 4-1. Schematic of the longitudinal section view of the threaded rod with wire 
 
In addition, threaded mandrels were machined from 316 stainless steel rods in the University of 
Waterloo Machine Shop. These mandrels were designed to accommodate either the round wire or the 
flat wire strip, 0.02” width and 0.005” thickness. Since they were customized, they were designed so 
that stents would fit better in the tube. Figure 4-2 is a schematic cutout of the mandrel with 
specifications, not drawn to scale. 
 
 
Figure 4-2. Schematic of longitudinal section view of the mandrel with wire strip 
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4.2.1.1 Sample preparation 
Ti-6Al-4V ELI wire was first cleaned by wiping with 70% ethanol. The threaded rod sections 
were cut into lengths between 40 mm and 65 mm. The mandrels were cut into lengths of about 30 
mm. The threaded rod sections and mandrels and nuts were first cleaned in 30% nitric acid for 10 
minutes in an ultrasonic cleaner. Wire segments were then wound around mandrels or threaded rod 
sections, along the threads, and held at both ends with nuts. 
4.2.1.2 Model stent shape setting 
Four methods were used for shape setting model stents.  (i) Furnace	   –	   In	   this	   method,	   the	   furnace	   was	   preheated	   to	   800°C.	   The	   wire-­‐rod/mandrel	  assemblies	  were	  placed	  on	  a	  316	  stainless	  steel	  open	  container	  and	  then	  inserted	  into	  the	  oven	   bore.	   The	   oven	  was	   closed	   and	   the	   assemblies	  were	   left	   to	   bake	   for	   20	  minutes	   at	  800°C	   and	   taken	   out	   of	   the	   oven	   after	   baking.	   The	   assemblies	  were	   either	   air-­‐cooled	   or	  water	  quenched	  for	  quick	  cooling.	  	  (ii) Furnace	   with	   argon	   –	   The	   wire-­‐rod/mandrel	   assemblies	   were	   heated	   in	   a	   furnace,	   in	  99.999%	   flowing	   argon	   at	   2L/min.	   	  Heating	   rate	   was	   25°C/min	   up	   to	   500°C	   with	   a	   20	  minute	  hold	  at	  500°C.	   	  The	   furnace	  power	  was	   then	  shut	  off	   to	  cool	  as	   fast	  as	  possible	   to	  room	  temperature	  (~60°C/min).	  (iii) Vacuum	  oven	  –	  This	  method	  used	  a	  large	  vacuum	  oven,	  model	  VAH	  1220	  HV-­‐2	  (Vac	  Aero	  International	   Inc.,	   Oakville,	   ON,	   Canada).	   The	   assemblies	  were	   placed	   inside	   the	   oven	   in	  crucibles.	  The	  oven	  was	  held	  at	  a	  vacuum	  of	   -­‐3	  torr	  and	  heated	  at	  25°C/min	  up	  to	  800°C,	  with	  a	  20	  minute	  hold	  at	  800°C.	  The	  vacuum	  was	  cooled	  slowly	  with	  water	  circulating	   in	  the	  oven	  jacket.	  (iv) Furnace	   (vacuum-­‐sealed	   tubes)	   –	   In	   this	  method,	   the	   assemblies	  were	   vacuum-­‐sealed	   at	  about	   1.5x10-­‐3	  mbar	   in	   quartz	   tubes,	  which	  were	   then	   heat	   treated	   in	   an	   oven	   at	   800°C.	  Figure	  4-­‐3(a)	  and	  (b)	  depict	  sealed	  tubes	  after	  heat	  treatment.	  The	  oven	  was	  held	  at	  800°C	  for	  20	  minutes	  and	  then	  turned	  off	  to	  cool	  slowly.	  The	  tubes	  were	  kept	  sealed	  until	  it	  was	  necessary	   to	   use	   the	   model	   stents,	   at	   which	   time	   the	   stents	   were	   unwound	   from	   the	  threads.	   However,	   contamination	   from	   the	   mandrel	   or	   nuts	   can	   easily	   remain	   on	   the	  surface	  of	   the	  stent	  and	  the	  tube	  due	  to	  small	  space.	  This	  was	  observed	  with	  some	  of	   the	  samples	  being	  discolored	  after	  oven	  treatment,	  Figure	  4-­‐3(b).	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Figure 4-3. Picture of mandrels with stents sealed in a quartz tube after heat treatment. (a) 
Purchased mandrel and (b) Machined mandrel, showing contamination 
 
4.2.2 Results and discussion 
Regardless of the method used, the results of shape setting 0.005” (0.127 mm) diameter Ti-
6Al-4V ELI wires on mandrels produced helical shaped model stents, Figure 4-4. The 800°C heat 
treatment produced an α-β microstructure [386]. However, the surface texture varied considerably 
depending on the method. The first method produced model stents with a thick oxide layer because of 
heating and cooling in air. When the stents were water quenched, the oxide layer was found to be 
thick and flakey in some cases, Figure 4-5. Some preliminary experiments were done with stents from 
this treatment but because it produced an unpredictable surface oxide thickness layer, it was not 
pursued. The furnace with argon method generally produced model stents with a smooth surface. 
There were limited cases of a rough textured oxide layer. Stents from this method produced consistent 
results, but unfortunately the oven was removed from service.  
The vacuum oven produced model stents with a very consistent surface layer. This method 
was desirable but expensive because of the size of the oven. Unfortunately, this oven was also taken 
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out of service. The sealed vacuum tube method produced good results when the seal was good. In 
some cases the seal may not have been complete as the stent surfaces showed a thick oxide layer. The 
sealed vacuum tube was the method of choice for the rest of the research. 
 
 
Figure 4-4. Typical model stent 
 
 
Figure 4-5. Scanning electron micrograph of stent surface heat treated and quenched in air 
 
For this research, model stents were cut into two sets of lengths, 20 mm and 35 mm. Typical 
model stent parameters for the machined mandrel are as presented in Table 4-2. It should be noted 
that for some of the stents made with a mandrel as specified in Table 4-1, the diameters would be 
slightly different. After heat treatment, it was necessary to determine the surface characteristic of the 
stents before performing in vitro experiments. 
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Table 4-2. Typical model stent parameters. For conversion, 3.224° = 0.056 radians. 
Stent 
length 
(mm) 
No. 
of 
ribs 
ℵ 
Pitch 
p  
(mm) 
Strut 
diameter 
ε  
(mm) 
Stent diameter (mm) Surface 
area 
A (cm2) 
Coil/helix angle 
 
ϕ = tan−1 p
πDm
"
#
$
%
&
'  
Outside 
D0  
Inside 
Di
D0 − 2ε( )
 
Mean 
Dm =
D0 −Di
2  
20 25 0.8 0.127 4.775 4.521 4.521 1.46 3.22° 
35 44 0.8 0.127 4.775 4.521 4.521 2.47 3.22° 
 
4.3 Model stent surface characterization 
4.3.1 Materials and methods 
In order to ensure the suitability of the designed model stents for application in in vitro 
investigations, it was necessary to carry out material surface characterization. Material surface 
characteristics that are of particular interest are surface topography and roughness, surface chemistry, 
wettability and electrochemistry. 
There are several qualitative and quantitative methods available for characterization of 
material surface morphology, chemistry and thermodynamics [294]. The characterization methods 
used in this study include scanning electron microscopy (SEM), atomic force microscopy (AFM), X-
ray-photoelectron spectroscopy, contact angle analysis and cyclic voltammetry. Before each 
characterization, Ti-6Al-4V wire samples and model stent samples were cleaned with 70% ethanol 
for 10 minutes in an ultrasonic cleaner and rinsed at least twice with a phosphate buffer saline (PBS) 
solution. Sample stents were first cleaned with 30% nitric acid before ethanol cleaning. The samples 
were air dried in a sterile safety cabinet for at least 20 hours. 
4.3.1.1 Scanning electron microscopy 
Scanning electron microscopy (SEM) is used to evaluate qualitative material surface 
topography and roughness. In SEM, the material sample surface is scanned and bombarded with a 
high-energy electron beam, which causes emission of secondary electrons from the material sample 
[294]. Information from the secondary electrons is translated into a qualitative image of the surface 
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topography. Scanning electron microscopy was used to qualitatively evaluate surface topographical 
differences between the wires and model stents after heat treatment. Ti-6Al-4V wire and model stent 
samples were mounted on SEM discs with conductive tape. Surface topography and roughness 
characterization for both samples was performed with scanning electron microscopy LEO 1530 
Gemini (Zeiss, USA) set at 10kV in secondary electron mode (SE2). 
4.3.1.2 Atomic force microscopy 
Atomic force microscopy (AFM) is used to characterize quantitative surface roughness. In 
AFM, the material sample surface is scanned by the sharp tip of the cantilever-tip assembly and as the 
tip interacts with the sample surface, the interaction forces cause deflections, which are detected by 
the laser-photodiode assembly [294]. The deflections are translated into topography information, and 
used to construct the high-resolution 3D surface topography of the sample image. AFM also provides 
detailed quantitative roughness information. 
Qualitative surface roughness for the Ti-6Al-4V wire and model stent samples, before and 
after heat treatment, were determined with the Nanoscope III atomic force microscope (Digital 
Instruments, Santa Barbara, CA), using Veeco software (Veeco Instruments, USA) for analysis. A 
scan rate of 1 Hz was used for this experiment. To reduce the error due to the wire curvature, a scan 
area of 10 µm x10 µm was used to measure surface roughness. The maximum allowable scanning 
area was determined as described in Appendix E. Surface roughness was measured in terms of 
average roughness (Ra) and root mean square (RMS) or Rq. Ra is the arithmetic mean, which 
measures the average deviation of roughness from the mean roughness profile while Rq is the 
quadratic mean [388]. Rq is generally considered more sensitive to surface texture than Ra since 
surfaces with very different textures can still have similar Ra [271]. Both parameters are commonly 
used to describe surface texture, but there are other additional parameters that can be included to 
provide a much more complete information about the surface morphology [270, 388]. Hence, surface 
area (SA) and surface area difference (Sd) parameters were also measured. Sd, which is a measure of 
surface area enlargement, is determined from the topographic area with respect to the projected or 
scanned area [270]. For the purpose of this research, these general surface characterization parameters 
were considered adequate and hence characterization was not performed to the level of detail referred 
to above.  
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4.3.1.3 Contact angle analysis 
Contact angle measurements characterize surface wettability, which indicates material 
hydrophobicity/hydrophilicity, commonly performed by either the sessile drop and the Wilhelmy 
method [294]. The method of choice may depend on the size and shape of the sample. For small wires 
or strips, the most suitable method is the dynamic contact angle analysis (DCA) using Wilhelmy 
method because of its operation principle [389]. Hence, this was the method of choice for this study. 
Details of the dynamic contact angle analysis method are described in Appendix F. The instrument 
used was the tensiometer Sigma 700 (KSV Instruments, Helsinki, Finland) with Milli-Q™ water. The 
analysis was performed with the following settings; immersion and emersion speed: 10 mm/min, start 
depth: 10mm, immersion depth: 20 mm and the first 2 mm were ignored. 
4.3.1.4 X-ray-photoelectron spectroscopy 
X-ray-photoelectron spectroscopy (XPS) is one of the methods that are used to characterize 
material surface chemistry. The others include secondary ion mass spectrometry-time of flight 
(SIMS-TOF) and Fourier transform infrared spectroscopy (FTIR) [390]. These have advantages and 
disadvantages in accuracy and specificity, which may depend on the material surface composition. In 
this research, material surface chemistry was determined with XPS because it is available and is easy 
to interpret. XPS was performed at 15 kV, 150W. TiO2 powder was used as reference standard. The 
reference standard was 99.9% metal basis titanium (IV) oxide powder with density of 3.9-4.23g/cm3 
at 20°C (Alfa Aesar, Ward Hill, MA, USA). Identification and quantification of surface element 
concentrations were performed with CasaXPS (Casa Software Ltd., Cheshire, UK). 
4.3.1.5 Cyclic voltammetry 
To characterize material surface film stability and corrosion resistance, potentiodynamics 
polarization measurements were performed using cyclic voltammetry. Test methods for cyclic 
potentiodynamics polarization measurements are described in ASTM F2129-08 standard [391]. In 
cyclic voltammetry (CV), the potential is cycled in both the positive and negative direction (anodic 
and cathodic polarization), within predetermined limits. The current is monitored as a function of 
time or potential. The current versus potential curve provides information on the susceptibility of the 
material for corrosion in a given solution. The point at which the current suddenly drops at a given 
potential is an indicator of the surface breakdown. The higher the potential at which the current drops, 
the higher the corrosion resistance or surface stability. 
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Cyclic voltammetry method was used to check the stability of the material surface and ensure 
that it is the same as commercially available material. Model stent samples, 20 mm long, were used 
for CV electrochemical tests with Ag/AgCl and platinum as reference and center electrodes, 
respectively. A simulated body fluid, sometime referred to as physiological solution, with ionic 
concentrations similar to blood plasma and pH 7.4 was used for electrochemical tests. The simulated 
body fluid was prepared from analytical chemistry as per procedure previously described by Oyane 
[392], summarized in Appendix G. The measurements were performed with the solution kept at 37°C. 
Cyclic voltammetry, with current cycled between -500mV and +1500 mV and scan rate of 1 mV/s, 
was used for the polarization test. During the test, nitrogen was bubbled through the physiological 
solution to reduce oxidation of the sample surface. 
4.3.2 Results  
4.3.2.1 Surface topography and roughness 
Scanning electron microscopy was used to qualitatively evaluate surface roughness and 
topographical differences between the wires and model stents after heat treatment. The SEM surface 
topography micrographs for the Ti-6Al-4V wire and the model stent are depicted on Figure 4-6. 
Comparison of the two surfaces does not show obvious differences in surface topography and 
roughness. 
 
 
Figure 4-6. Ti-6Al-4V SEM surface topography and roughness. (a) The wire surface before heat 
treatment shows patterned ridges or grooves, oriented along the length of the wire. (b) The model 
stent surface shows that the pattern is retained after heat treatment. Magnification for both 
micrographs at 1KX. 
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Surface topography and roughness were also evaluated by atomic force microscopy. 
Randomly selected areas were examined with AFM. Figure 4-7 depicts surface topography images of 
randomly selected typical samples. Three randomly selected areas on the untreated wire (control) 
were scanned with AFM and roughness values were averaged. Two randomly selected heat-treated 
stents, not from the same vacuum-sealed tube, were also examined with AFM. Two examination 
areas were scanned on each sample and the roughness values were averaged. 
 a	   b	  
 
Figure 4-7.  TI-6AL-4V AFM surface topography and roughness. (a) Wire before heat treatment. 
Horizontal axis at 2 µm/div and vertical axis at 550 nm/div. (b) Model stent after heat treatment. 
Horizontal axis at 2 µm/div and vertical axis at 500 nm/div. 
 
A summary data of the roughness values is presented on Table 4-3. The results show a slight 
increase in Ti-6Al-4V roughness after heat treatment. However, there was no difference in surface 
areas (SA) or surface area enlargement (Sd) between treated and untreated samples. A statistical 2-
tailed t-test comparison of the means between unheated and heat-treated samples showed that the 
increase in all roughness values on Table 4-3 was non-significant (p>0.6). The level of increase or 
decrease in roughness after heat treatment is very dependent on the treatment environment. An 
increase in roughness was previously observed after treatment in air [267]. It should be noted that, as 
highlighted by other investigators [393], these roughness parameters, though generally used, do not 
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adequately describe the geometric surface characteristics. Therefore, ideally a detailed 3D 
characterization would be necessary to adequately characterize the surface texture. 
 
Table 4-3. Ti-6Al-4V surface characteristics from AFM. Results are mean ±  SD. n=3. 
 Z range (nm) Ra (nm) Rq (nm) SA (µm2) Sd (%) 
Before heat treatment 996.1±275.0 113.0±21.4 148.0±33.9 114.0±2.7 14.0±0.03 
After heat treatment 1065.4±190.5 122.5±31.5 155.0±38.0 114.1±2.2 14.1±0.03 
 
4.3.2.2 Wettability 
Surface wettability was determined with the dynamic contact angle analysis method. The 
results of measurements for 6 cycle loops are presented on Table 4-4. A substantial difference 
between the advancing and receding contact angles was observed for the stent wires. Thermodynamic 
hysteresis has been associated with surface roughness and irregularities [389]. As observed from the 
roughness and topography characterization in the previous section, the experimental samples were not 
smooth, which may influence the wettability results. When hysteresis kinetics occurs, the advancing 
angle is used as the representative contact angle [393]. Therefore, the average contact angle for the 
wire sample is 65.39°±1.54° and the surface tension is 21.46±1.28 mN/m. It has previously been 
suggested that the approximate cutoff for hydrophobicity/hydrophilicity is at 65°, i.e. hydrophobic 
surfaces have contact angle θ>65° (water adhesion tension <30 mN/m) and hydrophilic surfaces have 
contact angle θ<65° (water adhesion tension >30 mN/m) [394]. Based on this cutoff and using the 
adhesion tension map [394], the Ti-6Al-4V samples can be characterized as weakly hydrophobic with 
water adhesion tension of approximately 21.5 mN/m (θ≈65.4°). 
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Table 4-4. Contact angle measurements 
Sample	   Cycle	   Advancing	  (degrees)	   Receding	  (degrees)	  
Surface	  
tension,	  F/L	  
(mN/m)	  
Cos	  θ 	   θ 	  (°)	   Surface	  
tension,	  F/L	  
(mN/m)	  
Cos	  θ 	   θ 	  (°)	  
Wire	   1	   18.861	   0.366	   68.54	   62.076	   1.204	   0.00	  
2	   21.956	   0.426	   64.80	   61.479	   1.192	   0.00	  
3	   22.044	   0.428	   64.69	   60.813	   1.179	   0.00	  
4	   22.140	   0.429	   64.57	   60.729	   1.178	   0.00	  
5	   21.794	   0.423	   65.00	   60.373	   1.171	   0.00	  
6	   21.966	   0.427	   64.75	   60.823	   1.180	   0.00	  
 
4.3.2.3 Surface composition 
Surface composition of the reference TiO2 power and two stent samples (unetched and acid-
etched) was performed with X-ray photoelectron spectroscopy (XPS). The survey spectra of the 
reference sample and the stent samples are shown on Figure 4-8. The titanium (Ti) and oxygen (O) 
spectral signals on the stent samples were similar to the reference sample, indicating that the stent 
sample surface was composed of titanium oxide (TiO2). However, the carbon (C) signal was very 
high on the stent surfaces. The presence of C on the stent samples, normally in the form of 
hydrocarbons, may be due to the atmospheric contamination, which is difficult to avoid [395], 
although it can be reduced through appropriate sample preparation and handling. Other contaminating 
elements such as nitrogen can be extracted from the spectra, but they were much lower than carbon 
and therefore were not included for simplicity. 
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Figure 4-8. XPS survey spectra from (a) TiO2 powder, (b) unetched stent sample and (c) acid-
etched stent sample. CPS: count per second (arbitrary units) 
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The concentrations of surface elements, in terms of atomic percentages, are listed on Table 
4-5. The carbon levels were relatively high for all the samples, but the lowest was observed on the 
reference sample, at 47%. Carbon levels for the unetched and acid-etched stent samples were 
approximately 75% and 80%, respectively.  The fact that even the reference sample had a high level 
of carbon suggests all the samples may have been exposed to the atmosphere for an extended period 
of time. The samples were processed by a third party and therefore there was little control on the 
handling process. Overall the analysis demonstrated that the samples had a TiO2 layer.  
 
Table 4-5. Relative concentration (atomic %) of surface elements Sample	   C	  1s	   O	  1s	   Al	  2p	   Ti	  2p	   V	  2p	  TiO2	  powder	   47.11	   39.13	   	  0	   13.76	   	  0	  Ti-­‐6Al-­‐4V	  (unetched)	   74.75	   22.83	   0	   2.42	   0	  Ti-­‐6Al-­‐4V	  (acid-­‐etched)	   78.57	   20.53	   0	   0.90	   0	  
 
4.3.2.4 Electrochemistry 
Figure 4-9 depicts the cyclic voltammetry curve for a Ti-6Al-4V model stent. The loop on the 
graph is produced by the reversal in the applied potential. The results show surface breakdown 
potential at about 1.2V, which is comparable to previously reported value for commercial Ti-6Al-4V 
for clinical use [282]. The small loop suggests that the surface is repassivated when the potential is 
reversed, after breakdown. While this test is mostly used as an indicator of corrosion resistance, here 
it is used to show that the material does not have any defect and is similar to commercially used 
material and that the titanium oxide layer formed after material treatment is stable. Thus, the results 
suggest that model stents have the characteristics of a stable passivation surface. 
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Figure 4-9. Cyclic voltammetry curve for Ti-6Al-4V model stent. The small loop suggests 
surface repassivation when the potential is cycled. 
 
4.4 Summary and conclusion 
In this part of the thesis, an inexpensive method was used to design and fabricate stents from 
Ti-6Al-4V ELI wires. In order to ensure that the surface titanium oxide layer was rutile type, model 
stents were shape-set in the oven at 800°C. Although other heat treatment methods can be used, it was 
found that the sealed vacuum treatment methods had the advantage of not requiring a special oven for 
heat treatment. The sealing also ensures consistency in surface oxide layer thickness since the stents 
can remain sealed until they need to be used. For simplicity, the design of model stents was based on 
a helical spring form. This facilitates analysis of the stent strut effect on flow, such as friction. 
Besides model stent geometry, surface characteristics are equally important. The investigation of 
surface characteristics of the fabricated model stents revealed that the prepared model stents had 
topography and roughness characteristics that were not significantly altered by heat treatment. In 
addition, the surface exhibited a stable titanium oxide passivation layer. 
This work has demonstrated an inexpensive method for fabricating model stents for in vitro 
studies. The work also highlights some of the advantages and disadvantages of different stent 
preparation and oven treatment methods. This would be beneficial to other investigators so that they 
do not have to reinvent the wheel. 
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Chapter 5 
Effect of Sample Volume on In Vitro Evaluation of Material-Induced 
Thrombogenicity 
5.1 Introduction 
In device-tissue investigations, a number of investigation methods can be used, both in vitro 
and in vivo. In all the methods, one of the common requirements is the standardization of processes to 
ensure comparability of experimental results. To that end, a number of standardization bodies, such as 
the International Organization for Standardization (ISO) and the American Standards for Testing and 
Measurement (ASTM) and AAMI/ANSI, have developed various equivalent guidance standards 
dealing with requirements for processing or testing of medical devices. The standards dealing with 
methods for testing for host response include ISO 10993-4:2002 Biological evaluation of medical 
devices – part 4: selection of tests for interactions with blood. In vivo investigations strictly adhere to 
these guidance standards. In vitro blood-biomaterial interaction studies, on the other hand, may or 
may not follow all or some of the guidance standards. This is despite the fact that in vitro studies are 
precursors for in vivo investigations. They play an important role in the initial investigation of 
complex biological systems and interpretation of their results serves as a guide on any decisions taken 
regarding further investigations or translation to the in vivo situation. It is therefore, important that 
attempts are made to follow guidance standards as well as standardize model parameters in order to 
improve the relevance of experimental results and facilitate comparison. 
  One of the important requirements in in vitro blood-biomaterial interaction studies is the 
relationship between the biomaterial sample size and the amount of blood sample, which is expressed 
using surface area-to-volume ratio. The significance of blood sample volume with regards to this 
parameter under flow conditions has been addressed in Chapter 3. While the ISO 10993 Standard 
compliance is important for maintaining a standard surface area-to-volume ratio, the length of time 
shear is applied to a stent has direct impact on time-averaged wall shear stress, one of the important 
physiological parameters. The other important factor is that sample volume affects the assumption of 
fully developed flow. For colloidal fluids like blood, whether the flow is fully developed or not is 
important because it influences particle-wall interaction, such as platelet dispersion [149], which 
affects the biochemical processes at the wall. Therefore, in using the Chandler loop model, it is 
necessary to ensure that all three conditions are met. Taking all these factors into consideration, the 
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CLSVF criterion was introduced in Chapter 3 to provide guidance on the selection of appropriate 
sample volume when the Chandler loop model is used with a model stent. 
In addition to developing the CLSVF criterion, flow in the model was characterized. 
Appropriate characterization of flow is important because it has been shown that the flow type 
influences a number of phenomena, such as particle dispersion [56, 57, 149, 339], platelet aggregation 
[204] and adhesion [396] and tissue factor expression [129, 397]. As a result of flow characterization, 
the effect of sample volume on hemodynamics was analytically described, with and without model 
stents. It was demonstrated that sample volume did not have a significant effect on shear stress in the 
absence of model stents, except for an immobilized particle. In addition, a time-averaged wall shear 
stress equation was developed, taking into account the blood sample volume and stent parameters, 
equation (38) in Chapter 3. This equation provides an improved estimate for wall shear stress in the 
Chandler loop model since it incorporates some of the important curved tube flow parameters. 
However, it is not sufficient to characterize hemodynamics without characterizing biological 
implications. Hence, the next step was to experimentally validate the theoretical analysis and the new 
equations.  
Since the time-averaged wall shear stress was shown to be dependent on blood sample 
volume, it was hypothesized that sample volume in the Chandler loop model influenced flow 
dynamics and consequently blood cell (platelets and leukocytes) activation. Therefore, the sensitivity 
of platelet and leukocyte activation and aggregation to sample volume, in the absence and presence of 
model stents, was investigated. Platelets are a key component of the hemostatic system but play 
diverse roles in inflammatory response and thrombosis [398]. Extracellular phospholipids exposed 
after activation act as binding surfaces for proteins of both the contact and coagulation systems. In 
addition, activated platelets produce pro/anti-inflammatory agents, form microparticles and express a 
variety of surface receptors [189]. Microparticles, which are cell fragments or microvesicles of 100-
1000 nm size [399], are a common feature of activated platelets and other cells, both in vitro and in 
vivo [209, 210, 400-403]. They are estimated to account for 25% of activated platelet activity [404]. 
The key receptor, which has fibrinogen as its ligand, is the glycoprotein receptor GPIIb/IIIa (integrin 
αIIbβ3). Platelets are activated by a variety of biological agonists as well as shear stress [202-204] and 
biomaterials, through adsorbed fibrinogen [155, 160]. Although platelets have been extensively 
studied because of their relative importance, their activation and aggregation is dependent on the 
characteristics of the model. Hence, it was important to include them in this study in order to 
understand the effect of these particular model characteristics on platelet activation. Platelet activation 
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was mainly characterized by platelet microparticle formation, a common feature in cardiovascular 
diseases [209] as well as in vitro and expression of the glycoprotein receptor GPIIb/IIIa (integrin 
αIIbβ3). These are, at the minimum, key indicators of platelet activation. 
Leukocytes are a key component of the innate immune response and therefore play an 
important role in biological response to implants [182]. Hence, blood-biomaterial studies would not 
be complete without leukocytes. In this research, leukocyte activation was investigated by expression 
of several surface receptors; Mac-1 (CD11b/CD18), tissue factor (TF, CD142), complement C3a 
receptor (C3aR) and toll-like receptor-4 (TLR-4). Mac-1 is one of the leukocyte integrin family of 
receptors that play important roles in health and disease [101]. Mac-1 is generally stored in the 
intracellular vesicles in quiescent leukocytes and expressed on the surface after activation by a variety 
of agonists [124]. It is a multifunctional leukocyte activation indicator and an important receptor in 
thrombosis because of its affinity to a variety of ligands, such as fibrinogen, soluble CD40 ligand 
(sCD40L), iC3b, and factor X (FX). In particular, Mac-1 has highest affinity for fibrinogen and FX 
zymogen, with dissociation constant Kd=2.2 µM and 20 nM, respectively [194]. Both of these 
proteins participate in the coagulation cascade. Although Mac-1 is usually upregulated by shear 
stress, there is evidence that there is a point at which it is down-regulated by high shear [168]. 
Therefore, Mac-1 response under the shear stress conditions predicted by Figure 3-8 (Chapter 3) is of 
particular interest in this study. 
Tissue factor is regarded as a key protein in the initiation of blood coagulation. It is a 
transmembrane receptor not constitutively expressed on leukocytes but expressed on the surface 
through transcription and translation upon activation [135]. Monocytes are the main leukocyte source 
of TF, which is also expressed on their microparticles. TF can be initiated by a vast number of 
stimulants under both in vitro and in vivo conditions [127]. TF, together with activated platelets, are 
key risk factors for acute in-stent thrombosis [405]. TF is also induced by biomaterial surface 
characteristics [170]. It has been correlated with TLR4 on monocytes [406]. It has also been 
implicated in a number of pathological conditions. Therefore, it is an important protein in material 
induced thrombosis. It is however, not an enzyme and its activity in coagulation is limited to 
complexing with FVIIa, which is the active component. Hence, it is investigated in this research on 
the understanding that it provides an indirect indication of the activity of the enzyme complex. 
As discussed in Chapter 2, complement protein C3 plays a key role in the complement 
cascade because it is a vital component of both the C3 and C5 convertases. The activation 
anaphylatoxin fragments C3a and C5a, and the opsonin iC3b play an important role in facilitating 
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inflammation and phagocytosis, respectively. To facilitate leukocytes activation and recruitment, 
leukocytes constitutively express complement fragment receptors, such as C3a receptor (C3aR) [69, 
107]. Previous studies have suggested that the presence of C3a, which is produced from complement 
amplification, causes internalization of its receptor, C3aR [407]. Since C3aR is an important receptor 
in inflammation, it is one of the receptors that play a role in complement-mediated thrombogenicity. 
The ligand-receptor specificity of C3a-C3aR also makes it an interesting receptor for possible 
diagnosis or intervention methods. Therefore, its regulation under different experimental conditions is 
of particular interest in this research.  
TLR4 as previously described in Chapter 2, is one of the ten human toll-like receptor family, 
which are the main pattern recognition receptors in innate immunity [67]. In an inflammatory 
response, it is engaged in leukocyte activation [66] and chemotaxis [92]. TLR4 is a receptor for LPS, 
which seems to have affinity to titanium surfaces [104, 105]. In addition, TLR4 was previously 
shown to be down-regulated by titanium particles in a murine monocyte/macrophage cell line [408]. 
More importantly, its stimulation on blood from normal subjects has been shown to correlate with TF 
[406] and modulate CD11b expression on blood of coronary artery disease patients [409]. Therefore, 
TLR4 is an important parameter in blood-biomaterial investigations. Although it has been studied 
before, it has not been characterized under the flow conditions described in this model. Hence, the 
need to investigate its expression in this research. 
In addition to investigating platelet and leukocyte activation in the fluid phase, cell adhesion 
on model stent surfaces was investigated in this chapter. Surface adhesion is important when 
investigating material thrombogenicity. Leukocyte adhesion has been shown to be both material and 
shear-dependent [19, 26, 27]. The negative correlation between shear and leukocyte adhesion has also 
been shown in a stenotic model [332]. On polymeric materials, adherent leukocyte sensitivity to shear 
stress was reduced above 7 dyn/cm2 and in general leukocyte adhesion seems to be highest in the 1-4 
dyn/cm2 shear stress range [332]. Interestingly, at high shear stress when shear sensitivity is lost, 
material-dependent adhesion may also be lost [19], although this might depend on other model 
parameters as a stent material effect was still observed after 2 hours in a loop model [26]. It is also 
interesting that inflammatory mediators such as PAF and fMLP can suppress leukocyte shear 
sensitivity in a dose dependent manner [410]. Thus, there are possible diverse leukocyte responses 
that depend on a variety of factors. The purpose of this part of the study was to investigate cell 
adhesion sensitivity to volume, in light of the new flow characterization, under different experimental 
conditions.  
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Therefore, the purpose of this study was to test the analytical predictions and the developed 
equations from Chapter 3 using numerical simulation and in vitro experimental investigations. While 
numerical investigation was only used to test the sample volume effect without model stents, in vitro 
experimental investigations were performed with and without model stents. Numerical simulation 
results have been previously published [411]. In vitro experiments were performed with the Chandler 
loop model parameters designed to closely mimic coronary arterial geometry and hemodynamics as 
depicted on Table 3-5. It was hypothesized that under shear and stent conditions, blood sample 
volume has an effect on blood cell activation and surface adhesion. To test this hypothesis in line with 
a systems approach, whole blood samples were used to investigate platelet and leukocyte activation 
and platelet-leukocyte aggregation. Although whole blood experiments are much more complex to 
interpret because isolating cause-effect is not straight forward, it provides a more appropriate 
biochemical environment [178] compared to isolated blood components. 
5.2 Materials and methods 
5.2.1 Flow model 
The flow model was made from a rotor and turntable as previously described in Chapter 3. 
The turntable for mounting blood sample tube loops was fixed in a vertical position. The sample tube 
loops were medical grade Silastic tubes (VWR, PA, USA) with 4.78 mm internal diameter. The tubes 
were cut into 371 mm long sections and spliced into loops with internal loop radius of about 59 mm. 
The loop volume was 6.64 ml. The wall shear stress for this model is as described by equation (19), 
and the improved time-averaged wall shear stress is equation (39), Chapter 3. 
5.2.2 Model stent design 
Model stents were made from Ti-6Al-4V 0.005” diameter wire (Fort Wayne Metals, Fort 
Wayne, IN, USA) as described in Chapter 4. Detailed specifications for the model stents are as 
described in Table 4-2. The stents were cut into sections of 20 mm and 35 mm lengths, giving surface 
area of 1.46 cm2 and 2.47 cm2, respectively. The stents were first ultrasonically cleaned in 30% nitric 
acid to reduce the endotoxin (LPS) contamination since LPS has been shown to have high affinity for 
titanium surfaces [105]. After rinsing with distilled water, the stents were ultrasonically cleaned in 
70% alcohol solution for about 10 minutes, and then rinsed at least twice in PBS (50 mM sodium 
phosphate plus 100 mM sodium chloride, pH 7.4). The prepared stents were stored in PBS at 4°C and 
used within 4 hours. 
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5.2.3 Antibodies and reagents 
Fluorescein isothiocyanate conjugated mouse monoclonal antibody against human 
glycoprotein GPIIb/IIIa (CD61-FITC), R-phycoerythrin monoclonal antibody against P-selectin 
(CD62-PE), Fluorescein isothiocyanate conjugated mouse monoclonal antibody against Mac-1 
(CD11b-FITC), R-phycoerythrin monoclonal antibody against tissue factor (CD142-PE), anti-C3a 
receptor (PE hC3aRZ8) and R-phycoerythrin-cytochrome 5 conjugated monoclonal antibody against 
PAN leukocytes (CD45-PE-Cy5) were purchased from BD Biosciences (San Diego, CA, USA). Anti-
human Toll-Like receptor 4 (CD284-PE) was purchased from eBioscience (San Diego, CA, USA). 
FACS lysing solution was purchased from BD Biosciences (San Diego, CA, USA). Phosphate-
buffered saline (PBS) was purchased from Fisher Scientific Inc (Ottawa, ON, Canada). 
Lipopolysaccharide (Escherichia coli serotype 0111:B4) (LPS), 50% glutaraldehyde solution, and 
paraformaldehyde were purchased from Sigma-Aldrich Co (Oakville, ON, Canada). Hepes Tyrode 
Buffer (HTB) solution pH 7.4 was made in the laboratory with a final concentration of 137mM NaCl, 
2.7mM KCl, 5mM MgCl2, 3.5mM HEPES, 1g/L Glucose, and 2g/L BSA (bovine serum albumin). 
5.2.4 Blood sample collection 
This study received ethics clearance from the University of Waterloo Research Ethics Office. 
Peripheral venous blood samples were drawn with formal consent from healthy volunteers, of age 
range 20 to 50 years, who indicated that they had not taken any medication in the last 72 hours. There 
was no restriction placed on the participants’ physical activity, the type of diet and eating time. 
Participants were however advised to drink lots of water ahead of the blood draw. Samples were 
drawn with a 21 Gauge Vacutainer needle and syringe (BD Biosciences, San Diego, CA, USA) by a 
qualified phlebotomist. Blood was immediately transferred into 10 ml conical tubes containing 
heparin (5U heparin/ml). Heparin was the anticoagulant of choice because it has previously been 
shown to cause less inhibition of platelet-monocyte aggregation, compared to other anticoagulants 
[412] and has also been found suitable for whole blood experiments [317]. Blood samples were kept 
in an insulated container and used in the blood activation experiments within 30 minutes of 
collection. 
5.2.5 Platelet and leukocyte activation and platelet-leukocyte aggregation 
To assess the volume effect, either 2 ml or 4 ml blood samples were transferred into silicone 
tube loops, which had been prepared by rinsing with PBS, less than 30 minutes before use. To assess 
   142 
the sample volume effect in the presence of biomaterial, either 20 mm or 35 mm model stents were 
included with the 2 ml and 4 ml blood samples, respectively. Additionally, 20 mm model stents were 
included with 4 ml samples to assess the effect of surface area-to-volume ratio. These gave surface 
area-to-volume ratios of 0.71 cm2/ml for 2 ml + 20 mm stents, 0.62 cm2/ml for 4 ml + 35 mm stents 
and 0.35 cm2/ml for 4 ml + 20 mm stents. Therefore, the experiments were carried out in three 
groups, Table 5-1. Experimental group one was composed of 2 ml blood samples with and without 20 
mm stents, group two was 4 ml samples with and without 35 mm stents and group three was 4 ml 
samples with and without 20 mm stents. To assess shear effect, each experimental group was exposed 
to the two experimental conditions; each composed of two setups. Experimental condition one setups 
were gentle agitation on a mini-shaker (VWR, PA, USA) and rotation at 24 RPM. Experimental 
condition two setups were gentle agitation on a mini-shaker and rotation at 45 RPM. For all the 
experiments, control samples were static and included blood alone (negative control/resting sample) 
and blood with lipopolysaccharide (LPS) (1 µg/mL) as a positive control. All samples were incubated 
at 37°C for 2 hours. The 2 hour experimental time was selected because it has been reported as the 
typical time required for steady state protein surface adsorption [174] and steady state leukocyte 
receptor expression [178].  
 
Table 5-1. Experimental conditions 
 Experimental condition 1 Experimental condition 2 
Experimental groups Agitate Rotate 24 RPM Agitate Rotate 45 RPM 
I 2 ml x x x x 
2 ml + 20 mm x x x x 
II 4 ml  x x x x 
4 ml + 35 mm x x x x 
III 4 ml x x x x 
4 ml + 20 mm x x x x 
 
5.2.6 Immunolabelling and flow cytometry analysis 
At the end of the 2-hour incubation, small blood samples were diluted in test tubes and 
incubated with respective antibodies for 30 minutes for receptor-antibody binding. To assess platelet 
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activation and platelet microparticle (PMPs) formation, 5 µL blood samples (about 1.25-2x106 
platelets/sample) were diluted with 50 µL HTB in test tubes and incubated for 30 minutes at 4°C with 
fluorescently-labeled antibodies against GPIIb/IIIa (CD61-FITC) and P-selectin (CD62PE). 
Following incubation, samples were further diluted with 200 µL HTB, fixed with 200 µL 2% 
paraformaldehyde and stored at 4°C before flow cytometry analysis.  
To assess leukocyte activation and platelet-leukocyte aggregation, 30µL of blood samples 
(about 150-300x103 leukocytes/sample) were diluted with 50 µL HTB in test tubes and incubated for 
30 minutes at 4°C with appropriate antibodies. Leukocytes were identified by PAN leukocyte marker 
(CD45 PE-Cy5.5). Leukocyte activation was identified by antibodies against Mac-1 (CD11b-FITC) 
and tissue factor (CD142-PE) on leukocytes. Leukocyte activation was additionally identified with 
antibodies against C3a receptor (anti-C3aR) and TLR4 (CD284-PE). Platelet-leukocyte aggregation 
was identified by antibodies against GPIIb/IIIa (CD61-FITC) on leukocytes. Following 30 minutes 
incubation, 700 µL of FACS Lyse solution was added to lyse red blood cells. Aliquots were 
concentrated by centrifuging at 1200g for 6 minutes and discarding supernatant. Resuspended pellets 
were washed and then diluted with 150 µL HTB and fixed with 150 µL 2% paraformaldehyde. All 
samples were stored at 4°C and analyzed on a BD FACS Calibur flow cytometer with CellQuest Pro 
software (BD Diagnostics, San Diego, CA, USA), within 5 days. 
In flow cytometry, cells can be isolated on the basis of size, granularity and antibody 
fluorescence colors and intensity. Cell size is indicated by forward scatter laser channel (FSC-H) 
signal, granularity is indicated by side scatter laser channel (SSC-H) signal and fluorescence levels 
are determined by the specific filter, labeled FL-1 (green), FL-2 (yellow) and FL-3 (red). Flow 
cytometry provides both qualitative and quantitative data. There are publications on the fundamentals 
of flow cytometry [413] and methods to reduce background fluorescence signal noise [414]. 
Fluorescence intensities are reported as median intensities by normalizing the geometric mean with 
the geometric mean of the respective positive control. This method is commonly used because it is 
independent of the shape of the histogram. 
5.2.7 Scanning electron microscopy 
After the experiment, stent samples were prepared for protein and cell surface adhesion 
analysis with a scanning electron microscope on a later date. Samples were first rinsed with 0.2M 
sodium phosphate buffer, pH 7.2 followed by fixing in 2.5% glutaraldehyde and storage at 4°C. Fixed 
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samples were then prepared for SEM analysis. Briefly, stent samples were first immersed and washed 
in 0.2M sodium phosphate buffer, pH 7.2. This was followed by dehydration through a series of steps 
in 10%, 25%, 50%, 70%, 90% and 100% ethanol. Samples were dried overnight and then coated with 
a thin layer of gold (8-10nm) in a vacuum chamber (Denton Vacuum, Desk II, USA) for 120sec, set 
at 50millitorr and 15 mA. Analysis was done with LEO 1530 Gemini (Zeiss, USA) set at 10kV in 
secondary electron mode (SE2). No specific marking was used to distinguish between the inner and 
outer stent wall, as it relates to the loop curvature. 
5.2.8 Statistical analysis 
Statistical analysis was done with the IBM SPSS Statistics version 20. Data were analyzed 
using analysis of variance (2-way ANOVA). For post-hoc analysis, Least Significant Difference 
(LSD) method was used to determine significant difference between groups. No specific analysis was 
performed to account for donor variability. Overall effects are not reported due to the complexity of 
the data; in some cases there are fewer than three groups, e.g. volume and stent samples. All data are 
presented as mean±standard deviation of a minimum of 3 separate experiments from different donors. 
For all analysis, p<0.05 was used to indicate significant difference. 
5.3 Results 
5.3.1 Effect of experimental groups and conditions on shear stress/rate 
Data from Table 3-9 and equations (38) and (39) can be used to calculate the shear stress and 
shear rate values, Table 5-2. These values correspond to values read directly from Figure 3-8, Chapter 
3. As previously observed, the new time-averaged wall shear stress reflects the effect of changes in 
sample volume and stent length on fluid dynamics. Hence, for the same angular velocity, the wall 
shear stress is different, depending on the sample volume and model stent length. 
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Table 5-2. Time-averaged wall shear stress/rate for the experimental groups and conditions 
	   Time-­‐averaged	  wall	  shear	  
stress/rate	  at	  24	  RPM	  
Time-­‐averaged	  wall	  shear	  
stress/rate	  at	  45	  RPM	  
Experimental	  groups	   τ 	  (dyn/cm2)	   γ 	  (s-­‐1)	   τ 	  (dyn/cm2)	   γ 	  (s-­‐1)	  
2	  ml	   13.3	   380.0	   27.8	   794.3	  
4	  ml	   33.3	   951.4	   55.7	   1591.4	  
2	  ml+20	  mm	   12.6	   360.0	   26.3	   751.4	  
4	  ml+20	  mm	   25.2	   720.0	   52.7	   1505.7	  
4	  ml+35	  mm	   24.1	   688.6	   50.4	   1440.0	  
 
5.3.2 Effect of sample volume, shear stress and stent on platelet activation 
The effect of volume on platelet activation was investigated under three conditions; without 
model stents, with model stents at similar surface area-to-volume ratio and at different surface area-
to-volume ratios. 
5.3.2.1 Effect of volume and shear on platelet activation – without stents 
After a 2-hour incubation, activated platelets were characterized by formation of platelet 
microparticles (PMPs), expression of receptor GPIIb/IIIa (CD61) on platelets and PMPs, and P-
selectin expression on platelets. Since both activated platelets and PMPs express CD61, circulating 
PMPs were distinguished from platelets and platelet aggregates based on size (flow cytometry 
forward light scatter). P-selectin expression was determined based on fluorescence levels. Figure 5-1 
depicts typical flow cytometry data analysis plots for circulating PMPs, activated platelets, excluding 
platelet aggregates with other platelets, leukocytes and RBC (region R3). PMPs are expressed as 
percentage of total events (platelets + PMPs) or number of particles per 100 platelets and 
microparticles.  
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Figure 5-1. Characteristic flow cytometry analysis plots of platelet activation in whole blood. 
Negative control (rest) sample: (a) light scatter dot plot showing PMPs (4.47%) distinguished by the 
forward light scatter signal and (b) histogram of events (platelets and PMPs) positive for CD61. 
Platelet activation after model stent contact under shear (360 s-1) for 2 ml + 20 mm stent: (c) light 
scatter dot plot showing PMPs (13.38%) and (d) histogram of events (platelets and PMPs) positive for 
CD61. FL1-H = CD61. 
 
As shown on Table 5-3, sample volume did not have any significant effect on platelet 
activation, as indicated by PMP formation and CD61 under all experimental conditions. However, 
there was a significant difference in P-selectin expression when sample volumes were compared at 45 
RPM (p<0.05). Shear stress did not have any significant effect on platelet activation for rotational 
speeds up to 45 RPM. The observed decrease in CD61 expression and P-sel increase at 45 RPM are 
consistent with platelet degranulation upon PMP formation. 
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Table 5-3. Effect of sample volume and shear rate on platelet activation 	   Activation	  marker	  (Negative	  control)	  
Experimental	  conditions	   %	  Platelet	  
microparticle	  
formation	  (5±1%)	  
CD61+	  Platelets	  
and	  PMPs	  	  (235±38)	  
P-­‐sel	  Platelets	  	  	  (21±7)	  
2	  ml	  sample	   Agitate	   5±1	   241±42	   18±4	  
24	  RPM	  (380	  s-­‐1)	   7±1	   260±10	   17±6	  
45	  RPM	  (790	  s-­‐1)	   7±2	   217±24	   21±2	  
4	  ml	  sample	   Agitate	   5±2	   228±36	   24±8	  
24	  RPM	  (950	  s-­‐1)	   5±1	   231±30	   24±3	  
45	  RPM	  (1590	  s-­‐1)	   7±3	   214±47	   31±16	  *	  
Percentages for PMPs are based on size (forward scatter signal). CD61 and P-sel expressions are 
reported as arbitrary fluorescent units. Bold indicates significant difference. *significantly different 
from 2 ml sample at 45 RPM (p<0.05). Results are mean ± SD, n=3-6. 
 
5.3.2.2 Effect of volume and shear on platelet activation – with stents 
To investigate the effect of volume on platelet activation in the presence of model stents, 
experiments were carried out with 2 ml + 20 mm and 4 ml + 35 mm stent samples, giving relatively 
similar surface area-to-volume ratios of 0.71 cm2/ml and 0.62 cm2/ml, respectively. Figure 5-2 depicts 
the results of PMP formation in the presence of model stents. Although shear stress alone did not 
have a significance effect on PMP formation, in the presence of model stents, a significant shear 
effect was observed for the 4 ml samples (p<0.01). When 2 ml + 20 mm and 4 ml + 35 mm samples 
were compared under rotational conditions, 1.5 and 2.0-fold increase in PMP formation was observed 
at 24 and 45 RPM, respectively; this was a significant volume effect (p<0.02). In addition, within the 
same volume sample and under identical rotational conditions, the presence of a stent resulted in a 
significant increase in PMP formation when compared with corresponding no-stent samples (p<0.02). 
Furthermore, the combined effect of shear stress and material produced significant effect when stent 
samples under shear were compared with agitated samples (p<0.03). 
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Figure 5-2. Effect of volume, shear and stent on platelet microparticle formation. Percentages for 
PMPs are based on size (forward scatter signal). *: p<0.02. #significantly different from 
corresponding stent samples under shear (p<0.03). Results are mean ± SD, n=3 to 6. 
 
Further confirmation of platelet activation was investigated by CD61 and P-selectin 
expression on platelets, Table 5-4. Similar to PMP formation, a significant material effect on CD61 
expression on platelets and PMPs was observed under rotational conditions (p<0.05). When stent 
samples were compared with no-stent samples under rotational conditions, material effect was only 
significant for the 4 ml samples (p<0.01). However, the combined effect of shear stress and material, 
when compared with agitated stent samples, was significant for both 2 and 4 ml samples at 45 RPM 
(p<0.04). P-selectin on the other hand did not show significant sensitivity to shear and/or biomaterial. 
In general, the results suggest that for wall shear stress up to 56 dyn/cm2, shear alone did not have a 
significant effect on platelet activation. On the other hand, shear in the presence of model stents 
resulted in significant platelet activation for the 4 ml samples. Similarly, there was a significant 
material effect under shear stress. Overall, the combined effect of sample volume, stent material and 
shear stress caused significant platelet activation. 
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Table 5-4. Effect of volume, shear and stent on CD61 and P-selectin expression 
Experimental conditions Activation marker  
(Negative control) 
CD61+ Platelets and PMPs 
(235±38) 
P-sel Platelets 
(21±7) 
2 ml sample Agitate 241±42 18±4 
24 RPM (380 s-1) 260±10 17±6 
45 RPM (790 s-1) 217±24 21±2 
4 ml sample Agitate 228±36 24±8 
24 RPM (950 s-1) 231±30 24±3 
45 RPM (1590 s-1) 214±47 31±16** 
2ml+20mm sample Agitate 225±40 17±5 
24 RPM (360 s-1) 222±37 17±7 
45 RPM (750 s-1) 184±25 @ 22±4 
4ml+35mm sample Agitate 216±30 22±3 
24 RPM (690 s-1) 166±13 * # @ 22±2 
45 RPM (1440 s-1) 143±39 * # @ 24±2 
CD61 and P-sel expression are reported as arbitrary fluorescent units. *Significantly different from 
corresponding 2 ml + 20 mm stent sample (p<0.05), #significantly different from corresponding no-
stent sample (p<0.01), @significantly different from corresponding agitated stent sample (p<0.04). 
**significantly different from 2 ml sample at 45 RPM (p<0.05). Results are mean ± SD, n=3 to 6. 
 
5.3.2.3 Effect of material surface area-to-volume ratio on platelet activation 
To investigate the effect of material surface area-to-volume ratio on platelet activation, 
experiments were performed with 4 ml + 20 mm and 4 ml + 35 mm stent samples, giving surface 
area-to-volume ratios of 0.35 cm2/ml and 0.62 cm2/ml, respectively. While the surface area-to-volume 
ratio of 0.35 cm2/ml (20 mm stent) caused a non-significant increase in PMP formation, the surface 
are-to-volume ratio of 0.62 cm2/ml (35 mm stent) resulted in a significant increase in platelet 
activation under shear conditions (p<0.01), Figure 5-3. Comparison of PMP formation at the two 
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surface area-to-volume ratios revealed that a 1.8-fold increase in surface area-to-volume ratio resulted 
in a significant (p<0.01) 2.6 and 3.7-fold increase in PMP formation at 24 and 45 RPM, respectively. 
 
 
Figure 5-3. Effect of surface area-to-volume ratio on platelet microparticle formation. PMP 
percentages are based on size (forward scatter signal). *: p<0.02. Results are mean ± SD, n=3 to 5. 
 
Platelet activation at 0.35 cm2/ml versus 0.62 cm2/ml was also reflected in CD61 expression. 
The presence of 35 mm stents (0.62 cm2/ml) caused a significant CD61 decrease on platelets and 
PMPs (p<0.01), while 20 mm stents (0.35 cm2/ml) caused a non-significant decrease, Table 5-5. 
When CD61 expression was compared between the two surface area-to-volume ratios, a significant 
difference was observed at 24 RPM (p<0.02). As in previous experiments, no changes were observed 
in P-sel expression. The results show that at low surface area-to-volume ratio (below 0.5 cm2/ml), the 
combined effect of shear and biomaterial was not sufficient to cause a significant platelet activation 
under experimental conditions for this study. However, when the surface area-to-volume ratio was 
increased above 0.5 cm2/ml, the lower limit of the recommended range, a significant increase in PMP 
formation was observed under both shear conditions. This suggests that shear significantly augments 
material-induced PMP formation only when there is sufficient surface-area-to volume ratio. Thus, our 
results suggest that PMP formation is surface area dependent. 
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Table 5-5. Effect of surface area-to-volume ratio on CD61 and P-sel expression 
Experimental conditions Activation marker  
(Negative control) 
CD61+ Platelets and PMPs 
(235±38) 
P-sel Platelets 
(21±7) 
4 ml sample 24 RPM (950 s-1) 231±30 24±3 
45 RPM (1590 s-1) 214±47 31±16 
0.35 cm2/ml sample 24 RPM (720 s-1) 220±17 24±5 
45 RPM (1510 s-1) 180±40 33±17 
0.62 cm2/ml sample 24 RPM (690 s-1) 166±13 * # 22±2 
45 RPM (1440 s-1) 143±39 #  24±2 
CD61 and P-sel expression are reported as arbitrary fluorescent units. *Significantly different from 
corresponding 0.35 cm2/ml sample (p<0.02), #significantly different from corresponding no-stent 
sample (p<0.01). Results are mean ± SD, n=3 to 5. 
 
5.3.3 Effect of sample volume, shear stress and stent on leukocyte activation 
Similar to platelet activation, the effect of volume on leukocyte activation was investigated 
under three conditions; without model stents, with model stents at similar surface area-to-volume 
ratio and at different surface area-to-volume ratios. 
5.3.3.1 Effect of sample volume and shear on leukocyte activation – without stents 
Leukocytes were determined by expression of CD45 and leukocyte sub-populations 
(monocytes, PMNs and lymphocytes) were distinguished by side and forward light scatter signals, i.e. 
cell granularity and size, respectively. Activated leukocytes were characterized by surface expression 
of CD11b (Mac-1) and TF (CD142) and complement C3a receptor (C3aR). Preliminary investigation 
of toll-like receptor 4 (TLR-4) expression on leukocytes was also performed.  
The effect of sample volume on leukocyte activation, as indicated by the percentage of 
monocytes expressing TF, and Mac-1 and C3aR expression on leukocytes, are presented in Table 5-6. 
Changing blood sample volume in the absence of model stents did not result in any changes in the 
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percentage of monocytes expressing TF. While volume changes did not affect TF expression on 
monocytes, a decrease in Mac-1 expression on monocytes was observed when sample volume was 
changed from 2 to 4 ml, which was significant at 24 RPM (p=0.05). The increase in volume also had 
a slight down-regulation effect on Mac-1 expression on PMNs. On the other hand, volume change did 
not have a significant effect on C3aR expression on both monocytes and PMNs.  
Unlike change in volume, increase in shear rate (380 s-1 to 790 s-1 for 2 ml and 950 s-1 to 1590 
s-1 for 4 ml sample) had a down-regulation effect on percentage of monocytes expressing TF, Table 
5-6. Increasing shear also had a down-regulation effect on Mac-1 expression on leukocytes. Similar to 
TF and Mac-1, C3aR expression was down-regulated when shear was increased. C3aR expression 
was significantly down-regulated compared to agitated samples on both monocytes and PMNs, 
p<0.01 and p<0.03, respectively. In general, increasing volume in the absence of stents had an 
insignificant effect on TF and C3aR expression, but had a down-regulation effect on Mac-1 
expression on leukocytes. Shear stress had a down-regulation effect on all the leukocyte activation 
markers. 
Preliminary investigations on the effect of volume and shear on TLR-4 expression on 
leukocytes were also performed and the results are presented in Table 5-7. Although there was a 
significant volume effect on some samples, conclusions on TLR-4 expression cannot be drawn from 
the preliminary data due to the small number of samples (n=2). 
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Table 5-6. Effect of volume and shear on leukocyte activation 
Marker 
(Negative control) 
Experimental condition p-value 
ω , RPM 2 ml 
sample 
4 ml 
sample 
2ml vs 4ml Agitate vs 
2ml 
Agitate vs 
4ml 
24 vs 45 RPM 
(2ml) 
24 vs 45 RPM 
(4ml) 
% Monocytes 
expressing TF 
(9±2) 
Agitate 18±6 17±4 0.81     
24 RPM 20±6 20±9 0.92 0.81 0.49   
45 RPM 16±4 15±7 0.90 0.70 0.74 0.55 0.33 
Mac-1 expression 
on monocytes (%) 
(29±12) 
Agitate 34±5 35±10 0.87      
24 RPM 55±4 39±16 0.05 0.01 0.43   
45 RPM 45±7 33±8 0.09 0.10 0.78 0.25 0.33 
Mac-1 expression 
on PMNs (%) 
(23±6) 
Agitate 18±6 26±7 0.11     
24 RPM 26±4 20±9 0.43 0.26 0.26   
45 RPM 24±14 18±5 0.30 0.31 0.11 0.85 0.66 
C3aR expression 
on monocytes (%) 
(115±18) 
Agitate 123±18 128±22 0.69     
24 RPM 111±6 118±16 0.68 0.44 0.39   
45 RPM 99±20 96±26 0.87 0.10 0.01 0.52 0.12 
C3aR expression 
on PMNs (%) 
(144±29) 
Agitate 150±17 137±32 0.36     
24 RPM 131±17 126±16 0.84 0.34 0.47   
45 RPM 110±29 123±40 0.49 0.03 0.36 0.36 0.86 
Bold indicates significant difference. Shear rate: 2 ml at 24 and 45 RPM is equivalent to 380 s-1 and 790 s-1, 4 ml at 24 and 45 RPM is equivalent 
to 950 s-1 and 1590 s-1. Results are mean ± SD, n=3 to 5. 
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Table 5-7. Effect of volume and shear on TLR-4 expression on leukocytes 
Marker 
(Negative control) 
Experimental conditions p-value 
 2 ml 4 ml 2 ml vs  
4 ml 
24 vs 45 RPM 
(2ml) 
24 vs 45 RPM 
(4ml) 
TLR4 expression 
on monocytes (%) 
(88±16) 
Agitate 87±32 101±19 0.22   
24 RPM 85±11 105±22 0.21   
45 RPM 87±30 85±13 ND ND 0.33 
TLR4 expression 
on PMNs (%) 
(92±21) 
Agitate 67±16 97±14 0.003   
24 RPM 69±11 94±11 0.05   
45 RPM  70±2 97±14 ND ND 0.79 
Bold indicates significant difference. Shear rate: 2 ml at 24 and 45 RPM is equivalent to 380 s-1 and 
790 s-1, 4 ml at 24 and 45 RPM is equivalent to 950 s-1 and 1590 s-1. 2 ml samples: n=5 except for 
samples at 45 RPM (n=2); 4 ml samples: n=3 to 5. ND: not determined due to small sample size. 
Results are mean ± SD. 
 
5.3.3.2 Effect of sample volume and shear on leukocyte activation – with model stents 
The effect of sample volume on leukocyte activation was also investigated in the presence of 
model stents. To perform this investigation, experiments were carried out with 2 ml + 20 mm stents 
and 4 ml + 35 mm stents sample, giving relatively similar surface area-to-volume ratios of 0.71 
cm2/ml and 0.62 cm2/ml, respectively and thus allowing us to assess the potential effect of sample 
volume on activation. 
The effect of volume on percentage of monocytes expressing TF is depicted on Figure 5-4. 
Changing blood sample volume in the presence of model stents did not result in any changes in the 
percentage of monocytes expressing TF. When stent samples were compared with no-stent samples, 
the presence of stents did not result in significant changes in TF expression under agitation while a 
significant increase in the percentage of monocytes expressing TF (p<0.01) was observed at both 24 
RPM and 45 RPM regardless of volume. Thus, the combined shear-stent interaction had a significant 
effect on TF expression. 
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Figure 5-4. Effect of volume, shear and stent on percentage of monocytes expressing TF. *: 
p<0.05. Results are mean ± SD, n=3 to 5. 
 
Table 5-8 depicts the results of the effect of sample volume on Mac-1 and C3aR receptor 
expression on leukocytes in the presence of model stents, for similar surface area-to-volume ratios. 
The presence of a stent led to an increase in Mac-1 expression on monocytes and PMNs. The increase 
in Mac-1 expression on monocytes was significant (p<0.02) for all 4 ml samples under all 
experimental conditions. Mac-1 expression on PMNs was significant (p<0.02) for all samples under 
agitate and 24 RPM. At 45 RPM, Mac-1 expression in both stent and non-stent samples was down 
regulated to the range of control values, and hence the difference between the samples was not 
significant. 
For C3aR expression on leukocytes, unlike TF and Mac-1 expression, the presence of stents 
did not result in any significant difference under all experimental conditions. In general, volume did 
not have a significant effect on Mac-1 and C3aR expression on leukocytes for samples with similar 
surface area-to-volume ratio. However, the results generally show a significant material effect on 
Mac-1 and TF expression and limited effect on C3aR expression. 
TLR-4 expression was also investigated and preliminary results are presented in Figure 5-5. 
Based on the 4 ml samples, the presence of stents under shear caused a significant upregulation in 
TLR-4 expression (p<0.02 for monocytes and p<0.04 for PMNs). In addition, the results suggest that 
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shear stress had a down regulation effect on TLR-4 expression on leukocytes. However, conclusions 
cannot be drawn due to the limited number of samples. 
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Table 5-8. Effect of volume in the presence of model stent on Mac-1 and C3aR expression on leukocytes 
Marker	  (Negative	  control)	   Experimental	  condition	   p-­‐value	  
ω ,	  RPM	   2ml	  	   2ml	  +	  20mm	   4ml	  	   4ml	  +	  35mm	   2ml	  
vs	  
2ml+20mm	  
4ml	  
vs	  
4ml+35mm	  
2ml+20mm	  
vs	  
4ml+35mm	  
% Mac-1 expression 
on monocytes 
(29±12)	  
Agitate	   34±5 49±10 35±10	   55±19	   0.01	   0.001	   0.33	  
24 RPM 55±4	   63±2	   39±16	   61±3	   0.36	   0.01	  	   0.81	  
45 RPM 45±7	   58±12	   33±8	   70±13	   0.11	   <0.001	  	   0.14	  
% Mac-1 expression 
on PMNs 
(23±6) 
Agitate	   18±6	   33±8	   26±7	   44±14	   0.01	   0.001	   0.03	  
24 RPM 26±4 44±5 20±9 43±8 0.02 0.002 0.84 
45 RPM 24±14 27±18 18±5 26±13 0.64 0.21 0.88 
% C3aR expression 
on monocytes 
(115±18)	  
Agitate	   123±18	   140±21	   128±22 	   143±40	   0.21	   0.22	   0.80	  
24 RPM 111±6 	   125±16	   118±16 	   144±27	   0.46	   0.12	   0.33	  
45 RPM 99±20	   114±42	   96±26 	   104±42	   0.37	   0.64	   0.59	  
% C3aR expression 
on PMNs 
(144±29)	  
Agitate	   150±17	   143±16	   137±32 	   124±45	   0.64	   0.40	   0.26	  
24 RPM 131±17	   125±19	   126±16 	   138±33	   0.80	   0.58	   0.59	  
45 RPM 110±29	   112±41	   123±40 	   111±62	   0.91	   0.57	   0.97	  
Bold indicates significant difference. Shear rates: 24 RPM with 2 ml and 4 ml = 380 s-1 and 950 s-1; 45 RPM with 2 ml and 4 ml = 790 s-1 and 1590 
s-1; 24 RPM with 2 ml + 20 mm and 4 ml + 35 mm stent = 360 s-1 and 690 s-1; 45 RPM with 2 ml + 20 mm and 4 ml + 35 mm = 750 s-1 and 1440 s-
1. Results are mean ± SD, n=3 to 5. 
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Figure 5-5. Effect of volume, shear and stent on TLR-4 expression. *: p<0.04. Results are mean ± 
SD. 2 ml samples: n=5 except for samples at 45 RPM (n=2); 4 ml samples: n=3 to 5. 
 
The effect of sample volume on Mac-1 and C3aR receptor expression on leukocytes in the 
presence of model stents, for similar surface area-to-volume ratios, were further investigated in Table 
5-9. Mac-1 expression on monocytes was not significantly changed by changing blood sample 
volume while keeping the surface area-to-volume ratio constant, for agitated and rotational samples. 
Increasing shear rate (by increasing rotational speed from 24 RPM to 45 RPM) in the presence of 
stents down-regulated Mac-1 expression on monocytes for the 2 ml + 20 mm stent but was 
upregulated for the 4 ml + 35 mm samples. Similar to Mac-1 expression on monocytes, changing the 
sample volume while keeping the surface area-to-volume ratio constant did not result in significant 
changes in Mac-1 expression on PMNs. However, unlike Mac-1 expression on monocytes, increasing 
shear rate in the presence of stents resulted in a significant down-regulation in Mac-1 expression on 
PMNs for both samples (p<0.05). 
There was also no observed significant difference in C3aR expression on leukocytes between 
samples with similar surface area-to-volume ratio when sample volume was changed, Table 5-9. 
However, similar to TF and Mac-1 expression, increasing shear stress in the presence of stents down-
regulated C3aR expression on leukocytes, which was significant (p=0.04) on monocytes for 4 ml + 35 
mm samples. It is interesting to note that the samples showing significant decrease in C3aR 
expression correspond to the samples with increased Mac-1 expression, which was contrary to other 
samples.  
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Although volume did not generally have a significant effect on Mac-1 expression on 
leukocytes for samples with similar surface area-to-volume ratio, the results suggest some differences 
under shear. Increasing shear rate generally down regulated Mac-1 expression, except for Mac-1 
expression on monocytes for the 4 ml with 35 mm stent samples. 
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Table 5-9. Effect of volume, shear and stent on Mac-1 and C3aR expression on leukocytes 
Marker	  (Negative	  control)	   Experimental	  condition	   p-­‐value	  
ω ,	  RPM	   2ml	  +	  20mm	  
sample	  	  
4ml	  +	  35mm	  
sample	  
Agitate	  vs	  
2ml+20mm	  
Agitate	  vs	  
4ml+35mm	  
24	  vs	  45	  RPM	  
(2ml+20mm)	  
24	  vs	  45	  RPM	  
(4ml+35mm)	  
% Mac-1 expression 
on monocytes 
(29±12)	  
Agitate 	   49±10 55±19	   	   	   	   	  
24 RPM 63±2	   61±3	   0.06	   0.43	   	   	  
45 RPM 58±12	   70±13	   0.19	   0.05	   0.53	   0.30	  
% Mac-1 expression 
on PMNs 
(23±6) 
Agitate	   33±8	   44±14	   	   	   	   	  
24 RPM 44±5 42±8 0.10 0.79   
45 RPM 27±18 26±13 0.32 0.01 0.02 0.04 
% C3aR expression 
on monocytes 
(115±18)	  
Agitate	   140±21	   143±40	   	   	   	   	  
24 RPM 125±16	   144±27	   0.39	   0.94	   	   	  
45 RPM 114±42	   104±42	   0.09	   0.02	   0.54	   0.04	  
% C3aR expression 
on PMNs (144±29) 
Agitate	   143±16	   124±45	   	   	   	   	  
24 RPM 125±19	   138±33	   0.38	   0.52	   	   	  
45 RPM 112±41	   111±62	   0.10	   0.54	   0.59	   0.27	  
Bold indicates significant difference. Shear rates: 24 RPM with 2 ml + 20 mm and 4 ml + 35 mm stent = 360 s-1 and 690 s-1; 45 RPM with 2 ml + 
20 mm and 4 ml + 35 mm = 750 s-1 and 1440 s-1. Results are mean ± SD, n=3 to 5. 
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5.3.3.3 Effect of surface area-to-volume ratio on leukocyte activation 
Since material surface area-to-volume ratio is an important factor, as previously discussed, its 
effect on leukocyte activation was investigated further. To investigate the effect of material surface 
area-to-volume ratio, experiments were performed with 4 ml + 20 mm and 4 ml + 35 mm stent 
samples, giving surface area-to-volume ratios of 0.35 cm2/ml and 0.62 cm2/ml, respectively. While 
the presence of a 20 mm stent did not cause a significant increase in Mac-1 expression on monocytes 
(Figure 5-6(a)), the presence of 35 mm stent resulted in a significant increase in Mac-1 expression 
under all experimental conditions (p<0.01). When the samples with stents were compared, higher 
Mac-1 expression was observed on the samples with higher surface area-to-volume ratio, which was 
significant at 45 RPM (p<0.01). Increasing shear rate resulted in Mac-1 down-regulation for the 20 
mm stent samples and upregulation for the 35 mm samples. The upregulation was significant when 
compared with agitated samples (p<0.05). 
Unlike Mac-1 expression on monocytes, there was a significant difference in Mac-1 
expression on PMNs (p<0.05) between 0.35 cm2/ml and 0.62 cm2/ml samples, for agitated and 24 
RPM conditions, Figure 5-6(b). Comparison of stent samples shows higher Mac-1 expression on 
samples with higher surface area-to-volume ratio, similar to expression on monocytes. Increasing 
shear significantly down regulated Mac-1 expression on PMNs (p<0.04), for both stent samples. The 
down-regulation was also significant when compared with the agitated samples (p<0.02). 
Overall, Mac-1 expression on leukocytes was upregulated with surface area-to-volume ratio. 
Shear rate had an upregulation effect on Mac-1 expression on monocytes for the 0.62 cm2/ml sample, 
but generally had a significant down-regulation effect on PMNs.  
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Figure 5-6. Effect of surface area-to-volume ratio on Mac-1 expression on (a) monocytes, (b) 
PMNs. #: p<0.05. Results are mean ± SD, n=3 to 5. 
 
For C3aR expression on both monocytes and PMNs, neither the presence of model stents nor 
the difference in surface area-to-volume ratio had any significant effect, Table 5-10. Comparison of 
stent samples shows a slight upregulation in C3aR expression on both monocytes and PMNs with 
increased surface area-to-volume ratio at 24 RPM for the 0.62 cm2/ml sample (690 s-1) compared with 
the 0.35 cm2/ml sample (720 s-1). However, at 45 RPM the results are opposite; expression on the 
0.62 cm2/ml (1440 s-1) is lower compare to the 0.35 cm2/ml (1510 s-1). When shear rate was increased 
(24 RPM to 45 RPM), a down-regulation in C3aR expression on monocytes was observed on both 
stent samples, which was significant for the 0.62 cm2/ml sample (p<0.05). Similarly, increase in shear 
rate down-regulated C3aR expression on PMNs for the high surface area-to-volume ratio samples, 
albeit non-significant, but slightly upregulated C3aR expression for the low surface area-to-volume 
ratio. Therefore, C3aR sensitivity to surface area was not significant but there was significant shear 
sensitivity on monocytes. 
TLR-4 expression on the other hand showed sensitivity to material surface area-to-volume 
ratio, Table 5-10. TLR-4 expression on leukocytes was upregulated in the presence of model stents, 
when compared with non-stent samples, which was significant for the higher surface area-to-volume 
ratio under all shear conditions (p<0.05). When stent samples were compared, higher TLR-4 
expression was observed on samples with high surface area-to-volume ratio compared with low 
surface area-to-volume samples. The difference was significant for PMN at 24 RPM. Although 
increasing shear rate (24 RPM to 45 RPM), resulted in the down-regulation of TLR-4 on all stent 
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samples, no definitive conclusion can be drawn from this observation due to the small number of 
samples at 45 RPM. In general, leukocytes showed sensitivity to material surface area-to-volume 
ratio. 
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Table 5-10. Effect of surface area-to-volume ratio on C3aR and TLR-4 expression on leukocytes 
Marker	  (Negative	  control)	  
Experimental	  condition	   p-­‐value	  
ω ,	  RPM	   4ml	  
sample	  
0.35 
cm2/ml 
sample	  
0.62 
cm2/ml	  
sample	  
4ml	  
vs	  
0.35 cm2/ml	  
4ml	  	  
vs	  	  
0.62 cm2/ml	  
0.35 cm2/ml 
vs	  
0.62 cm2/ml	  
24	  vs	  45	  
RPM	  
(0.35 cm2/ml)	  
24	  vs	  45	  RPM	  
(0.62 cm2/ml)	  
% C3aR 
expression on 
monocytes 
(115±18)	  
Agitate	   128±22	   143±23	   143±40	   0.26	   0.22	   0.99	   	   	  
24 RPM 118±16	   127±8	   144±27	   0.60	   0.12	   0.37	   	   	  
45 RPM 96±26	   119±15	   104±42	   0.19	   0.64	   0.45	   0.69	   0.04	  
% C3aR 
expression on 
PMNs 
(144±29)	  
Agitate	   137±32	   145±19	   124±45	   0.62	   0.40	   0.25	   	   	  
24 RPM 126±16	   111±7	   138±33	   0.48	   0.58	   0.28	   	   	  
45 RPM 123±40	   132±10	   111±62	   0.68	   0.57	   0.40	   0.41	   0.27	  
% TLR-4 
expression on 
monocytes 
(88±17)	  
Agitate	   101±19	   110±6	   121±34	   0.41	   0.05	   0.36	   	   	  
24 RPM 105±22	   127±19	   153±22	   0.12	   0.001	   0.11	   	   	  
45 RPM 85±13	   101±12	   126±6	   0.35	   0.01	   0.17	   0.15	   0.10	  
% TLR-4 
expression on 
PMNs 
(94±21) 
Agitate	   97±14	   107±12	   119±21	   0.25	   0.01	   0.20	   	   	  
24 RPM 94±11	   116±16	   142±14	   0.06 <0.001 0.05   
45 RPM 97±14	   100±22	   125±15	   0.83 0.02 0.09 0.28 0.20 
Bold indicates significant difference. Results are mean ± SD, n = 2 to 5 (n=2 for TLR4-4 0.35 cm2/ml, 45 RPM). 
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5.3.4 Effect of sample volume, shear and stent on platelet-leukocyte aggregation 
To understand and relate the effect of platelet and leukocyte activation on platelet-leukocyte 
aggregation, the effect of blood sample volume on fluid phase platelet-leukocyte aggregation was also 
investigated under three similar conditions as above. Platelet-leukocyte aggregates were characterized 
by GPIIb/IIIa expression on CD45 expressing leukocytes. Orthogonal light scatter, as previously 
described, was used to distinguish leukocyte sub-population aggregates. 
5.3.4.1 Effect of volume and shear on platelet-leukocyte aggregation – without stents 
The results of sample volume effect on platelet-leukocyte aggregation, in the absence of 
model stents, are depicted on Table 5-11. When 2 ml and 4 ml samples were compared under the 
same experimental conditions, lower platelet-leukocyte aggregation was observed for the 4 ml 
samples, although non-significant. Increasing shear rate by increasing angular velocity (24 to 45 
RPM) resulted in a decrease in platelet-leukocyte aggregation in both 2 ml and 4 ml samples. The 
platelet-monocyte aggregation decrease was significant in the 4 ml sample at 45 RPM (1590 s-1) 
compared with the agitated sample (p<0.01). 
 In general, higher platelet-monocyte aggregation was observed compared with platelet-PMN 
aggregation under all experimental conditions. A noticeable but non-significant difference in platelet-
leukocyte aggregation was observed between the volume samples under shear. Generally, shear rate 
had a reducing effect on platelet-leukocyte aggregation. 
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Table 5-11. Effect of volume and shear on platelet-leukocyte aggregation 
Marker 
(Negative control) 
Experimental condition p-value 
ω  (shear rate) 2 ml 
sample 
4 ml 
sample 
2 ml vs 4ml Agitate 
vs 
2ml 
Agitate 
vs 
4ml 
24 vs 45 RPM 
(2ml) 
24 vs 45 RPM 
(4ml) 
Platelet-monocyte 
aggregates 
(180.8±109.9) 
Agitate 381±132 287±105 0.17     
24 RPM (380 s-1) 379±147 189±63 0.06 0.98  0.17   
45 RPM (790 s-1) 247±164 72±28 0.06 0.13  0.003 0.22  0.15 
Platelet-PMN 
aggregates 
(33.3±15.7) 
Agitate 67±39 51±24 0.66     
24 RPM (950 s-1) 112±53 58±24 0.30 0.33  0.88   
45 RPM (1590 s-1) 17±2 16±3 0.97 0.23  0.32 0.07  0.34 
Platelet-monocyte/PMN aggregates are reported as arbitrary fluorescent units. Results are mean ± SD, n=3 to 5. 
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5.3.4.2 Effect of volume and shear on platelet-leukocyte aggregation – with stents 
To investigate the effect of volume on leukocyte activation in the presence of model stents, 
experiments were carried out with different sample volumes but relatively similar surface area-to-
volume ratio; 2 ml + 20 mm stents (0.71 cm2/ml) and 4 ml + 35 mm stents sample (0.62 cm2/ml). The 
presence of model stents produced a significant increase (p<0.01) in platelet-monocyte aggregation 
under all experimental conditions, Figure 5-7(a). Comparison of stent samples under the same 
experimental conditions showed that there was no sample volume effect on platelet-monocyte 
aggregation for agitated and 24 RPM conditions. However, a significant volume effect was observed 
at 45 RPM (p<0.03). When shear was increased, a decrease in platelet-monocyte aggregation was 
observed for the 2 ml + 20 mm stent sample while an increase was observed for the 4 ml + 35 mm 
stent sample, which was significant when compared with the agitated sample (p<0.01). In fact, both 4 
ml + 35 mm stent samples under shear were significantly higher than the agitated sample (p<0.01). 
For platelet-PMN aggregation, the presence of model stents resulted in a significant increase 
in platelet-PMN aggregation (p<0.02), except for the 2 ml + 20 mm samples at 45 RPM (p=0.64), 
Figure 5-7(b). Similar to platelet-monocyte aggregation, there was no significant volume effect 
observed either when the stent samples were compared under the same conditions. When shear was 
increased, there was a significant decrease in platelet-PMN aggregation for both stent samples 
(p<0.05). 
In general sample volume did not have a significant effect on platelet-leukocyte aggregation 
for similar surface area-to-volume ratio samples, except at high sear. The presence of model stents 
produced significant aggregation, which was diminished at high shear due to the significant shear-
dependent decrease in platelet-leukocyte aggregation. The exception was platelet-monocyte 
aggregation, which was increased at high shear. 
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Figure 5-7. Effect of volume, shear and stent on platelet-leukocyte aggregation: (a) platelet-
monocyte and (b) platelet-PMN aggregation. * :p<0.05. Results are mean ± SD, n=3 to 5. 
 
5.3.4.3 Effect of material surface area-to-volume ratio on platelet-leukocyte aggregation 
To investigate the effect of material surface area-to-volume ratio on platelet-leukocyte 
aggregation, experiments were performed with 4 ml + 20 mm (0.35 cm2/ml) and 4 ml + 35 mm (0.62 
cm2/ml) stent samples. The presence of model stents had a significant effect on platelet-monocyte 
aggregation under all conditions (p<0.04 for 0.35 cm2/ml and p<0.01 for 0.62 cm2/ml samples), 
Figure 5-8(a). When stent samples were compared at the same experimental conditions, a significant 
surface area-to-volume ratio dependent difference in platelet-monocyte aggregation was observed 
under shear conditions (p<0.01). The introduction of shear (agitate to 24 RPM) resulted in a 
significant increase (p<0.01) in platelet monocyte-aggregation for the 0.62 cm2/ml sample. On the 
other hand, the increase in shear (24 RPM to 45 RPM) significantly decreased platelet-monocyte 
aggregation (p<0.04) for the 0.35 cm2/ml sample but increased aggregation for the 0.62 cm2/ml 
sample, which was significantly higher compared with the agitated sample (p<0.01). 
For the platelet-PMN aggregation, the presence of stents had a significant effect under 
agitation and 24 RPM for both surface area-to-volume ratios (p<=0.05), Figure 5-8(b). At 45 RPM, a 
significant effect of the presence of a stent was observed for the 35 mm samples (p<0.02). The 
difference in surface area-to-volume ratio had a significant effect on platelet-PMN aggregation at 
high shear rate (p<0.04). When shear was introduced, an increase in aggregation was observed for the 
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high surface area-to-volume ratio and when shear was increased, there was a significant decrease in 
aggregation (p<0.02 for the 0.35 cm2/ml samples and p<0.05 for the 0.62 cm2/ml samples). 
In general the higher surface area-to-volume ratio samples had significantly higher platelet-
leukocyte aggregation under shear. Increasing shear generally had decreasing effect on platelet-
leukocyte aggregation for most samples, with the exception of monocytes for the high surface area-to-
volume samples. 
 
 
Figure 5-8. Effect of surface area-to-volume ratio on platelet-leukocyte aggregation. *: p<=0.05. 
Results are mean ± SD, n=3 to 5. 
 
5.3.5 Effect of sample volume and shear on surface adhesion 
To investigate the effect of sample volume and shear stress on protein adsorption and cell 
adhesion after a 2-hour incubation, model stent samples were fixed in 2.5% glutaraldehyde and 
subsequently prepared for examination with a scanning electron microscope (SEM), as described 
under Materials and methods. Figure 5-9 to Figure 5-11 depict typical SEM results for some of the 
experimental conditions for 2 ml + 20 mm, 4 ml + 20 mm and 4 ml + 35 mm stent samples, 
respectively. 
There was visible variation in the morphology of surface adherent leukocytes. While some 
samples show ruggered morphology, even membrane blebbing (Figure 5-9), some show pancake 
morphology (Figure 5-10). However, these variations could not be associated with either specific 
material/experimental conditions or individual variability. In general, the pattern of cell adhesion 
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showed a shear-dependent reduction in adherent leukocytes when shear samples were compared with 
agitated samples. 
 
 
Figure 5-9. Scanning electron micrograph of cell adhesion pattern for 2 ml + 20 mm stent 
samples. (a) Agitated sample at 500X and (b) 24 RPM (13 dyn/cm2) sample at 500X (insert at 5kX). 
 
 
Figure 5-10. Scanning electron micrograph of cell adhesion pattern for 4 ml + 20 mm stent 
samples. (a) Agitated sample at 500X (2.52kX insert) and (b) 45 RPM (53 dyn/cm2) sample at 
1.01kX 
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Figure 5-11. Scanning electron micrograph of cell adhesion pattern for 4 ml + 35 mm stent 
samples. (a) Agitated sample at 500X and (b) 24 RPM (24 dyn/cm2) sample at 500X. 
 
5.4 Discussion 
The purpose of this work was to investigate the effect of blood sample volume, in the 
presence of shear stress and/or material, on blood activation, using the Chandler loop as described in 
Chapter 3. Since the model time-averaged wall shear stress equation proposed in Chapter 3 is a 
function of sample volume fraction and model stent parameters, the combined effect of volume-shear-
material interaction was of particular interest. Hence, investigations on the effect of sample volume 
and shear stress were performed with and without model stents. 
In this investigation, whole blood was used and a variety of cell activation parameters were 
investigated. This is in line with the need to provide a parameter profile in a systems approach to 
experimental investigations. Although the listed parameters are far from providing the profile 
necessary to characterize transient interactions, they are meant to demonstrate the need to take into 
account the various factors in the investigations. 
5.4.1 Effect of experimental groups and conditions on shear stress/rate 
Comparison of wall shear stress developed in the loop as predicted by the original Gardner 
equation [354] and the proposed time-averaged wall shear stress [29] suggest that the shear stress in 
the loop is much higher than originally thought. The effect of sample volume is particularly 
observable. This was also obvious in Chapter 3 (Figure 3-8), where the plot lines were clustered by 
sample volume. Although the time-averaged wall shear rate at the highest angular velocity for this 
   172 
study, 45 RPM, is much higher compared with the unmodified equation, it is still within the low 
range of what is considered pathologically high shear stress, since physiological shear rate range is 
100-1000 s-1 [52] or even up to 1200 s-1 [229]. 
5.4.2 Platelet activation 
This study has demonstrated that, in the absence of model stents, blood sample volume did 
not have a significant effect on platelet activation for the rotational speeds used in this study, i.e. up to 
the highest time-averaged wall shear stress/rate without stents of 56 dyn/cm2 (1590 s-1). This is 
consistent with the theoretical prediction as discussed in Chapter 3. It is also in agreement with the 
results of numerical simulation [411] and a previously published study [29]. Minimal shear-dependent 
platelet activation has also been reported in previously published studies with whole blood but 
different in vitro models [168, 415]. A microfluidic model with porcine blood also did not show any 
platelet aggregation at shear rates below 1500 s-1 [416]. These results suggest that under a 
physiological shear range, shear alone may not significantly activate platelets in whole blood. It 
should be noted that the results of platelet activation within physiological shear in whole blood 
experiments, as observed in this and previous studies [168, 415], are contrary to results from platelet 
rich plasma (PRP) experiments [204]. This implies that the use of whole blood is important as also 
demonstrated by the difference in material-dependent thrombin-antithrombin complex generation and 
platelet activation in a different model [417]. Since isolated platelets are very sensitive to shear stress 
compared to platelets in whole blood, and there is a difference in material response, it is important to 
take into consideration the platelet environment when interpreting and comparing results of the effect 
of shear stress on platelets.  
Although low shear stress did not significantly affect platelet activation, pathologically high 
shear stress has been shown to activate platelets in whole blood [415, 418]. The physiological 
relevance of the results of the current study is consistent with previous findings that, except in the 
reactive lumen, leukocytes play a bigger role in thrombosis at low shear rates while platelets play a 
key role at higher shear rates, since they have developed the mechanism to adhere even at high shear 
rates [419]. At high wall shear rates, above 1000 s-1, the platelets receptor complex GPIb-IX-V is able 
to bind to the vWF factor [420, 421]. In vivo, the importance of vWF at arterial shear has been 
demonstrated by correlation of vWF deficiency with reduced prevalence of arterial thrombosis [422]. 
This work has emphasized the importance of using whole blood versus blood components because it 
may affect interpretation and translation of results. 
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The presence of a stent resulted in platelet activation, which was significant under shear 
conditions. Numerous studies have demonstrated material-induced platelet activation under static 
[317] and flow conditions [27, 349]. The observed difference in platelet activation in the presence of 
model stents, for samples with similar surface area-to-volume ratio, even at the same rotational speed 
can be attributed to the effect of volume and stent on shear rate. It was previously hypothesized in 
Chapter 3 that the combined effect of volume and stent, for the same surface area-to-volume ratio is 
high shear stress, dominated by a volume effect. This is non-linear and increases rapidly with 
rotational speed and the Dean number as depicted on Figure 3-8, Chapter 3. Thus, the difference in 
time-averaged wall shear stress (≈63%), at the same rotational speed, partly explains the observed 
difference in platelet activation. 
Another variable that is important to consider in the volume-stent interaction is the shear 
exposure time to the stent, which is related to the periodic circulation of the sample volume in the 
loop. The fractional period of circulation for the sample volume can be expressed as Tc = 30λ πω , 
where λ is the dimensionless volume fraction as previously defined and Tc is in seconds. When the 
volume fraction is doubled, the exposure period is also doubled. Since platelet activation is sensitive 
to shear exposure time [204, 415], although to a less extent compared to shear level [204], the 
fractional difference in volume, and hence exposure time, may contribute to the difference in platelet 
activation observed at the same rotational speed. That means, in reality the effective interaction is 
volume-stent-time-frequency. Hence the material effect in semi-static conditions (where material 
effect is only in terms of surface area) is not significant but becomes significant under shear (surface 
area + friction). In line with these explanations, was the observed significant platelet activation, for 
the 4 ml + 35 mm stent samples, when rotational speed was increased from 24 to 45 RPM, which 
increases the shear rate and the volumetric flow rate. This suggests that it is the combined shear-
volume-stent-time-frequency interaction that is responsible for the observed results. 
One of the consequences of shear-volume-stent-time interactions was observed when the 
surface area-to-volume ratio was decreased below the ISO Standard. No significant increase in 
platelet activation was observed under all experimental conditions (Figure 5-3). This suggests that if 
the surface area-to-volume ratio is low, below the ISO range, then the threshold for platelet activation 
is high, since high shear rate of 1510 s-1 did not produce significant activation. However, for 
sufficient surface area-to-volume ratio, the threshold for platelet activation is low. Therefore, when a 
material is included in vitro studies, it is important to maintain an appropriate surface area-to-volume 
ratio in order to ensure that results are not misinterpreted. For that reason, sample volume, as it relates 
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to surface area-to-volume ratio, is an important parameter in this model. Thus, this study has 
demonstrated the importance of sample volume in platelet activation, in the presence of a model 
stents, not only for hemodynamic conditions but, for sufficient surface area-to-volume ratio as per the 
ISO 10993 Standard. This effect could not be predicted using the existing shear rate equation 
developed by Gardner [354]. It is worth noting that under all experimental conditions, there was no 
condition that had any significant effect on P-selectin expression. This seems to agree with previous 
suggestions that P-selectin is more time-dependent than shear dependent [423]. In vivo P-selectin 
tracking in baboons showed a half-life of 5 minutes and remained relatively unchanged beyond 20 
minutes [424]. In general, the results suggest that sample volume has an effect in the Chandler loop 
model and are in agreement with the theoretical predictions. 
5.4.3 Leukocyte activation 
Leukocyte activation was also investigated in this study. The tissue factor results showed 
great variability, which is a recognized phenomenon [137, 406, 425]. Generally the monocyte 
subpopulation expressing TF decreased at high shear rate, for both samples with and without stents. 
The presence of model stents significantly increased the monocyte subpopulation expressing TF 
under shear conditions. Material-dependent TF expression has previously been shown [170]. The 
observed decrease in monocytes expressing TF with increasing shear seems to agree with previous 
studies in whole blood [418] as well as endothelial cell type [426]. Interestingly, studies on 
endothelial cell type have shown TF expression at about 400s-1 peaked at 2hrs, followed by a decrease 
[427]. Although this was a different cell type, it suggests that TF peak for our experiment at high 
shear could have occurred before the 2hr end point, resulting in observed down-regulation. 
The mechanism of TF down-regulation is not clear at this point but there has been evidence 
of time-dependent TF internalization on fibroblasts in the presence of FVIIa, peaking at 60 minutes 
[138]. If monocytes follow the same mechanism, this suggests mechanical stimulus may directly or 
indirectly mediate other mechanisms that induced TF down-regulation. This may include shear-
dependent leukocyte reduced sensitivity to shear through internalization of formyl peptide receptor 
(FPR) and retraction of pseudopods [94, 166]. More so, TF has been shown to be upregulated by FPR 
ligand, formyl-methionyl-leucyl-phenylalanine (fMLP) [140]. In addition, monocytes form 
microparticles upon stimulation, which express TF. Although leukocyte microparticles were not 
characterized in this study, it is possible that the release of TF bearing microparticles may also 
provide partial explanation for TF down-regulation on leukocytes under shear. Since TF expression 
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and activity are sensitive to the type [129] and level [249] of flow shear, further studies would be 
necessary to elucidate the interaction of shear, volume and material influence on TF expression. 
Similar to TF expression, Mac-1 expression on monocytes and PMNs showed shear-
dependent down-regulation in the absence of stents. However, in the presence of stents, Mac-1 on 
monocytes showed upregulation, which seemed to correspond with PMP formation, while PMNs 
showed down-regulation. This was also reflected on the difference in surface-area-to-volume ratios. 
The results suggest that in stent-shear interactions, Mac-1 expression on monocytes was sensitive to 
the level of platelet activation while PMNs were sensitive to shear. This agrees with previous studies, 
although using a different model and biomaterial, that suggested that platelet activation in the bulk 
did not necessarily translate into leukocyte activation [178]. The down-regulation in leukocyte Mac-1 
expression at higher shear rates has been observed previously in different in vitro models [166, 168, 
428]. This may be partly due to the shear-induced proteolytic cleavage of the β2 integrin, CD18 [429] 
or inactivation of αMβ2 [166], resulting in internalization of formyl peptide receptor and retraction of 
pseudopods [94, 166] and reduced leukocyte sensitivity to shear stress. However, further studies are 
necessary to quantify the trigger point for Mac-1 down-regulation in our whole blood model. The 
results of isolated neutrophils in Hank’s buffered salt solution in the cone and plate model suggested 
the trigger point at about 0.75 dyn/cm2 [166]. In general, volume did not appear to have a significant 
effect on Mac-1 expression except in terms of surface area-to-volume ration under high shear.  
 An important aspect of Mac-1 expression is the relationship to function under different 
conditions. Although Mac-1 expression is an important leukocyte activation marker, there is evidence 
that receptor affinity may be more important than density [430]. There is also evidence that Mac-1 
affinity to its ligands can be increased by extracellular adenosine 5’-diphosphate (ADP), which 
increases affinity to fibrinogen and FX through up-regulation of cytosolic Ca2+ concentration without 
increasing Mac-1 expression [194]. Since activated platelets produce ADP, it follows that leukocyte 
adhesion will be increased in the presence of platelets. This supports the previously reported findings 
that leukocyte adhesion seems to depend on the presence of platelets [178]. Much of the research has 
examined material-induced Mac-1 expression but not affinity. Therefore, in addition to the effect of 
specific biomaterial characteristics on Mac-1 expression, the question of whether there is material-
mediated affinity under specific flow conditions is a valid question that needs further investigation. 
The result of leukocyte constitutively expressed receptor, C3aR, did not show any significant 
sensitivity to sample volume in the absence of model stents. In the presence of model stents, C3aR 
expression was slightly upregulated mostly on monocytes. The results of the effect of surface area-to-
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volume ratio seemed to suggest a complex shear-dependent interaction. Shear had a down regulating 
effect on C3aR expression on leukocytes, which was significant for the 4 ml sample corresponding to 
significant Mac-1 upregulation. Since complement activation was expected to produce C3a in these 
experiments, the results seem to agree with previous findings that the presence of C3a causes C3aR 
internalization [407]. It is interesting to note that although previously studies have shown that 
monocytes and PMNs express fewer C3aR than C5aR and monocytes express 2-fold more C3aR than 
PMNs [108], this difference is not manifested in the above results. This may be explained by the fact 
that monocyte response to C3a has been found to be quite diverse, suggesting a subpopulation not 
responding to C3a [107]. In this study, this was also observed. Since these receptors seem to have 
distinct roles in other conditions [431], their roles reach further than merely recruitment and 
activation. There is need to investigate their signaling role simultaneously in blood-biomaterial 
studies. Further investigations are necessary to elucidate relative expression of C3aR to C5aR under 
different conditions.  
TLR-4 expression on leukocytes seemed to be influenced by sample volume. Shear increase 
seemed to down-regulate TLR-4 expression. The presence of stents resulted in increased TLR-4 
expression, as did the high surface area-to-volume ratio. On the contrary, titanium particles in mice 
have been found to down regulate TLR-4 expression [408]. The regulation of TLR-4 under the 
current experimental condition is not clear. As previously discussed, conclusions cannot be drawn on 
TLR-4 expression from this study. However, since TLR-4 may play an important role in material 
recognition [432], further studies are necessary to elucidate its regulation mechanism in the presence 
of biomaterials. 
5.4.4 Platelet-leukocyte aggregation 
Platelet-leukocyte aggregation results showed preferential aggregation of platelets with 
monocytes compared with PMNs (minimum 3-fold) under all experimental conditions, which has 
been previously observed [178, 424]. A general material and shear-dependent platelet-leukocyte 
aggregation was also observed. Samples with higher surface area-to-volume ratio, which seemed to 
correspond with PMP formation, CD11b and TLR4 expression. While platelet-leukocyte aggregation 
generally exhibited shear-dependent decrease, platelet-monocyte aggregation was increased for 
samples corresponding to Mac-1 upregulation and increased PMP formation at high shear. The 
preferential platelet aggregation with monocytes, which has been observed in vivo [424], may partly 
explain the observed low sensitivity of platelet-monocyte aggregation to shear. Extracellular ADP 
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from activated platelets may contribute to this shear-resistant aggregation since ADP induces integrin 
αIIbβ3 (GPIIb/IIIa) expression as well increases Mac-1 affinity to fibrinogen without increasing Mac-1 
expression [194]. Moreover, there is evidence that receptor affinity may be more important than 
density [430]. Yet another contributing factor to the stability of the platelet-monocyte aggregate may 
be the role played by FXIIa, which can directly interact with activated platelets and fibrin(ogen) to 
stabilize the network [184]. Hence, factors emanating from increased platelet activation may result in 
increased platelet-monocyte aggregation. 
On the other hand, the general decrease in platelet-leukocyte aggregation could be due to 
shear inactivation of Mac-1. The decrease could also be due to the previously reported shear-induced 
increase in coagulation time; partly linked to change in kinetics at higher shear rate [354] or the 
dissociation of the platelet P-selectin and leukocyte PSGL-1 bond, which is an important platelet-
leukocyte bond under flow [97, 99]. Moreover, P-selectin did not show significant increase in the 
experiments. However, there is also the possibility of the in vitro model “closed-loop effect”. The in-
circuit leukocytes activation in cardiopulmonary bypass is a known phenomenon [433], which may 
lead to leukocyte exhaustion leading to subsequent clearance by phagocytosis. Indeed, a noticeable 
C5b-9 increase was previously observed after 1 hour in a loop model at a shear rate of 530 s-1 [349]. 
The question of whether the dose and time-dependent increase in C5b-9 on platelets [434] does not 
come into effect at the higher shear rate for the length of time in our experiments also arises. An 
interesting twist to the presence of C5b-9 on platelets is that it has been shown to cause formation of 
microparticles, which contain the complement C5b-9 pores [78, 79]. More interestingly, complement 
C5b-9-induced increase in PMP formation is accompanied by increased expression of GPIIb/IIIa, 
which is incompetent in binding fibrinogen [435]. This would suggest the possibility of observing 
increased PMP and GPIIb/IIIa but without necessarily a corresponding increase in platelet-leukocyte 
aggregation. While this phenomenon was not investigated in this study, it is possible that it may 
partly explain the observed low platelet-leukocyte aggregation even though PMP formation was high, 
especially for 4 ml + 35 mm samples at 45 RPM (1440 s-1). Therefore, the disaggregation from shear 
may not be the only explanation for the observed results. Further studies are necessary to elucidate the 
dominant mechanism and the critical influencing factors. 
Another interesting question that arises from the results of complement-induced PMP 
formation is whether PMP formation is only for hemostatic and pro/anti-inflammatory response as 
generally thought. The fact that C5b-9 is carried on the microparticles raises the curious question of 
platelet survival. The issue of cell survival has been discussed [403], but PMP formation as a form of 
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platelet survival is not usually discussed. This may be a subject that warrants further investigation as 
it may influence their function. Combining the two observations, it is possible that platelets PMP 
formation takes two paths – inflammatory path, which has competent GIIb/IIIa and the survival path, 
which has incompetent GPIIb/IIIa. It makes sense that the survival path may not bind fibrinogen 
because by so doing it will defeat the purpose as it will result in amplified platelet degranulation. If 
that is the case then the use of PMP formation as a biomarker [436] without accompanying 
information on functional capacity, may in some case be only accurate for platelet activation, but not 
for prediction of thrombogenicity. This is particularly important because 80% of circulating PMPs 
have been shown to lack procoagulant activity as assessed by annexin V binding [437]. Moreover 
procoagulant activity is dependent on the agonist [437] and PMP formation seems to be dependent on 
the type of platelet subsets [438]. It remains unclear whether there is any difference in 
phosphatidylserine expression, i.e. functional/procoagulant capacity, between suggested inflammatory 
path activated degranulation (IPAD) and survival path activated degranulation (SPAD) PMPs. 
Because PMPs are responsible for a variety of functions, including contact system-dependent 
coagulation [162], it would be informative to establish this fact with different biomaterials. 
Therefore, several mechanisms may be responsible for the observed shear and material-
dependent platelet-leukocyte aggregation. In general there was no volume effect except at high shear, 
which may be partly due to the complex stent-shear interactions. This suggests a complex cell 
activation and aggregation function, which may be generally expressed as, Ca = f (τ ,σ ,ξ, t) , where 
τ is wall shear stress, σ is surface area-to-volume ratio, ξ is collision efficiency/frequency and t is 
exposure time. This proposed function is an expansion of the generally accepted platelet activation 
function, which is shear and time-dependent. Based on experimental results in this study and previous 
studies, the effect of shear stress on platelet and leukocyte activation and aggregation can be 
illustrated by the schematic in Figure 5-12. The general broad implication of the schematic is that 
shear-induced TF-dependent thrombogenicity occurs at low shear while PMP-dependent 
thrombogenicity occurs at high shear as previously described. Furthermore, from a systems approach 
point of view, the results illustrate the importance of a holistic approach to blood-biomaterial 
interaction studies as it assists in understanding the effects of a stimulus on different activation 
pathways, and hence provide better guidance for appropriate intervention methods. Hence, from an 
intervention perspective, the result suggest that while a balanced approach is always necessary, at low 
shear, emphasis may be better placed in reducing leukocyte activation, which could partly be 
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achieved through complement inhibition. Further investigation into the effect of complement 
inhibition on cell activation at nominal shear is necessary. 
 
 
Figure 5-12. Schematic of shear stress sensitivity of platelet and leukocyte activation and 
platelet-leukocyte aggregation 
 
5.4.5 Surface adhesion 
Cell surface adhesion was reduced in shear samples compared to agitated samples, which is 
in agreement with previous findings of shear-dependent leukocyte adhesion on different surfaces [19, 
332, 334]. The threshold for isolated adherent leukocyte diminished sensitivity to shear has 
previously been shown to be above 7 dyn/cm2 in a rotating disc model [19] and flow chamber [419]. 
The threshold of leukocyte sensitivity to shear stress was not investigated in this study. However, 
examination of the data suggests that it may be above time-averaged wall shear stress of 13 dyn/cm2 
(360 s-1), but depends on the experimental conditions. The level of shear stress and type (intermittent 
vs continuous) and the exposure time will affect the threshold of shear sensitivity. Shear-dependent 
adhesion has been linked to integrin molecules, αMβ2 [166] and α4β1 [439]. Thus, the observed 
reduction in leukocyte adhesion at higher shear may be due to the cleavage/inactivation of the Mac-1 
integrin receptors, as discussed previously, since they also act as surface adhesion molecules. 
However, shear stress does not affect cell adhesion only through its influence on cell receptors. It also 
affects protein adsorption [440, 441], which subsequently would affect cell adhesion. Of particular 
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interest to this study is the previously reported loss of fibrinogen which was observed in a curved tube 
model due to secondary flow effects [441]. Although the loss of proteins was not specifically 
investigated in this study, it may also play a role. In general, the combined effect of shear on protein 
adsorption and cell cytoskeleton and subsequent receptor expression could partly explain previous 
observations that when leukocyte shear sensitivity is lost at high shear stress, material-dependent 
adhesion may also be lost [19].  
The shapes of adherent leukocytes showed some variations. These differences could not be 
linked to specific parameters in this study. It was also not possible to quantify adhesion in this study 
but in general the observed cell adhesion is consistent with other previous studies. A detailed 
characterization of surface adhesion is necessary in order to elucidate the effect of volume-stent-shear 
on cell adhesion. 
A summary of overall observations on the effect of experimental conditions on platelet and 
leukocyte activation and aggregation is presented on Table 5-12. The summarized observations are 
for the maximum observed effect, except where it was necessary to specify the sample volume. The 
summary is for samples with similar surface area-to-volume ratio only. The general observation was 
that all the three variables, shear stress, sample volume and model stent had varying effects on 
platelet and leukocyte activation and aggregation. Sample volume, which is of particular interest in 
this study, had direct effects as well as indirect effects upon interaction with the other variables. It is 
important to note that the lack of significant difference in some of the parameters in no way 
diminishes the importance of the results. The fact that sample volume without stent did not show 
significant effect is important because it suggests that in the absence of stents, it may not be necessary 
to use large volumes of blood.  
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Table 5-12. Summary of the effects of experimental conditions on platelets and leukocytes 
 No stent Similar surface area-to-volume ratio 
 Volume Shear Volume 
(low shear) 
Volume 
(high shear) 
Stent 
(low shear) 
Shear 
PMP formation 
(%) 
⎯ ⎯ ⇑ ⇑ ⇑ ⇑ 
Monocytes 
expressing TF (%) 
⎯ ↓ ⎯ ⎯ ⇑ ↓ 
Mac-1 expression 
on monocytes (%) 
↓ ↓ ⎯ ↑ ⇑ ↓↑ 
Mac-1 expression 
on PMNs (%) 
↓ ↓ ⎯ ⎯ ⇑ ⇓ 
Platelet-monocyte 
aggregates 
↓ ↓ ⎯ ⇑ ⇑ ↓ 
Platelet-PMN 
aggregates 
↓ ↓ ⎯ ⇑ ⇑ ⇓ 
C3aR expression on 
monocytes (%) 
⎯ ↓ ↑ ↓ ↑ ⇓ 
C3aR expression on 
PMN (%) 
⎯ ↓ ↑ ⎯ ↓↑ ↓ 
⎯ No effect or barely discernible effect 
↓, ↑ Non-significant decrease or increase, respectively 
⇓, ⇑ Significant decrease or increase, respectively 
↓↑ 2 ml decrease and 4 ml increase 
NB. The effect of the presence of stent is depicted only when the shear effect is minimum (low 
shear). At high shear, the combined effect is included under volume (high shear).  
 
5.5 Conclusions 
In this chapter, the effect of blood sample volume under shear, with and without model stents, 
was investigated. The results are interpreted using an improved time-averaged wall shear stress for 
   182 
the Chandler loop model. While the effect of sample volume without stents was minimum as 
analytically predicted in Chapter 3, there was a volume effect in the presence of model stents. The 
fact that data interpretation may vary depending on the blood sample volume, even with similar 
surface area-to-volume ratio has significant implications when screening materials for blood 
compatibility. Therefore, the results confirm the importance of selecting appropriate model 
parameters to reflect a reasonable simulation of in vivo parameters to reduce misinterpretation of in 
vitro results due to experimental parameters. 
The effect of sample volume in the presence of model stents is reflected in surface-area-to-
volume ratio, in shear rate and in differences in the fraction time of exposure per cycle. Analysis 
suggests that the interaction of all the variables in this model is much more complex than previously 
thought. The combined volume-stent-time-shear-frequency interactions, as a result of changes in 
volume, can have a significant effect on in vitro model results. Hence, the results of this chapter 
overall support the hypothesis that sample volume plays an important role in influencing the results of 
this in vitro model. This in turn would have implications for the investigation of biomaterials and 
comparison of results. Therefore, sample volume selection for this model needs to be considered 
carefully.  
Besides highlighting the complex interactions, this work raises a number of pertinent 
questions with regards to cell activation and aggregation mechanisms. The importance of Mac-1 
affinity vs expression level, the trigger level for Mac-1 and TF cleavage/internalization, the issue of 
platelet survival path under high shear stress (>50 dyn/cm2), the effect of material on constitutively 
expressed receptors in thrombosis and the possibility of reducing leukocyte activation through 
complement inhibition. Further experimental studies and simulation would be necessary to elucidate 
the mechanism of shear-volume-stent-time interaction effect on flow characteristics and blood 
activation, at different experimental conditions and for a wider range of physiological and pathologic 
shear stress. 
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Chapter 6 
Effect of Complement Inhibition on Platelet and Leukocyte 
Response to Shear and Biomaterials 
6.1 Introduction 
In Chapter 2, the important role that complement proteins play in health as well as in a 
variety of disease conditions was described. More importantly, the central role that complement plays 
through its elaborate intrinsic pathways and the cross-talk interactions with extrinsic pathways from 
platelets and the coagulation system was highlighted. These interactions present additional challenges 
for blood-biomaterial interaction investigators because, besides pathologic conditions, complement 
also plays an important role in blood-biomaterial interactions [7, 22, 82, 182]. Complement role in 
this regard has been demonstrated both in vitro [85, 442] as well as in vivo in medical devices such as 
hemodialysis [443], extracorporeal circuits [442] and coronary stents [88]. These findings place 
complement at the center of blood-biomaterial interaction investigations. 
In vivo, complement anaphylatoxins C5a and C3a have common as well as distinct 
physiological and inflammatory effects. Their inflammatory effect on leukocytes can be detrimental 
as activated leukocytes, particularly PMNs, generate reactive oxygen species (ROS), which can cause 
tissue damaging oxidative stress. Complement fragment C5a, the most potent in foreign body 
response, has been correlated with implantation of drug-eluting stents, while C3a has correlated with 
development of in-stent thrombosis [88]. However, both have been correlated with late lumen loss in 
drug-eluting stents [88], which incidentally delays reendothelialization [43, 444] and can leave stent 
struts uncovered for up to 2 years [444]. The exposed struts result in chronic inflammation, which 
consequently causes late in-stent thrombosis and adverse patient outcomes, raising questions about 
their cost-effectiveness [445] and long-term patient outcome [446]. These developments, which are 
evidently linked to complement activation, show the central role that complement plays in influencing 
inflammatory response and thrombosis under a variety of conditions. For that reason, complement has 
lately been a subject of intense investigations with the aim of developing therapeutic interventions. 
We previously showed indirectly, through investigation of material-dependent complement 
C3aR expression, that complement was activated in our in vitro model [447]. This was also shown in 
Chapter 5. Furthermore, in Chapter 5, the effect of shear and the presence of model stents on platelet 
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and leukocyte activation and surface adhesion were demonstrated. Activated platelets express P-
selectin, which binds C3b of the alternative pathway [448], as well as the global C1q receptor 
(gC1qR), which binds C1q of the classical pathway to activate platelets and/or complement [449]. 
Consequently, platelet activation has been associated with increased complement C3a and C5a 
fragments [74]. The capacity of platelets to activate either the classical or alternative pathway 
depends on the stimulant, with shear preferentially activating the classical pathway [74]. Regarding 
leukocytes, they constitutively express complement receptors C3aR and C5aR [108]. Therefore, any 
initial complement activation produces anaphylatoxins that induce expression of CD11b and TF in 
leukocytes [141]. TF expression initiates the TF-dependent coagulation cascade, which produces 
thrombin. Thrombin, which has a variety of physiological functions, in turn activates complement 
[450] and platelets, thus creating feedback loops. Certainly, blood activation involves complex cross-
talk and co-stimulation between the various systems, with platelet, complement and leukocytes 
playing an important role in material-induced thrombogenicity [317]. Since complement plays such 
an important part in the initiating and amplification of the inflammatory response, it would be 
informative to understand the level of its contribution under specific experimental conditions. We 
hypothesized that complement inhibition should significantly reduce platelet and leukocyte activation 
under simulated physiological conditions.  
The divergent roles that the complement system plays in disease conditions as well as 
material-induced thrombogenicity, has made complement proteins and receptors targets for possible 
therapeutic interventions. A number of inhibitors and blockers have been investigated experimentally 
and clinically [70, 451]. The number of proteins involved in complement activation and regulation 
pathways means that there are enumerable points at which complement inhibition or modulation can 
be achieved [451]. Hence, efforts have been placed on specific as well as broad spectrum inhibitors. 
Some of the specific targets include the C5aR-C5a complex [452]. Inhibition of specific complement 
pathways (classical and alternative) has also been targeted with the soluble complement receptor 1 
(sCR1) inhibitor, which has been shown to reduce leukocyte activation and adhesion in a 
cardiopulmonary circuit model [453]. Inhibitors have also targeted the central protein C3 from 
cleavage, which has seen the development of inhibitors such as compstatin [454]. Compstatin has 
been shown to inhibit complement activation and cell surface adhesion in an extracorporeal model 
[455] and has been advocated for hemodialysis because of its broad implications on complement 
activation [456]. Another inhibitor with broad anti-inflammatory effects that has been used in dialysis 
is nafamostat mesilate (FUT-175) [457], which has found use in other clinical conditions. Although 
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some of the therapeutic intervention methods have been proven to function in vivo, there is still no 
consensus on one method of inhibition, especially in blood-biomaterial interactions. 
Nafamostat mesilate (FUT-175) or futhan is of particular interest in blood-biomaterial 
interactions because it is a general serine protease inhibitor and an inhibitor of the complement 
classical and alternative pathways [458]. Since FUT-175 has broad specificity, it has been used in 
other clinical conditions, such as an anticoagulant option in cardiopulmonary bypass surgery [459]. 
Serine proteases make one third of known proteases and they form an intricate activation and 
inhibition network between the cascade systems [460]. Hence, their inhibition can have great effect 
on coagulation and thrombosis. FUT-175 is appropriate for complement inhibition since many of the 
complement activation interactions are the result of serine protease activity. Its specific inhibition 
effects on C3a, C4a and C5a, which are all mediators of inflammation, have been previously 
demonstrated [458]. While futhan has a broad spectrum inhibition effect on complement and 
coagulation systems, both in vitro and in vivo, to our knowledge there is generally limited 
investigations on its effect in whole blood in the presence of biomaterials using the Chandler loop 
circulation model with metallic stents, especially with the new fluid dynamics characterization. 
Therefore, the purpose of this research was to investigate the effect of complement inhibition by 
FUT-175 on platelet and leukocyte activation and aggregation in the presence of model stents, under 
flow simulating nominal physiological shear conditions. It was hypothesized that under flow and stent 
conditions, complement inhibition reduces leukocyte and platelet activation and surface adhesion. 
The overall objective was to understand its relevance for application in material-induced 
thrombogenicity, with broad applications for stent implantation. 
6.2 Materials and methods 
6.2.1 Flow model 
The flow model was made from a rotor and turntable as previously described in Chapter 3. 
The turntable for mounting blood sample tube loops was fixed in a vertical position. The sample tube 
loops were medical grade Silastic tubes (VWR, PA, USA) with 4.78 mm internal diameter. The tubes 
were cut into 371 mm long sections and spliced into loops with internal loop radius of about 59 mm. 
The wall shear stress for this model is as previously described with the improved time-averaged wall 
shear stress [29].  
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6.2.2 Model stents 
Model stents were made from Ti-6Al-4V 0.005” diameter wire (Fort Wayne Metals, Fort 
Wayne, IN, USA) as described in Chapter 4. Detailed specifications for the model stents are as 
described in Table 4-2. The stents were cut into sections of 20 mm lengths, giving surface area of 
1.46 cm2. The stents were first ultrasonically cleaned in 30% nitric acid to reduce the endotoxin (LPS) 
contamination, followed by rinsing with distilled water. The stents were then ultrasonically cleaned in 
70% alcohol solution for about 10 minutes, and then rinsed at least twice in (PBS; 50 mM sodium 
phosphate plus 100 mM sodium chloride, pH 7.4). The prepared stents were stored in PBS at 4°C and 
used within 4 hours. 
6.2.3 Antibodies and reagents 
Fluorescein isothiocyanate conjugated mouse monoclonal antibody against human 
glycoprotein GPIIb/IIIa (CD61-FITC), R-phycoerythrin monoclonal antibody against P-selectin 
(CD62-PE), Fluorescein isothiocyanate conjugated mouse monoclonal antibody against Mac-1 
(CD11b-FITC), R-phycoerythrin monoclonal antibody against tissue factor (CD142-PE), anti-C3a 
receptor (PE hC3aRZ8), R-phycoerythrin-cytochrome 5 conjugated monoclonal antibody against 
PAN leukocytes (CD45-PE-Cy5) and FUT-175 (Futhan, chemical name: 6-amidino-2-naphthyl p-
guanidinobenzoate dimethanesulfonate) were purchased from BD Biosciences (San Diego, CA, 
USA). Anti-human Toll-Like receptor 4 (CD284-PE) was purchased from eBioscience (San Diego, 
CA, USA). FACS lysing solution was purchased from BD Biosciences (San Diego, CA, USA). 
Phosphate-buffered saline (PBS) was purchased from Fisher Scientific Inc (Ottawa, ON, Canada). 
Lipopolysaccharide (Escherichia coli serotype 0111:B4) (LPS), 50% glutaraldehyde solution, and 
paraformaldehyde were purchased from Sigma-Aldrich Co (Oakville, ON, Canada). Hepes Tyrode 
Buffer (HTB) solution PH 7.4 was made in the laboratory with a final concentration of 137mM NaCl, 
2.7mM KCl, 5mM MgCl2, 3.5mM HEPES, 1g/L Glucose, and 2g/L BSA. 
6.2.4 Blood sample collection 
This study received ethics clearance from the University of Waterloo Research Ethics Office. 
Peripheral venous blood samples were drawn with formal consent from healthy volunteers, of age 
range 20 to 50 years, who indicated that they had not taken any medication in the last 72 hours. There 
was no restriction placed on the participants’ physical activity, the type of diet and eating time. 
Participants were however advised to drink lots of water ahead of the blood draw. Samples were 
   187 
drawn with a 21 Gauge Vacutainer safety-lok blood collection set and syringe (BD Biosciences, San 
Diego, CA, USA) by a qualified phlebotomist. Blood was immediately transferred into 10 ml conical 
tubes containing heparin (5U heparin/ml). Blood samples were kept in an insulated container and 
used in the blood activation experiments within 30 minutes of collection. 
6.2.5 Platelet and leukocyte activation and platelet-leukocyte aggregation 
To assess complement inhibition effects, collected blood samples were first mixed with FUT-
175 (Futhan) at 10 µl/ml. Futhan is a synthetic serine protease inhibitor with a half-life of 
approximately 8 minutes [458]. 2 ml blood samples were then transferred into silicone tube loops, 
which had been prepared by rinsing with PBS, as illustrated on Figure 6-1. To assess the effects of 
complement inhibition in the presence of biomaterials, 20 mm model stents were included with the 
blood samples. For this study, only setups composed of 2 ml blood samples with and without 20 mm 
stents were used, which gave surface area-to-volume ratios of 0.71 cm2/ml. To assess activation 
effects under shear, half of the experimental sample loops were mounted on the flow model turntable 
set to rotate at either 24 RPM and the other half were placed on a mini-shaker (VWR, PA, USA) set 
at 200 RPM for the semi-static condition. The equivalent wall shear stresses for the 24 RPM rotation 
is 13 dyn/cm2, which changes very little in the presence of a stent, as was shown in Chapter 5, Table 
5-2. This shear stress was chosen to simulate nominal physiological shear stress, which is 
approximately 15 dyn/cm2 [250]. For all the experiments, control samples were static and included 
only blood (negative control/resting sample) and blood with lipopolysaccharide (LPS) (1 µg/mL) as a 
positive control. All samples were incubated at 37°C for 2 hours.  
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Figure 6-1. Schematic of experimental conditions 
 
6.2.6 Immunolabelling and flow cytometry analysis 
At the end of the 2-hour incubation, small blood samples were diluted in test tubes and 
incubated with respective antibodies for 30 minutes for receptor-antibody binding. To assess platelet 
activation and platelet microparticle (PMPs) formation, 5 µL blood samples (about 1.25-2x106 
platelets/sample) were diluted with 50 µL HTB in test tubes and incubated for 30 minutes at 4°C with 
fluorescently-labeled antibodies against GPIIb/IIIa (CD61-FITC) and P-selectin (CD62PE). 
Following incubation, samples were further diluted with 200 µL HTB, fixed with 200 µL 
paraformaldehyde (1% final concentration) and stored at 4°C before flow cytometry analysis. 
To assess leukocyte activation and platelet-leukocyte aggregation, 30µL of blood samples 
(about 150-300x103 leukocytes/sample) were diluted with 50 µL HTB in test tubes and incubated for 
30 minutes at 4°C with appropriate antibodies. Leukocytes were identified by PAN leukocyte marker 
(CD45 PE-Cy5.5). Leukocyte activation was identified by antibodies against Mac-1 (CD11b-FITC) 
and tissue factor (CD142-PE) on leukocytes. Leukocyte activation was additionally identified with 
antibodies against C3a receptor (anti-C3aR) and TLR4 (CD284-PE). Platelet-leukocyte aggregation 
was identified by antibodies against GPIIb/IIIa (CD61-FITC) on leukocytes. Following 30 minutes 
incubation, 700 µL of FACS Lyse solution was added to lyse red blood cells. Aliquots were 
concentrated by centrifuging at 1200g for 6 minutes and discarding supernatant. Resuspended pellets 
were washed and then diluted with 150 µL HTB and fixed with 150 µL 2% paraformaldehyde. All 
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samples were stored at 4°C and analyzed on a BD FACS Calibur flow cytometer with CellQuest Pro 
software (BD Diagnostics, San Diego, CA, USA), within 5 days. 
6.2.7 Scanning electron microscopy 
After the experiments, stent samples were prepared for protein and cell surface adhesion 
analysis with a scanning electron microscope on a later date. Samples were first rinsed with 0.2M 
sodium phosphate buffer, pH 7.2 followed by fixing in 2.5% glutaraldehyde and storage at 4°C. Fixed 
samples were then prepared for SEM analysis. Briefly, stent samples were first immersed and washed 
in 0.2M sodium phosphate buffer, pH 7.2. This was followed by dehydration through a series of steps 
in 10%, 25%, 50%, 70%, 90% and 100% ethanol. Samples were dried overnight and then coated with 
a thin layer of gold (8-10nm) in a vacuum chamber (Denton Vacuum, Desk II, USA) for 120sec, set 
at 50millitorr and 15 mA. Analysis was done with LEO 1530 Gemini (Zeiss, USA) set at 10kV in 
secondary electron mode (SE2). No specific marking was used to distinguish between the inner and 
outer stent wall, as it relates to the loop curvature. 
6.2.8 Statistical analysis 
Statistical analysis was done with the IBM SPSS Statistics version 20. Data were analyzed 
using analysis of variance (2-way ANOVA). For post-hoc analysis, Least Significant Difference 
(LSD) method was used to determine significant difference between groups. No specific analysis was 
performed to account for donor variability. Overall effects are not reported due to the complexity of 
the data; in some cases there are fewer than three groups, e.g. volume and stent samples. All data are 
presented as mean ± standard deviation of a minimum of 3 separate experiments. For all analysis, 
p<0.05 was used to indicate significant difference. 
6.3 Results 
6.3.1 Effect of complement inhibition on platelet response to shear and model stents 
After a 2-hour incubation, activated platelets were characterized by formation of platelet 
microparticles (PMPs), expression of receptor GPIIb/IIIa (CD61) on platelets and PMPs, and P-
selectin (CD62) expression on platelets. Since both activated platelets and PMPs express CD61, 
circulating PMPs were distinguished from platelets and platelet aggregates based on size (flow 
cytometry forward light scatter). P-selectin expression was determined based on fluorescence levels. 
Figure 6-2 depicts typical flow cytometry data analysis dot plots for platelet activation, as 
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characterized by circulating PMPs, with and without complement inhibition. PMPs are expressed as a 
percentage of total events (platelets + PMPs) or number of particles per 100 platelets and 
microparticles. As can be observed, PMP formation is reduced in the negative control/resting sample 
in the presence of complement inhibitor. 
 
 
Figure 6-2. Characteristic flow cytometry analysis dot plots for platelets forward (FSC-H) 
versus side (SSC-H) light scatter events. Negative control (rest): (a) without FUT-175, (b) with 
FUT-175. All events are positive for CD61, hence platelet microparticles are distinguished based on 
size (forward light scatter). Events in region R3 represent aggregates and are not included in PMP 
percentage determination. 
 
The results of platelet activation as illustrated by PMP formation are presented on Figure 6-3. 
The presence of stent under shear had a significant effect (p<0.001) on PMP formation when 
compared to shear alone. In general, complement inhibition reduced PMP formation under all 
experimental conditions. However, complement inhibition had a higher effect in reducing PMP 
formation on samples with stents compared to non-stent samples. The inhibition effect was significant 
in stent samples under shear (p<0.001).  
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Figure 6-3. Effect of complement inhibition on platelet microparticle formation. Percentage 
microparticles are based on size (forward scatter signal) and expressed relative to total events (platelet 
+ microparticles). Negative control:  6±1% and 4±1% (inhibitor). *: p<0.001. Comparison of agitated 
stent samples gives p=0.07. Results are mean ± SD, n=3 to 4. Ti64: Ti-6Al-4V stent.  
 
The effect of complement inhibition on platelet activation was also investigated by CD61 and 
P-selectin expression on platelets. In the absence of the inhibitor, the presence of a stent under shear 
had a significant effect on platelet consumption (p=0.05), Table 6-1. Consistent with PMP formation, 
the results of CD61 expression suggest complement inhibitor induced less platelet consumption 
compared to samples with no inhibitor. P-selectin on the other hand did not show sensitivity to 
complement inhibition. In general the results suggest that complement inhibition influenced CD61 
expression, but did not show any effect on one of the recognized platelet activation markers, P-
selectin. 
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Table 6-1. Effect of complement inhibition on CD61 and P-sel expression on platelets 
 CD61+ Platelets and PMPs P-sel platelets 
Experimental conditions Without 
FUT-175 
(259±67) 
With  
FUT-175 
(205±74) 
Without 
FUT-175 
(18±4) 
With  
FUT-175 
(12±5) 
2 ml Agitate 249±54 214±51 19±4 15±4 
24 RPM (380 s-1) 240±61 207±29 20±3 16±2 
Ti64 Agitate 222±46 210±48 19±3 17±5 
24 RPM (360 s-1) 163±56* # 194±22 19±4 17±1 
Negative control: CD61 and P-sel expressions are reported as arbitrary fluorescent units. 
*significantly different from corresponding shear without stent (p=0.05), #significantly different from 
corresponding control (p<0.001). Results are mean ± SD, n=3 to 4. n=2 for P-sel with inhibitor. 
 
6.3.2 Effect of complement inhibition on leukocyte response to shear and model 
stents 
To investigate the effect of complement inhibition on leukocytes, experiments were carried 
out with and without inhibitor, under semi-static and shear conditions. In addition to shear, activation 
was induced by the presence of model stents in some of the samples. Activated leukocytes were 
characterized by expression of CD11b (Mac-1) and TF. Constitutively expressed receptors, C3aR and 
TLR4, were also investigated. Typical flow cytometry data analysis plots for negative and positive 
controls, for CD11b expression on monocytes and PMNs, are depicted on Figure 6-4 and Figure 6-5, 
respectively. Only CD11b is presented to illustrate the difference with and without FUT-175. As 
illustrated, the geometric means for the samples with the inhibitor FUT-175 are lower than for 
samples without the inhibitor. 
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Figure 6-4. Characteristic flow cytometry events histogram plots for CD11b on monocytes.  (a) 
Negative control (rest) samples and (b) positive control (LPS) samples. Histograms are in arbitrary 
fluorescent intensity units. A higher relative decrease in fluorescent intensity is observed in negative 
control samples compared with positive control, in the presence of FUT-175. FL1-H = CD11b. 
 
 
Figure 6-5. Characteristic flow cytometry events histogram plots for CD11b on PMNs. (a) 
Negative control (rest) samples and (b) positive control (LPS) samples. Histograms are in arbitrary 
fluorescent intensity units. A decrease in the fluorescent intensity is observed in the presence of FUT-
175. FL1-H = CD11b. FL1-H = CD11b. 
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As shown on Figure 6-6, the percentage of monocytes expressing TF, which corresponds to 
TF expression on monocytes, was dependent on shear and the presence of a stent in the absence of 
FUT-175. Although in the presence of FUT-175 the results seem to show inhibition of TF expression, 
conclusions cannot be drawn because of the limited number of samples. 
 
 
Figure 6-6. Effect of complement inhibition on percentage of monocytes expressing TF. Negative 
control: 10±3 and 8±5 (inhibitor). Results are mean ± SD, n=4 except for samples with inhibitor (n=1 
to 2). 
 
The effect of FUT-175 on Mac-1 expression on leukocytes in the presence of a model stent is 
depicted in a typical flow cytometry data analysis plot, Figure 6-7. The reduction in fluorescent 
intensity or geometric mean in samples with futhan illustrates the effect of complement inhibition on 
Mac-1 expression. The average results of Mac-1 expression on monocytes and PMNs are as depicted 
on Figure 6-8 and Figure 6-9, respectively. In the absence of model stents, FUT-175 down-regulated 
Mac-1 expression on monocytes, which, while non-significant on agitated samples (p=0.06), was 
significant for samples at shear rate of 380 s-1 (p<0.001). Parallel to this observation, in the presence 
of model stents, FUT-175 did not induce a significant down regulation of Mac-1 on agitated stent 
samples but induced a significant down regulation (p<0.001) in stent samples under shear (360 s-1). 
Since FUT-175 did not significantly reduce Mac-1 expression in agitated stent samples, consequently, 
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a significant (p<0.01) Mac-1 upregulation on monocytes was still observed under inhibition; when 
agitated stent samples with the inhibitor were compared to agitated samples without inhibitor.  
 
 
Figure 6-7. Representative flow cytometry histogram plots showing FUT-175 effect on Mac-1 
expression in stent samples at 360 s-1. Histograms are in arbitrary fluorescent intensity units. A 
decrease in the fluorescent intensity is observed in the presence of FUT-175. FL1-H = CD11b. 
 
 
Figure 6-8. Effect of complement inhibition on Mac-1 expression on monocytes. Percentages are 
expressed relative to positive control (LPS). Negative control: 20±1% and 16±10% (inhibitor). *: 
p<0.001. **Significantly different from negative control with no inhibitor (p<0.01), #significantly 
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different from corresponding agitated sample with inhibitor (p<0.01). Results are mean ± SD, n=3 to 
4. 
 
Similar to what was observed with monocyte samples, FUT-175 did not induce a significant 
Mac-1 down regulation on agitated PMN samples (p=0.09) while it induced a significant (p<0.01) 
down regulation on samples at 380 s-1, Figure 6-9. Likewise, in the presence of model stents, FUT-
175 did not induce significant Mac-1 down regulation on agitated samples while a significant 
(p<0.001) Mac-1 down regulation was observed on stent sample at shear rate 360 s-1. Mac-1 
expression was significantly (p<0.02) upregulated when agitated stent samples with inhibitor were 
compared with corresponding agitated samples. On the whole, FUT-175 down regulated Mac-1 
expression on leukocytes under all experimental conditions, although not always at a level that 
reached statistical significance of 0.05. The inhibition effect was not significant for samples with 
stents only but was significant for all shear samples, with or without model stents. 
 
 
Figure 6-9. Effect of complement inhibition on Mac-1 expression on PMNs. Percentages are 
expressed relative to positive control (LPS). Negative control: 17±4% and 9±8% (inhibitor). *: 
p<0.01. **Significantly different from negative control with no inhibitor (p<0.01), #significantly 
different from corresponding agitated sample with inhibitor (p<0.02). Results are mean ± SD, n=3 to 
4. 
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Regarding C3aR expression, complement inhibition did not show any significant effect on 
both monocytes and PMNs, Table 6-2. FUT-175 caused a slight C3aR upregulation on non-stent 
shear samples on monocytes but had little effect for PMNs. On the other hand, for shear samples with 
stents, FUT-175 showed little effect on monocytes but induced slight C3aR upregulation on PMNs. 
Shear induced general C3aR down regulation, with some exceptions. In the case of TLR-4 receptor, 
complement inhibition resulted in consistent upregulation of TLR-4 expression under all conditions, 
for both monocytes and PMNs. However, definitive conclusions are not possible due to the limited 
number of samples. 
 
Table 6-2. Effect of complement inhibition on C3aR and TLR4 expression 
Marker 
(Control: 
without, 
with FUT-175) (%) 
Experimental condition Without 
FUT-175 
(%) 
With  
FUT-175 
(%) 
p-value 
FUT-175 
Vs 
No FUT-175 
C3aR expression on 
monocytes (%) 
(-FUT: 115±12, 
+FUT: 132±34) 
Agitate 135±16 130±29 0.77 
24 RPM (380 s-1) 112±5 124±19 0.52 
Ti64+Agitate 149±27 132±30 0.34 
Ti64+24 RPM (360 s-1) 124±17 125±16 0.99 
C3aR expression on 
PMNs (%) 
(-FUT: 164±15, 
+FUT: 180±70) 
Agitate 164±15 174±80 0.81 
24 RPM (380 s-1) 129±21 129±21 0.42 
Ti64+Agitate 154±15 151±52 0.94 
Ti64+24 RPM (360 s-1) 128±15 163±70 0.40 
TLR4 expression on 
monocytes (%) 
(93±11, 
94±25) 
Agitate 71±30 112±17 ND 
24 RPM (380 s-1) 81±12 116±7 ND 
Ti64+Agitate 90±6 128±22 ND 
Ti64+24 RPM (360 s-1) 85±24 114±41 ND 
TLR4 expression on 
PMNs (%) 
(80±6, 
88±18) 
Agitate 57±16 89±7 ND 
24 RPM (380 s-1) 66±8 93±14 ND 
Ti64+Agitate 79±14 105±17 ND 
Ti64+24 RPM (360 s-1) 75±32 90±22 ND 
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Percentages for C3aR and TLR4 are expressed relative to positive control (LPS). n=3 except for 
TLR-4 samples with inhibitor (n=2). ND: not determined due to small sample size. Results are mean 
± SD. 
 
To further examine the difference in the leukocyte expression of Mac-1, C3aR and TLR-4 
receptors, the results of the controls were compared, Table 6-3. For each control, when samples with 
and without inhibitor were compared, the presence of the complement inhibitor did not result in any 
significant difference in Mac-1 expression on leukocytes. Mac-1 expression was generally lower on 
samples with inhibitor. However, significant Mac-1 down-regulation was observed in samples with 
inhibitor when compared to samples without inhibitor, under shear conditions (Figure 6-8 and Figure 
6-9). Therefore, the fact that the inhibitor did not induce significant differences in Mac-1 expression 
under control conditions, and Mac-1 expression was lower in inhibitor samples, suggests that the 
differences observed in the experimental results were related to the experimental conditions and not 
due to the control samples. It is interesting to note that the difference in Mac-1 expression between 
the negative control and the corresponding positive control, with and without inhibitor, are both 
significant. 
Similar to Mac-1 expression, the presence of the FUT-175 did not result in a significant 
difference in C3aR expression in the control samples. C3aR expression also seemed to be lower for 
samples with inhibitor. Since the low C3aR expression in LPS control samples with FUT-175 
did not correspondingly produce high C3aR expression in all experimental results with FUT-
175 (Table 6-2), this suggests that the observed experimental results may not have been 
influenced by the control samples. 
For TLR-4, the presence of complement inhibitor in either control sample did not result in a 
significant difference in TLR-4 expression on leukocytes. Complement inhibition had minimal effect 
on monocytes but slightly discernible effect on PMNs. In the absence of inhibitor, the results also 
showed slight increase in TLR-4 expression on leukocytes. Since TLR-4 expression seemed to 
show an increase in the presence of FUT-175, under all experimental conditions (Table 6-2), 
this suggests that the differences observed in the experimental results were not due to the 
control samples. Thus, the results of Mac-1, C3aR and TLR-4 expression can generally be 
attributed to experimental conditions. 
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Table 6-3. Comparison of inhibitor effects on controls for Mac-1, C3aR and TLR-4. All 
markers are reported as arbitrary fluorescent units. 
Marker	  expression	   Negative	  control	   Positive	  control	   p-­‐value	  
Negative	   Positive	  
-­‐	  FUT	   +	  FUT	   -­‐	  FUT	   +	  FUT	   -­‐FUT	  vs	  
+FUT	  
-­‐FUT	  vs	  
+FUT	  
Mac-­‐1	  	   Monocytes	   21±3	   18±8	   106±12#	   126±34*	   0.83	   0.17	  
PMNs	   63±30	   35±37	   353±95#	   318±105*	   0.62	   0.55	  
C3aR	  	   Monocytes	   135±24	   92±60	   119±31	   70±44	   0.25	   0.19	  
PMNs	   162±23	   128±71	   100±19	   79±43	   0.37	   0.58	  
TLR-­‐4	   Monocytes	   246±5	   251±55	   268±36	   269±14	   ND	   ND	  
PMNs	   212±13	   250±79	   270±14	   282±31	   ND	   ND	  
Results are mean ± SD. n=3-4 except TLR-4 samples with inhibitor (n=2). #Significantly different 
from corresponding negative control without inhibitor (p<0.001), *significantly different from 
corresponding negative control with inhibitor (p<0.002) 
 
6.3.3 Effect of complement inhibition on platelet-leukocyte aggregation response to 
shear and model stents 
In addition to leukocyte activation, platelet-leukocyte aggregation was investigated with and 
without complement inhibitor. In the absence of model stents, complement inhibition did not have a 
significant effect on platelet-monocyte aggregations, Figure 6-10. It was observed that the presence of 
model stents in the absence of the inhibitor caused significant platelet-monocyte aggregation when 
compared with corresponding non-stent agitate (p<0.02) and shear (p<0.001) samples. The presence 
of complement inhibitor significantly (p<0.001) reduced platelet-monocyte aggregation at shear rate 
360 s-1. Generally, complement inhibition reduced platelet-monocyte aggregation. 
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Figure 6-10. Effect of complement inhibition on platelet-monocyte aggregation. Aggregation 
values are reported as arbitrary fluorescent units. Negative control: 166±77 and 119±106 (inhibitor). 
*: p<0.02, #: p=0.12. Results are mean ± SD, n=3 to 4. 
 
Similar to platelet-monocyte aggregation, in the absence of a stent, platelet-PMN aggregation 
was not significantly affected by complement inhibition, Figure 6-11. The presence of a stent in the 
absence of the inhibitor caused significant platelet-PMN aggregation when compared to 
corresponding non-stent agitate (p<0.001) and shear (p<0.001) samples. In the presence of model 
stents, complement inhibition significantly (p<0.001) reduced platelet-PMN aggregation under both 
agitation and shear conditions. In general, complement inhibition reduced platelet-leukocyte 
aggregation, which seems to be more effective on platelet-PMN aggregation. Overall the effect of 
complement inhibition on platelet-leukocyte aggregation was greater for stent samples and was 
significant under shear. 
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Figure 6-11. Effect of complement inhibition on platelet-PMN aggregation. Aggregation values 
are reported as arbitrary fluorescent units. Negative control: 41±16 and 31±34 (inhibitor). *: p<0.001. 
Results are mean ± SD, n=3 to 4. 
 
6.3.4 Effect of complement inhibition on surface adhesion 
Figure 6-12 depicts typical scanning electron microscopy images of protein deposition and 
cell adhesion on model stent samples with and without complement inhibitor. Adherent leukocytes 
can be observed on both samples without inhibitor, Figure 6-12(a) and (b), although the morphologies 
are different. Agitated sample shows pancake morphology while shear sample shows rugged surface 
morphology. It should be noted that some of the cells may be RBCs. Agitated sample with inhibitor, 
Figure 6-12(c), shows predominantly adherent platelets, although there are some leukocytes. What 
appear like floating cells are actually cells that have fallen onto the adhesion tape. For shear sample, 
Figure 6-12(d), platelets can still be observed with even fewer leukocytes. There also seems to be a 
layer of protein deposition as shown by the insert in (d), which is presented in a magnified view in 
Figure 6-13. 
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Figure 6-12. SEM cell adhesion pattern for sample with and without inhibitor. Samples without 
inhibitor: (a) agitated sample and (b) 24 RPM (360 s-1) sample; samples with inhibitor: (c) agitated 
and (d) 24 RPM sample. SEM magnification for all samples at 500X (insert at 5kX). 
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Figure 6-13. Magnified SEM cell adhesion pattern for sample with inhibitor. 24 RPM sample, 
magnification at 5kX. 
 
6.4 Discussion 
Blood-biomaterial interaction involves a lot of cross-talk and co-stimulation of blood cells 
from the various systems. In this study, the effect of broad spectrum complement inhibition, which 
eliminated some of the co-stimulators, was investigated with the complement inhibitor FUT-175. 
FUT-175 was introduced at 10µl/ml into the blood samples at the beginning of the experiments. 
Following 2-hour whole blood incubation under mild agitation and shear, with and without model 
stents, platelet and leukocyte activation and aggregation were characterized to determine the effect of 
complement inhibition. 
6.4.1 Platelet activation 
The level of shear in this study did not significantly increase platelet activation in the absence 
of model stents; it was below the threshold of platelet activation in whole blood. Hence, complement 
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inhibition did not significantly reduce platelet activation, as characterized by PMP formation. This 
seems to be consistent with previous findings that the ability of platelets to activate complement is 
time and shear dependent [434]. While some of our values appear to be different from values reported 
in Chapter 5, this is due to the fact that the donor samples in these experiments were not necessarily 
the same as donors compared to the initial experiments in Chapter 5 where low platelet response 
donors were present. 
However, in the presence of model stents, FUT-175 significantly inhibited material-induced 
PMP formation. Platelet activation in the presence of a biomaterial can be induced through a number 
of mechanisms, which include complement activation fragments such as C5b-9 [78], thrombin from 
the coagulation system, Ca2+ bound to the negatively charged TiO2 [461] and binding of platelet 
integrin receptor GPIIb/IIIa to fibrinogen [219], which also binds metallic biomaterials [220]. In order 
to significantly reduce platelet activation, as characterized by PMP formation, FUT-175 would have 
to inhibit complement activation as well as the other mechanisms that contribute to platelet activation. 
Since FUT-175 inhibits complement activation [458], it blocks the formation of C5b-9 and therefore, 
the reduction in PMP formation in the presence of FUT-175 is understandable. Regarding calcium, 
futhan can inhibit intracellular platelet calcium mobilization in a dose-dependent manner, with or 
without extracellular calcium [462]. In addition, it is possible that FUT-175 interacts with the platelet 
calcium channels as another mechanism of regulating PMP formation. Indeed, there has been 
evidence of futhan blocking acid-sensing ion channels [463] and in another model, futhan was shown 
to preferentially target ion channels; abolishing calcium influx [464]. Hence, it is plausible that a 
similar inhibition mechanism could occur with platelets and thus, partly explain the reduction in PMP 
formation in the presence of futhan. Concerning platelet activation from the binding of integrin 
receptor GPIIb/IIIa to material-bound fibrinogen, FUT-175 may also be interfering with the platelet 
receptor GPIIb/IIIa. Futhan can certainly antagonize the GPIIb/IIIa receptor since it has been shown 
to inhibit platelet aggregation from a variety of agonists, such as ADP [462, 465]. This is further 
supported by the reported disaggregation of platelets after ADP stimulation in the presence of futhan 
[465]. Thus, the interaction of futhan with GPIIb/IIIa, which would interfere with the outside-in 
signaling effects, such as mobilization of intracellular calcium, may also provide an explanation for 
reduced platelet activation. 
The reported double role of futhan, reduced PMP formation and aggregation, has significance 
for thrombosis reduction. The reduction in PMP formation by complement inhibition has some 
clinical relevance since PMPs, and other cell microparticles, are associated with a variety of clinical 
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conditions, including arterial thrombosis. While the results have promising applications, there is a 
need to further elucidate the mechanism of inhibition.  
The results of platelet consumption as characterized by GPIIb/IIIa expression suggest that 
futhan reduced platelet consumption. This is interesting because under physiological conditions it 
means activation is controlled, as demonstrated by suppression of PMP formation, and the 
preservation of platelets. The reduction in platelet consumption seems to agree with the results of an 
extracorporeal model using futhan, which showed that platelet count was preserved after 2 hours of 
circulation [466]. Thus, futhan could reduce platelet participation in material-induced thrombosis.  
6.4.2 Leukocyte activation 
Complement inhibition down regulated Mac-1 expression on leukocytes under all conditions. 
However, the down regulation of Mac-1 on both monocytes and PMNs was only significant in 
samples under shear, with and without a model stent. Interestingly, both samples (shear alone and 
shear with model stents) were reduced to similar levels. Shear is known to activate leukocytes and 
induce CD11b upregulation or down-regulation as shown in Chapter 5 and other studies [168, 428]. 
In the presence of model stents under mild agitation, complement inhibition caused minimal 
reduction in CD11b expression. Taken together, these results suggest shear-dependent inhibition of 
Mac-1 expression. The question that arises is whether shear sensitizes leukocytes to futhan inhibition, 
regardless of material presence. Mac-1 down regulation has also been observed in other in vitro and 
in vivo models using compstatin [443, 467]. However, in a 2-hour extracorporeal circulation model, 
no effect was observed on CD11b expression [466]. The interesting aspect of the extracorporeal 
model results was that they showed reduction in PMN F-actin. This did not only suggest preserved 
PMN deformability under flow but also suggested that futhan may interact with leukocyte mechano-
sensing receptors that control the intracellular calcium-dependent cytoskeleton filaments. If that is the 
case, then this may partly explain our observed shear-dependent Mac-1 inhibition. 
Furthermore, platelets under shear have been reported to preferentially activate the classical 
pathway [74], which could be through C1q of the classical pathway either binding to the global C1q 
receptor (gC1qR) on activate platelets [449] or to chondroitin sulfate A released from α-granules of 
activated platelets [468, 469]. Since this pathway will add to leukocyte activation, it may be a major 
contributing pathway to leukocyte activation under nominal physiological shear through 
amplification. If so, that would also be a factor in explaining the observed shear-dependent leukocyte 
CD11b down regulation. 
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Futhan had limited effect on Mac-1 expression in the presence of model stents under mild 
agitation. In fact, CD11b expression was significantly higher than the corresponding agitated samples 
without stents. In a polymeric bead model using sCR1, CD11b expression was previously found to be 
material dependent [317]. This then raises the question of whether in the absence of shear, futhan 
inhibition is material dependent. However, since futhan is reported to have a short half-life of 
approximately 8 minutes, the question is whether the CD11b expression is time and material-
dependent. Indeed blood activation is known to be time and material dependent. More importantly it 
has previously been shown that CD11b expression rate on titanium surfaces was dependent on surface 
characteristics. CD11b expression was found to increase slowly on hydrophobic surfaces [293]. 
Interestingly, in Chapter 4, the characterization of the stent wire revealed a weakly hydrophobic 
contact angle of 65.4° (water adhesion tension approximately 21.5 dyn/cm2). If the increase in CD11b 
expression was indeed slow due to the surface wettability, then in a semi-static condition with other 
agonists inhibited, it may be even slower. Thus, as futhan effects diminished, CD11b expression 
increased. Therefore, this may provide another explanation for the observed increase in CD11b 
expression even with futhan inhibition. Yet, another factor could be related to the previously alluded 
binding of calcium to titanium oxide [461]. If it indeed plays a role in platelet activation, this would 
support the observed platelet inhibition in agitated stent samples and no inhibition on leukocytes for 
the corresponding samples.  
Tissue factor expression, which is also anaphylatoxin induced [141], was down regulated by 
futhan in a similar manner as Mac-1. Complement inhibitor mediated TF down regulation has also 
been reported in a hemodialysis model using another broad effect inhibitor, compstatin, [443]. 
Although the TF samples were limited, the results suggest shear-dependent down regulation and 
limited effect in the presence of model stents under agitation, similar to Mac-1 expression. It is 
plausible that the mechanism responsible for Mac-1 pattern of regulation may be similar as they both 
can be induced by complement. It should be noted however that the implications of TF upregulation 
or down regulation for material-induced thrombogenicity in the presence of futhan would have been 
limited anyway due to the fact that the activity of the TF/FVIIa would be reduced by futhan inhibition 
[470]. 
The effect of complement inhibition on C3aR expression on leukocytes was minimal. It has 
previously been shown that complement activation and the presence of C3a fragment causes 
internalization of C3aR [407]. Therefore, when complement activation is inhibited, the lack of C3a 
from either the classical or alternative pathway would keep the C3aR expression at the basal level. 
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Since FUT-175 also blocks serine protease thrombin, which is another pathway for generating C3a, 
there are limited pathways for contributing C3a. This is not surprising that no significant change was 
observed in C3aR expression.  
The initial results for TLR-4 expression suggest that it was upregulated in the presence of 
complement inhibitor. Since LPS, without inhibitor, can increase TLR-4 mRNA [406], the question 
of possible influence from the positive control was raised. However, our LPS investigation revealed 
no influence from positive control, especially on monocytes, which predominantly express the LPS 
receptor (CD14) compared with PMNs [125]. This seems to agree with the results of a rabbit model 
in which futhan did not have any effect on endotoxin-induced inflammation [458]. Therefore, the 
observed increase in TLR-4 expression was not due to futhan effect on LPS. It is possible that in the 
absence of other co-stimulators as a result of complement inhibition, activation of compensatory 
mechanisms, could occur since there is cross-talk between complement and TLR-4 mediated 
pathways. Additional studies are necessary to elucidate the mechanisms at play. 
6.4.3 Platelet-leukocyte aggregation 
The presence of model stents under all experimental conditions resulted in a significant 
increase in fluid phase platelet-leukocyte aggregation, without an inhibitor. The presence of FUT-175 
in samples with stents substantially reduced platelet-leukocyte aggregation; platelet-monocyte, up to 
2-fold, and platelet-PMN aggregation up to 5-fold. Platelet-leukocyte aggregation is facilitated by 
platelet P-selectin and leukocyte PSGL-1 interaction as well as fibrinogen bridging between platelet 
GPIIb/IIIa and leukocyte Mac-1; the latter interaction proving to be the most stable binding. In the 
platelet and leukocyte investigations, it was shown that complement inhibition significantly reduced 
both platelet and leukocyte activation under shear conditions, in the presence of model stents. Hence 
aggregation receptors were reduced for both platelets and leukocytes, resulting in reduced platelet-
monocyte and platelet-PMN aggregation, 2.4-fold and 4.5-fold, respectively. 
For agitated stent samples, platelet PMP activation was still substantially reduced. Mac-1 
expression was also down regulated, albeit not significantly. The combined effect was reduced 
platelet-leukocyte aggregation. It is interesting to note that consistent with previously observed 
preferential platelet aggregation with monocytes compared to PMNs [29, 178, 424], the reduction in 
platelet-monocyte aggregation (1.5-fold) was not significant while it was significant for platelet-PMN 
aggregation (3-fold). The reduction in platelet-leukocyte aggregation is desirable since these 
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aggregates have the potential to adhere to the stent surface and therefore contribute to material-
induced thrombosis.  
6.4.4 Surface adhesion 
In the absence of complement inhibitor, qualitative evaluation showed that there was visible 
shear-dependent leukocyte adhesion to the model stents. While there was still shear-dependent 
adhesion in the presence of FUT-175, complement inhibition substantially reduced cell adhesion 
under both conditions. For samples under shear, leukocyte adhesion was almost abolished while there 
was still limited platelet adhesion and visible protein adsorption. Complement inhibition would 
generally result in reduced availability of anaphylatoxins and the iC3b fragment, which is a Mac-1 
ligand for leukocyte surface adhesion. In addition, complement inhibition reduced Mac-1 expression, 
especially under shear, hence the observed reduction in leukocyte adhesion. The decrease in 
leukocyte adhesion has significance for material-induced thrombosis since adherent leukocytes, 
especially monocytes because of their persistence in foreign body response, express TF and C3aR, 
which play a role in thrombosis. Tissue factor [405] as well as the C3aR ligand, C3a [88], have been 
associated with development of in-stent thrombosis. In addition, inhibition of leukocyte adhesion has 
significance for reducing possible leukocyte oxidative stress at the surface, which has beneficial 
effect in vivo. This suggests that complement may be one of the main driving forces behind leukocyte 
mediated foreign body response. Hence, control of complement activation could be one of the 
possible mechanisms to regulate material-induced thrombosis.  
Platelets, on the other hand, even not activated can still bind surface adsorbed fibrinogen 
through GPIIb/IIIa and be activated, since fibrinogen is not directly affected by complement 
inhibition. As a result, platelet adhesion was not completely abolished. Since proteins generally 
unfold and expose binding epitopes upon contact and adsorption to biomaterial surfaces, targeting 
proteins such as inhibiting complement or blocking conformational change may be one of the better 
ways to reduce the effect of material-induced thrombogenicity. It is interesting to note that similar 
results were observed in a different model using complement inhibitor compstatin, where leukocyte 
adhesion was reduced but platelet adhesion was not affected [455]. However, the rate of platelet 
activation is limited partly because feedback loops for some of the agonists, such as thrombin, are 
reduced by futhan inhibition. In general the results suggest that futhan may have the potential to 
reduce material-induced thrombosis.  
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The effects of complement inhibition on platelet and leukocyte activation and aggregation are 
summarized on Table 6-4. An interesting aspect of this inhibition is that even though FUT-175 has a 
short half-life and its effects are reversible, the inhibition effects were still significant after 2-hour 
incubation. Thus, the mode of interaction in an in vitro model is unclear. The results of this study 
raise important questions about the mechanisms of inhibition of shear and material-induced 
complement activation with futhan. Further investigations are necessary to elucidate these 
mechanisms. 
 
Table 6-4. Summary of inhibition effect. Arrows show comparison of samples with and without 
FUT-175 at each experimental condition. Ti64: Ti-6Al-4V stent sample. 
  Agitate Shear Ti64+agitate Ti64+shear 
Platelets PMP formation (%) ↓ ↓ ↓ ⇓  
CD61  ↓ ↓ ↓ ↑ 
P-seletin ⎯ ⎯ ⎯ ⎯ 
Monocytes 
(% expression) 
% expressing TF ↓ ↓ ↓ ↓ 
Mac-1 ↓ ⇓  ↓ ⇓  
C3aR ↓ ↑ ↓ ⎯ 
TLR-4 ↑ ↑ ↑ ↑ 
PMNs 
(% expression) 
Mac-1 ↓ ⇓  ↓ ⇓  
C3aR ↑ ⎯ ↓ ↑ 
TLR-4 ↑ ↑ ↑ ↑ 
Platelet-monocyte aggregates ↓ ⎯ ⇓  ⇓  
Platelet-PMN aggregates ↓ ↓ ⇓  ⇓  
⎯ No effect or barely discernible effect 
↓, ↑ Non-significant decrease or increase, respectively 
⇓  Significant decrease 
6.5 Conclusion 
This study has demonstrated that complement inhibition with futhan provides an effective 
method to reduce platelet and leukocyte activation and adhesion to a Ti-6Al-4V surface. This in turn 
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may reduce the local production of superoxides from leukocytes, which can have detrimental effects 
in vivo, such as lumen loss. The interesting aspect of this compound is that from this and other 
studies, it did not completely impair platelet function. This would be important in vivo for active 
hemostasis with reduced coagulation effects. The importance of this finding is that while under 
normal circumstances platelet adhesion correlates with leukocyte adhesion, when complement is 
inhibited, the correlation does not seem to exist or is substantially reduced. Which means platelet 
adhesion can occur with limited influence on leukocyte adhesion, thus reducing the effect of the 
coagulation cascade and subsequent thrombosis. 
This study has also raised important questions regarding the mode of interaction and the 
effect of inhibiting material-induced complement activation. Further investigations are necessary to 
elucidate the specific extent and time course of activation of each complement pathway in material-
induced thrombogenicity. Such information is crucial for in vivo applications in developing drug 
strategies throughout the healing process after stent implantation. The interaction of futhan with cell 
receptors also needs further examination. Detailed studies are necessary to elucidate the futhan effect 
on platelet receptors such as P-selectin and other receptors that play a role in the regulation of PMP 
formation. Studies are also necessary to elucidate the possible interaction of futhan with constitutively 
expressed leukocyte receptors, such as C3aR, as well as activation receptors, such as Mac-1. These 
investigations would go a long way in understanding the effect of futhan on platelet and leukocyte 
functions. Furthermore, there is an important issue of cell adaptation in the absence of co-stimulators, 
which remains unclear. This can possibly occur if there is stimulus imbalance in an environment 
where cross-talk and co-stimulation play an essential role.  
Material-dependence was also raised in this study. Whether futhan interacts with the metallic 
implant is not clear. The effect of material chemistry, in this case titanium oxide, in blood activation 
and subsequently determining the effect of futhan is an important factor that needs to be investigated.  
These studies were performed under nominal shear conditions. The effect of experimental conditions 
on the threshold of inhibition remains undetermined. Therefore, further studies are necessary to 
elucidate the effect of inhibition under high physiologic and pathologic shear conditions. Overall the 
study supports the hypothesis that complement inhibition could reduce material-induced 
thrombogenicity. The results have significance in further investigation of the use of futhan in 
reducing material-induced thrombosis. 
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Chapter 7 
Effect of Surface Roughness on Blood Activation and Complement 
Inhibition 
7.1 Introduction 
Biomaterial surface characteristics, such as surface chemistry, morphology (roughness and 
topography), wettability, energy, and their effects on blood-biomaterial interaction were described 
briefly in Chapter 2. All the surface characteristics are equally important in blood-biomaterial 
interaction because any material surface can be uniquely described by a specific combination of 
parameters pertaining to these characteristics. Hence, the specific combination of surface 
characteristics influences the sequence of events at the blood-biomaterial interface, such as protein 
conformational change and subsequent adsorption and cell adhesion; a sequence which ultimately is 
associated with the level of material thrombogenicity. Thus, considering all other factors equal (such 
as individual immune response and hemodynamics [471]), material thrombogenicity is uniquely 
determined by its surface characteristics. Although the question of the relationship between the 
different material characteristics and biological system response has long been asked [472], and 
despite years of research in blood-biomaterial interactions, “the fundamental principles of the 
causation of specific cellular responses as a result of the influence of materials are still not well 
known” [50]. Therefore, there is need for continued investigation of the relationship between material 
surface properties and protein and cell behavior. 
One material surface characteristic that is of particular interest is surface morphology, which 
is often described in terms of roughness and topography. As previously described in Chapter 2, 
roughness and topography are often used interchangeably since they both describe surface texture. 
However, surface roughness is usually quantitative, in terms of either an average or root-mean-square 
value but topography is often qualitative, e.g. surface waviness, although it can also be specified 
quantitatively if the topography is defined. Hence, topography can be used as a distinguishing 
qualitative description for surfaces with diverse geometries but similar average or root-mean-square 
roughness values. For that reason, at the minimum, the description of surface morphology requires the 
inclusion of both the topographic and the quantitative description of roughness. Both parameters are 
equally important in blood/cell-biomaterial studies. In this study, both roughness and topography are 
used but the use of roughness alone will be understood to include topography. 
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Surface roughness, with or without defined topography, is one of the significant biomaterial 
properties that can easily be modified during or after manufacturing to influence both specific and 
non specific surface binding, for a variety of applications, which include cardiovascular stents [473, 
474]. Surface roughness and topography define both the physical and thermodynamic characteristics 
of the material. They influence biological response through three main mechanisms; (i) physical 
increase in surface area, (ii) physical patterned guidance of cell response and (iii) the thermodynamics 
of wettability and the related surface energy. The physical increase in surface area, as well as the level 
and structure/topography of roughness have been shown to influence cell adhesion and proliferation 
[272-274, 475]. These physical properties also have implications for the contact system and 
recognition molecules, such as complement, and regulation of cell responses. The level and structure 
of roughness have certainly been found to be important factors in influencing material roughness-
induced complement activation and adhesion [25, 85] and endothelialization [476-478]. The 
activation of complement, which results in the formation of anaphylatoxins C3a and C5a, whose main 
function is activation and recruitment of leukocytes through their respective receptors C3aR and 
C5aR. These receptors are constitutively expressed by leukocytes [69, 107] and their regulation by 
agonists/antagonists has pharmacological relevance. Their ligand specificity, particularly C3aR, 
whose ligand has been used as an indicator of complement activation [85], suggests the possibility of 
its use for leukocyte activation studies. Indeed, C3aR can be regulated by a variety of agonists and 
antagonists [479]. However, there is limited understanding on how it is regulated in the presence of a 
biomaterial with specific physical characteristics such as roughness. The receptor regulation by 
biomaterial characteristics such as roughness is of particular interest as it may have implications for 
leukocyte recruitment and material-induced thrombogenicity. 
Furthermore, surface patterning of vascular implants has enhanced endothelialization [476-
478], suggesting possible use of stent surface roughness to reduce thrombogenicity. While stent 
endothelialization is desirable in vivo, it occurs in a longer time scale than an acute inflammatory 
response or blood activation, which occurs in a matter of seconds for platelets (10 seconds) and 
minutes for PMNs (10 minutes) [171, 480]. Surface roughness has indeed been shown to influence 
blood cell activation and adhesion. It also influences platelet activation and adhesion [480-483] and 
tissue factor expression [170], which are key risk factors for acute in-stent thrombosis [405]. 
Therefore, any continued surface exposure of either bare-metal stents or drug-eluting stents, raises 
concern for a roughness-induced inflammatory response. Incidentally, drug-eluting stents have been 
shown to leave stent struts uncovered for up to 2 years in 20% of the patients [444], and the late 
   213 
lumen loss has been correlated with complement anaphylatoxins C3a and C5a [88]. Furthermore, 
drug-eluting stents have been associated with late in-stent thrombosis [484, 485]. Although recent 
studies suggest comparable performance between metallic and polymer coated drug-eluting stents 
[486, 487], without the use of anticoagulant/antiplatelet therapies there is still increased likelihood of 
material-induced thrombosis once the drug release is complete. So, while surface roughness has some 
applications in drug delivery to promote endothelialization, it also raises concerns for triggering some 
of the immune response systems and possible material-induced thrombosis. 
Besides, the physical effects, the level of roughness influences the thermodynamics of surface 
wettability [50, 304], which is also related to surface energy. Surface thermodynamics specifically 
influences water structure at material surface [59], which in turn influences protein adsorption and 
conformational change, e.g. activation of the complement [85] and contact system [488], and 
subsequent cell adhesion. Thus, surface roughness and topography induce a variety of effects on 
blood activation, from the initial water and protein interaction to cell activation and the development 
of thrombosis. Since complement plays an important role in material-induced inflammation, 
complement inhibition was previously investigated in Chapter 6. However, the effect of material 
surface properties on the effectiveness of complement inhibition with FUT-175 remains unclear. 
Therefore, the purpose of this chapter was two-fold; (i) to investigate the effect of multiscale 
roughness on blood activation using helical model stents as previously described and (ii) to 
investigate the effect of roughness on the effectiveness of complement inhibition. We hypothesized 
that, under flow conditions, multiscale roughness with relatively heterogeneous topography has an 
effect on blood activation as well as complement inhibition. Interaction between surface roughness 
and biological systems has implications for material-induced thrombogenicity since roughness 
influences activation of the various biological systems (complement, contact, coagulation and 
hemostatic systems). For that reason, the effect of roughness on complement inhibition is also 
investigated. Investigating the mechanism of roughness effect on platelet and leukocyte activation and 
adhesion is of particular interest as they play a key role in coagulation and thrombosis.  
7.2 Materials and methods 
7.2.1 Flow model 
The Chandler loop model, with a silastic tube of 4.78 mm internal diameter and 59 mm loop 
diameter, as previously described in Chapter 3, was used for this experiment. 
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7.2.2 Model stents surface treatment 
Model stents were made as described in Chapter 4. Before forming stents, one set of stent 
wires was acid-etched to create surface roughness and the other set was used as obtained from the 
manufacturer. Acid etching was done by immersing the wires in a mixture of 15% hydrofluoric acid, 
40% nitric acid and 45% distilled water at room temperature for 10 seconds. This acid mixture has 
previously been used by other investigators, sometimes with different concentrations [306]. Model 
stents were ultrasonically cleaned in 30% nitric acid for 20 minutes, followed by rinsing in distilled 
water and ultrasonic cleaning in 70% ethanol for 10 minutes. Stents were then rinsed at least twice in 
phosphate buffer saline (PBS) and stored at 4°C, for use within 4 hours. 
7.2.3 Model stent surface characterization 
Surface characterizations, using a scanning electron microscope, atomic force microscopy 
and contact angle measurements were conducted as described in Chapter 4.  
7.2.4 Antibodies and reagents 
Fluorescein isothiocyanate conjugated mouse monoclonal antibody against human 
glycoprotein GPIIb/IIIa (CD61-FITC), R-phycoerythrin monoclonal antibody against P-selectin 
(CD62-PE), Fluorescein isothiocyanate conjugated mouse monoclonal antibody against Mac-1 
(CD11b-FITC), R-phycoerythrin monoclonal antibody against tissue factor (CD142-PE), anti-C3aR 
PE hC3aRZ8 and R-phycoerythrin-cytochrome 5 conjugated monoclonal antibody against PAN 
leukocytes (CD45-PerCP-Cy5.5) were purchased from BD Biosciences (San Diego, CA, USA). 
FACS lysing solution was purchased from BD Biosciences (San Diego, CA, USA). Phosphate-
buffered saline (PBS) was purchased from Fisher Scientific Inc (Ottawa, ON, Canada). 
Lipopolysaccharide (Escherichia coli serotype 0111:B4) (LPS), 50% glutaraldehyde solution, and 
paraformaldehyde were purchased from Sigma-Aldrich Co (Oakville, ON, Canada). Hepes Tyrode 
Buffer (HTB) solution PH 7.4 was prepared in the laboratory with a final concentration of 137mM 
NaCl, 2.7mM KCl, 5mM MgCl2, 3.5mM HEPES, 1g/L Glucose, and 2g/L BSA. 
7.2.5 Blood sample collection 
This study received ethics clearance from the University of Waterloo Research Ethics Office. 
Peripheral venous blood samples were drawn with formal consent from healthy volunteers, of age 
range 20 to 50 years, who indicated that they had not taken any medication in the last 72 hours. There 
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was no restriction placed on the participants’ physical activity, the type of diet and eating time. 
Participants were however advised to drink lots of water ahead of the blood draw. Briefly, blood 
samples were drawn with a 21G Vacutainer safety-lok blood collection set and syringe (BD 
Biosciences, San Diego, CA, USA) by a qualified phlebotomist. Blood was immediately transferred 
into 10 ml conical tubes containing heparin (5U heparin/ml). Blood samples were kept in an insulated 
container and used in the blood activation experiments within 30 minutes of collection. 
7.2.6 Platelet, complement and leukocyte activation and aggregation 
To assess material effect on blood activation, 2 ml blood samples were transferred into 
silicone tube loops, with or without appropriate 20 mm model stents. Therefore, the experiments were 
carried out in two groups. Group one was composed of 2 ml blood samples with 20 mm un-etched 
stents and group two was 2 ml samples with 20 mm acid-etched stents. To assess activation effects 
under shear, experiments were performed under two conditions, Figure 7-1. Experimental condition 
one was composed of gentle agitation and rotation at 24 RPM on a mini-shaker (VWR, PA, USA) and 
experimental condition two was composed of gentle agitation and rotation at 45 RPM. For all the 
experiments, control samples were static and included only blood (negative control/resting sample) 
and blood with lipopolysaccharide (LPS) (1 µg/mL) as a positive control. All samples were incubated 
at 37°C for 2 hours. 
 
 
Figure 7-1. Schematic of experimental conditions. UnTx: un-etched, AcidTx: acid-etched. 
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7.2.7 Immunolabelling and flow cytometry analysis 
At the end of the 2-hour incubation, aliquots of blood samples were incubated in tubes 
containing fluorescently-labeled antibodies for flow cytometry. To assess platelet activation and 
platelet microparticle (PMPs) formation, 5 µL blood samples were diluted with 50 µL HTB in test 
tubes and incubated for 30 minutes at 4°C with fluorescently-labeled antibodies against GPIIb/IIIa 
(CD61-FITC). Following incubation, samples were further diluted with 200 µL HTB, fixed with 200 
µL 2% paraformaldehyde and stored at 4°C before flow cytometry analysis. In flow cytometry 
analysis, platelets and PMPs are distinguished on the basis of size. First, events are acquired based on 
anti-CD61 expression. Light scatter analysis on granularity and size then distinguishes the events 
related to PMP, platelet and platelet aggregates. Based mostly on size, PMPs, which are smaller than 
platelet, are then reported as percentage of the total events (PMP + platelets). 
To assess complement and leukocyte activation and platelet-leukocyte aggregation, 30µL of 
blood samples were diluted with 50 µL HTB in test tubes and incubated for 30 minutes at 4°C with 
appropriate antibodies. Leukocytes were identified by PAN leukocyte marker (CD45 PE-Cy5). The 
effect of complement activation was assessed with anti-C3aR PE hC3aRZ8. Leukocyte activation was 
identified by antibodies against Mac-1 (CD11b-FITC) and tissue factor (CD142-PE) on leukocytes. 
Platelet-leukocyte aggregation was characterized with antibodies against GPIIb/IIIa (CD61-FITC) on 
leukocytes. Following 30 minutes incubation, 700 µL of FACS Lyse solution was added to lyse red 
blood cells. Aliquots were concentrated by centrifuging at 1200g for 6 minutes and discarding 
supernatant. Resuspended pellets were washed and then diluted with 200 µL HTB and fixed with 200 
µL paraformaldehyde (1% final concentration). All samples were stored at 4°C and analyzed on a BD 
FACS Calibur flow cytometer with CellQuest Pro software (BD Diagnostics, San Diego, CA, USA), 
within 5 days. 
7.2.8 Surface adhesion characterization 
After the experiment, stent samples were first rinsed with 0.2M sodium phosphate buffer, pH 
7.2. Adherent proteins and cells were then fixed in 2.5% glutaraldehyde and stored at 4°C until 
analyzed. To prepare fixed samples for SEM analysis, samples were first immersed and washed in 
0.2M sodium phosphate buffer, pH 7.2. This was followed by dehydration through a series of steps in 
10%, 25%, 50%, 70%, 90% and 100% ethanol. Samples were dried overnight and then coated with a 
thin layer of gold (8-10nm) in a vacuum chamber (Denton Vacuum, Desk II, USA) for 120sec, set at 
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50millitorr and 15 mA. Analysis was done with a LEO 1530 Gemini (Zeiss, USA) set at 10kV in 
secondary electron mode (SE2). No specific marking was used to distinguish between the inner and 
outer stent wall, as it relates to the loop curvature. 
7.2.9 Statistical analysis 
Statistical analysis was done with the IBM SPSS Statistics version 20. Data were analyzed 
using analysis of variance (2-way ANOVA). For post-hoc analysis, Least Significant Difference 
method was used to determine significant difference between groups. No specific analysis was 
performed to account for donor variability. Overall effects are not reported due to the complexity of 
the data; in some cases there are fewer than three groups, e.g. volume and stent samples. All data are 
presented as mean ± standard deviation of a minimum of 3 separate experiments. For all analysis, 
p<0.05 was used to indicate significant difference. 
7.3 Results 
7.3.1 Lumen characterization 
Model stent struts introduce roughness inside the tube lumen as previously described by the 
friction factor in Chapter 2. As a result, there were two levels of roughness – the macro level 
roughness due to the stent struts and the stent surface nano/micro level roughness. Hence, part of the 
lumen is characterized by a roughness with a length scale of 127 µm, which is the thickness of the 
stent strut. An illustration of the lumen roughness is depicted on Figure 7-2. The effective strut size to 
lumen diameter is ε D = 2.7% . The length scale of stent surface roughness (εʹ′) is characterized in 
section 7.3.2. 
 
 
Figure 7-2. Schematic illustration of lumen and stent surface roughness (not drawn to scale) 
   218 
 
7.3.2 Model stent characterization 
Model stent surface characterization by scanning electron microscopy (SEM) is depicted in 
Figure 7-3. The unetched surface (Figure 7-3(a)) had somewhat heterogeneous multi-scale roughness 
with a general pattern of rugged grooves with sharp cliffs, predominately aligned along the length of 
the wire. The grooves varied in length, depth and width (average approximately 1 µm wide). In 
addition, the spacing between the grooves was found to be random; from approximately 0.1 µm to 2 
µm. There were also some round grooves or pits. While the acid-etched surface (Figure 7-3(b)) also 
showed multi-scale roughness, it had a different morphology from the unetched surface. The acid-
etched surface had a high degree of sharp-edged and irregular cavities or pits, which varied in size 
from sub-micron to 1 µm. The average diameter of the deep pits was approximately 0.5 µm. Although 
the acid-etched surface was relatively rugged, it was generally uniform compared to the unetched 
surface. Visual observation of both surfaces suggests that the maximum depth of roughness grooves 
occurred on unetched stent, Figure 7-3(a). Since both the unetched and acid-etched stents were heat 
treated under the same oven conditions, it can be safely assumed that the titanium oxide layers would 
be similar in chemistry; in particular the rutile TiO2. Hence, surface roughness and the related surface 
energy would be the key differentiating factor between the two types of stent surfaces. In addition, 
visual inspection suggests that the number of valleys or pits is higher on the acid-etched surfaces 
compared to the unetched surface. 
 
 
Figure 7-3. SEM micrograph comparison of unetched and acid-etched stent surfaces. (a) 
Unetched surface, shows random rugged grooves along wire length, mag 15KX and (b) 10 sec acid-
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etched wire surface, shows more uniform random pattern roughness varying up to 1 µm wide, mag 
15KX. 
 
Model stents were also characterized by atomic force microscopy to determine surface profile 
and quantitative roughness values under dry conditions, Figure 7-4. The scan area was 10x10 µm2 at a 
scan rate of 1 Hz, in tapping mode. The difference in AFM surface profile between unetched surface 
(Figure 7-4(a)) and acid-etched surface (Figure 7-4(b)) was observed to be similar to topographic 
difference observed with SEM, Figure 7-3. As observed in SEM topography analysis, the unetched 
surface (Figure 7-4(a)) showed a higher peak to valley depth than the acid-etched surface, (Figure 
7-4(b)). 
 a b 
 
Figure 7-4. Atomic force micrograph of model stent surface topography and roughness. (a) 
Unetched surface. Horizontal axis at 2 µm/div and vertical axis at 500 nm/div. (b) Acid-etched 
surface. Horizontal axis at 2 µm/div and vertical axis at 400 nm/div. 
 
Quantitative surface roughness measurement values were obtained from AFM, Table 7-1. 
There was a non-significant increase (p=0.2) in average roughness of the acid-etched surface 
compared to the unetched surface. This is partly because the unetched stent was not really smooth. In 
some cases, acid-etching may also reduce the surface roughness, depending on the initial processing 
of the material [489]. The roughness length scales of both samples can be considered to be in the 
upper range of the nanoscopic length scale range (1-100 nm) or at the lower range of what is 
sometimes referred to as the subcellular length scale (<10 µm) [490]. Comparison of the surface areas 
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also suggests that the surface areas were similar. Thus, the main difference seems to be the surface 
topography, which would influence contact angle and surface energy. 
Similar to what was observed with SEM, for the same AFM scan area, the number of surface 
peaks and valleys is higher on acid-etched stents, which may have implications in blood activation. In 
addition, there were deeper valleys in the unethed surface and hence a wider z-range, Table 7-2. Table 
7-2 also includes a new defined ratio parameter, which may be important under flow conditions. The 
new parameter !ε ε  has a wider range, 0.4% to 1% (4.4x10-3 to 10.2x10-3), for the unetched surface 
and a narrow range, 0.7% to 0.9% (7.3x10-3 to 9.0x10-3), for the acid-etched surface. 
 
Table 7-1. Surface roughness measurements 
Surface	   Parameter	   Sample	   Average	  ± 	  SD	  1	   2	   3	  
Unetched	  	   Ra	  (nm)	   137.6	   103.1	   98.4	   113.0±21.4	  
RMS	  (nm)	   187.1	   128.6	   128.32	   148.0±33.9	  
Surface	  area	  (nm2)	   115.0	   116.1	   111.0	   114.0±2.7	  
Projected	  surface	  area	   100.0	   100.0	   100.0	   100	  
Surface	  area	  difference	  (%)	   15.0	   16.1	   11.0	   14.0±2.7	  
Acid-­‐etched	  	   Ra	  (nm)	   144.8	   121.1	   204.1	   156.7±42.7	  
RMS	  (nm)	   178.6	   149.9	   251.0	   193.2±52.1	  
Surface	  area	  (nm2)	   115.1	   113.4	   123.4	   117.3±5.4	  
Projected	  surface	  area	   100.0	   100.0	   100.0	   100	  
Surface	  area	  difference	  (%)	   15.1	   13.4	   23.4	   17.3±5.4	  
 
Table 7-2. The Z range and roughness ratio 	   Z	  range	  (nm)	  	   ε D 	  %	   !ε ε (range)	  %	  
Unetched	   927±368	   2.7	   0.7	  (0.4-­‐1.0)%	  
Acid-­‐etched	   896±90	   2.5	   0.8	  (0.7-­‐0.9)%	  
ε=127 µm (unetched), ε≈120 µm (acid-etched) 
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Contact angle analysis was conducted on both samples using the dynamic contact angle 
analyzer as previously described. Six immersion and emersion cycles were carried out continuously at 
a velocity of 10 mm/min, giving six successive time-dependent hysteresis loops. Therefore, Six 
advancing and receding contact angle measurements were determined from each loop and the 
averages were calculated, Table 7-3. The acid-etched surface had slightly higher variation that the 
unetched surface. Based on statistical 2-tailed t-test comparison of the means between unetched and 
acid-etched sample readings, both the surface tension and contact angle measures were significantly 
different (p<0.03). 
 
Table 7-3. Contact angle measurements for unetched and acid-etched samples 
	   Surface	  tension	  
(mN/m)	  
Contact	  angle	  
θ 	  (°)	  
Unetched	  wire	   21.5±1.3	   65.4±1.5	  
Acid-­‐etched	  wire	   13.5±6.1	  *	   74.7±7.1	  *	  
*Significantly different from unetched surface (p<0.03). Results are mean ± SD, n=6. 
 
7.3.3 Effect of surface roughness on platelet activation 
The effect of surface roughness on platelet activation as characterized by formation of platelet 
microparticles (PMPs) are depicted on Figure 7-5. As previously observed, shear did not have a 
significant effect on PMP formation in the absence of model stents. In the presence of model stents, 
there was a shear-dependent increase in PMP formation. Under shear conditions, both stent samples 
produced significant PMP formation when compared to non-stent samples. At higher shear rate, the 
samples with acid-etched stents produced significantly higher PMP formation compared to samples 
with unetched stents. In general, samples with acid-etched stents had higher PMP formation 
compared to samples with unetched samples. 
Platelet activation was also confirmed with the expression of the integrin glycoprotein 
receptor GPIIb/IIIa, Table 7-4. Stent samples under shear showed a reduction in CD61 expression, 
which corresponded to the increase in PMP formation observed above. Increase in shear (by 
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increasing angular velocity from 24 to 45 RPM) also reduced CD61 expression. Acid-etched stents 
caused higher platelet activation compared to unetched stents. 
 
 
Figure 7-5. Effect of surface roughness on PMP formation. Percentage microparticles are based on 
size (forward scatter signal) and expressed relative to total events (platelet + microparticles). Negative 
control: 5±2%. *: p<0.01. Results are mean ± SD, n=4 to 6. 
 
Table 7-4. Effect of surface roughness on CD61 expression on platelets and PMPs 
Experimental 
conditions 
CD61+ Platelets and PMPs p-value 
No stent 
sample 
Unetched 
stent 
sample 
Acid-etched 
stent sample 
Unetched 
Vs 
No stent 
Acid-etched 
Vs 
No stent 
Unetched 
Vs 
Acid-etched 
Agitate 214±64 188±75 * 195±51 0.36 0.52 0.84 
24 RPM  212±58 172±81 * 137±60 * 0.32 0.06 0.45 
45 RPM  179±69 * 129±52 * 117±59 * 0.15 0.12 0.78 
Negative control: 245±67. CD61 expression is reported as arbitrary fluorescent units. Shear rate: 2 ml 
at 24 and 45 RPM is 380 s-1 and 790 s-1, respectively; 2 ml + 20 mm stent at 24 and 45 RPM is 360 s-1 
and 750 s-1, respectively. *Significantly different from negative control (p<0.05). Results are mean ± 
SD, n=4 to 6. 
   223 
 
7.3.4 Effect of surface roughness on leukocyte activation 
The effect of surface roughness on leukocyte activation, as characterized by TF, Mac-1 and 
C3aR express, was also investigated, Table 7-5. The presence of both unetched and acid-etched stents 
increased percentage of monocytes expressing TF, which was significant at 45 RPM (p<0.03). 
Although no significant difference in TF expression between samples with unetched and acid-etched 
stents was observed, no conclusions can be drawn because n=2 for the acid-etched samples at 24 
RPM. For Mac-1 expression, samples with acid-etched stents had slightly higher Mac-1 expression on 
monocytes compared to samples with unetched stents. The effect of roughness on PMNs was less 
discernible for samples under shear. A slight shear-dependent down-regulation of Mac-1 expression 
on leukocytes was observed for both stent samples. With regards to C3aR expression, similar to TF 
expression, no conclusions can be drawn on the effect of surface roughness because n=2 for the acid-
etched samples at 24 RPM. However, the effect of shear-dependent down-regulation of C3aR 
expression was observed for unetched stents. In general, the results suggest slightly higher leukocyte 
activation on samples with acid-etched stents. 
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Table 7-5. Effect of surface roughness on leukocyte activation 
Marker 
(Negative control) 
ω  No stent 
sample 
Unetched 
stent sample 
Acid-etched 
stent sample 
% Monocytes expressing TF 
(9±3) 
Agitate 15±8 18±10 19±16 
24 RPM 26±13 46±12 * 36±18 
45 RPM 20±10 37±21 # 43±11 # 
Mac-1 expression on monocytes 
(%) 
(29±14) 
Agitate 37±12 48±10 55±15 
24 RPM 54±11 61±6 64±14 
45 RPM 42±16 55±13 61±16 
Mac-1 expression on PMNs (%) 
(21±10) 
Agitate 21±10 33±8 40±17 
24 RPM 24±8 38±13 38±15 
45 RPM 27±17 35±22 32±20 
C3aR expression on monocytes 
(%) 
(108±15) 
Agitate 116±21 139±22 112±20 
24 RPM 106±9 125±16 99±2 
45 RPM 95±18 106±30 115±31 
C3aR expression on PMNs (%) 
(132±28) 
Agitate 131±26 143±16 108±19 
24 RPM 113±27 125±19 78±15 
45 RPM 103±20 100±22 104±10 
Shear rate: 2 ml at 24 and 45 RPM is 380 s-1 and 790 s-1, respectively; 2 ml + 20 mm stent at 24 and 
45 RPM is 360 s-1 and 750 s-1, respectively. *Significantly different from same shear non-stent sample 
(p<0.05), #Significantly different from same shear non-stent sample (p<0.03). Results are mean ± SD, 
n=4 to 6 (Mac-1), n=2 to 4 (TF), n=2 to 5 (C3aR), n=2 for acid-etched at 24 RPM. 
 
7.3.5 Effect of surface roughness on platelet-leukocyte aggregation 
The presence of both acid-etched and unetched stent samples caused a significant increase in 
fluid phase platelet-monocyte aggregation (p<0.001), Figure 7-6. When samples with acid-etched 
stents were compared to samples with unetched stents, an increase in platelet-monocyte aggregation 
was observed, which was significant at a shear rate of 750 s-1 (p<0.001). When shear was increased, 
there was a significant reduction (p=0.03) in platelet-monocyte aggregation for non-stent and 
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unetched stent samples. On the other hand, the samples with acid-etched stents had an opposite effect; 
a slight increase in platelet-monocyte aggregation. 
Similar to platelet-monocyte aggregation, the presence of both types of model stents resulted 
in a significant increase in platelet-PMN aggregation under shear (p<0.001), Figure 7-7. The presence 
acid-etched stents caused higher platelet-PMN aggregation compared to unetched stents, which was 
significant at higher shear rate (p<0.001). Increasing shear resulted in reduced platelet-PMN 
aggregation, which was significant for non-stent and unetched stent samples (p<0.05). In general, 
acid-etched stents caused higher platelet-leukocyte aggregation compared to unetched stents.  
 
 
Figure 7-6. Effect of surface roughness on platelet-monocyte aggregation. Platelet-monocyte 
aggregation is reported as arbitrary fluorescent units. Negative control: 185±99. *: p<0.001, 
#significantly different from corresponding sample at 24 RPM (p=0.03). Results are mean ± SD, n=4 
to 6. 
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Figure 7-7. Effect of surface roughness on platelet-PMN aggregation. Platelet-PMN aggregation 
is reported as arbitrary fluorescent units. Negative control: 45±32. *: p<0.001, #significantly different 
from corresponding sample at 24 RPM (p<0.05). Results are mean ± SD, n=4 to 6. 
 
7.3.6 Effect of surface roughness on FUT-175 efficacy 
To investigate the effect of model stent roughness on the efficacy of FUT-175, experiments 
were carried out with 2 ml + 20 mm stent sample at an angular velocity of 24 RPM, representing a 
nominal time-averaged wall shear rate of 360 s-1. 
The results of the impact of surface roughness on the effectiveness of FUT-175 to inhibit 
platelet activation are presented in Table 7-6. Comparison of PMP formation results between 
unetched and acid-etched stent samples did no show any significant difference, suggesting minimal 
influence from surface roughness. Similarly, CD61 and P-selectin expression did not show any 
significant difference when results from unetched stents samples were compared to acid-etched stent 
samples. Thus, the results suggest that for the conditions of this study, surface roughness did not 
influence the efficacy of the complement inhibitor to reduce platelet activation. 
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Table 7-6. Effect of surface roughness on FUT-175 efficacy to reduce platelet activation 
Marker 
(Negative control) 
ω  FUT-175 
+ 
Non-stent 
sample 
FUT-175 
+ 
Unetched 
stent sample 
FUT-175 
+ 
Acid-etched 
stent sample 
% PMP formation 
(5±1) 
Agitate 4±1 5±1 5±2 
24 RPM 6±3 7±5 7±3 
CD61+ expression on platelets + 
PMPs (233±68) 
Agitate 227±47 210±48 225±51 
24 RPM 218±49 194±22 215±60 
P-sel expression  
(14±3) 
Agitate 16±3 17±5 18±1 
24 RPM 17±2 17±1 18±1 
CD61 and P-sel expressions are reported as arbitrary fluorescent units. Shear rate: 2 ml at 24 RPM is 
380 s-1; 2 ml + 20 mm stent at 24 RPM is 360 s-1. Results are mean ± SD, n=2-3, n=2 for P-sel. 
 
The influence of roughness on the efficacy complement inhibition was also investigated on 
leukocytes. No conclusions could be drawn from TF expression due to the limited number of samples. 
For Mac-1, under mild agitation, the presence of both stent samples resulted in a significant increase 
(p<0.02) in Mac-1 expression on leukocytes, when compared to non-stent samples, Table 7-7. This 
suggests that, in the presence of model stents, complement inhibition was not effective in reducing 
Mac-1 expression on leukocytes under agitation. However, there was no significant difference in 
Mac-1 expression between unetched and acid-etched stent samples under all experimental conditions, 
suggesting minimal impact of roughness on the effectiveness of FUT-175. Similar to Mac-1 
expression, no significant difference in C3aR and TLR-4 expression on leukocytes was observed 
when unetched stent samples were compared to acid-etched stent samples. No significant difference 
was observed on platelet-leukocyte aggregation either when stent samples were compared. The results 
suggest that for the conditions in this study, surface roughness did not significantly influence the 
efficacy of complement inhibitor FUT-175.  
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Table 7-7. Effect of surface roughness on FUT-175 efficacy to reduce leukocyte activation 
Marker 
(Negative control) 
ω  FUT-175 
+ 
Non-stent 
sample 
FUT-175 
+ 
Unetched 
stent sample 
FUT-175 
+ 
Acid-etched 
stent sample 
% Monocytes expressing TF 
(8±5) 
Agitate 8±3 21 7 
24 RPM 9±3 14 13 
% Mac-1 expression on 
monocytes (12±8) 
Agitate 18±6 40±6 * 32±13 * 
24 RPM 24±6 25±10 23±8 
% Mac-1 expression on PMNs  
(8±6) 
Agitate 9±4 25±7 # 26±4 # 
24 RPM 11±5 9±4 14±6 
% C3aR expression on 
monocytes (114±29) 
Agitate 135±16 132±30 114±10 
24 RPM 121±22 125±16 108±10 
% C3aR expression on PMNs  
(153±54) 
Agitate 151±57 151±52 122±12 
24 RPM 146±51 163±70 130±20 
% TLR-4 expression on 
monocytes (93±20) 
Agitate 112±22 128±22 112±28 
24 RPM 116±17 114±41 115±23 
% TLR-4 expression on PMNs  
(82±12) 
Agitate 89±9 105±17 89±12 
24 RPM 92±11 90±22 90±11 
Platelet-monocyte aggregation 
(109±76) 
Agitate 277±104 505±153 391±78 
24 RPM 520±265 479±405 618±460 
Platelet-PMN aggregation 
(27±24) 
Agitate 23±10 100±69 53±11 
24 RPM 65±56 102±149 123±101 
Platelet-leukocyte aggregation is reported as arbitrary fluorescent units. Shear rate: 2 ml at 24 RPM is 
380 s-1; 2 ml + 20 mm stent at 24 RPM is 360 s-1. *Significantly different from corresponding non-
stent sample (p<0.02), #Significantly different from corresponding non-stent sample (p<0.001). 
Results are mean ± SD, n=2-3, n=2 for TLR-4 acid-etched samples and n=1-2 (TF). 
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7.3.7 Surface adhesion 
The effect of roughness on cell adhesion was observed on acid-etched stents, Figure 7-8. A 
thick mesh covering the whole stent was observed on the agitated acid-etched stent sample, Figure 
7-8(a). The acid-etched stent sample under shear showed reduced surface adhesion, but the fiber mesh 
seemed dense and adherent platelets were visible, Figure 7-8(b). Adherent leukocytes were not 
visible. There was increased adhesion compared to adhesion on unetched stent samples as previously 
presented on Chapter 5.  
 
 
Figure 7-8. SEM of cell adhesion pattern on acid-etched samples. (a) Agitated sample at 1.0 KX 
and (b) 45 RPM (750 s-1) sample at 1.0 KX. Acid-etching increased surface adhesion 
 
Figure 7-9 depicts typical scanning electron microscopy images of cell adhesion on acid-
etched stent samples with complement inhibitor, FUT-175. While adherent leukocytes can be 
observed on the agitated sample (Figure 7-9(a)), there are no visible leukocytes on samples at shear 
rate of 360 s-1 (Figure 7-9(b)). However, adherent platelets can be observed on the sample at shear, as 
indicated by the magnified SEM, Figure 7-9(c). Thus, leukocyte adhesion is abolished but some 
platelet adhesion is retained. 
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Figure 7-9. SEM of cell adhesion pattern on acid-etched sample, with inhibitor. (a) Agitated 
sample at 1.0 KX, (b) 24 RPM (360 s-1) sample at 1.0 KX, (c) agitated sample (same as (a)) at 2.58 
KX, (d) 24 RPM sample (same as (b)) at 6.96 KX. FUT-175 abolished leukocyte adhesion. 
 
7.4 Discussion 
Biomaterial surface roughness is known to induce a variety of cell responses [491] and hence 
can be exploited for bone integration and anchoring [492]. In stent technology, surface patterning can 
be used for drug delivery on polymer covered or metallic stents [493]. However, once the drug is 
exhausted, the bare metal surface may still cause roughness-induced thrombosis because evidence 
suggests surface roughness enhances blood activation and cell adhesion [483, 494]. While this is 
known, there is still no defined roughness for specific blood-biomaterial applications. Furthermore, it 
is not clear if material surface topography has an effect on the efficacy of one of the complement 
inhibitors, FUT-175. 
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In this chapter, the effect of material surface (model stent) roughness was investigated to 
elucidate some of the important factors to consider under flow conditions. For this study, two levels 
of roughness were considered – the macro-level introduced by the stent struts and the micro-level 
introduced by acid etching of the stent struts. The macro-level lumen roughness has been shown to 
influence time-averaged wall shear stress [29], [495] as well as platelet deposition [496], and hence 
activation. For this investigation, the macro-level roughness was held constant while the micro-level, 
model stent surface roughness, was changed. Acid etching was considered appropriate due to the 
multiscale nature of the roughness, which is suitable since biomolecules come in different sizes and 
shapes. 
7.4.1 Surface roughness 
The surface morphology of the acid-etched model stent was generally multiscale roughness 
with sharp-edged pits, which was comparable to other acid-etched titanium surfaces [393, 497]. The 
averaged roughness was found to be similar to the unetched stent although the morphology was 
different. These differences were only qualitatively observed from SEM and AFM micrographs. Due 
to time constraints, no quantitative 3D analysis was performed. It is important to note that the 
difference in morphology would also be reflected in the surface energy and contact angle, which is 
further confirmed by some of the differences observed in our surface energy and contact angle results. 
It has been previously shown that in some cases, acid-etching may also reduce the surface roughness, 
depending on the initial processing of the material [489]. The roughness length scale for both samples 
was in the nanoscopic (1-100 nm) to the subcellular (<10 µm) length scale, which falls in the range of 
cell receptors and other proteins [490]. One parameter that was defined in this investigation was the 
ratio of the surface stent strut roughness to the macroscopic roughness. There is no benchmark for this 
ratio that was found but it is possible that this may impact the thickness of the wetting film during the 
circulation gas phase. This emanates from the fact that the circulation loop is partly filled with blood, 
and hence there is a liquid and a gas phase in the loop. This parameter may introduce the boundary 
layer problem, which is not discussed in this thesis. However, this parameter may need to be 
incorporated into the broad activation and aggregation function discussed in Chapter 5. Further 
studies are necessary to elucidate the implications of the strut surface roughness on the surface flow 
dynamics. 
Contact angle measurements for both unetched and acid-etched wires could be characterized 
as hydrophobic based on the previously suggested approximate cutoff for hydrophobicity/ 
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hydrophilicity of 65° [394]. Also based on the adhesion tension map [394], it is noted that both 
samples fall in the region where both dispersive and polar components of the surface energy play an 
important role, which has implications for blood activation. It has previously been shown that 
titanium oxide wettability is greatly influenced by treatment and storage conditions [305, 497]. The 
reduction of expected metallic hydrophilicity is not only due to the formation of the TiO2 but also the 
atmospheric hydrocarbons [395, 497]. As a result the contact angle on a titanium surface increases 
when stored in air [497]. This effect could partly explain the observed hydrophobic tendency of the 
samples used in this study. 
7.4.2 Platelet activation 
Acid-etched stents used in this study caused an increase in platelet activation when compared 
to unetched stents, which was significant at high shear rate. Material-induced platelet activation is 
mediated by a number of material-dependent mechanisms, which include the density of surface bound 
fibrinogen [498], complement activation fragment C5b-9 [417], Ca2+ bound to the negatively charged 
TiO2 [461] and thrombin from the coagulation system [417]. Fibrinogen, which can adsorb on a 
variety of metallic surfaces [220, 499, 500], activates platelets by binding to the integrin glycoprotein 
receptor GPIIb/IIIa. Fibrinogen surface adsorption is influenced by surface chemistry [501] as well as 
surface energy and roughness [499, 502]. Although fibrinogen adsorption was not investigated in this 
study, some surface adsorption would be expected on weakly hydrophobic surfaces, like the ones 
used in this study. It is a key protein in platelet activation and adhesion and hence any roughness-
mediated surface adsorption that may occur, as in the above quoted studies, would partly explain the 
observed increase in platelet activation in this study. Characterization of fibrinogen adsorption would 
be necessary to elucidate the relationship with platelet activation and adhesion. 
Protein interaction with material surfaces is also influenced by electrolytes [503]. The 
influence of electrolytes on protein-material interaction is an important phenomena because blood 
contains electrolytes, which would not only interact with the material surface, but would also 
influence cell activation and function, such as Ca2+-dependent platelet activation in the presence of 
biomaterials [217] and phospholipid expression on platelets [504]. The impact of material-mediated 
electrolyte platelet activation has also been previously demonstrated by the activation of platelet from 
Ca2+ bound to TiO2 surface [461]. The implications of the acid-etched surface on the presence of 
hydrated cations, which influences the material surface charge and subsequently fibrinogen 
adsorption, is not clear. Although this was not investigated in this study, it may contribute to the 
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observed platelet activation. Therefore, further studies are necessary to elucidate the effect of 
roughness on electrolyte surface retention and subsequent influence on fibrinogen adsorption and its 
implications for roughness-induced thrombogenicity. 
Material-induced complement fragments also activate platelets [82]. The classical pathway 
complement C1q, which binds to material adsorbed immunoglobulins like IgG [25, 85], enhances 
platelet activation by binding to the global C1q receptor (gC1qR) on activated platelets [449] or 
through binding to chondroitin sulfate A secreted from activated platelet α-granules [469]. 
Complement C5b-9, which is also dependent on surface characteristics [349, 417, 494, 505], induces 
platelet α-granule secretions and PMP formation [196]. Besides complement, another mechanism that 
may contribute to platelet activation is the roughness-induced contact system activation [417, 494]. 
Contact system activation would induce thrombin formation and subsequent platelet activation. Thus, 
a variety of roughness-mediated mechanisms may contribute to the increased platelet activation as 
observed in this study. Under shear, which has been shown to activate platelets in the presence of 
model stents (Chapters 5 and 6), the effect of these mechanisms may be amplified through feedback, 
resulting in significant platelet activation as observed at high shear.  
In addition to surface adsorbed protein-mediated platelet activation, isolated platelet adhesion 
and activation in direct contact with material have been shown to be dependent on the type as well as 
the pattern of TiO2 topography [506]. Thus, the results of isolated platelets and whole blood flow 
models [27, 494] generally agree with our findings that acid-etched roughness, directly and indirectly, 
increased platelet activation. However, in whole blood and under flow conditions, the stimulus and 
response are much more complex as discussed above and hence, the cause and effect cannot be easily 
deduced. Therefore, further studies, which incorporate the issues raised above, such as fibrinogen 
adsorption, electrolyte surface retention, complement and contact system activation, are necessary to 
elucidate the impact of patterned surfaces on platelet activation. In particular, it is necessary to 
elucidate the conditions that may emphasize one system or synergistically amplify all systems. 
7.4.3 Leukocyte activation 
Unetched and acid-etched stents samples caused similar leukocyte activation, although Mac-1 
expression on monocytes seemed to be slightly higher in samples with acid-etched stents. Some of the 
material-dependent mechanisms that mediate leukocyte activation are linked to platelet activation 
[182]. These include surface bound fibrinogen [507] and complement activation [22]. Nanoparticle 
size and roughness-dependent fibrinogen conformational change exposes the C-terminus of the γ-
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chain, which binds and activates leukocyte integrin receptor Mac-1 [507]. It is interesting to note that 
similar to fibrinogen density-dependent platelet activation [498], leukocyte Mac-1 binding to 
fibrinogen on nanoparticles was also found to be size and density-dependent – increasing with 
decreasing fibrinogen density [507]. Fibrinogen binding to Mac-1 activates the nuclear factor-kappa 
B (NF-κB) transcription factor pathway [507, 508], and thus induces inflammatory mediators [507]. 
Since the NF-κB is also one of the pathways for TF expression, this may partly explain the observed 
material-dependent TF expression. However, the roughness effect on TF expression was not 
observed. 
Leukocyte activation could also occurs as a result of material-induced complement activation 
and formation of anaphylatoxins [25, 85, 417, 494], since complement plays an important role in 
immune response to biomaterials [7, 22, 82, 182]. Moreover, C3 fragments can even adsorb on other 
plasma proteins [83]. Complement activation anaphylatoxins induce Mac-1 and TF expression on 
leukocytes [141, 443] and anaphylatoxin C3a has also been shown to induce internalization of C3a 
receptor (C3aR) on leukocytes [407]. Therefore, the observed material-induced leukocyte activation 
for both unetched and acid-etched stent samples may partly be mediated by complement activation. 
However, the effect of roughness on leukocyte activation was not obvious.  
Although the results of this study generally suggest increased blood activation with roughness 
as found by others [27], other results have suggested the contrary [509]. Several factors may account 
for the seemingly contradictory results. One main factor, as already alluded to in this discussion, is 
the fact that roughness alone cannot be used to explain the blood activation. The slight differences in 
surface thermodynamics, electrostatics and chemistry play an important role. Hence, further studies 
with profiled surface characteristics are necessary to elucidate material surface effect on all the 
factors that mediate blood activation. 
7.4.4 Platelet-leukocyte aggregation 
Platelet-leukocyte activation was higher in samples with acid-etched stents compared to 
samples with unetched stents, which seemed to correspond with increased platelet and leukocyte 
activation. Platelet-leukocyte aggregation is facilitated by fibrinogen as it can bind with both platelet 
and leukocyte integrin receptors GPIIb/IIIa and Mac-1, respectively. Under shear, the platelet P-
selectin and leukocyte PSGL-1 receptor interactions facilitate platelet-leukocyte aggregation. Thus, 
increased activation from acid-etched stents would result in increased platelet-leukocyte aggregation 
as observed in this study. 
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However, as discussed in previous sections, other biochemical entities, such as thrombin and 
calcium play an important role in platelet activation. More importantly thrombin and calcium have 
been shown to mediate platelet aggregation independent of fibrinogen and von Willebrand factor 
[510]. Thus, a variety of mechanisms may contribute to the observed increase in platelet-leukocyte 
aggregation. 
7.4.5 Surface adhesion 
Acid-etched stents had greater surface adhesion than unetched stents, which was previously 
observed [511]. The fact that the acid-etched surface was slightly more hydrophobic suggests the 
possibility of increased protein adsorption, such as fibrinogen and complement fragment iC3b. 
Fibrinogen is a ligand for both platelet and leukocyte integrin receptors GPIIb/IIIa and Mac-1, 
respectively. Complement iC3b is a ligand for Mac-1 receptor. Hence, adsorption of both fibrinogen 
and iC3b facilitates cell adhesion. Moreover, both platelets and leukocytes were activated in acid-
etched stents. Under flow conditions, platelet and leukocyte aggregation and adhesion is also 
facilitated by interaction of platelet P-selectin with leukocyte PSGL-1 receptors. Thus, these 
conditions increased the likelihood of surface adhesion. 
Furthermore, the results seem to agree with another whole blood loop model study comparing 
electropolished and unpolished stents [27]. This is supported by the finding that increased roughness 
resulted in increased cell resistance to shear detachment in microsphere roughness [512] and 
nanopores roughness [513]. This may partly explain the observed adhesion on acid-etched stents 
because of increased surface peaks and valleys than the unetched stents, in spite of similar average 
roughness values. 
7.4.6 Complement inhibition effect 
Since material properties influence the distribution of electrolytes at the surface, there is a 
possibility that some of the drugs, such as the complement inhibitor FUT-175, could interact with the 
surface. We are not aware of investigations into the effect of patterned titanium oxide on the efficacy 
of FUT-175. Hence, the effect of model stent roughness on complement inhibitor, FUT-175, was 
investigated in this study. 
Complement inhibition in the presence of model stents reduced the level of platelet and 
leukocyte activation to similar values. The possible mechanisms through which FUT-175 can reduce 
platelet and leukocyte activation and aggregation were discussed in Chapter 6. The fact that FUT-175 
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reduced platelet and leukocyte activation to similar levels suggests that surface roughness did not 
have an effect on the efficacy of the complement inhibitor, FUT-175. Thus, the results imply that 
FUT-175 could have the potential to be used with nano/micro-structured surfaces, without affecting 
its efficacy. These results have relevance for drug eluting stents since they have patterned surfaces. 
More detailed studies are necessary to elucidate inhibition under different surface structures.  
The presence of FUT-175 abolished leukocyte adhesion to acid-etched surfaces. This is 
important because leukocytes play an important role in material-induced thrombosis. However, some 
platelets were still adherent, although the whole surface was not covered. The results are similar to 
what was observed in Chapter 6. This may be possibly due to the fact that unactivated platelets can 
still adhere to surface adsorbed fibrinogen. The results suggest that FUT-175 has the potential to 
reduce material-induced thrombosis on rough surface material. 
Overall, the issues raised in this study, taken together with other studies that have 
demonstrated the various parameters that influence the interactions at the biomaterial surface, suggest 
that the material-protein interaction is really material-electrolyte-water-protein-cell interactions [175], 
and therefore needs to be modeled appropriately. Hence, efforts made to investigate and/or control 
material-protein interactions need to take all the system factors into account. While efforts are made 
to control the specific interactions at the biomaterial surface, it is not clear if there are surface 
modifications that may inadvertently promote non-specific binding. Regardless of the binding 
mechanism, it is necessary to characterize and investigate further the key contributing factors to 
material-induced blood activation. 
Furthermore, the limitations in the use of 2D roughness parameters should be noted. 
Materials with the same average roughness values and different topographies can produce very 
different responses [272], and therefore 2D roughness parameters, although commonly used, are not 
sufficient to completely characterize surface roughness [388]. They are sufficient as a proof of 
concept, as done in this study, but for detailed surface interaction studies, it would be necessary to 
perform 3D characterization. 
7.5 Conclusion 
 In this chapter, the effect of acid-etched surface roughness on platelet activation and platelet-
leukocyte activation was demonstrated. For the roughness surface used in this study, leukocyte 
activation markers were relatively similar between the different surfaces. It is not clear if there are 
some parameters that are more sensitive to material surface area and roughness and some that are 
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more sensitive to other factors, such as surface water, electrolytes and plasma proteins, which may be 
influenced by subtle differences between surfaces that have similar average roughness values. Thus, 
although the effect of roughness was demonstrated, the precise details of how the specific surface 
characteristics influence the synergistic contribution of each biological system are not clear. Further 
studies are necessary to investigate the contributory role of the various factors. 
The possible role of the parameter relating the stent strut surface nano/micro scale roughness 
and the macro scale lumen roughness in surface flow dynamics was also raised in this chapter. 
Although no defined relationship was established, this parameter may have implications for fluid-
solid interface and subsequent platelet and leukocyte activation and aggregation. Detailed 
investigations are necessary to establish the relationship and possible role of this parameter in blood 
activation. There is also need for surface profiling in order to elucidate the contributions of surface 
thermodynamics, electrostatics and chemistry. 
The results of the investigation into the impact of surface roughness on the effectiveness of 
FUT-175 suggest that there was little or no impact. Thus, these results disprove the hypothesis that 
roughness has an effect on complement inhibition. The lack of a roughness effect on complement 
inhibition has possible significance for micro-structured devices such as drug eluting stents as this 
suggests the possibility of using FUT-175 to reduce complement activation without loss of efficacy. 
Further investigations are however necessary, with different surface structures, such as pores versus 
surface roughness and at different shear rates. 
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Chapter 8 
Summary of Contributions and Future Work 
8.1 Summary and perspectives 
The approach taken in this thesis was to link fundamentals with system interactions and the 
broader picture and in so doing highlight the significance of a systems approach in blood-biomaterial 
interaction studies. 
8.1.1 Significance of a systems approach 
In this thesis, the significance of a systems approach has been highlighted and demonstrated. 
More importantly, the case for a systems approach in blood-biomaterial studies has been presented, 
together with examples that demonstrate the importance of this approach in analyzing complex 
systems such as the blood-biomaterial interaction system. In addition, a framework for a systems 
approach was developed. This provides the basis for further development and refinement of this 
concept. The significance of a systems approach was demonstrated by the analysis and design of the 
in vitro flow model used in the experiments. Furthermore, by using a systems approach and 
examining system components, it allowed for the examination of the main functions such as 
activation and regulation of the inhibition control mechanism. Thus, making it possible to identify 
some of the missing links regarding activation control by inhibition, such as factors that influence 
platelet and leukocyte inhibition under different flow and material surface conditions, and other 
mechanisms. A lot of work has been done. It is time to put the pieces of the big puzzle together. 
Somewhere in the vast number of combinations lies the solution for the key to the holy grail of 
biocompatibility. 
8.1.2 A systems approach to in vitro model design 
The systems approach proposed in this thesis was used to design the in vitro model 
parameters. From all the physiological parameters, a systematic method was followed to rationalize 
the selection of parameters to ensure appropriate mimicking of the physiological location of interest 
by the in vitro model. Therefore, the contribution of this work was in demonstrating the usefulness of 
a systems approach in model design for blood-biomaterial interaction studies. 
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8.1.3 Model stent design, fabrication and characterization 
Model stents were designed, fabricated and characterized. In designing the model stents, strut 
and stent geometry were considered as well as strut surface characteristics. Although basic surface 
characterization parameters were determined, it was noted that there is a need to consider detailed 
surface characterization as other surface parameters besides roughness may be equally important. 
There are other pertinent parameters that may be relevant. These include the stent surface area to its 
volume or to its surface structure/morphology. Thus, the contribution of this work is in demonstrating 
model stent fabrication and raising pertinent material parameters that may need closer attention. 
8.1.4 A method for determining appropriate blood sample volume 
Although the Chandler loop model has been used by a number of investigators, there has 
been little discussion on the appropriateness of the sample volume, the sample volume selection 
method and its implications on fluid dynamics. Thus, there has been no guidance on the method for 
determining the appropriate sample volume for the Chandler loop model. For that reason, this study 
developed a method for determining the blood sample volume that takes into account the 
hemodynamic and biochemical requirements for the Chandler loop model. The proposed criterion is 
named the Chandler loop sample volume fraction (CLSVF) equation. The significance of the criterion 
is that it is general and therefore can be used with any defined range of the surface area-to-volume 
ratio. 
This study has demonstrated that the sample volume influences the fluid mechanics of the 
Chandler loop model. This is important because fluid mechanics greatly influence thrombus 
formation. Hence, appropriate fluid mechanics characterization is very beneficial in investigating the 
effect of shear on material-induced molecular/cellular activity in initiating, dissolving or enhancing 
thrombus formation. Therefore, the contributions of this work are in developing a tool for 
determining sample volume (the CLSVF criterion) and demonstrating the effect of sample volume on 
the loop fluid mechanics.  
8.1.5 Fluid mechanics of the Chandler loop model 
Although the fluid mechanics of the Chandler loop model was previously developed, the wall 
shear stress equation approximation did not incorporate some of the key parameters that characterize 
curved tube flow. In this study, fluid flow was appropriately characterized and a new time-averaged 
wall shear stress equation was developed. Appropriate flow characterization is important because 
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blood activation is influenced by the level as well as the type of flow. The significance of the 
developed equation is that it can be used for any stent with defined friction factor. The equation can 
also be used in the absence of a stent to evaluate the effect of shear on blood activation or to evaluate 
protein adsorption on new tube material under appropriately characterized flow conditions. Thus, the 
major contributions of this work are appropriate flow characterization and the development of a better 
approximation of the time-averaged wall shear stress equation for the Chandler loop model. 
8.1.6 Effect of sample volume on platelet and leukocyte activation 
The contribution of the experimental investigation was in validating the effect of blood 
sample volume on platelet and leukocyte activation. This fact was demonstrated by the experimental 
results, especially in the presence of model stents. 
8.1.7 Effect of complement inhibition on platelet and leukocyte activation 
The effect of futhan on blood activation was demonstrated under different experimental 
conditions. The contribution of this work was in demonstrating the potential for futhan to be used to 
reduce material-induced thrombogenicity under flow and possibly retaining the platelet hemostatic 
functions. 
8.1.8 Effect of surface roughness 
The effect of surface roughness on blood activation was demonstrated in this research. It was 
also demonstrated that roughness did not reduce the effectiveness of complement inhibition. The 
contribution of this work was in demonstrating the possible use of futhan to reduce material-induced 
thrombosis on devices with patterned surfaces, such as drug-eluting stents. 
8.1.9 Perspectives on receptor expression and function 
The importance of leukocytes in material-induced thrombosis has previously been 
highlighted. Platelets also seem to regard leukocytes as key partners in aggregation – they express 
receptors/ligands to bind leukocytes and then they enhance the Mac-1 binding affinity through ADP 
without increasing expression. Mac-1 expression and affinity are interesting because there has also 
been evidence that fMLP increases Mac-1 expression without increasing affinity – quite the opposite 
of ADP. To some extent, one may see the logic behind the fMLP effect, as it is a chemoattractant. 
The interesting thing is that this expression without function is also observed with platelet 
microparticle formation. The curious question that arises then is whether most agonists fall into these 
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two categories of either inducing expression or affinity. If that is the case then it may be time to 
consider classifying agonists as activators (the ones that activate function/affinity) and stimulators 
(stimulate expression). This is particularly important because targeting, in this case a stimulator, for 
therapeutic intervention may not be as effective as targeting an activator. Further studies are 
necessary to elucidate the validity of this classification. Even if the classification is not generalized, it 
is still necessary to understand if material characteristics, all or some, induce either or both expression 
and function. An additional point is to consider a standard to investigate both expression and function 
such as the SAXSA sequence. 
8.2 Major contributions 
(a) Proposed a pyramid and cube representation for blood-biomaterial interaction 
(b) Proposed the SAXSA sequence to understand and visualize mode of interaction 
(c) Proposed a systems approach framework for blood-biomaterial interaction studies 
(d) Developed a method to determine the appropriate blood sample volume and demonstrated the 
importance of selecting appropriate sample volume 
(e) Characterized fluid mechanics and developed improved time-average wall shear stress 
equation for the Chandler loop model 
(f) Experimentally demonstrated the effect of blood sample volume in blood-biomaterial 
investigations with model stents 
(g) Proposed an improved cell activation and aggregation model function that incorporates 
surface area-to-volume ratio as well as roughness 
(h) Demonstrated the possible use of complement inhibitor, futhan, as an effective intervention to 
control coagulation and material-induced thrombosis 
(i) Demonstrated that although roughness affects cell activation, it did not have an effect on 
futhan, which has possible applications for reducing material-induced thrombosis from 
patterned surfaces such as on drug-eluting stents. 
8.3 Future work 
In this section, a brief discussion of possible future work is presented to build on this thesis, 
taking into consideration information from other studies. 
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A systems approach 
The development of the framework for systems design is only the beginning. There is need to 
build on this work and develop a framework with established parameters that can be accepted by 
consensus and will guide future research in blood-biomaterial interaction studies. The weighting 
factors for the relative importance of various physiological parameters for databases with some of the 
important parameters, such as the surface concentrations of ions or molecules on specific surfaces, 
under specific conditions, e.g. OH-, Ca2+, fibrinogen, etc., are necessary. Some of these data may 
already exist but may need to be compiled. 
In order to elucidate the cause and effect relationship between material surface characteristics 
and blood cell activation, it is necessary to clearly identify and characterize all the entities involved at 
the blood-biomaterial interface, as previously discussed in chapter 2. A schematic of the system 
interactions at the surface is provided to highlight the key players that should be investigated 
simultaneously, Figure 8-1. 
 
 
Figure 8-1. Schematics of events at a material surface and mediating factors. Closed arrows 
represent interactions and open arrows represent mediating factors. Question mark means, depending 
on the level of roughness, surface flow may mediate some the interactions. 
 
The butterfly effect 
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The idea that butterfly wings can cause a hurricane is well known in physics. This 
understanding is founded on chaos theory, which states that small perturbations can result in very 
large and divergent effects or system responses over time. With the complexity of the biological 
system, it is entirely possible that while we often look for statistically significant changes, some of the 
changes that are not significant may have subsequent large effects. It is possible that in some cases 
the significant differences may indicate terminal change and the seemingly insignificant changes may 
be hiding the true effects that cause final undesirable consequences. This idea needs to be explored in 
blood-biomaterial interaction studies because it has not been disproved that it is not applicable. With 
current computing simulation power, this needs closer attention in models that have been refined 
through appropriate and valid assumptions. Hence, chaos theory may hold the key to some of the 
unanswered questions. 
 
In vitro model parameters 
While there will continue to be innovation and inventions in the development of new in vitro 
models, it is important to ‘standardized’ or determine the minimum design parameters necessary for 
models used for investigating blood-biomaterial interaction studies related to specific physiological 
locations of interest. Here the use of a systems approach and engineering design methods would be 
invaluable. If there is to be progress in standardization, it is in the interest of the biomaterials 
community to take the development of such guidelines as a priority. This will greatly facilitate 
comparison of experimental results. 
 
In vitro model air-to-blood sample ratio 
It was shown in this thesis that there is little hemodynamic (shear) effect from the air sample 
in the loop. However, from a biochemical point of view, there are other factors such as the difference 
in oxygen partial pressure between the air and blood sample that need to be considered. The effect of 
this difference is not clear and therefore further investigation is warranted. 
 
Time-averaged wall shear stress (TAWSS) 
This work has introduced the concept of time-averaged wall shear stress for the circulating 
loop model. While this concept is also applied in vivo, the time-averaged oscillatory shear index is 
deemed to be a better indicator for the shear effect. The question then is whether for in vitro models 
the time-averaged wall shear stress is the ultimate indicator of the shear effect or if it has some 
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limitations. This is because different combinations of the circulation period and shear magnitude for 
the same experimental model may theoretically produce similar time-averaged wall sear stress but 
different activation results. Therefore, there is a need to explore whether there is a better indicator 
based on TAWSS for in vitro studies using the Chandler loop model. 
There is also a need to develop a platelet activation model, which incorporates surface-area-
to-volume ratio. The current shear and time depend model is not sufficient to explain activation in the 
presence of biomaterials. 
 
Computational fluid dynamics 
It is necessary to further explore the fluid dynamics of the Chandler loop model with 
numerical methods, especially in the presence of stents. This will assist with investigating shear 
sensitivity to various model parameters. 
 
Leukocyte activation and adhesion kinetics 
The dynamics adsorption and desorption of proteins, especially complement fragments, plays 
a key role in building surface bound convertases and subsequent leukocyte activation and adhesion. 
Real-time monitoring of the different hydroxyl and amino bonds and the related complement 
fragments would be informative in elucidating the point at which the combinations may tip the scale 
to thrombus growth. 
It is known that ADP from platelets enhances the affinity of Mac-1 to its ligands, e.g. FX and 
fibrinogen, but the kinetics of the ADP and other agents and how they relate to fibrinolytic agents in 
an in vitro model is not well understood. It is not clear if any of the agents are depleted in an in vitro 
model and at what time-point. This information would be useful in understanding and explaining 
observations at both short and long experimental end points. 
The effect of intermittent flow on cell adhesion was not studied in detail in this research. 
Since there is a possibility that intermittent flow, as in this model, may increase cell adhesion due to 
the possibility of adhesion stabilizing during the reduced shear part of the cycle, it can be 
hypothesized that intermittent flow could increase cell adhesion. Therefore, it would be informative to 
further examine the effect of frequency in this model. 
TF-FVIIa complex and FXa play much more diverse roles through PAR signaling. It is 
therefore important that in investigating coagulation, the effects of these proteins are not confined to 
extracellular roles only as the signaling effects occur concurrently with coagulation. These 
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investigations would be useful in understanding some of the observations, such as down-regulation of 
TF at high shear rates. This is in line with the idea of profiling receptors that are not normally 
included in coagulation investigations and yet play an important role. 
The issue of material-induced Mac-1 affinity has not been addressed. There has been 
evidence that while receptor density is important, affinity may be a much more deciding factor. This 
makes sense because expression is not equivalent to activity. Expressed receptors may be 
incompetent in activity and may depend on the sub-population. Therefore, further work is necessary 
to elucidate the issue of affinity. 
The effect of biomaterial on TF expression is known but the exact mechanism is not well 
understood. Hence, it is not possible to predict the outcome based on a set of material input 
parameters/characteristics. This is due to a lack of quantitative parameters that characterize the 
network as well as the kinetics of the multiple contributing factors. An argument for a systems 
approach has been presented. That will ensure that both experimental and computational simulations 
are carried out hand in hand to understand the mechanism of activation and signal propagation and 
control. 
Some of the constitutively expressed receptors were investigated in this research. However, 
further investigations are necessary to elucidate their regulation in the presence of biomaterials.  
 
Contact system in thrombosis 
There is evidence that the contact system may be playing a bigger role in the structure, and 
thus the stability, of thrombii. Since biomaterial implants, depending on their surface characteristics, 
could bind FXII as well as fibrinogen and fibrin, it is possible that this combination could contribute 
to propagation of material-induced thrombosis. Therefore, further investigations are necessary to 
elucidate the role of the contact system in material-induced thrombosis, in light of the new 
information.  
 
Role of inhibitory pathways in blood-biomaterial interactions 
While it is known that inhibitory pathways work in tandem with activation pathways, a lot of 
effort is placed on elucidating the cell activation mechanism and not enough is done to examine the 
effect of materials on the various inhibitory mechanisms. It will be difficult to understand the cause 
and effect without accounting for the equally important regulatory mechanisms. Therefore, regulatory 
mechanisms need to be investigated and profiled in the presence of biomaterials. 
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For those measurements that are not sensitive to the current measurement methods, it is 
necessary to either amplify their signal to noise ratio since they may be designed to work under small 
concentrations but may still have information that is buried in the noise. 
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Chapter 9 
Summary of Conclusions 
The use of a systems approach in blood-biomaterial studies is invaluable in the analysis of the 
response of complex biological networks to biomaterial stimulus 
Numerous blood-biomaterial interaction studies, both in vitro and in vivo, have produced 
enormous amounts of information and data. These complex interactions cannot be understood without 
the use of a complex systems methods. The case for a systems approach in blood-biomaterial 
interaction studies has been presented and a framework was proposed as a starting point to develop 
methods in this area.  
 
Geometric and hemodynamics parameters of in vitro models are important to mimic 
physiological location of interest 
The design of appropriate model parameters to mimic the physiological location of interest 
cannot be over emphasized. In this study, geometric parameters were selected based on the 
physiological location of interest. For hemodynamic parameters, flow was appropriately characterized 
and an improved time-averaged wall shear stress equation was proposed. This equation is considered 
more accurate than the original equation as it takes into account some of the curved tube flow 
parameters not included in the Gardener equation.  
Furthermore, the results suggest that data interpretation may vary depending on whether one 
is looking at the results from exposing stents to 2 ml or 4 ml of blood, even with similar surface area-
to-volume ratio. Therefore, the results confirm the importance of selecting appropriate model 
parameters to reflect a reasonable simulation of in vivo parameters as in vitro results may be 
misinterpreted due to experimental parameters. Simulation and further experimental studies would be 
necessary to elucidate the mechanism of a shear-volume-stent interaction effect on flow 
characteristics and blood activation, over a wider range of physiological and pathologic shear stress. 
 
Blood sample volume has multifactorial effects on in vitro flow model experimental results 
In blood-biomaterial interaction studies, blood sample volume is an important parameter 
because of its implications on hemodynamics and biochemical processes. Under flow conditions, it is 
necessary to have sufficient sample volume that exceeds entrance length to ensure the assumption of 
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fully developed flow conditions. In the presence of a biomaterial, an additional consideration is 
surface area-to-volume ratio, as stipulated by the ISO standard. Furthermore, sample volume 
determines shear exposure time. For these reasons, sample volume is a critical parameter in the shear-
volume-stent-time interaction effect on blood activation. In this study, the effect of sample volume on 
platelet and leukocyte activation was demonstrated. The possibility of misinterpretation of results due 
to differences in volume, even at the same surface area-to-volume ratio, has significant implications 
when screening materials for blood compatibility. Overall this study supports the hypothesis that 
sample volume consideration is important in this model, especially in biomaterial studies. 
 
Complement inhibition could reduce leukocyte activation and adhesion. 
We have demonstrated that leukocyte adhesion on Ti-6Al-4V can be reduced without 
reducing platelet adhesion. The formation of an adsorbed protein layer was also not affected. The 
importance of these results, if extrapolated to possible in vivo implications, is that complement 
inhibition could be one mechanism to reduce leukocyte adhesion and possible localized effects of 
superoxide production on vascular walls. 
Furthermore, it was also demonstrated that surface patterning did not reduce the effectiveness 
of complement inhibition with futhan. This suggests possible application with drug-eluting stents to 
reduce material-induced thrombosis. Further investigations are necessary to elucidate the implications 
of these findings. 
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Appendix A 
Material Composition and Properties 
Ti-6Al-4V ELI (extra low interstitial), Table A-1, is a higher purity alloy with lower iron, 
carbon and oxygen elements compared to the standard Ti-6Al-4V. Since it has both alpha (Al) and 
beta (V) stabilizers, it can be heat treated and transformed to stabilize between the alpha (hexagonal) 
and beta (cube) phase. Ti-6Al-4V has the advantage of toughness and corrosion resistance. 
 
Table A-1. Properties and specifications of Ti-6Al-4V ELI. Adapted from [514]. 
 Ti-6Al-4V ELI 
(max ave. Wt %) 
Bulk chemical 
composition 
Ti 
Al 
V 
Fe 
O 
C 
N 
H 
89.7082 
6.06 
3.97 
0.12 
0.11 
0.015 
0.011 
0.0058 
Physical/Mechanical 
properties 
Density 
Ultimate tensile strength 
Modulus of elasticity 
Thermal conductivity 
0.160 lbs/in2 
1000-1172 MPa 
16.5x106 psi 
6.6-6.8 W/m K 
Electrical properties Electrical resistivity 1.71 µohms-m 
Thermal properties Melting point 1604-1660 °C 
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Appendix B 
Application of Blasius Correlation 
Substituting average velocity from Table 3-4 into the Blasius correlation, 
 
τ =
f ρv2
2  
 
Gives, 
 
τ =
f ρ
2 .
πR0ω
30 .
πR0ω
30  
 
Grouping terms and multiplying by R R  and µ µ  terms gives, 
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The first bracket can be recognized as Re from Table 3-4 and the second bracket can also be 
recognized as wall shear stress τw from equation (19). Therefore, the equation can be written as, 
 
τ = f Re16
!
"
#
$
%
&τ w  
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Appendix C 
Determination of Density, Viscosity and Wall Shear Stress Effect of 
Humid Air 
The density of humid air can be determined from basic gas principles, as briefly describe 
below [515]. The following constants are known: 
Atmospheric air pressure, pa = 760 mmHg =101.325 kPa . 
Gas constants: 
Rair = 286.9 J kgK  
Rw.vapor = 461.5 J kgK  
 
The saturated vapor pressure at the actual temperature (T in Kelvin) is expressed as, 
 
pws = e77.3450+0.0057T−7235/T( ) T 8.2  
 
At 37°C, the temperature in Kelvin is given by T = 37+ 273.16 = 310.16K . Substituting gives, 
pws = 6261.142 pascal . 
 
The specific humidity at saturation is given by the equation, 
 
xs = 0.62198
pws
pa − pws( )
 
 
The density of dry air from ideal gas law is ρa = 0.0035pa T =1.1434 kg m3 at 37°C. The density 
of moist air is expressed as, 
 
ρw = ρa
1+ xs
1+1.609xs( )
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After substitution, the density of moist air in the loop at 37°C is ρw =1.1166kg m3 . 
 The viscosity of humid air at 37°C is given by the equation [516], 
 
ηa = 17.1+ 0.067T − 0.0004T 2( ) x10−6  
 
where T is in °C. After substituting 37°C, η =19.03x10−6 Pa.s . 
With density and viscosity determined, the contribution of humid air to the shear stress can be 
determined. The second terms of equation (42) and (43) representing air contribution to time-
averaged wall shear stress are expressed separately below as equation (42air) and (43air) in the 
presence and absence of model stent, respectively. 
 
τ =
ρaν
2
2 β fcra + 1−λ −β( ) fcsa
"# $%        (42air) 
 
τ =
ρaν
2
2 1−λ( ) fcsa          (43air) 
 
Equation (42air) and (43air) are plotted on Figure C-1. Similar to shear stress due to blood sample 
volume, the effect of air sample volume shows clustering of the plots around the two volume samples. 
The results suggest that air sample volume does not have a significant effect on the overall wall shear 
stress as all the time-averaged wall shear stress values are below 0.04 dyn/cm2. 
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Figure C-1. Time-averaged wall shear stress due to moist air in the loop 
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Appendix D 
Rotor Calibration 
The Roto-Torque™, model RT50 (Cole-Palmer Instrument Co., Illinois, USA) was specified 
to have electronic speed control from about 3 to about 80 RPM. The disk was specified to rotate as 
high as 60 RPM. However, it was necessary to calibrate the rotor because the markings on the speed 
control knob were not related to any quantitative rotational speed values. 
Calibration setup: The rotor calibration was done with a Digital Stroboscope Tachometer, model 
461831 (Extech Instruments, Melrose, MA, USA). The stroboscope specifications are as presented on 
Table D-1. The stroboscope was mounted on a mini-tripod stand and positioned at about 25 cm from 
the rotor disc, in line with the center of the rotating disc, Figure D-1. Since the lower limit of the 
measurement range of the stroboscope (100 RPM) was above the maximum rotational speed of the 
rotor, the measurements were based on harmonics, i.e. there was no 1:1 measurements, only 2:1, 3:1 
or higher ratios were possible. This meant that, if there was one marker on the rotor disk, and it 
showed as four stationary marks when rotating under the stroboscope light, then the strobe flash rate 
to disk speed was 4:1. In this case, since the rotor maximum speed was far below the minimum strobe 
measurement range limit, a ration of 10:1 was necessary, i.e. the rotor speed was 1/10 of the 
stroboscope reading. 
 
Table D-1. Stroboscope specifications 
Measuring range 100 to 10000 RPM/FPM (FPM – flashes per minute) 
Resolution 0.1 (<1000 RPM/FPM) 
1 (1000 to 9999 RPM/FPM) 
10 (10000 RPM/FPM) 
Accuracy ± (0.05%+1 digits) 
Sampling time 1 second 
Strobe flash adjustment range LOW: 100 to 1000 RPM/FPM 
HIGH: 1000 to 10000 RPM/FPM 
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Figure D-1. Rotor calibration setup 
 
Results: Using the LOW range setting on the stroboscope, the results of the calibration are presented 
on Table D-2. 
 
Table D-2. Calibrated rotor rotation speed 
Marker setting on rotor Stroboscope reading 
(RPM/FPM) 
Disk speed (RPM) 
1 N/A N/A 
2 106.0 10.6 
3 178.1 17.8 
4 239.4 23.9* 
5 308.0 30.8 
6 370.6 37.1 
7 447.8 44.8* 
8 558.6 55.9 
9 565.7 56.6 
10 569.6 57.0 
N/A – it was not possible to measure very low speeds. *Angular velocities used in the experiments. 
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Appendix E 
Determining AFM Scanning Area 
The atomic force microscopy (AFM) scanning area is usually easy to determine on a flat 
surface. For a curved surface, curvature error may occur if the scan area is too large. Since the model 
stent wire has a circular cross-section and has a small diameter, its curvature imposes a limit on the 
maximum AFM scan area, without curvature error. Scanning along the length of the wire does not 
pose any problems except in the case where the wire is in the form of a coil, in which case the coil 
radius of curvature should be taken into account. For this configuration, the coil radius of curvature 
(4.775 mm/2 = 2.388 mm) is much larger than the radius of the wire (0.0635 mm). Therefore, it is 
sufficient calculate scan area base on the radius of the wire. A cross section of the wire is presented 
on Figure E-1. 
 
 
Figure E-1. Schematic cross-section of stent wire 
 
s = arc length  
h = straight line across curvature = scan length 
r = radius of wire 
R = length from center to h (perpendicular to h and divides h in half)  
 
Diameter of wire = 0.127 mm 
∴ r = 0.0635 mm 
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where θ is in degrees. But, 
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 In order to scan without curvature error, ideally h ≈ s. Typical values of s for possible 
scan areas are presented on Table E-1. Hence, scan area less than 15 µm may be acceptable. The 
maximum scan area selected for this study was 10x10 µm2. 
 
Table E-1. AFM scan area determination 
Scan length, h (µm) Arc length, s (µm) Relative error 
10 10.01 0.1% 
15 15.04 0.2% 
20 20.08 0.4% 
25 25.16 0.7% 
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Appendix F 
Dynamic Contact Angle Analysis 
The Wilhelmy dynamic contact angle method is based on the force equation [389], 
 
F =mg+γLcosϑ −Fb  
 
where F is total force, m is mass of the solid sample (e.g. wire), g is gravitational constant, γ is the 
surface tension of the liquid, L is wetted perimeter (wetted length) of the solid sample, θ is the contact 
angle between the solid and the liquid and Fb is the buoyancy force. In performing the measurement, 
the electro-balance was reset to zero with autocal so that the gravity force mg did not contribute to the 
recorded force. For the measurement, the surface tension of water and the wetted length are known. 
Thus, force can be accurately measure with a high precision instrument. The instrument uses linear 
regression to eliminate the buoyance force so that the equation resembles the Young’s equation, from 
which the contact angle can be determined. 
 The setup consists of an electro-balance, an immersion liquid and sample, Figure F-1. The 
electro-balance was the auto-calibrating Sigma 700 (KSV Instruments, Helsinki, Finland) and the 
working liquid used was MilliQ water. Six immersion and emersion loops were carried out 
continuously at a velocity of 10 mm/min, giving six successive time-dependent hysteresis loops 
(force loops). Advancing and receding contact angle measurements were obtained from each loop. 
 
 
Figure F-1. Schematic illustration of the Wilhelmy method 
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Appendix G 
Physiological Solution Preparation  
The physiological solution was prepared with reagents as listed on Table G-1, as per 
procedure described by Oyane et al [392]. Before preparing the solution, HEPES was dissolved in 10 
ml of ultrapure water and 1.0 M NaOH was prepared by dissolving 0.4 g NaOH in 10 ml of ultrapure 
water. To prepare the solution, 70 ml of ultrapure water was poured in a beaker and kept at 35°C. The 
reagents were then dissolved sequentially as listed on Table G-1, with the aid of a magnetic stirrer. 
The solution volume was adjusted to 100 ml by adding ultrapure water. The solution was then filtered 
into 50 ml conical tubes and stored at 4°C. The solution was used within two days of preparation. 
 
Table G-1. Reagents for 100 ml simulated body fluid 
Reagent Common Name Reagent Quantity 
Sodium Chloride NaCl 0.5403 g 
Sodium Bicarbonate NaHCO3 0.0740 g 
Sodium Carbonate Na2CO3 0.2046 g 
Potassium Chloride KCl 0.0225 g 
Potassium Phosphate K2HPO4 0.0230 g 
Magnesium Chloride MgCl2 0.0311 g 
HEPES C8H18N2O4S 1.1928 g 
Calcium Chloride CaCl2 0.0293 g 
Sodium Sulfate Na2SO4 0.0072 g 
Sodium Hydroxide 1.0 M NaOH 0.08 ml 
 
Results 
The ionic concentration of the prepared physiological solution was not measured but has been 
found to have similar ionic concentration to blood plasma, Table G-2. 
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Table G-2. Simulated body fluid ion concentration (mM). Adapted from [392]. 
Ions Total Blood Plasma Expected Simulated Body Fluid 
Na+ 142.0 142.0 
K+ 5.0 5.0 
Mg2+ 1.5 1.5 
Ca2+ 2.5 2.5 
Cl- 103.0 103.0 
HCO3- 27.0 27.0 
HPO42- 1.0 1.0 
SO42- 0.5 0.5 
 
 
 
 
 
 
